WO2024102674A1 - Antigen binding molecules targeting sars-cov-2 - Google Patents
Antigen binding molecules targeting sars-cov-2 Download PDFInfo
- Publication number
- WO2024102674A1 WO2024102674A1 PCT/US2023/078868 US2023078868W WO2024102674A1 WO 2024102674 A1 WO2024102674 A1 WO 2024102674A1 US 2023078868 W US2023078868 W US 2023078868W WO 2024102674 A1 WO2024102674 A1 WO 2024102674A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- amino acid
- acid sequence
- domain
- polypeptide
- Prior art date
Links
- 230000027455 binding Effects 0.000 title claims abstract description 173
- 239000000427 antigen Substances 0.000 title claims abstract description 98
- 102000036639 antigens Human genes 0.000 title claims abstract description 97
- 108091007433 antigens Proteins 0.000 title claims abstract description 97
- 230000008685 targeting Effects 0.000 title description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 700
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 695
- 229920001184 polypeptide Polymers 0.000 claims abstract description 692
- 241001678559 COVID-19 virus Species 0.000 claims abstract description 154
- 239000012634 fragment Substances 0.000 claims abstract description 101
- 238000000034 method Methods 0.000 claims abstract description 97
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 51
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 51
- 239000002157 polynucleotide Substances 0.000 claims abstract description 51
- 208000025721 COVID-19 Diseases 0.000 claims abstract description 42
- 241000008904 Betacoronavirus Species 0.000 claims abstract description 29
- 101710114810 Glycoprotein Proteins 0.000 claims abstract description 8
- 101710167605 Spike glycoprotein Proteins 0.000 claims abstract description 8
- 102000005962 receptors Human genes 0.000 claims abstract description 8
- 108020003175 receptors Proteins 0.000 claims abstract description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 1149
- 238000006467 substitution reaction Methods 0.000 claims description 359
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 claims description 106
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 86
- 239000000203 mixture Substances 0.000 claims description 75
- 239000003814 drug Substances 0.000 claims description 47
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 35
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 claims description 30
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 claims description 30
- 241000700605 Viruses Species 0.000 claims description 30
- 229940124597 therapeutic agent Drugs 0.000 claims description 28
- 201000010099 disease Diseases 0.000 claims description 25
- 230000035772 mutation Effects 0.000 claims description 23
- 239000002105 nanoparticle Substances 0.000 claims description 16
- 239000003112 inhibitor Substances 0.000 claims description 15
- 229920001223 polyethylene glycol Polymers 0.000 claims description 15
- 229960005486 vaccine Drugs 0.000 claims description 15
- 125000003729 nucleotide group Chemical group 0.000 claims description 14
- 229920000642 polymer Polymers 0.000 claims description 14
- 208000019622 heart disease Diseases 0.000 claims description 12
- 239000002202 Polyethylene glycol Substances 0.000 claims description 11
- 229940051181 cilgavimab Drugs 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 10
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 10
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 10
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 10
- 239000003443 antiviral agent Substances 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 9
- 206010019280 Heart failures Diseases 0.000 claims description 8
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 8
- 108020004459 Small interfering RNA Proteins 0.000 claims description 8
- 239000003430 antimalarial agent Substances 0.000 claims description 8
- 125000000539 amino acid group Chemical group 0.000 claims description 7
- 230000003115 biocidal effect Effects 0.000 claims description 7
- 208000019693 Lung disease Diseases 0.000 claims description 6
- 239000003242 anti bacterial agent Substances 0.000 claims description 6
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 6
- 230000002757 inflammatory effect Effects 0.000 claims description 6
- 229940051871 tixagevimab Drugs 0.000 claims description 6
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims description 5
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 5
- 229940125678 AZD7442 Drugs 0.000 claims description 5
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 5
- 208000011191 Pulmonary vascular disease Diseases 0.000 claims description 5
- 229960004099 azithromycin Drugs 0.000 claims description 5
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 5
- 229940052143 bamlanivimab Drugs 0.000 claims description 5
- 229940051183 casirivimab Drugs 0.000 claims description 5
- 229960003677 chloroquine Drugs 0.000 claims description 5
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims description 5
- 229940051243 etesevimab Drugs 0.000 claims description 5
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 claims description 5
- 229950008454 favipiravir Drugs 0.000 claims description 5
- 229940051184 imdevimab Drugs 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 210000003281 pleural cavity Anatomy 0.000 claims description 5
- 229940051283 regdanvimab Drugs 0.000 claims description 5
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims description 4
- 108020005544 Antisense RNA Proteins 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 4
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 claims description 4
- 206010035664 Pneumonia Diseases 0.000 claims description 4
- 108091030071 RNAI Proteins 0.000 claims description 4
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 4
- 229960003805 amantadine Drugs 0.000 claims description 4
- 239000003184 complementary RNA Substances 0.000 claims description 4
- 230000009368 gene silencing by RNA Effects 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 229930182817 methionine Natural products 0.000 claims description 4
- 229940023146 nucleic acid vaccine Drugs 0.000 claims description 4
- 229960003752 oseltamivir Drugs 0.000 claims description 4
- PGZUMBJQJWIWGJ-ONAKXNSWSA-N oseltamivir phosphate Chemical compound OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 PGZUMBJQJWIWGJ-ONAKXNSWSA-N 0.000 claims description 4
- KQOXLKOJHVFTRN-UHFFFAOYSA-N pleconaril Chemical compound O1N=C(C)C=C1CCCOC1=C(C)C=C(C=2N=C(ON=2)C(F)(F)F)C=C1C KQOXLKOJHVFTRN-UHFFFAOYSA-N 0.000 claims description 4
- 229960000471 pleconaril Drugs 0.000 claims description 4
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 claims description 4
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 claims description 4
- 229960000888 rimantadine Drugs 0.000 claims description 4
- 229940061367 tamiflu Drugs 0.000 claims description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 3
- 108010088751 Albumins Proteins 0.000 claims description 3
- 102000009027 Albumins Human genes 0.000 claims description 3
- 208000006029 Cardiomegaly Diseases 0.000 claims description 3
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 201000006306 Cor pulmonale Diseases 0.000 claims description 3
- 208000005189 Embolism Diseases 0.000 claims description 3
- 206010014561 Emphysema Diseases 0.000 claims description 3
- 206010024971 Lower respiratory tract infections Diseases 0.000 claims description 3
- 208000009525 Myocarditis Diseases 0.000 claims description 3
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 3
- 206010030113 Oedema Diseases 0.000 claims description 3
- 235000021314 Palmitic acid Nutrition 0.000 claims description 3
- 206010035603 Pleural mesothelioma Diseases 0.000 claims description 3
- 208000004186 Pulmonary Heart Disease Diseases 0.000 claims description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 3
- 206010046306 Upper respiratory tract infection Diseases 0.000 claims description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 3
- 208000037849 arterial hypertension Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 206010006451 bronchitis Diseases 0.000 claims description 3
- 208000029078 coronary artery disease Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 239000000032 diagnostic agent Substances 0.000 claims description 3
- 229940039227 diagnostic agent Drugs 0.000 claims description 3
- 206010014665 endocarditis Diseases 0.000 claims description 3
- 208000018578 heart valve disease Diseases 0.000 claims description 3
- 239000000017 hydrogel Substances 0.000 claims description 3
- 208000015210 hypertensive heart disease Diseases 0.000 claims description 3
- 238000002650 immunosuppressive therapy Methods 0.000 claims description 3
- 208000037841 lung tumor Diseases 0.000 claims description 3
- 201000003144 pneumothorax Diseases 0.000 claims description 3
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 3
- 208000004124 rheumatic heart disease Diseases 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 239000008024 pharmaceutical diluent Substances 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 241000208125 Nicotiana Species 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 abstract description 38
- 108020001507 fusion proteins Proteins 0.000 abstract description 38
- 239000013598 vector Substances 0.000 abstract description 12
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 description 235
- 210000004027 cell Anatomy 0.000 description 116
- 238000006386 neutralization reaction Methods 0.000 description 70
- 150000001413 amino acids Chemical class 0.000 description 63
- 108010032595 Antibody Binding Sites Proteins 0.000 description 61
- 239000008194 pharmaceutical composition Substances 0.000 description 44
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 40
- -1 homocitruline Chemical compound 0.000 description 37
- 241001112090 Pseudovirus Species 0.000 description 33
- 235000002639 sodium chloride Nutrition 0.000 description 33
- 241000315672 SARS coronavirus Species 0.000 description 32
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 32
- 230000002401 inhibitory effect Effects 0.000 description 32
- 108090000623 proteins and genes Proteins 0.000 description 30
- 102000004169 proteins and genes Human genes 0.000 description 28
- 239000003795 chemical substances by application Substances 0.000 description 27
- 102220308254 rs1554106843 Human genes 0.000 description 27
- 239000003937 drug carrier Substances 0.000 description 25
- 150000003839 salts Chemical class 0.000 description 25
- 230000003472 neutralizing effect Effects 0.000 description 23
- 238000011282 treatment Methods 0.000 description 22
- 230000003612 virological effect Effects 0.000 description 18
- 208000015181 infectious disease Diseases 0.000 description 17
- 241000494545 Cordyline virus 2 Species 0.000 description 16
- 229940024606 amino acid Drugs 0.000 description 16
- 241000314928 Cordyline virus 1 Species 0.000 description 15
- 102200128238 rs201124247 Human genes 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 241001678561 Sarbecovirus Species 0.000 description 14
- 230000004927 fusion Effects 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- 101710198474 Spike protein Proteins 0.000 description 12
- 102220599406 Spindlin-1_N501Y_mutation Human genes 0.000 description 12
- 102220642430 Spindlin-1_P681R_mutation Human genes 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 230000003993 interaction Effects 0.000 description 11
- 230000001404 mediated effect Effects 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 10
- 229940036185 synagis Drugs 0.000 description 10
- 102220579649 ATP-dependent RNA helicase A_K417N_mutation Human genes 0.000 description 9
- 229940096437 Protein S Drugs 0.000 description 9
- 108091005774 SARS-CoV-2 proteins Proteins 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 238000013461 design Methods 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 102220031793 rs431825282 Human genes 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 239000013638 trimer Substances 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 8
- 102220599672 Spindlin-1_D614G_mutation Human genes 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 231100000252 nontoxic Toxicity 0.000 description 8
- 230000003000 nontoxic effect Effects 0.000 description 8
- 230000000069 prophylactic effect Effects 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 208000035415 Reinfection Diseases 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 230000000670 limiting effect Effects 0.000 description 7
- 102220114694 rs763810935 Human genes 0.000 description 7
- 102220077512 rs797044926 Human genes 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 241000699800 Cricetinae Species 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 102000044437 S1 domains Human genes 0.000 description 6
- 108700036684 S1 domains Proteins 0.000 description 6
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 6
- 102220599659 Spindlin-1_E484A_mutation Human genes 0.000 description 6
- 102220599422 Spindlin-1_L452R_mutation Human genes 0.000 description 6
- 102220599613 Spindlin-1_N679K_mutation Human genes 0.000 description 6
- 102220599606 Spindlin-1_N764K_mutation Human genes 0.000 description 6
- 102220599634 Spindlin-1_Q954H_mutation Human genes 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 102220350121 c.1513T>C Human genes 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 210000005260 human cell Anatomy 0.000 description 6
- 230000002998 immunogenetic effect Effects 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102200080054 rs121908980 Human genes 0.000 description 6
- 102200056390 rs12204826 Human genes 0.000 description 6
- 102220249089 rs1553970560 Human genes 0.000 description 6
- 102200038843 rs199472766 Human genes 0.000 description 6
- 102220036845 rs587780085 Human genes 0.000 description 6
- 102200113705 rs72551353 Human genes 0.000 description 6
- 102220076412 rs772589363 Human genes 0.000 description 6
- 102220029076 rs78775072 Human genes 0.000 description 6
- 102220074121 rs796052019 Human genes 0.000 description 6
- 102220087615 rs864622785 Human genes 0.000 description 6
- 238000000954 titration curve Methods 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000288906 Primates Species 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 241000711573 Coronaviridae Species 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- 102220486250 Glucosidase 2 subunit beta_D405N_mutation Human genes 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- 102220599627 Spindlin-1_D950N_mutation Human genes 0.000 description 4
- 102220590621 Spindlin-1_T19R_mutation Human genes 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 238000004020 luminiscence type Methods 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000036515 potency Effects 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 102220282987 rs1555618704 Human genes 0.000 description 4
- 102200031792 rs267606720 Human genes 0.000 description 4
- 102220075059 rs529697285 Human genes 0.000 description 4
- 102200110418 rs570878629 Human genes 0.000 description 4
- 102200107909 rs886039483 Human genes 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- BNMFQWUHWYJTRI-BQFCYCMXSA-N 7-chloro-N-[(2S)-1-[[(1S)-1-cyano-2-[(3S)-2-oxopiperidin-3-yl]ethyl]amino]-3-cyclopropyl-1-oxopropan-2-yl]-1H-indole-2-carboxamide Chemical compound ClC=1C=CC=C2C=C(NC=12)C(=O)N[C@H](C(=O)N[C@@H](C[C@H]1C(NCCC1)=O)C#N)CC1CC1 BNMFQWUHWYJTRI-BQFCYCMXSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 3
- 102220585969 Claspin_S982A_mutation Human genes 0.000 description 3
- 108091035707 Consensus sequence Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102220599400 Spindlin-1_D1118H_mutation Human genes 0.000 description 3
- 230000010530 Virus Neutralization Effects 0.000 description 3
- 229960003767 alanine Drugs 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000001493 electron microscopy Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229940093915 gynecological organic acid Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 235000014304 histidine Nutrition 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 235000006109 methionine Nutrition 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- HTNPEHXGEKVIHG-QCNRFFRDSA-N molnupiravir Chemical compound C(OC(=O)C(C)C)[C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C(=O)N=C(NO)C=C1 HTNPEHXGEKVIHG-QCNRFFRDSA-N 0.000 description 3
- HTNPEHXGEKVIHG-ZJTJHKMLSA-N molnupiravir Chemical compound CC(C)C(=O)OC[C@H]1O[C@H](C(O)C1O)N1C=C\C(NC1=O)=N\O HTNPEHXGEKVIHG-ZJTJHKMLSA-N 0.000 description 3
- 229940075124 molnupiravir Drugs 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- NENPYTRHICXVCS-YNEHKIRRSA-N oseltamivir acid Chemical compound CCC(CC)O[C@@H]1C=C(C(O)=O)C[C@H](N)[C@H]1NC(C)=O NENPYTRHICXVCS-YNEHKIRRSA-N 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 102200109922 rs1085307741 Human genes 0.000 description 3
- 102220053106 rs199537178 Human genes 0.000 description 3
- 102220256968 rs368859380 Human genes 0.000 description 3
- 102220020383 rs397508214 Human genes 0.000 description 3
- 102220046286 rs587782805 Human genes 0.000 description 3
- 102200024304 rs886037751 Human genes 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- DIHXSRXTECMMJY-MURFETPASA-N 2-[dimethyl-[(9z,12z)-octadeca-9,12-dienyl]azaniumyl]acetate Chemical group CCCCC\C=C/C\C=C/CCCCCCCC[N+](C)(C)CC([O-])=O DIHXSRXTECMMJY-MURFETPASA-N 0.000 description 2
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 206010060964 Arterial haemorrhage Diseases 0.000 description 2
- 108091033409 CRISPR Proteins 0.000 description 2
- 238000010354 CRISPR gene editing Methods 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000282832 Camelidae Species 0.000 description 2
- 108700022167 ChAdOx1 nCoV-19 Proteins 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 231100000491 EC50 Toxicity 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102220543270 Eukaryotic peptide chain release factor GTP-binding subunit ERF3A_Y453F_mutation Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229940125583 Inovio COVID-19 vaccine Drugs 0.000 description 2
- 229940024452 Janssen COVID-19 vaccine Drugs 0.000 description 2
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 229940026232 Novavax COVID-19 vaccine Drugs 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 229940025109 Oxford–AstraZeneca COVID-19 vaccine Drugs 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 2
- 108091005634 SARS-CoV-2 receptor-binding domains Proteins 0.000 description 2
- 229940025291 Sinovac-CoronaVac COVID-19 vaccine Drugs 0.000 description 2
- 102220590697 Spindlin-1_A67V_mutation Human genes 0.000 description 2
- 102220590324 Spindlin-1_D80A_mutation Human genes 0.000 description 2
- 102220590696 Spindlin-1_G142D_mutation Human genes 0.000 description 2
- 102220599628 Spindlin-1_L981F_mutation Human genes 0.000 description 2
- 102220599420 Spindlin-1_N501T_mutation Human genes 0.000 description 2
- 102220599641 Spindlin-1_N856K_mutation Human genes 0.000 description 2
- 102220599679 Spindlin-1_T547K_mutation Human genes 0.000 description 2
- 102220590684 Spindlin-1_T95I_mutation Human genes 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 2
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000010382 chemical cross-linking Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 108700005843 ensovibep Proteins 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 2
- 229960004171 hydroxychloroquine Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229960004525 lopinavir Drugs 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical compound CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 2
- 229960000311 ritonavir Drugs 0.000 description 2
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 2
- 102200059660 rs104894317 Human genes 0.000 description 2
- 102200089032 rs1554935371 Human genes 0.000 description 2
- 102220030033 rs398123766 Human genes 0.000 description 2
- 102220020940 rs55906931 Human genes 0.000 description 2
- 102220045931 rs587782500 Human genes 0.000 description 2
- 102220033185 rs62646881 Human genes 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000012916 structural analysis Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000003319 supportive effect Effects 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- AYRXSINWFIIFAE-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanal Chemical compound OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- LMVGXBRDRZOPHA-UHFFFAOYSA-N 2-[dimethyl-[3-(16-methylheptadecanoylamino)propyl]azaniumyl]acetate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O LMVGXBRDRZOPHA-UHFFFAOYSA-N 0.000 description 1
- TYIOVYZMKITKRO-UHFFFAOYSA-N 2-[hexadecyl(dimethyl)azaniumyl]acetate Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)CC([O-])=O TYIOVYZMKITKRO-UHFFFAOYSA-N 0.000 description 1
- SNQVCAOGQHOSEN-UHFFFAOYSA-N 2-[methyl(octadecyl)amino]acetic acid Chemical compound CCCCCCCCCCCCCCCCCCN(C)CC(O)=O SNQVCAOGQHOSEN-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- PKRSYEPBQPFNRB-UHFFFAOYSA-M 2-phenoxybenzoate Chemical compound [O-]C(=O)C1=CC=CC=C1OC1=CC=CC=C1 PKRSYEPBQPFNRB-UHFFFAOYSA-M 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- DIROHOMJLWMERM-UHFFFAOYSA-N 3-[dimethyl(octadecyl)azaniumyl]propane-1-sulfonate Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O DIROHOMJLWMERM-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- PVXPPJIGRGXGCY-TZLCEDOOSA-N 6-O-alpha-D-glucopyranosyl-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 PVXPPJIGRGXGCY-TZLCEDOOSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108091028075 Circular RNA Proteins 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 206010050685 Cytokine storm Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 101710160621 Fusion glycoprotein F0 Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- GIZQLVPDAOBAFN-UHFFFAOYSA-N HEPPSO Chemical compound OCCN1CCN(CC(O)CS(O)(=O)=O)CC1 GIZQLVPDAOBAFN-UHFFFAOYSA-N 0.000 description 1
- 101000989062 Homo sapiens Immunoglobulin heavy variable 5-51 Proteins 0.000 description 1
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102100029414 Immunoglobulin heavy variable 5-51 Human genes 0.000 description 1
- 108010005716 Interferon beta-1a Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- DNDWZFHLZVYOGF-KKUMJFAQSA-N Leu-Leu-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O DNDWZFHLZVYOGF-KKUMJFAQSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- NBGXQZRRLOGAJF-UHFFFAOYSA-N Maltulose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)(CO)OCC1O NBGXQZRRLOGAJF-UHFFFAOYSA-N 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102220635877 Phospholipid phosphatase-related protein type 5_R346T_mutation Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108091005609 SARS-CoV-2 Spike Subunit S1 Proteins 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 101000629313 Severe acute respiratory syndrome coronavirus Spike glycoprotein Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- 102220592182 Spindlin-1_A222V_mutation Human genes 0.000 description 1
- 102220599656 Spindlin-1_E484K_mutation Human genes 0.000 description 1
- 102220599629 Spindlin-1_Q1071H_mutation Human genes 0.000 description 1
- 102220599614 Spindlin-1_Q677H_mutation Human genes 0.000 description 1
- 102220590680 Spindlin-1_S13I_mutation Human genes 0.000 description 1
- 102220599642 Spindlin-1_T859N_mutation Human genes 0.000 description 1
- 102220599418 Spindlin-1_V1176F_mutation Human genes 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- LHAOFBCHXGZGOR-NAVBLJQLSA-N alpha-D-Manp-(1->3)-alpha-D-Manp-(1->2)-alpha-D-Manp Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1 LHAOFBCHXGZGOR-NAVBLJQLSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 210000002588 alveolar type II cell Anatomy 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000009833 antibody interaction Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- ZOMSMJKLGFBRBS-UHFFFAOYSA-N bentazone Chemical compound C1=CC=C2NS(=O)(=O)N(C(C)C)C(=O)C2=C1 ZOMSMJKLGFBRBS-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 238000012575 bio-layer interferometry Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229950011350 bococizumab Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 102220349414 c.1380T>G Human genes 0.000 description 1
- 102220429344 c.456G>T Human genes 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000000604 cryogenic transmission electron microscopy Methods 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- ZVTDLPBHTSMEJZ-UPZRXNBOSA-N danoprevir Chemical compound O=C([C@@]12C[C@H]1\C=C/CCCCC[C@H](C(N1C[C@@H](C[C@H]1C(=O)N2)OC(=O)N1CC2=C(F)C=CC=C2C1)=O)NC(=O)OC(C)(C)C)NS(=O)(=O)C1CC1 ZVTDLPBHTSMEJZ-UPZRXNBOSA-N 0.000 description 1
- 229950002891 danoprevir Drugs 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940125027 ensovibep Drugs 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960004461 interferon beta-1a Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 108010049589 leucyl-leucyl-leucine Proteins 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229960002337 magnesium chloride Drugs 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- JCQLYHFGKNRPGE-HFZVAGMNSA-N maltulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-HFZVAGMNSA-N 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- NZXVYLJKFYSEPO-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]-16-methylheptadecanamide Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)NCCCN(C)C NZXVYLJKFYSEPO-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229960000402 palivizumab Drugs 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000002837 percent inhibition normalization Methods 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 150000008298 phosphoramidates Chemical group 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 102220223340 rs1060502592 Human genes 0.000 description 1
- 102220023973 rs112534524 Human genes 0.000 description 1
- 102220154653 rs143982186 Human genes 0.000 description 1
- 102200088972 rs1801133 Human genes 0.000 description 1
- 102200147934 rs190521996 Human genes 0.000 description 1
- 102220005147 rs34173382 Human genes 0.000 description 1
- 102220046173 rs587782706 Human genes 0.000 description 1
- 102200110598 rs61749448 Human genes 0.000 description 1
- 102220058658 rs771746264 Human genes 0.000 description 1
- 102220088189 rs773831600 Human genes 0.000 description 1
- 102220059328 rs786202822 Human genes 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 238000009394 selective breeding Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229940100996 sodium bisulfate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- HSFQBFMEWSTNOW-UHFFFAOYSA-N sodium;carbanide Chemical group [CH3-].[Na+] HSFQBFMEWSTNOW-UHFFFAOYSA-N 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- DFVFTMTWCUHJBL-BQBZGAKWSA-N statine Chemical compound CC(C)C[C@H](N)[C@@H](O)CC(O)=O DFVFTMTWCUHJBL-BQBZGAKWSA-N 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
- C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Definitions
- compositions e.g., polypeptides, pharmaceutical compositions
- Spike e.g., SARS-CoV-2-Spike
- polypeptides e.g., antibodies and antigen binding fragments thereof
- an RBD of a betacoronavirus Spike glycoprotein e.g., an RBD of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoprotein.
- SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
- the polypeptides have one or more properties selected from: a broadly neutralizing activity against a plurality of known and predicted betacoronaviruses (e.g., past, present, emergent, and future betacoronaviruses), and a binding affinity for an RBD epitope (e.g., RBD class 4 epitope) that is highly conserved across a plurality of betacoronaviruses.
- a polypeptide has a broadly neutralizing activity against a plurality of known and predicted betacoronaviruses, and a binding affinity for an RBD domain epitope (e.g., RBD class 4 epitope) that is highly conserved across a plurality of betacoronaviruses.
- the disclosure provides, among other things, polypeptides that specifically bind SARS-CoV-2-Spike, wherein the polypeptide comprises a paratope that is substantially similar to a paratope of an antibody comprising a V H /V L pair selected from: SEQ ID NO:4 and SEQ ID NO:9 (AB-1a); SEQ ID NO:4 and SEQ ID NO:10 (AB-1b); SEQ ID NO:4 and SEQ ID NO:11 (AB-1c); SEQ ID NO:4 and SEQ ID NO:12 (AB-1d); SEQ ID NO:5 and SEQ ID NO:13 (AB-2a); SEQ ID NO:5 and SEQ ID NO:14 (AB-2b); SEQ ID NO:5 and SEQ ID NO:15 (AB-2c); - 2 - 3839034.v1 5708.1076005 SEQ ID NO:5 and SEQ ID NO:16 (AB-2d); SEQ ID NO:6 and SEQ ID NO:17 (AB-3a); SEQ ID NO:
- the disclosure provides, among other things, polypeptides that specifically bind SARS-CoV-2-Spike, wherein the polypeptide comprises a paratope that is substantially similar to a paratope of an antibody comprising a V H /V L pair selected from: SEQ ID NO:4 and SEQ ID NO:9 (AB-1a); SEQ ID NO:4 and SEQ ID NO:10 (AB-1b); SEQ ID NO:4 and SEQ ID NO:11 (AB-1c); SEQ ID NO:4 and SEQ ID NO:12 (AB-1d); SEQ ID NO:5 and SEQ ID NO:13 (AB-2a); SEQ ID NO:5 and SEQ ID NO:14 (AB-2b); SEQ ID NO:5 and SEQ ID NO:15 (AB-2c); SEQ ID NO:5 and SEQ ID NO:16 (AB-2d); SEQ ID NO:6 and SEQ ID NO:17 (AB-3a); SEQ ID NO:6 and SEQ ID NO:18 (AB-3b); SEQ ID NO:
- the disclosure also provides, among other things, a polypeptide that specifically binds SARS-CoV-2-Spike, wherein the polypeptide comprises: an immunoglobulin heavy chain variable domain (V H ) amino acid sequence comprising a heavy chain complementarity determining region 1 (HCDR1), a heavy chain complementarity determining region 2 (HCDR2) and a heavy chain complementarity determining region 3 (HCDR3) that are substantially similar to an HCDR1, an HCDR2 and an HCDR3, respectively, of SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6; and an immunoglobulin light chain variable domain (V L ) amino acid sequence comprising a light chain complementarity determining region 1 (LCDR1), a light chain complementarity - 3 - 3839034.v1 5708.1076005 determining region 2 (LCDR2) and a light chain complementarity determining region 3 (LCDR3) that are substantially similar to an LCDR1, an LCDR2 and an LCDR3,
- the disclosure also provides, among other things, a polypeptide that specifically binds SARS-CoV-2-Spike, wherein the polypeptide comprises: an immunoglobulin heavy chain variable domain (V H ) amino acid sequence comprising a heavy chain complementarity determining region 1 (HCDR1), a heavy chain complementarity determining region 2 (HCDR2) and a heavy chain complementarity determining region 3 (HCDR3) that are substantially similar to an HCDR1, an HCDR2 and an HCDR3, respectively, of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:89 or SEQ ID NO:90; and an immunoglobulin light chain variable domain (V L ) amino acid sequence comprising a light chain complementarity determining region 1 (LCDR1), a light chain complementarity determining region 2 (LCDR2) and a light chain complementarity determining region 3 (LCDR3) that are substantially similar to an LCDR1, an LCDR2 and an LCDR3, respectively, of SEQ ID
- a polypeptide disclosed herein comprises an HCDR1, HCDR2 and HCDR3, and an LCDR1, LCDR2 and LCDR3, of an antibody comprising an amino acid sequence selected from: SEQ ID NO:4 and SEQ ID NO:9 (AB-1a); SEQ ID NO:4 and SEQ ID NO:10 (AB-1b); SEQ ID NO:4 and SEQ ID NO:11 (AB-1c); SEQ ID NO:4 and SEQ ID NO:12 (AB-1d); SEQ ID NO:5 and SEQ ID NO:13 (AB-2a); SEQ ID NO:5 and SEQ ID NO:14 (AB-2b); SEQ ID NO:5 and SEQ ID NO:15 (AB-2c); SEQ ID NO:5 and SEQ ID NO:16 (AB-2d); SEQ ID NO:6 and SEQ ID NO:17 (AB-3a); SEQ ID NO:6 and SEQ ID NO:18 (AB-3b); SEQ ID NO:6 and SEQ ID NO:19 (AB-3c); or
- a polypeptide disclosed herein comprises an HCDR1, HCDR2 and HCDR3, and an LCDR1, LCDR2 and LCDR3, of an antibody comprising an amino acid sequence selected from: SEQ ID NO:4 and SEQ ID NO:9 (AB-1a); SEQ ID NO:4 and SEQ ID NO:10 (AB-1b); SEQ ID NO:4 and SEQ ID NO:11 (AB-1c); SEQ ID NO:4 and SEQ ID NO:12 (AB-1d); SEQ ID NO:5 and SEQ ID NO:13 (AB-2a); SEQ ID NO:5 and SEQ ID NO:14 (AB-2b); SEQ ID NO:5 and SEQ ID NO:15 (AB-2c); SEQ ID NO:5 and SEQ ID NO:16 (AB-2d); SEQ ID NO:6 and SEQ ID NO:17 (AB-3a); SEQ ID NO:6 and SEQ ID NO:18 (AB-3b); SEQ ID NO:6 and SEQ ID NO:19 (AB-3c); SEQ ID NO:4 and SEQ
- a polypeptide disclosed herein comprises a paratope that is identical to a paratope of an antibody comprising an amino acid sequence selected from: SEQ ID NO:4 and SEQ ID NO:9 (AB-1a); SEQ ID NO:4 and SEQ ID NO:10 (AB-1b); SEQ ID NO:4 and SEQ ID NO:11 (AB-1c); SEQ ID NO:4 and SEQ ID NO:12 (AB-1d); SEQ ID NO:5 and SEQ ID NO:13 (AB-2a); SEQ ID NO:5 and SEQ ID NO:14 (AB-2b); SEQ ID NO:5 and SEQ ID NO:15 (AB-2c); SEQ ID NO:5 and SEQ ID NO:16 (AB-2d); SEQ ID NO:6 and SEQ ID NO:17 (AB-3a); SEQ ID NO:6 and SEQ ID NO:18 (AB-3b); SEQ ID NO:6 and SEQ ID NO:19 (AB-3c); or SEQ ID NO:6 and SEQ ID NO:9 (AB-1a); SEQ
- a polypeptide disclosed herein comprises a paratope that is identical to a paratope of an antibody comprising an amino acid sequence selected from: SEQ ID NO:4 and SEQ ID NO:9 (AB-1a); SEQ ID NO:4 and SEQ ID NO:10 (AB-1b); SEQ ID NO:4 and SEQ ID NO:11 (AB-1c); SEQ ID NO:4 and SEQ ID NO:12 (AB-1d); SEQ ID NO:5 and SEQ ID NO:13 (AB-2a); SEQ ID NO:5 and SEQ ID NO:14 (AB-2b); SEQ ID NO:5 and SEQ ID NO:15 (AB-2c); SEQ ID NO:5 and SEQ ID NO:16 (AB-2d); SEQ ID NO:6 and SEQ ID NO:17 (AB-3a); SEQ ID NO:6 and SEQ ID NO:18 (AB-3b); SEQ ID NO:6 and SEQ ID NO:19
- the disclosure further provides, among other things, a polypeptide that comprises a V H comprising SEQ ID NO:2, wherein: X 1 is not G; X 2 is not I; X 3 is not F; X 4 is not N; X 5 is not M; X 6 is not S; X 7 is not M; X 8 is not N; X 9 is not G; X 10 is not N; X 11 is not I; or any combination of the foregoing.
- a polypeptide disclosed herein comprises a V L comprising SEQ ID NO:7, wherein: X 12 is not N; - 6 - 3839034.v1 5708.1076005 X 13 is not D; X 14 is not C; X 15 is not N; X 16 is not S; X 17 is not L; X 18 is not S; X 19 is not G; X 20 is not N; or any combination of the foregoing.
- the disclosure provides a polypeptide that specifically binds SARS-CoV-2-Spike, comprising: a V H sequence that has at least 70% sequence identity to SEQ ID NO:3; or a V L sequence that has at least 70% sequence identity to SEQ ID NO:8; or a combination thereof, wherein the V H sequence does not comprise SEQ ID NO:3, the V L sequence does not comprise SEQ ID NO:8, or both.
- a polypeptide disclosed herein is a fusion protein.
- the disclosure provides a polynucleotide encoding a polypeptide disclosed herein, a vector comprising such polynucleotide, and a host cell comprising such polynucleotide and/or vector.
- the disclosure provides methods of treating a patient and/or subject in need thereof (e.g., a subject having a SARS-CoV infection, such as COVID-19), comprising administering to the subject an effective amount (e.g., a therapeutically effective amount) of one or more polypeptides disclosed herein and/or a composition (e.g., pharmaceutical composition) comprising one or more polypeptides disclosed herein.
- the disclosure provides uses of one or more polypeptides disclosed herein in the manufacture of a medicament for treating a patient and/or subject in need thereof (e.g., a subject having a SARS-CoV infection, such as COVID-19).
- the disclosure provides pharmaceutical compositions for use in a method of treating an infection (e.g., a SARS-CoV infection, such as a COVID-19 infection) in a subject, comprising one or more polypeptides disclosed herein and/or a composition (e.g., pharmaceutical composition) comprising one or more polypeptides disclosed herein, the method comprising administering an effective amount (e.g., a therapeutically effective amount) of one or - 7 - 3839034.v1 5708.1076005 more polypeptides disclosed herein and/or a composition (e.g., pharmaceutical composition) comprising one or more polypeptides disclosed herein (e.g., for a time sufficient to treat the infection).
- an effective amount e.g., a therapeutically effective amount
- the disclosure provides methods of neutralizing SARS-CoV-2 variants in a cell (e.g., a cell in a subject), comprising contacting the cell with an effective amount of a composition comprising a polypeptide disclosed herein or a composition (e.g., pharmaceutical composition) comprising a polypeptide disclosed herein.
- a composition comprising a polypeptide disclosed herein or a composition (e.g., pharmaceutical composition) comprising a polypeptide disclosed herein.
- FIG.1 depicts an alignment of non-limiting examples of heavy chain variable domain (V H ) amino acid sequences that are useful in polypeptides as disclosed herein.
- V H heavy chain variable domain
- HCDR heavy chain complementarity determining region amino acid sequences (indicated using boxes) are determined by ImMunoGeneTics (IMGT) numbering (www.imgt.org/IMGTScientificChart/Nomenclature/IMGT-FRCDRdefinition.html, also accessible at www.imgt.org/). Identical residues are represented by dots, and variable residues are represented by letters (designated throughout this disclosure by “X n ”) in the depicted sequences. Also see V H consensus sequence (SEQ ID NO:2) in Table 1. The antibody sequences were computationally generated using information from the sequence and structure of a reference polypeptide (Reference).
- FIG.2 depicts an alignment of non-limiting examples of light chain variable domain (V L ) amino acid sequences that are useful in polypeptides as disclosed herein.
- the light chain complementarity determining region (LCDR) amino acid sequences (indicated using boxes) are determined by IMGT numbering. Identical residues are represented by dots, and variable residues are represented by letters (designated throughout this disclosure by “X n ”) in the depicted sequences.
- V L consensus sequence SEQ ID NO:7 in Table 2.
- the antibody sequences were computationally generated using information from the sequence and structure of a reference polypeptide (Reference).
- FIGs.3A-3B show pseudovirus neutralization data of each antibody (represented as dot) expressed as the Log fold change (FC) of IC 50 values (i.e., log 10 (FC of IC 50 ) over a reference polypeptide (Reference) (FIG.3A) or percentage neutralization versus concentration (FIG.3B) for the indicated viruses.
- FIGs.4A-4B show pseudovirus neutralization data expressed as normalized signal versus concentration of antibody.
- Seeds refers to test antibodies that have been selected for project learning. Sotrovimab is a clinical-stage antibody.
- FIG.5A shows binding (expressed as Log EC 50 fold change over Sotrovimab) and pseudovirus neutralization data (expressed as percentage neutralization at 0.28 ⁇ g/ml) for BA.4/5, where each dot represents an antibody.
- FIG.5B shows neutralization data for BA.4/5 (expressed as percentage neutralization at 0.28 ⁇ g/ml) as a function of Hamming distance from Reference.
- FIG.6 shows developability of the top VS-341 hits (i.e., antibodies selected from Project Learning results).
- Benchmark comparison ranges 1 (Tm 1 >60 °C acceptable, Tm 1 50-60 °C may be acceptable, Tm 1 ⁇ 50°C outside acceptable range); 2 (SEC monomer level >95% acceptable, SEC monomer level 95% ⁇ 90% not applicable; SEC monomer level ⁇ 90% outside acceptable range); 3 (relative to PRO-18404, Z-score ⁇ 1 acceptable, Z-score 1 ⁇ 1.5 not applicable, Z-score >2 outside acceptable range; c.f.9.5 ⁇ 0.3 and 7.5 ⁇ 1.0 for PSR-DNA and PSR-Insulin of Bococizumab ctrl); 4 ( ⁇ shift ⁇ 10nm acceptable, ⁇ shift 10 ⁇ 15 nm not applicable, ⁇ shift >15 nm outside acceptable range); and 5 ( ⁇ % >-5% acceptable, ⁇ % -5 ⁇ -10% not applicable, ⁇ % ⁇ - 10% outside acceptable range).
- Ranges based on TSLP developability studies where appropriate, are arbitrary and separated at least by averaged std errors or SDs. Additional notes are as follows: a (Method optimization ongoing), *(Melting curve suggestive of the compromised Fab thermal stability), ⁇ (acceptable), (may be acceptable), **(outside acceptable range), and N/A (not applicable). Value +/- ranges are standard deviations for at least duplicates where available.
- FIGs.7A-7B show pseudovirus neutralization profiles of selected class 4 anti-RBD screening hits (AB-1a, AB-2a, AB-3a, AB-4a, AB-7) and Reference antibody for BA.4/5.
- FIGs.8A-8B show binding profiles of selected class 4 anti-RBD screening hits (AB- 3a, AB-4a) and clinical-stage antibodies (Sotrovimab, Bebtelovimab, AZD1061) to RBDs representative of Sarbecovirus clades expressed on yeasts.
- FIG.8C shows neutralization of a VSV-dG pseudovirus representative of SARS-CoV-2 BQ.1.1 by the class 4 anti-RBD screening hits AB-3a and clinical-stage antibodies (Sotrovimab, Bebtelovimab, AZD1061). SYNAGIS® was used as isotype control.
- FIGs.9A-9C shows pseudovirus neutralization profiles of AB-4a, a class 4 anti-RBD antibody identified in the variant set VS-341, and an anti-S2 monoclonal antibody alone and in combination, as well as clinical-stage antibodies Sotrovimab, Bebtelovimab, Cilgavimab + Tixagevimab (EVUSHELD®) for BA.4/5 (FIG.9A) and BA.4/5 + K444T (FIG.9B). SYNAGIS® was used as isotype control.
- FIG.9C reports respective EC 50 and EC 90 values as ng/ml.
- FIG.10A shows pseudovirus neutralization profiles of the class 4 anti-RBD hits AB- 3a, Sotrovimab and Bebtelovimab alone or combined with an anti-S2 monoclonal antibody (also tested alone) for BA.4/5 and BA.4/5 + K444T. SYNAGIS® was used as isotype control.
- FIG. 10B shows results of the neutralization profiles shown in FIG.10A reported as Area Under the Curve (AUC) and efficacy (% max neutralization).
- FIGs.11A is two graphs, and FIG.11B is a chart, showing that AB-3a combined with an anti-S2 antibody (“S2_AB-1”) demonstrates improved neutralization potency and efficacy against Omicron BQ.1.1 pseudovirus.
- FIGs.11A-11B show neutralization profiles. SYNAGIS® was used as isotype control. Standard deviation (SD) is applied as error bars in FIG.11A.
- FIG. 11C reports results shown in FIG.11A as EC 50 (95% confidence interval (CI)) and % median neutralization at 18 ⁇ g/ml (95% CI) values.
- FIG.11D is two graphs showing that an anti-S2 antibody (S2_AB-1) combined with class 4 anti-RBD antibody 3a (“RBD Class 4 mAb-3a” or “AB-3a”) demonstrates improved neutralization potency and efficacy against Omicron BQ.1.1 pseudovirus.
- the graphs are neutralization profiles. Synagis was used as isotype control. Standard error of the mean (SEM) is applied as error bars.
- FIGs.12A and 12B are graphs, and FIG.12C is a chart, showing that AB-4a combined with an anti-S2 antibody (“S2_AB-1”) demonstrates improved neutralization potency and efficacy against Delta and Omicron BA.5 live viruses.
- FIGs.12A and 12B show neutralization profiles against SARS-CoV-2 Delta and BA.5 live viruses, respectively.
- SYNAGIS® was used as isotype control. Standard deviation (SD) is applied as error bars in FIGs.12A and 12B.
- FIG.12C reports results shown in FIG.12A-12B as EC 50 (95% CI) and % median neutralization at 18 ⁇ g/ml (95% CI) values.
- FIGs.13A-13B show binding profiles of the class 4 anti-RBD molecule AB-2b and a clinical-stage antibody Bebtelovimab to RBDs representative of Sarbecovirus clades expressed on yeast. SYNAGIS® was used as isotype control.
- FIG.14A shows neutralization profiles of the class 4 anti-RBD molecule AB-2b in combination with an anti-S2 monoclonal antibody (S2_AB-1) or an isotype control, for SARS- - 10 - 3839034.v1 5708.1076005 CoV-2 D614G, Delta, BQ.1.1, or XBB.1.5. Also shown are neutralization profiles of S2_AB-1 or a clinical-stage antibody Bebtelovimab, in combination with the isotype control. SYNAGIS® was used as the isotype control.
- FIG.14B reports corresponding EC 50 values, EC 90 values, and 95% confidence intervals (95% CI) against the indicated pseudoviruses.
- FIG.15A shows neutralization profiles of the class 4 anti-RBD molecule AB-2b in combination with an anti-S2 monoclonal antibody (S2_AB-1) or an isotype control, for SARS- CoV-2 D614G, SARS-CoV-1, or WIV1. Also shown are neutralization profiles of S2_AB-1 or a clinical-stage antibody Bebtelovimab, in combination with the isotype control. SYNAGIS® was used as the isotype control.
- FIG.15B reports corresponding EC 90 values and 95% confidence intervals (95% CI) against the indicated pseudoviruses.
- FIGs. 15C-15D Neutralization of SARS-CoV-2 variants by Anti-S2 in combination with AB-2b.
- FIG.16 shows that AB-2b has comparable activity to sotrovimab V H /V L - hIgG1-LS in terms of lung viral titer reduction (as measured by TCID50) in a hamster challenge model with SARS-CoV-2 BA.2.
- a combination of AB-2b and S2_AB-1 achieved a much greater reduction in lung viral titer.
- FIGs.17A-17B depict structural analysis of AB-2b Fab binding to SARS-CoV-2 BA.1 RBD and related contact residues.
- FIG.17C is a low-pass filtered Cryo-EM map of the SARS-CoV-2 BA.1 spike trimer with AB-3a Fab binding RBD and anti-S2 antibody (S2_AB-1) binding S2 stem helix. Map is shown from a side profile and from below. Each of the presumptive Fabs is labeled.
- FIG.17D is a density-docked atomic model of the SARS-CoV-2 spike assembly with bound Fabs. Spike trimer: a high-resolution structure of the SARS-CoV-2 spike with the S2 stem helix resolved.
- AB-3a the designed model for AB-3a Fab.
- FIGs.18A-18B show neutralization of SARS-CoV-2 live virus variants by AB-2b in combination with S2_AB-1. Neutralization profiles of AB-2b + S2_AB-1 combination, as well as AB-2b, S2_AB-1, and bebtelovimab as single agents, and isotype control antibody against SARS-CoV-2 ancestral strain (Eng20 (WT)), Delta, BQ.1.1, XBB.1.1) live viruses are shown.
- the anti-Spike antibodies tested as single agents were combined with isotype at the same concentrations to control for overall mass of anti-Spike antibodies tested as combinations.
- the x- axis indicates the concentration of each individual antibody in the combinations, or of the antibody with the highest concentration if the concentrations differ.
- the results are reported as % neutralization and shown as mean ⁇ standard deviation (representative of one experiment, two to three technical replicates).
- AB-2b combined with S2_AB-1 demonstrates improved neutralization of SARS-CoV-2 Omicron BQ1.1 and XBB.1.1 live viruses.
- DETAILED DESCRIPTION [0046] A description of example embodiments follows. [0047] Several aspects of the disclosure are described below, with reference to examples for illustrative purposes only.
- a polypeptide includes a single polypeptide, and two or more polypeptides.
- the term “comprise,” and variations such as “comprises” and “comprising”, will be understood to imply the inclusion of, e.g., a stated integer or step or group of integers or steps, but not the exclusion of any other integer or step or group of integer or step.
- the term “comprising” can be substituted with the term “containing” or “including.”
- the term “consisting of” excludes any element, step, or ingredient not specified in the claim element.
- the term “consisting essentially of” does not exclude materials or steps that do not materially affect the basic and novel characteristics of the claim.
- Also provided herein are corresponding embodiments for each and every embodiment featuring the term “comprising,” “containing,” “including,” or “having,” wherein those terms are replaced by the term “consisting of” and/or “consisting essentially of”.
- the conjunctive term “and/or” between multiple recited elements is understood as encompassing both individual and combined options. For instance, where two elements are conjoined by “and/or,” a first option refers to the applicability of the first element without the second. A second option refers to the applicability of the second element without the first. A third option refers to the applicability of the first and second elements together. Any one of these options is understood to fall within the meaning, and, therefore, satisfy the requirement of the term “and/or” as used herein.
- an acceptable error range for a particular value depends, at least in part, on how the value is measured or determined, e.g., the limitations of the measurement system. For example, “about” can mean within an acceptable standard deviation, per the practice in the art. Alternatively, “about” can mean a range of ⁇ 20%, e.g., ⁇ 10%, ⁇ 5% or ⁇ 1% of a given value. It is to be understood that the term “about” can precede any particular value specified herein, except for particular values used in the Exemplification. When “about” precedes a range, as in “90-99.9%,” the term “about” should be read as applying to both given values of the range, such that “about 90-99.9%” means about 90% repeats to about 99.9%.
- polypeptide refers to a polymer of at least two amino acids covalently linked by an amide bond, regardless of length or post-translational modification (e.g., glycosylation or phosphorylation).
- a polypeptide can comprise any suitable L-and/or D-amino acid, for example, common ⁇ -amino acids (e.g., alanine, glycine, valine), non- ⁇ -amino acids (e.g., ⁇ -alanine, 4-aminobutyric acid, 6-aminocaproic acid, sarcosine, statine), and unusual amino acids (e.g., citrulline, homocitruline, homoserine, norleucine, norvaline, ornithine).
- the amino, carboxyl, and/or other functional groups on a polypeptide can be free (e.g., unmodified) or protected with a suitable protecting group.
- Suitable protecting groups for amino and carboxyl groups, and methods for adding or removing protecting groups are known in the art and are disclosed in, for example, Green and Wuts, “Protecting Groups in Organic Synthesis,” John Wiley and Sons, 1991.
- the functional groups of a polypeptide can also be derivatized (e.g., alkylated) or labeled (e.g., with a detectable label, such as a fluorogen or a hapten) using methods known in the art.
- a polypeptide can comprise one or more modifications (e.g., amino acid linkers, acylation, acetylation, amidation, methylation, terminal modifiers (e.g., cyclizing modifications), N-methyl- ⁇ -amino group substitution), if desired.
- a polypeptide can be an analog of a known and/or naturally-occurring peptide, for example, a peptide analog having conservative amino acid residue substitution(s).
- a “polynucleotide” is defined as a plurality of nucleotides and/or nucleotide analogs linked together in a single molecule.
- a polynucleotide - 14 - 3839034.v1 5708.1076005 disclosed herein comprises deoxyribonucleotides.
- the polynucleotide comprises ribonucleotides.
- Non-limiting examples of polynucleotides include single-, double- or multi-stranded DNA or RNA, DNA-RNA hybrids (e.g., each “T” position may be independently substituted by a “U” or vice versa), or a polymer comprising purine and pyrimidine bases, or other natural, chemically, or biochemically modified, non-natural, or derivatized nucleotide bases.
- sequence identity refers to the extent to which two nucleotide sequences have the same residues at the same positions when the sequences are aligned to achieve a maximal level of identity, expressed as a percentage. For sequence alignment and comparison, typically one sequence is designated as a reference sequence, to which test sequences are compared.
- Sequence identity between reference and test sequences is expressed as a percentage of positions across the entire length of the reference sequence where the reference and test sequences share the same nucleotide or amino acid upon alignment of the reference and test sequences to achieve a maximal level of identity.
- two sequences are considered to have 70% sequence identity when, upon alignment to achieve a maximal level of identity, the test sequence has the same nucleotide residue at 70% of the same positions over the entire length of the reference sequence.
- Alignment of sequences for comparison to achieve maximal levels of identity can be readily performed by a person of ordinary skill in the art using an appropriate alignment method or algorithm. In some instances, alignment can include introduced gaps to provide for the maximal level of identity. Examples include the local homology algorithm of Smith & Waterman, Adv.
- the sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the - 15 - 3839034.v1 5708.1076005 designated program parameters.
- a commonly used tool for determining percent sequence identity is Protein Basic Local Alignment Search Tool (BLASTP) available through National Center for Biotechnology Information, National Library of Medicine, of the United States National Institutes of Health. (Altschul et al., 1990).
- the term “substantially similar to” refers to a polypeptide disclosed herein that is substantially similar in amino acid sequence (e.g., has at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% of the amino acid residues amino acid sequence identity) and substantially preserves one or more functional properties of a specified polypeptide disclosed herein (e.g., AB-1).
- the one or more functional properties are selected from, without limitation, a substantially similar binding affinity, a substantially similar binding specificity, a substantially similar inhibitory activity, a substantially similar neutralization activity, and a substantially similar self-association property.
- CDR complementarity determining region
- Two antibodies are determined to have the same CDR as one another with respect to an HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and/or LCDR3, when the identity of that CDR is determined for both antibodies using the same method.
- the extent of the framework region and the CDRs of an antibody can be identified using one of several suitable methodologies that are well known in the art, for example, by the Kabat definition, the Chothia definition, the AbM definition, and/or the contact definition.
- the term “paratope” refers to a set of amino acid residues in an antibody or an antigen-binding fragment thereof that contribute to a binding interaction with an epitope of a target protein.
- the binding interaction can be a hydrogen bond, a salt bridge, a van der Waal interaction, an ionic bond or a combination thereof.
- a binding interaction may be direct, or indirect, e.g., via a coordinated intermediate molecule, such as an ion or water.
- the residues of a paratope in some embodiments, comprise only residues that are part of a defined CDR. In other embodiments, the residues of a paratope further comprise one or more residues that are not part of a defined CDR.
- antibody mimetic refers to polypeptides capable of mimicking an antibody’s ability to bind an antigen, but structurally differ from native antibody structures.
- antibody mimetics include, but not limited to, Adnectins, Affibodies, Affilins, Affimers, Affitins, Alphabodies, Anticalins, Avimers, DARPins, Fynomers, Kunitz domain peptides, monobodies, nanobodies, nanoCLAMPs, and Versabodies.
- K D also referred to as “binding constant,” “equilibrium dissociation constant” or “affinity constant,” is a measure of the extent of a reversible association between two molecular species (e.g., antibody and target protein) and includes both the actual binding affinity as well as the apparent binding affinity. Binding affinity can be determined using methods known in the art including, for example, by measurement of surface plasmon resonance, e.g., using a Biolayer interferometry (Octet, ForteBio) or a surface plasmon resonance (Biacore) system and assay.
- Binding affinity can be determined using methods known in the art including, for example, by measurement of surface plasmon resonance, e.g., using a Biolayer interferometry (Octet, ForteBio) or a surface plasmon resonance (Biacore) system and assay.
- subject and “patient” are used herein interchangeably to refer to an animal (e.g., a mammal, such as a human) to be treated according to a method disclosed herein.
- a subject to be treated according to methods described herein may be one who has been diagnosed with a particular condition (e.g., COVID-19), or one at risk of developing such conditions.
- Diagnosis may be performed by any method or technique known in the art.
- a subject to be treated according to the present disclosure may have been - 17 - 3839034.v1 5708.1076005 subjected to standard tests or may have been identified, without examination, as one at risk due to the presence of one or more risk factors associated with the disease or condition.
- pharmaceutically acceptable means that the substance or composition the phrase modifies is, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, and are commensurate with a reasonable benefit/risk ratio.
- the term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of mammals without undue toxicity, irritation, allergic response, and the like, and are commensurate with a reasonable benefit/risk ratio.
- Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, the relevant teachings of which are incorporated herein by reference in their entirety.
- Pharmaceutically acceptable salts of the agents/compounds described herein include salts derived from suitable inorganic and organic acids, and suitable inorganic and organic bases.
- salts derived from suitable acids include salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid, or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art, such as ion exchange.
- inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid
- organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art, such as ion exchange.
- salts derived from suitable acids include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, cinnamate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, glutarate, glycolate, hemisulfate, heptanoate, hexanoate, hydroiodide, hydroxybenzoate, 2-hydroxy-ethanesulfonate, hydroxymaleate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate,
- Salts derived from appropriate bases include salts derived from inorganic bases, such as alkali metal, alkaline earth metal, and ammonium bases, and salts derived from aliphatic, alicyclic or aromatic organic amines, such as methylamine, trimethylamine and picoline, or N + ((C 1 -C 4 )alkyl) 4 salts.
- Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, barium and the like.
- compositions include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxyl, sulfate, phosphate, nitrate, lower alkyl sulfonate and aryl sulfonate.
- “Pharmaceutically acceptable carrier” refers to a non-toxic carrier or excipient that does not destroy the pharmacological activity of the agent with which it is formulated and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the agent.
- Pharmaceutically acceptable carriers that may be used in the compositions described herein include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.
- ion exchangers alumina, aluminum stearate, lecithin
- serum proteins such as human serum albumin
- buffer substances such as phosphates, glycine,
- Treating” or “treatment,” as used herein, refers to taking steps to deliver a therapy to a subject, such as a mammal, in need thereof (e.g., as by administering to a mammal one or more therapeutic agents). “Treating” or “treatment” includes inhibiting the disease or condition (e.g., as by slowing or stopping its progression or causing regression of the disease or condition) and relieving the symptoms resulting from the disease or condition. [0077] The term “treating,” or “treatment” refers to the medical management of a subject with the intent to improve, ameliorate, stabilize (i.e., not worsen), prevent, or cure a disease, pathological condition, or disorder—such as the particular indications exemplified herein.
- This term includes active treatment (treatment directed to improve the disease, pathological condition, or disorder), causal treatment (treatment directed to the cause of the associated disease, pathological condition, or disorder), palliative treatment (treatment designed for the relief of symptoms), preventative treatment (treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder); and - 19 - 3839034.v1 5708.1076005 supportive treatment (treatment employed to supplement another therapy). Treatment also includes diminishment of the extent of the disease or condition; preventing spread of the disease or condition; delay or slowing the progress of the disease or condition; amelioration or palliation of the disease or condition; and remission (whether partial or total), whether detectable or undetectable.
- “Ameliorating” or “palliating” a disease or condition means that the extent and/or undesirable clinical manifestations of the disease, disorder, or condition are lessened and/or time course of the progression is slowed or lengthened, as compared to the extent or time course in the absence of treatment. “Treatment” can also mean prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already with the condition or disorder, as well as those prone to have the condition or disorder or those in which the condition or disorder is to be prevented. [0078]
- a “pharmaceutical composition” refers to a formulation of one or more therapeutic agents and a medium generally accepted in the art for delivery of a biologically active agent to subjects, e.g., humans.
- a pharmaceutical composition may include one or more pharmaceutically acceptable excipients, diluents, or carriers.
- a pharmaceutical composition suitable for use in methods disclosed herein further comprises one or more pharmaceutically acceptable carriers.
- “Pharmaceutically acceptable carrier, diluent, or excipient” includes any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals.
- “Pharmaceutically acceptable carrier” refers to an ingredient in a pharmaceutical composition, other than an active ingredient, which is nontoxic to a subject.
- a pharmaceutically acceptable carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative.
- the carrier may be a diluent, adjuvant, excipient, or vehicle with which the agent (e.g., polynucleotide) is administered.
- Such vehicles may be liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like. For example, 0.4% saline and 0.3% glycine can be used.
- compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, stabilizing, - 20 - 3839034.v1 5708.1076005 thickening, lubricating, and coloring agents, etc.
- concentration of the agent in such pharmaceutical formulation may vary widely, i.e., from less than about 0.5%, to at least about 1%, or to as much as 15% or 20%, 25%, 30%, 35%, 40%, 45% or 50% by weight. The concentration will be selected primarily based on required dose, fluid volumes, viscosities, etc., according to the mode of administration.
- Suitable vehicles and formulations, inclusive of other human proteins, e.g., human serum albumin, are described, for example, in Remington: The Science and Practice of Pharmacy, 21 st Edition, Troy, D.B. ed., Lipincott Williams and Wilkins, Philadelphia, PA 2006, Part 5, Pharmaceutical Manufacturing: 691-1092 (e.g., pages 958-89).
- Non-limiting examples of pharmaceutically acceptable carriers are solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible, such as salts, buffers, antioxidants, saccharides, aqueous or non-aqueous carriers, preservatives, wetting agents, surfactants or emulsifying agents, or combinations thereof.
- Non-limiting examples of buffers are acetic acid, citric acid, formic acid, succinic acid, phosphoric acid, carbonic acid, malic acid, aspartic acid, histidine, boric acid, Tris buffers, HEPPSO, and HEPES.
- Non-limiting examples of antioxidants are ascorbic acid, methionine, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite, lecithin, citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, and tartaric acid.
- Non-limiting examples of amino acids are histidine, isoleucine, methionine, glycine, arginine, lysine, L-leucine, tri-leucine, alanine, glutamic acid, L-threonine, and 2-phenylamine.
- Non-limiting examples of surfactants are polysorbates (e.g., polysorbate-20 or polysorbate-80); polyoxamers (e.g., poloxamer 188); Triton; sodium octyl glycoside; lauryl-, myristyl-, linoleyl-, or stearyl-sulfobetaine; lauryl-, myristyl-, linoleyl- or stearyl-sarcosine; linoleyl-, myristyl-, or cetyl-betaine; lauroamidopropyl-, cocamidopropyl-, linoleamidopropyl-, myristamidopropyl-, palmidopropyl-, or isostearamidopropyl-betaine (e.g., lauroamidopropyl); myristamidopropyl-, palmidopropyl-, or
- Non-limiting examples of preservatives are phenol, m-cresol, p-cresol, o-cresol, chlorocresol, benzyl alcohol, phenylmercuric nitrite, phenoxyethanol, formaldehyde, chlorobutanol, magnesium chloride, alkylparaben (methyl, ethyl, propyl, butyl, and the like), - 21 - 3839034.v1 5708.1076005 benzalkonium chloride, benzethonium chloride, sodium dehydroacetate, and thimerosal, or mixtures thereof.
- Non-limiting examples of saccharides are monosaccharides, disaccharides, trisaccharides, polysaccharides, sugar alcohols, reducing sugars, nonreducing sugars such as glucose, sucrose, trehalose, lactose, fructose, maltose, dextran, glycerin, dextran, erythritol, glycerol, arabitol, sylitol, sorbitol, mannitol, mellibiose, melezitose, raffinose, mannotriose, stachyose, maltose, lactulose, maltulose, glucitol, maltitol, lactitol, or iso-maltulose.
- nonreducing sugars such as glucose, sucrose, trehalose, lactose, fructose, maltose, dextran, glycerin, dextran, erythritol, g
- Non-limiting examples of salts are acid addition salts and base addition salts.
- Acid addition salts include those derived from nontoxic inorganic acids, such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydroiodic, phosphorous, and the like, as well as from nontoxic organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, aromatic acids, aliphatic and aromatic sulfonic acids, and the like.
- Base addition salts include those derived from alkaline earth metals, such as sodium, potassium, magnesium, calcium, and the like, as well as from nontoxic organic amines, such as N,N’-dibenzylethylenediamine, N-methylglucamine, chloroprocaine, choline, diethanolamine, ethylenediamine, procaine, and the like.
- the salt is sodium chloride (NaCl).
- Agents e.g., polynucleotides
- described herein may be prepared in accordance with standard procedures and are administered at dosages that are selected to reduce, prevent, or eliminate, or to slow or halt progression of, a condition being treated (see, e.g., Remington’s Pharmaceutical Sciences, Mack Publishing Company, Easton, PA, and Goodman and Gilman’s The Pharmaceutical Basis of Therapeutics, McGraw-Hill, New York, N.Y., the contents of which are incorporated herein by reference, for a general description of methods for administering various agents for human therapy).
- administering refers to providing a compound, composition, or pharmaceutically acceptable salt thereof described herein to a subject in need of treatment or prevention.
- Administering can be performed, for example, once, a plurality of times, and/or over one or more extended periods.
- Administration includes both direct administration (including self-administration), and indirect administration (including an act of prescribing a drug or directing a subject to consume an agent).
- one e.g., a physician who instructs a subject (e.g., a human patient) to self-administer an agent (e.g., a drug), or to have an agent administered by another and/or who provides a patient with a prescription for a drug is administering an agent to a subject.
- a subject e.g., a human patient
- an agent e.g., a drug
- administering an agent to a subject e.g., a subject who instructs a subject to self-administer an agent (e.g., a drug), or to have an agent administered by another and/or who provides a patient with a prescription for a drug is administering an agent to a subject.
- a therapeutically effective amount refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic result (e.g., treatment, healing, inhibition or amelioration of physiological response or condition, etc.).
- a full therapeutic effect does not necessarily occur by administration of one dose and may occur only after administration of a series of doses.
- a therapeutically effective amount may be administered in one or more administrations.
- a therapeutically effective amount may vary according to factors such as the disease state, age, sex, and weight of a mammal (e.g., a human patient), mode of administration, and the ability of a therapeutic or a combination of therapeutics to elicit a desired response.
- An effective amount of an agent to be administered can be determined by a clinician of ordinary skill using the guidance provided herein and other methods known in the art.
- suitable dosages can be from about 0.001 mg/kg to about 100 mg/kg, from about 0.01 mg/kg to about 100 mg/kg, from about 0.01 mg/kg to about 10 mg/kg, from about 0.01 mg/kg to about 1 mg/kg body weight per treatment. Determining the dosage for a particular agent, subject and disease is well within the abilities of one of skill in the art. Preferably, the dosage does not cause or produces minimal adverse side effects. [0093] Desired response or desired results include effects at the cellular level, tissue level, or clinical results.
- a therapeutically effective amount or synonym thereto depends upon the context in which it is being applied. For example, in some embodiments it is an amount of the composition sufficient to achieve a treatment response as compared to the response obtained without administration of the composition. In other embodiments, it is an amount that results in a beneficial or desired result in a subject as compared to a control. As defined herein, a therapeutically effective amount of a composition (e.g., a pharmaceutical composition) disclosed herein may be readily determined by one of ordinary skill by routine methods known in the art. Dosage regimen and route of administration may be adjusted to provide the optimum therapeutic response.
- each of the various individual and collective combinations and permutations of these compounds may not be explicitly disclosed, each is specifically contemplated and described herein.
- a class of elements A, B, and C are disclosed as well as a class of elements D, E, and F and an example of a combination of elements A-D is disclosed, then, even if each is not individually recited, each is individually and collectively contemplated.
- each of the combinations A-E, A-F, B-D, B-E, B-F, C-D, C-E, and C-F are specifically contemplated and should be considered disclosed from disclosure of A, B, and C; D, E, and F; and the example combination A-D.
- any subset or combination of these is also specifically contemplated and disclosed.
- the sub-groups of A-E, B-F, and C-E are specifically contemplated and should be considered disclosed from disclosure of A, B, and C; D, E, and F; and the example combination A-D.
- This concept applies to all aspects of this application, including elements of a composition of matter and steps of method of making or using the compositions.
- a polypeptide has one or more properties selected from: a broadly neutralizing activity against a plurality of known and predicted betacoronaviruses (e.g., past, present, emergent, and future betacoronaviruses), a binding affinity for an RBD domain epitope (e.g., RBD class 4 epitope) that is highly conserved across a plurality of betacoronaviruses, and an inhibitory activity against potential emerging betacoronavirus escape variants.
- a polypeptide specifically binds the RBD of a sarbecovirus (e.g., a SARS-CoV-1 virus, a SARS-CoV-2 virus) Spike protein.
- a polypeptide specifically binds the RBD of a SARS-CoV- 1 virus (e.g., a plurality of SARS-CoV-1 variants) Spike protein.
- a polypeptide specifically binds the RBD of a SARS-CoV-2 virus (e.g., a plurality of SARS-CoV- - 24 - 3839034.v1 5708.1076005 2 variants) Spike protein.
- a polypeptide specifically binds the RBD of a SARS-CoV-1 virus (e.g., a plurality of SARS-CoV-1 variants) Spike protein and the RBD of a SARS-CoV-2 virus (e.g., a plurality of SARS-CoV-2 variants) spike protein.
- a polypeptide has a broadly neutralizing activity (e.g., as measured using a neutralization assay described herein or otherwise known to those of ordinary skill the art) against a plurality of betacoronaviruses.
- a polypeptide has neutralizing activity against a plurality of sarbecoviruses (e.g., SARS-CoV-1 viruses, SARS- CoV-2 viruses). In some embodiments, a polypeptide has neutralizing activity against a plurality of SARS-CoV-1 viruses (e.g., a plurality of SARS-CoV-1 variants). In some embodiments, a polypeptide has neutralizing activity against a plurality of SARS-CoV-2 viruses (e.g., a plurality of SARS-CoV-2 variants).
- a polypeptide has neutralizing activity against a plurality of SARS-CoV-1 viruses (e.g., a plurality of SARS-CoV-1 variants) and a plurality of SARS-CoV-2 viruses (e.g., a plurality of SARS-CoV-2 variants).
- a polypeptide has a binding affinity for an RBD epitope (e.g., RBD class 4 epitope) that is conserved (e.g., highly conserved) across a plurality of betacoronaviruses.
- an RBD epitope is highly conserved across a plurality of sarbecoviruses (e.g., SARS-CoV-1 viruses, SARS-CoV-2 viruses). In some embodiments, an RBD epitope is highly conserved across a plurality of SARS-CoV-1 viruses (e.g., a plurality of SARS-CoV-1 variants). In some embodiments, an RBD epitope is highly conserved across a plurality of SARS-CoV-2 viruses (e.g., a plurality of SARS-CoV-2 variants).
- an RBD epitope is highly conserved across a plurality of SARS-CoV-1 viruses (e.g., a plurality of SARS-CoV-1 variants) and a plurality of SARS-CoV-2 viruses (e.g., a plurality of SARS-CoV-2 variants).
- SARS-CoV-2 is the causative agent of COVID-19.
- the genome of SARS-CoV-2 encodes the nucleoprotein (N), the membrane glycoprotein (M), the small envelope glycoprotein (E), and the spike protein (S), in addition to 16 non-structural proteins (Song et al., Cytokine storm induced by SARS-CoV-2, Clin Chim Acta.509:280-7 (2020)).
- SARS-CoV-2-Spike or S of the SARS-CoV-2, facilitates entry of the SARS-CoV-2 virus into a host cell, such as a human host cell.
- S is a trimer with protomers composed of S1 and S2 subunits.
- S1 contains an RBD that binds ACE2 receptors, and S2 is necessary for fusion of viral and host membranes.
- S A non-limiting example of a wildtype SARS-CoV-2-Spike (S) sequence is NCBI RefSeq YP_009724390 (SEQ ID NO:1).
- SARS-CoV-2-Spike includes wild-type SARS-CoV-2 Spike proteins (e.g., SEQ ID NO:1 (RefSeq YP_009724390) or homologs thereof) and truncated forms thereof, mutant and engineered versions of full-length and truncated SARS-CoV-2 Spike proteins, and modified forms (e.g., post-translationally modified forms) of full-length and truncated SARS- CoV-2 Spike proteins.
- a polypeptide binds to a SARS-CoV-2 Spike protein comprising SEQ ID NO:1.
- a polypeptide binds to a mutant, engineered and/or modified form of SARS-CoV-2-Spike.
- a mutant, engineered or modified form of SARS-CoV-2-Spike comprises an amino acid sequence that has at least about 90% sequence identity to a wildtype SARS-CoV-2-Spike sequence (e.g., SEQ ID NO:1), for example, having at - 26 - 3839034.v1 5708.1076005 least about: 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to a wildtype SARS-CoV-2-Spike sequence.
- a mutant, engineered or modified form of SARS-CoV-2-Spike comprises an amino acid sequence that has about: 90-99.9%, 90-99.8%, 92-99.8%, 92-99.6%, 94-99.6%, 94-99.5%, 95-99.5%, 95-99.4%, 96-99.4%, 96-99.2%, 97-99.2%, or 97-99% sequence identity to a wildtype SARS-CoV-2-Spike sequence (e.g., SEQ ID NO:1).
- a mutant, engineered, or modified form of SARS-CoV-2- Spike comprises, relative to SEQ ID NO:1, one or more mutations selected from: L5F, S13I, T19R, A67V, del69, del70, del69-70, D80G, T95I, G142D, del142-144, del144, Y145D, W152C, E154K, F157S, del211, L212I, ins214EPE, A222V, D253G, G261D, G339D, V367F, S371L, S371L, S373P, S375F, K417N, N439K, N440K, G446S, L452R, Y453F, S477N, T478K, E484A, E484K, E484Q, F486L, S494P, Q493R, G496S, Q498R, N501
- a mutant, engineered, or modified form of SARS-CoV-2- Spike comprises, relative to SEQ ID NO:1, one or more mutations selected from: 69del, 70del, 144del, E484K, S494P, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H, or K1191N, or a combination thereof.
- a mutant, engineered, or modified form of SARS-CoV-2-Spike comprises 69del, 70del, 144del, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H.
- a mutant, engineered or modified form of SARS- CoV-2-Spike further comprises E484K, S494P, or K1191N, or a combination thereof.
- a mutant, engineered, or modified form of SARS-CoV-2- Spike comprises, relative to SEQ ID NO:1, one or more mutations selected from: D80A, D215G, 241del, 242del, 243del, K417N, E484K, N501Y, D614G, or A701V, or a combination thereof.
- a mutant, engineered or modified form of SARS-CoV-2-Spike comprises D80A, D215G, 241del, 242del, 243del, K417N, E484K, N501Y, D614G, and A701V.
- a mutant, engineered, or modified form of SARS-CoV-2- Spike comprises, relative to SEQ ID NO:1, one or more mutations selected from: T19R, G142D, 156del, 157del, R158G, L452R, T478K, D614G, P681R, or D950N, or a combination thereof.
- a mutant, engineered, or modified form of SARS-CoV-2-Spike comprises - 27 - 3839034.v1 5708.1076005 T19R, 156del, 157del, R158G, L452R, T478K, D614G, P681R, and D950N.
- a mutant, engineered, or modified form of SARS-CoV-2-Spike further comprises G142D.
- a mutant, engineered, or modified form of SARS-CoV-2- Spike comprises, relative to SEQ ID NO:1, one or more mutations selected from: 69del, 70del, 144del, A222V, G261D, V367F, K417N, N439K, Y453F, S477N, E484K, F486L, N501T, N501Y, A570D, or D614G, or a combination thereof.
- a mutant, engineered, or modified form of SARS-CoV-2- Spike comprises, relative to SEQ ID NO:1, one or more mutations selected from: E484K, N501Y, or D614G, or a combination thereof.
- a mutant, engineered, or modified form of SARS-CoV-2 Spike protein comprises, relative to SEQ ID NO:1, one or more mutations selected from: F817P, A892P, A899P, A942P, K986P, or V987P, or a combination thereof.
- a mutant, engineered, or modified form of SARS-CoV-2 Spike protein comprises, relative to SEQ ID NO:1, one or more mutations selected from: L452R, F486V, or R493Q, or a combination thereof.
- a mutant, engineered, or modified form of SARS-CoV-2 Spike protein comprises, relative to SEQ ID NO:1, one or more mutations selected from: A67V, del69-70, T95I, del142-144, Y145D, del211, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, or L981F, or a combination thereof.
- the modified SARS-CoV-2 Spike protein comprises, relative to SEQ ID NO:1, one or more mutations selected from: T19I, del24-26, A27S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, or N969K, or a combination thereof.
- the modified SARS-CoV-2 Spike protein comprises, relative to SEQ ID NO:1, one or more mutations selected from: T19I, del24-26, A27S, del69-70, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, or N969K, or a combination thereof.
- the modified SARS-CoV-2 Spike protein comprises, relative to SEQ ID NO:1, one or more mutations selected from: T19I, del24-26, A27S, del69-70, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, K444T, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, or N969K, or a combination thereof.
- a modified SARS-CoV-2 Spike protein comprises, relative to SEQ ID NO:1, one or more mutations selected from: T19I, del24-26, A27S, del69-70, G142D, V213G, G339D, R346T, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, K444T, L452R, N460K, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, or N969K, or a combination thereof.
- Additional modified SARS-CoV-2 Spike proteins can be found at https://covariants.org/shared-mutations, the contents of which are incorporated herein by reference.
- Non-limiting examples include Alpha, Beta, Gamma, Delta, Kappa, Epsilon, Eta, Iota, Lambda, Mu, and/or Omicron, for example, B.1, B.1.1, B.1.1.1, B.1.1.529, B.1.1.7, B.1.177, B.1.2, B.1.351, B.1.427/429, B.1.525, B.1.526, B.1.617.1,B.1.617.2, B.1.621, BA.1, BA.1.1, BA.2, BA.2.12.1, BA.2.75, BA.2.75.2, BA.3, BA.4, BA.4/5, BA.4/5+K444T, BA.4.6, BA.5, BA.5.2.6, BF.7, BF.11, BN.1, BQ.1, BQ.1.1, C.37, D.2, GA.5,
- a polypeptide binds to a RBD of a SARS-CoV-2 Spike (S) protein.
- RBD includes full-length RBD (e.g., having the amino acid sequence of SEQ ID NO:46 or homologs thereof) and truncated forms thereof, mutant and engineered versions of full-length and truncated RBD (e.g., an epitope within the RBD (e.g., RBD class 4 epitope)), and modified forms (e.g., post-translationally modified forms) of full-length and truncated RBD.
- full-length RBD e.g., having the amino acid sequence of SEQ ID NO:46 or homologs thereof
- mutant and engineered versions of full-length and truncated RBD e.g., an epitope within the RBD (e.g., RBD class 4 epitope)
- modified forms e.g., post-translationally modified forms
- a polypeptide binds SARS-CoV-1-Spike (e.g., of CoV-1 and/or WIV1) and/or SARS-CoV-2-Spike (e.g., of Alpha, Beta, Gamma, Delta, Kappa, Epsilon, Eta, Iota, Lambda, Mu, and/or Omicron, for example, AY.3, AY.4, AY.41, AY.44, AY.64, AY.103, B.1, B.1.1, B.1.1.1, B.1.1.529, B.1.1.7, B.1.177, B.1.2, B.1.351, B.1.427/429, B.1.525, B.1.526, B.1.533, B.1.617.1, B.1.617.2, B.1.621, BA.1, BA.1.1, BA.1.15, BA.1.17.2, BA.2, BA.2+P1162L, and BA.2+P1162S, BA.2.3.20, BA
- a polypeptide binds SARS- CoV-1-Spike (e.g., of CoV-1 and/or WIV1) and/or SARS-CoV-2-Spike (e.g. of Alpha, Beta, Gamma, Delta, Kappa, Epsilon, Eta, Iota, Lambda, Mu, and/or Omicron, for example, AY.3, AY.4, AY.41, AY.44, AY.64, AY.103, B.1, B.1.1, B.1.1.1, B.1.1.529, B.1.1.7, B.1.177, B.1.2, B.1.351, B.1.427/429, B.1.525, B.1.526, B.1.533, B.1.617.1, B.1.617.2, B.1.621, BA.1, BA.1.1, BA.1.15, BA.1.17.2, BA.2, BA.2+P1162L, and BA.2+P1162S, BA.2.3.20, BA.2.10, BA
- a polypeptide binds to a mutant, engineered, or modified form of an RBD.
- a mutant, engineered, or modified form of an RBD comprises an amino acid sequence that has at least about 90% sequence identity to a wild-type full length RBD (e.g., SEQ ID NO:46), for example, having at least about: 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity.
- sequence identity is about: 90-99.9%, 90-99.8%, 92-99.8%, 92-99.6%, 94-99.6%, 94-99.5%, 95-99.5%, 95-99.4%, 96-99.4%, 96-99.2%, 97- 99.2%, or 97-99%.
- a mutant, engineered or modified form of SARS- CoV-2-Spike comprises an amino acid sequence that has about: 90-99.9%, 90-99.8%, 92-99.8%, 92-99.6%, 94-99.6%, 94-99.5%, 95-99.5%, 95-99.4%, 96-99.4%, 96-99.2%, 97-99.2%, or 97- 99% sequence identity to a wildtype full length RBD (e.g., SEQ ID NO:46).
- Comparator Polypeptides refers to a polypeptide (e.g., immunoglobulin molecule) that specifically binds to a SARS-CoV-2-Spike and is not a polypeptide of the disclosure.
- the sequence of a comparator polypeptide and a polypeptide of the disclosure may be compared to illustrate structural differences between them (e.g., differences at one or more amino acid positions, such as amino acid substitutions).
- Polypeptides of the disclosure have more than insubstantial differences (e.g., one or more substantial differences) in comparison to a comparator polypeptide, such that, polypeptides disclosed herein will, under controlled conditions, exhibit one or more (i.e., one, two, or all three) of: a different function, in a different way, to achieve a different result, in comparison to a comparator polypeptide.
- a comparator polypeptide may vary from a polypeptide of the disclosure by one or more amino acids, e.g., in some embodiments, by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more amino acids.
- a comparator polypeptide diverges from a polypeptide of the disclosure by at least about: 0.4%, 0.8%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, or more amino acid percent identity.
- a comparator polypeptide is an antibody comprising: a) an immunoglobulin heavy chain variable (V H ) domain comprising a heavy chain complementarity determining region 1 (HCDR1), an HCDR2, and an HCDR3 amino acid sequences of SEQ ID NO:22, SEQ ID NO:26, and SEQ ID NO:31, respectively; b) an immunoglobulin light chain variable (V L ) domain comprising a light chain complementarity determining region 1 (LCDR1), an LCDR2, and an LCDR3 amino acid sequences of SEQ ID NO:35, SEQ ID NO:38, and SEQ ID NO:42, respectively; or both a) and b).
- a comparator polypeptide is an antibody comprising: a) a V H domain comprising an HCDR1, an HCDR2, and an HCDR3 sequences of SEQ ID NO:22, SEQ ID NO:26, and SEQ ID NO:31, respectively; and b) a V L domain comprising an LCDR1, an LCDR2, and an LCDR3 sequences of SEQ ID NO:35, SEQ ID NO:38, and SEQ ID NO:42, respectively. [00125] See Table 3 and FIGs.1-2 for SEQ ID NOs:22, 26, 31, 35, 38, 42.
- a comparator polypeptide is an antibody comprising: a) a V H domain comprising the amino acid sequence of SEQ ID NO:3; b) a V L domain comprising the amino acid sequence of SEQ ID NO:8, or both a) and b).
- a comparator polypeptide is an antibody comprising: a) a V H domain comprising the amino acid sequence of SEQ ID NO:3; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:8. - 31 - 3839034.v1 5708.1076005 [00128] See Table 1 and FIG.1 for SEQ ID NO:3. See Table 2 and FIG.2 for SEQ ID NO:8.
- a comparator polypeptide is an antibody referred to herein as the “Reference Antibody”, which comprises a V H domain comprising the amino acid sequence of SEQ ID NO:3, a V L domain comprising the amino acid sequence of SEQ ID NO:8, a heavy chain comprising the amino acid sequence of SEQ ID NO:47 and/or SEQ ID NO:48, and a light chain comprising the amino acid sequence of SEQ ID NO:49.
- the Reference Antibody binds SARS-CoV-2 RBD and neutralizes SARS-CoV-2 variants.
- a CDR (e.g., HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and/or LCDR3) can be a CDR defined by any art-recognized method for identifying CDR residues of an antibody, as described further herein (e.g., a CDR as defined by Kabat, a CDR as defined by Chothia, or a CDR as defined by IMGT).
- a polypeptide (e.g., an antibody or antigen-binding fragment thereof) does not comprise all six CDRs of an antibody that comprises a V H amino acid sequence - 32 - 3839034.v1 5708.1076005 of SEQ ID NO:3 and a V L amino acid sequence of SEQ ID NO:8.
- a polypeptide does not comprise all six sequences of SEQ ID NO:22, SEQ ID NO:26, SEQ ID NO:31, SEQ ID NO:35, SEQ ID NO:38, and SEQ ID NO:42.
- a polypeptide comprises fewer than six (e.g., 1, 2, 3, 4 or 5) CDRs of an antibody that comprises a V H amino acid sequence of SEQ ID NO:3 and a V L amino acid sequence of SEQ ID NO:8.
- a polypeptide comprises 1, 2, 3, 4 or 5 sequences, but not all 6 sequences, selected from SEQ ID NO:22, SEQ ID NO:26, SEQ ID NO:31, SEQ ID NO:35, SEQ ID NO:38, and SEQ ID NO:42.
- a polypeptide comprises all six CDRs of a specific polypeptide disclosed herein. In some embodiments, a polypeptide comprises fewer than six (e.g., 1, 2, 3, 4 or 5) of CDRs of a specific polypeptide disclosed herein.
- a polypeptide comprises: a) a V H domain comprising a heavy chain complementarity determining region 1 (HCDR1), an HCDR2, and an HCDR3 that are substantially similar (e.g., having at least about 90% sequence identity) in amino acid sequence to an HCDR1, an HCDR2, and an HCDR3, respectively, of a V H amino acid sequence set forth in any of SEQ ID NOs:4-6; b) a V L domain comprising a light chain complementarity determining region 1 (LCDR1), an LCDR2, and an LCDR3 that are substantially similar (e.g., having at least about 90% sequence identity) in amino acid sequence to an LCDR1, an LCDR2, and an LCDR3, respectively, of a V L amino acid sequence set forth in any of SEQ ID NOs:9-20; or both a) and b).
- HCDR1 heavy chain complementarity determining region 1
- HCDR3 substantially similar (e.g., having at least about 90% sequence identity) in amino acid sequence to an
- a polypeptide comprises: a) a V H domain comprising a heavy chain complementarity determining region 1 (HCDR1), an HCDR2, and an HCDR3 that are substantially similar (e.g., having at least about 90% sequence identity) in amino acid sequence to an HCDR1, an HCDR2, and an HCDR3, respectively, of a V H amino acid sequence set forth in any of SEQ ID NOs:4-6; - 33 - 3839034.v1 5708.1076005 b) a V L domain comprising a light chain complementarity determining region 1 (LCDR1), an LCDR2, and an LCDR3 that are substantially similar (e.g., having at least about 90% sequence identity) in amino acid sequence to an LCDR1, an LCDR2, and an LCDR3, respectively, of a V
- a polypeptide comprises: a) a V H domain comprising an HCDR1, an HCDR2, and an HCDR3 that substantially preserve one or more functional properties of an HCDR1, an HCDR2 and an HCDR3, respectively, of a V H amino acid sequence of any one or more of SEQ ID NOs:4-6; b) a V L domain comprising an LCDR1, an LCDR2, and an LCDR3 that substantially preserve one or more functional properties of an LCDR1, an LCDR2 and an LCDR3, respectively, of a V L amino acid sequence of any one or more of SEQ ID NOs:9-20; or both a) and b).
- a polypeptide comprises: a) a V H domain comprising an HCDR1, an HCDR2, and an HCDR3 that substantially preserve one or more functional properties of an HCDR1, an HCDR2 and an HCDR3, respectively, of a V H amino acid sequence of any one or more of SEQ ID NOs:4-6; and b ) a V L domain comprising an LCDR1, an LCDR2, and an LCDR3 that substantially preserve one or more functional properties of an LCDR1, an LCDR2 and an LCDR3, respectively, of a V L amino acid sequence of any one or more of SEQ ID NOs:9-20.
- a polypeptide comprises an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2, and an LCDR3 that substantially preserve one or more functional properties of an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2, and an LCDR3 of a polypeptide selected from any one of AB-1a, AB-1b, AB-1c, AB-1d, AB-2a, AB-2b, AB-2c, AB-2d, AB-3a, AB-3b, AB-3c, and AB-3d.
- a polypeptide comprises: a) a V H domain that comprises an HCDR1, an HCDR2, and an HCDR3 comprising only one or more conservative substitutions (e.g., only one or more highly - 34 - 3839034.v1 5708.1076005 conservative substitutions), relative to an HCDR1, an HCDR2 and an HCDR3, respectively, of a V H amino acid sequence of any one or more of SEQ ID NOs:4- 6; or b) a V L domain that comprises an LCDR1, an LCDR2, and an LCDR3 comprising only one or more conservative substitutions (e.g., only one or more highly conservative substitutions), relative to an LCDR1, an LCDR2 and an LCDR3, respectively, of a V L amino acid sequence of any one or more of SEQ ID NOs:9- 20, or both a) and b).
- a V H domain that comprises an HCDR1, an HCDR2, and an HCDR3 comprising only one or more conservative substitutions (e.g
- an amino acid substitution is a conservative substitution.
- the term “a conservative amino acid substitution” or “a conservative substitution” refers to an amino acid substitution having a value of 0 or greater in BLOSUM62.
- an amino acid substitution is a highly conservative substitution.
- the term “a highly conservative amino acid substitution” or “a highly conservative substitution” refers to an amino acid substitution having a value of at least 1 (e.g., at least 2) in BLOSUM62.
- a polypeptide comprises: a) a V H domain that comprises an HCDR1, an HCDR2, and an HCDR3 comprising only one or more conservative substitutions (e.g., only one or more highly conservative substitutions), relative to an HCDR1, an HCDR2 and an HCDR3, respectively, of a V H amino acid sequence of any one or more of SEQ ID NOs:4- 6; and b) a V L domain that comprises an LCDR1, an LCDR2, and an LCDR3 comprising only one or more conservative substitutions (e.g., only one or more highly conservative substitutions), relative to an LCDR1, an LCDR2 and an LCDR3, respectively, of a V L amino acid sequence of any one or more of SEQ ID NOs:9- 20.
- a polypeptide comprises: a) a V H domain that comprises an HCDR1, an HCDR2, and an HCDR3 comprising up to 1, 2, or 3 conservative substitutions (e.g., up to 1, 2, or 3 highly conservative substitutions), relative to an HCDR1, an HCDR2 and an HCDR3, respectively, of a V H amino acid sequence of any one or more of SEQ ID NOs:4-6; or - 35 - 3839034.v1 5708.1076005 b) a V L domain that comprises an LCDR1, an LCDR2, and an LCDR3 comprising up to 1, 2, or 3 conservative substitutions (e.g., up to 1, 2, or 3 highly conservative substitutions), relative to an LCDR1, an LCDR2 and an LCDR3, respectively, of a V L amino acid sequence of any one or more of SEQ ID NOs:9-20, or both a) and b).
- a V H domain that comprises an HCDR1, an HCDR2, and an HCDR3 comprising up to 1, 2, or
- a polypeptide comprises: a) a V H domain that comprises an HCDR1, an HCDR2, and an HCDR3 comprising up to 1, 2, or 3 conservative substitutions (e.g., up to 1, 2, or 3 highly conservative substitutions), relative to an HCDR1, an HCDR2 and an HCDR3, respectively, of a V H amino acid sequence of any one or more of SEQ ID NOs:4-6; and b) a V L domain that comprises an LCDR1, an LCDR2, and an LCDR3 comprising up to 1, 2, or 3 conservative substitutions (e.g., up to 1, 2, or 3 highly conservative substitutions), relative to an LCDR1, an LCDR2 and an LCDR3, respectively, of a V L amino acid sequence of any one or more of SEQ ID NOs:9-20.
- a polypeptide comprises: a) a V H domain that comprises an HCDR1, an HCDR2, and an HCDR3 having 100% sequence identity to an HCDR1, an HCDR2 and an HCDR3, respectively, of a V H amino acid sequence of any one or more of SEQ ID NOs:4-6; or b) a V L domain that comprises an LCDR1, an LCDR2, and an LCDR3 having 100% sequence identity to an LCDR1, an LCDR2 and an LCDR3, respectively, of a V L amino acid sequence of any one or more of SEQ ID NOs:9-20, or both a) and b).
- a polypeptide comprises: a) a V H domain that comprises an HCDR1, an HCDR2, and an HCDR3 having 100% sequence identity to an HCDR1, an HCDR2 and an HCDR3, respectively, of a V H amino acid sequence of any one or more of SEQ ID NOs:4-6; and b) a V L domain that comprises an LCDR1, an LCDR2, and an LCDR3 having 100% sequence identity to an LCDR1, an LCDR2 and an LCDR3, respectively, of a V L amino acid sequence of any one or more of SEQ ID NOs:9-20.
- a polypeptide comprises an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2, and an LCDR3, of an antibody comprising a V H /V L pair selected from: SEQ ID NO:4 and SEQ ID NO:9 (AB-1a); SEQ ID NO:4 and SEQ ID NO:10 (AB-1b); - 36 - 3839034.v1 5708.1076005 SEQ ID NO:4 and SEQ ID NO:11 (AB-1c); SEQ ID NO:4 and SEQ ID NO:12 (AB-1d); SEQ ID NO:5 and SEQ ID NO:13 (AB-2a); SEQ ID NO:5 and SEQ ID NO:14 (AB-2b); SEQ ID NO:5 and SEQ ID NO:15 (AB-2c); SEQ ID NO:5 and SEQ ID NO:16 (AB-2d); SEQ ID NO:6 and SEQ ID NO:17 (AB-3a); SEQ ID NO:6 and SEQ ID NO:18 (AB
- a polypeptide comprises: a) a V H domain comprising an HCDR1, an HCDR2, and an HCDR3 that are substantially similar (e.g., having at least about 90% sequence identity) in amino acid sequence to an HCDR1, an HCDR2 and an HCDR3, respectively, of a V H amino acid sequence of SEQ ID NO:5; b) a V L domain comprising an LCDR1, an LCDR2 and an LCDR3 that are substantially similar (e.g., having at least about 90% sequence identity) in amino acid sequence to an LCDR1, an LCDR2 and an LCDR3, respectively, of a V L amino acid sequence of SEQ ID NO:14, or both a) and b).
- a polypeptide comprises: a) a V H domain comprising an HCDR1, an HCDR2, and an HCDR3 that are substantially similar (e.g., having at least about 90% sequence identity) in amino acid sequence to an HCDR1, an HCDR2 and an HCDR3, respectively, of a V H amino acid sequence of SEQ ID NO:5; and b) a V L domain comprising an LCDR1, an LCDR2 and an LCDR3 that are substantially similar (e.g., having at least about 90% sequence identity) in amino acid sequence to an LCDR1, an LCDR2 and an LCDR3, respectively, of a V L amino acid sequence of SEQ ID NO:14.
- a polypeptide comprises: a) a V H domain comprising an HCDR1, an HCDR2, and an HCDR3 that substantially preserve one or more functional properties of an HCDR1, an - 37 - 3839034.v1 5708.1076005 HCDR2 and an HCDR3, respectively, of a V H amino acid sequence of SEQ ID NO:5; or b) a V L domain comprising an LCDR1, an LCDR2, and an LCDR3 that substantially preserve one or more functional properties of an LCDR1, an LCDR2 and an LCDR3, respectively, of a V L amino acid sequence of SEQ ID NO:14, or both a) and b).
- a polypeptide comprises: a) a V H domain comprising an HCDR1, an HCDR2, and an HCDR3 that substantially preserve one or more functional properties of an HCDR1, an HCDR2 and an HCDR3, respectively, of a V H amino acid sequence of SEQ ID NO:5; and b) a V L domain comprising an LCDR1, an LCDR2, and an LCDR3 that substantially preserve one or more functional properties of an LCDR1, an LCDR2 and an LCDR3, respectively, of a V L amino acid sequence of SEQ ID NO:14.
- a polypeptide comprises: a) a V H domain that comprises an HCDR1, an HCDR2, and an HCDR3 comprising only one or more conservative substitutions (e.g., only one or more highly conservative substitutions), relative to an HCDR1, an HCDR2 and an HCDR3, respectively, of a V H amino acid sequence of SEQ ID NO:5; or b) a V L domain that comprises an LCDR1, an LCDR2, and an LCDR3 comprising only one or more conservative substitutions (e.g., only one or more highly conservative substitutions), relative to an LCDR1, an LCDR2 and an LCDR3, respectively, of a V L amino acid sequence of SEQ ID NO:14, or both a) and b).
- a polypeptide comprises: a) a V H domain that comprises an HCDR1, an HCDR2, and an HCDR3 comprising only one or more conservative substitutions (e.g., only one or more highly conservative substitutions), relative to an HCDR1, an HCDR2 and an HCDR3, respectively, of a V H amino acid sequence of SEQ ID NO:5; and b) a V L domain that comprises an LCDR1, an LCDR2, and an LCDR3 comprising only one or more conservative substitutions (e.g., only one or more highly conservative substitutions), relative to an LCDR1, an LCDR2 and an LCDR3, respectively, of a V L amino acid sequence of SEQ ID NO:14.
- a polypeptide comprises: a) a V H domain that comprises an HCDR1, an HCDR2, and an HCDR3 having 100% sequence identity to an HCDR1, an HCDR2 and an HCDR3, respectively, of a V H amino acid sequence of SEQ ID NO:5; or b) a V L domain that comprises an LCDR1, an LCDR2, and an LCDR3 having 100% sequence identity to an LCDR1, an LCDR2 and an LCDR3, respectively, of a V L amino acid sequence of SEQ ID NO:14, or both a) and b).
- a polypeptide comprises: a) a V H domain that comprises an HCDR1, an HCDR2, and an HCDR3 having 100% sequence identity to an HCDR1, an HCDR2 and an HCDR3, respectively, of a V H amino acid sequence of SEQ ID NO:5; and b) a V L domain that comprises an LCDR1, an LCDR2, and an LCDR3 having 100% sequence identity to an LCDR1, an LCDR2 and an LCDR3, respectively, of a V L amino acid sequence of SEQ ID NO:14.
- a polypeptide comprises: a) an HCDR1 comprising at least one amino acid substitution relative to at least one amino acid sequence set forth in SEQ ID NOs:22-24 (e.g., at least one amino acid sequence set forth in SEQ ID NO:23 or SEQ ID NO:24); b) an HCDR2 comprising at least one amino acid substitution relative to at least one amino acid sequence set forth in SEQ ID NOs:26-29 (e.g., at least one amino acid sequence set forth in SEQ ID NOs:27-29); c) an HCDR3 comprising at least one amino acid substitution relative to at least one amino acid sequence set forth in SEQ ID NOs:31-33 (e.g., at least one amino acid sequence set forth in SEQ ID NO:32 or SEQ ID NO:33); d) an LCDR1 comprising at least one amino acid substitution relative to at least one amino acid sequence set forth in SEQ ID NOs:35-37 (e.g., at least one amino acid sequence set forth
- a polypeptide comprises an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2, and an LCDR3 comprising only one or more conservative substitutions (e.g., only one or more highly conservative substitutions), relative an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2, and an LCDR3 of a polypeptide selected from any one of AB- 1a, AB-1b, AB-1c, AB-1d, AB-2a, AB-2b, AB-2c, AB-2d, AB-3a, AB-3b, AB-3c, and AB-3d.
- a polypeptide comprises an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2, and an LCDR3 comprising up to 1, 2, or 3 conservative substitutions (e.g., up to 1, 2, or 3 highly conservative substitutions), relative an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2, and an LCDR3 of a polypeptide selected from any one of AB- 1a, AB-1b, AB-1c, AB-1d, AB-2a, AB-2b, AB-2c, AB-2d, AB-3a, AB-3b, AB-3c, and AB-3d.
- a polypeptide comprises an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2, and an LCDR3 having 100% sequence identity to an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2, and an LCDR3 of a polypeptide selected from any one of AB-1a, AB-1b, AB-1c, AB-1d, AB-2a, AB-2b, AB-2c, AB-2d, AB-3a, AB-3b, AB-3c, and AB-3d.
- a polypeptide comprises: a) an HCDR1 comprising the amino acid sequence of SEQ ID NO:24; b) an HCDR2 comprising the amino acid sequence of SEQ ID NO:28; c) an HCDR3 comprising the amino acid sequence of SEQ ID NO:33; d) an LCDR1 comprising the amino acid sequence of SEQ ID NO:37; e) an LCDR2 comprising the amino acid sequence of SEQ ID NO:40; f) an LCDR3 comprising the amino acid sequence of SEQ ID NO:44; or any combination of the foregoing.
- a polypeptide comprises: a) an HCDR1 comprising the amino acid sequence of SEQ ID NO:24; b) an HCDR2 comprising the amino acid sequence of SEQ ID NO:28; c) an HCDR3 comprising the amino acid sequence of SEQ ID NO:33; d) an LCDR1 comprising the amino acid sequence of SEQ ID NO:37; e) an LCDR2 comprising the amino acid sequence of SEQ ID NO:40; and - 40 - 3839034.v1 5708.1076005 f) an LCDR3 comprising the amino acid sequence of SEQ ID NO:44.
- a polypeptide comprises: a) an HCDR1 consisting of the amino acid sequence of SEQ ID NO:24; b) an HCDR2 consisting of the amino acid sequence of SEQ ID NO:28; c) an HCDR3 consisting of the amino acid sequence of SEQ ID NO:33; d) an LCDR1 consisting of the amino acid sequence of SEQ ID NO:37; e) an LCDR2 consisting of the amino acid sequence of SEQ ID NO:40; f) an LCDR3 consisting of the amino acid sequence of SEQ ID NO:44; or any combination of the foregoing.
- a polypeptide comprises: a) an HCDR1 consisting of the amino acid sequence of SEQ ID NO:24; b) an HCDR2 consisting of the amino acid sequence of SEQ ID NO:28; c) an HCDR3 consisting of the amino acid sequence of SEQ ID NO:33; d) an LCDR1 consisting of the amino acid sequence of SEQ ID NO:37; e) an LCDR2 consisting of the amino acid sequence of SEQ ID NO:40; and f) an LCDR3 consisting of the amino acid sequence of SEQ ID NO:44.
- a polypeptide comprises: a) a V H domain comprising an HCDR1, an HCDR2, and an HCDR3 having 100% sequence identity to an HCDR1, an HCDR2, and an HCDR3, respectively, of a V H amino acid sequence set forth in Table 1 or Table 4 herein; b) a V L domain comprising an LCDR1, an LCDR2, and an LCDR3 having 100% sequence identity to an LCDR1, an LCDR2, and an LCDR3, respectively, of a V L amino acid sequence set forth in Table 2 or Table 4 herein; or both a) and b), optionally wherein the V H amino acid sequence set forth in Table 1 or Table 4 herein and the V L amino acid sequence set forth in Table 2 or Table 4 herein are a sequence pair set forth in Table 5 herein.
- a polypeptide comprises: a) a V H domain comprising an HCDR1, an HCDR2, and an HCDR3 having 100% sequence identity to an HCDR1, an HCDR2, and an HCDR3, respectively, of a V H amino acid sequence set forth in Table 1 or Table 4 herein; and - 41 - 3839034.v1 5708.1076005 b) a V L domain comprising an LCDR1, an LCDR2, and an LCDR3 having 100% sequence identity to an LCDR1, an LCDR2, and an LCDR3, respectively, of a V L amino acid sequence set forth in Table 2 or Table 4 herein, optionally wherein the V H amino acid sequence set forth in Table 1 or Table 4 herein and the V L amino acid sequence set forth in Table 2 or Table 4 herein are a sequence pair set forth in Table 5 herein.
- a polypeptide comprises: a) a V H domain comprising an HCDR1, an HCDR2, and an HCDR3 that are substantially similar (e.g., having at least about 90% sequence identity) in amino acid sequence to an HCDR1, an HCDR2, and an HCDR3, respectively, of a V H amino acid sequence set forth in Table 1 or Table 4 herein; b) a V L domain comprising an LCDR1, an LCDR2, and an LCDR3 that are substantially similar (e.g., having at least about 90% sequence identity) in amino acid sequence to an LCDR1, an LCDR2, and an LCDR3, respectively, of a V L amino acid sequence set forth in Table 2 or Table 4 herein; or both a) and b), optionally wherein the V H amino acid sequence set forth in Table 1 or Table 4 herein and the V L amino acid sequence set forth in Table 2 or Table 4 herein are a sequence pair set forth in Table 5 herein.
- a polypeptide comprises: a) a V H domain comprising an HCDR1, an HCDR2, and an HCDR3 that substantially preserve one or more functional properties of an HCDR1, an HCDR2 and an HCDR3, respectively, of a V H amino acid sequence set forth in Table 1 or Table 4 herein; b) a V L domain comprising an LCDR1, an LCDR2, and an LCDR3 that substantially preserve one or more functional properties of an LCDR1, an LCDR2 and an LCDR3, respectively, of a V L amino acid sequence set forth in Table 2 or Table 4 herein; or both a) and b), optionally wherein the V H amino acid sequence set forth in Table 1 or Table 4 herein and the V L amino acid sequence set forth in Table 2 or Table 4 herein are a sequence pair set forth in Table 5 herein.
- a polypeptide comprises: - 42 - 3839034.v1 5708.1076005 a) a V H domain comprising an HCDR1, an HCDR2, and an HCDR3 that substantially preserve one or more functional properties of an HCDR1, an HCDR2 and an HCDR3, respectively, of a V H amino acid sequence set forth in Table 1 or Table 4 herein; and b) a V L domain comprising an LCDR1, an LCDR2, and an LCDR3 that substantially preserve one or more functional properties of an LCDR1, an LCDR2 and an LCDR3, respectively, of a V L amino acid sequence set forth in Table 2 or Table 4 herein, optionally wherein the V H amino acid sequence set forth in Table 1 or Table 4 herein and the V L amino acid sequence set forth in Table 2 or Table 4 herein are a sequence pair set forth in Table 5 herein.
- a polypeptide comprises an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2, and an LCDR3 that substantially preserve one or more functional properties of an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2, and an LCDR3 of a polypeptide selected from any antibody set forth in Table 5 herein.
- a polypeptide comprises: a) a V H domain that comprises an HCDR1, an HCDR2, and an HCDR3 comprising only one or more conservative substitutions (e.g., only one or more highly conservative substitutions), relative to an HCDR1, an HCDR2 and an HCDR3, respectively, of a V H amino acid sequence set forth in Table 1 or Table 4 herein; or b) a V L domain that comprises an LCDR1, an LCDR2, and an LCDR3 comprising only one or more conservative substitutions (e.g., only one or more highly conservative substitutions), relative to an LCDR1, an LCDR2 and an LCDR3, respectively, of a V L amino acid sequence set forth in Table 2 or Table 4 herein, or both a) and b), optionally wherein the V H amino acid sequence set forth in Table 1 or Table 4 herein and the V L amino acid sequence set forth in Table 2 or Table 4 herein are a sequence pair set forth in Table 5 herein.
- a polypeptide comprises: a) a V H domain that comprises an HCDR1, an HCDR2, and an HCDR3 comprising only one or more conservative substitutions (e.g., only one or more highly - 43 - 3839034.v1 5708.1076005 conservative substitutions), relative to an HCDR1, an HCDR2 and an HCDR3, respectively, of a V H amino acid sequence set forth in Table 1 or Table 4 herein; and b) a V L domain that comprises an LCDR1, an LCDR2, and an LCDR3 comprising only one or more conservative substitutions (e.g., only one or more highly conservative substitutions), relative to an LCDR1, an LCDR2 and an LCDR3, respectively, of a V L amino acid sequence set forth in Table 2 or Table 4 herein, optionally wherein the V H amino acid sequence set forth in Table 1 or Table 4 herein and the V L amino acid sequence set forth in Table 2 or Table 4 herein are a sequence pair set forth in Table 5 here
- a polypeptide comprises: a) a V H domain that comprises an HCDR1, an HCDR2, and an HCDR3 comprising up to 1, 2, or 3 conservative substitutions (e.g., up to 1, 2, or 3 highly conservative substitutions), relative to an HCDR1, an HCDR2 and an HCDR3, respectively, of a V H amino acid sequence set forth in Table 1 or Table 4 herein; or b) a V L domain that comprises an LCDR1, an LCDR2, and an LCDR3 comprising up to 1, 2, or 3 conservative substitutions (e.g., up to 1, 2, or 3 highly conservative substitutions), relative to an LCDR1, an LCDR2 and an LCDR3, respectively, of a V L amino acid sequence set forth in Table 2 or Table 4 herein, or both a) and b), optionally wherein the V H amino acid sequence set forth in Table 1 or Table 4 herein and the V L amino acid sequence set forth in Table 2 or Table 4 herein are a sequence pair set forth in Table 5 herein
- a polypeptide comprises: a) a V H domain that comprises an HCDR1, an HCDR2, and an HCDR3 comprising up to 1, 2, or 3 conservative substitutions (e.g., up to 1, 2, or 3 highly conservative substitutions), relative to an HCDR1, an HCDR2 and an HCDR3, respectively, of a V H amino acid sequence set forth in Table 1 or Table 4 herein; and b) a V L domain that comprises an LCDR1, an LCDR2, and an LCDR3 comprising up to 1, 2, or 3 conservative substitutions (e.g., up to 1, 2, or 3 highly conservative substitutions), relative to an LCDR1, an LCDR2 and an LCDR3, respectively, of a V L amino acid sequence set forth in Table 2 or Table 4 herein, - 44 - 3839034.v1 5708.1076005 optionally wherein the V H amino acid sequence set forth in Table 1 or Table 4 herein and the V L amino acid sequence set forth in Table 2 or Table 4 herein are a
- a polypeptide comprises: a) a V H domain that comprises an HCDR1, an HCDR2, and an HCDR3 having 100% sequence identity to an HCDR1, an HCDR2 and an HCDR3, respectively, of a V H amino acid sequence set forth in Table 1 or Table 4 herein; or b) a V L domain that comprises an LCDR1, an LCDR2, and an LCDR3 having 100% sequence identity to an LCDR1, an LCDR2 and an LCDR3, respectively, of a V L amino acid sequence set forth in Table 2 or Table 4 herein, or both a) and b), optionally wherein the V H amino acid sequence set forth in Table 1 or Table 4 herein and the V L amino acid sequence set forth in Table 2 or Table 4 herein are a sequence pair set forth in Table 5 herein.
- a polypeptide comprises: a) a V H domain that comprises an HCDR1, an HCDR2, and an HCDR3 having 100% sequence identity to an HCDR1, an HCDR2 and an HCDR3, respectively, of a V H amino acid sequence set forth in Table 1 or Table 4 herein; and b) a V L domain that comprises an LCDR1, an LCDR2, and an LCDR3 having 100% sequence identity to an LCDR1, an LCDR2 and an LCDR3, respectively, of a V L amino acid sequence set forth in Table 2 or Table 4 herein, optionally wherein the V H amino acid sequence set forth in Table 1 or Table 4 herein and the V L amino acid sequence set forth in Table 2 or Table 4 herein are a sequence pair set forth in Table 5 herein.
- a polypeptide comprises an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2, and an LCDR3, of an antibody comprising a V H /V L pair selected from Table 5 herein.
- an HCDR1 amino acid sequence corresponds to positions 26-33 of a V H amino acid sequence set forth in Table 4; b) an HCDR2 amino acid sequence corresponds to positions 51-58 of a V H amino acid sequence set forth in Table 4; - 45 - 3839034.v1 5708.1076005 c) an HCDR3 amino acid sequence corresponds to positions 97-115 of a V H amino acid sequence set forth in Table 4; d) an LCDR1 amino acid sequence corresponds to positions 26-34 of a V L amino acid sequence set forth in Table 4; e) an LCDR2 amino acid sequence corresponds to positions 52-54 of a V L amino acid sequence set forth in Table 4; f) an LCDR3 amino acid sequence corresponds to positions 91-103 of a V L amino acid sequence set forth in Table 4.
- a polypeptide comprises: a) an HCDR1 comprising at least one amino acid substitution relative to at least one amino acid sequence set forth in SEQ ID NOs:22-24 and (HCDR1 amino acid sequences set forth in) Table 4 (e.g., at least one amino acid sequence set forth in SEQ ID NOs:23-24 and Table 4); b) an HCDR2 comprising at least one amino acid substitution relative to at least one amino acid sequence set forth in SEQ ID NOs:26-29 and (HCDR2 amino acid sequences set forth in) Table 4 (e.g., at least one amino acid sequence set forth in SEQ ID NOs:27-29 and Table 4); c) an HCDR3 comprising at least one amino acid substitution relative to at least one amino acid sequence set forth in SEQ ID NOs:31-33 and (HCDR3 amino acid sequences set forth in) Table 4 (e.g., at least one amino acid sequence set forth in SEQ ID NOs:32-33 and Table 4); d) an HCDR1 comprising at least
- a polypeptide comprises: a) a V H domain comprising: i. an HCDR1 comprising GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 comprising IILLPGYA (SEQ ID NO:604); and iii. an HCDR3 comprising ARGFNRDYYGWGDDDAFDF (SEQ ID NO:605); and b) a V L domain comprising: i. an LCDR1 comprising SSNIGAGYR (SEQ ID NO:37); ii. an LCDR2 comprising GRS; and iii. an LCDR3 comprising QSYDSSLFDPHWV (SEQ ID NO:44).
- a polypeptide comprises: a) a V H domain comprising: i. an HCDR1 comprising GDTEDTYT (SEQ ID NO:606); ii. an HCDR2 comprising IILLSGYA (SEQ ID NO:28); and iii. an HCDR3 comprising ARGFNGDYYGWGDDDAFDF (SEQ ID NO:33); and b) a V L domain comprising: i. an LCDR1 comprising ESNIGAGYR (SEQ ID NO:606); ii. an LCDR2 comprising GRS; and iii. an LCDR3 comprising QSYDSSLFDPHWV (SEQ ID NO:44).
- a polypeptide comprises: a) a V H domain comprising: i. an HCDR1 comprising GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 comprising IILLSGYG (SEQ ID NO:607); iii. an HCDR3 comprising ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a V L domain comprising: i. an LCDR1 comprising SSNIGAGYR (SEQ ID NO:37); ii. an LCDR2 comprising GRS; and - 47 - 3839034.v1 5708.1076005 iii.
- a polypeptide comprises: a) a V H domain comprising: i. an HCDR1 comprising GDYSDVYT (SEQ ID NO:609); ii. an HCDR2 comprising IILLLGYA (SEQ ID NO:610); and iii. an HCDR3 comprising ARGFNGDYYGWGDDDAFDF (SEQ ID NO:33); and b) a V L domain comprising: i. an LCDR1 comprising SSNIGAGYY (SEQ ID NO:611); ii. an LCDR2 comprising GRS; and iii.
- a polypeptide comprises: a) a V H domain comprising: i. an HCDR1 comprising GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 comprising IILLSGYT (SEQ ID NO:612); and iii. an HCDR3 comprising ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a V L domain comprising: i. an LCDR1 comprising LSNIGAGYR (SEQ ID NO:613); ii. an LCDR2 comprising GRS; and iii.
- a polypeptide comprises: a) a V H domain comprising: i. an HCDR1 comprising GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 comprising IILLSGYS (SEQ ID NO:614); and iii. an HCDR3 comprising ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a V L domain comprising: i. an LCDR1 comprising ESNIGAGYD (SEQ ID NO:615); ii. an LCDR2 comprising GRS; and iii.
- a polypeptide comprises: a) a V H domain comprising: - 48 - 3839034.v1 5708.1076005 i. an HCDR1 comprising GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 comprising IILLSGYA (SEQ ID NO:28); and iii. an HCDR3 comprising ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a V L domain comprising: i. an LCDR1 comprising LSNIGAGYR (SEQ ID NO:613); ii.
- a polypeptide comprises: a) a V H domain comprising: i. an HCDR1 comprising GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 comprising IILLSDYT (SEQ ID NO:609); and iii. an HCDR3 comprising ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a V L domain comprising: i. an LCDR1 comprising ESNIGAGYR (SEQ ID NO:606); ii.
- a polypeptide comprises: a) a V H domain comprising: i. an HCDR1 comprising GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 comprising IILLSGYA (SEQ ID NO:28); and iii. an HCDR3 comprising ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a V L domain comprising: i. an LCDR1 comprising ESNIGAGYR (SEQ ID NO:606); ii.
- a polypeptide comprises: a) a V H domain comprising: i. an HCDR1 comprising GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 comprising IILLSGYA (SEQ ID NO:28); and - 49 - 3839034.v1 5708.1076005 iii. an HCDR3 comprising ARGFNGDYYGWGDDDAFDF (SEQ ID NO:33); and b) a V L domain comprising: i.
- a polypeptide comprises: a) a V H domain comprising: i. an HCDR1 comprising GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 comprising IILLSGYT (SEQ ID NO:612); and iii. an HCDR3 comprising ARGFNEDYYGWGDDDAFDF (SEQ ID NO:614); and b) a V L domain comprising: i.
- a polypeptide comprises: a) a V H domain comprising: i. an HCDR1 comprising GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 comprising IILLSGYA (SEQ ID NO:28); and iii. an HCDR3 comprising ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a V L domain comprising: i.
- a polypeptide comprises: a) a V H domain comprising: i. an HCDR1 comprising GDTSDIYT (SEQ ID NO:617); ii. an HCDR2 comprising IILLSGYT (SEQ ID NO:612); and iii.
- a polypeptide comprises: a) a V H domain comprising: i. an HCDR1 comprising GDTSDTYT (SEQ ID NO:24); ii.
- a polypeptide comprises: a) a V H domain comprising: i. an HCDR1 comprising GDTSDTYT (SEQ ID NO:24); ii.
- a polypeptide comprises: a) a V H domain comprising: i. an HCDR1 comprising GDTSDTYT (SEQ ID NO:24); ii.
- a polypeptide comprises: a) a V H domain comprising: i.
- a polypeptide comprises: a) a V H domain comprising: i.
- a polypeptide comprises: a) a V H domain comprising: i.
- a polypeptide comprises: a) a V H domain comprising: i.
- an HCDR1 comprising GDTSDTYT (SEQ ID NO:24); - 52 - 3839034.v1 5708.1076005
- a V L domain comprising: i. an LCDR1 comprising ESNIGAGYR (SEQ ID NO:606); ii. an LCDR2 comprising GRS; and iii. an LCDR3 comprising QSYDSSLFDPHWV (SEQ ID NO:44).
- a polypeptide comprises: a) a V H domain comprising: i. an HCDR1 consisting of GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 consisting of IILLPGYA (SEQ ID NO:604); and iii. an HCDR3 consisting of ARGFNRDYYGWGDDDAFDF (SEQ ID NO:605); and b) a V L domain comprising: i. an LCDR1 consisting of SSNIGAGYR (SEQ ID NO:37); ii. an LCDR2 consisting of GRS; and iii. an LCDR3 consisting of QSYDSSLFDPHWV (SEQ ID NO:44).
- a polypeptide comprises: a) a V H domain comprising: i. an HCDR1 consisting of GDTEDTYT (SEQ ID NO:606); ii. an HCDR2 consisting of IILLSGYA (SEQ ID NO:28); and iii. an HCDR3 consisting of ARGFNGDYYGWGDDDAFDF (SEQ ID NO:33); and b) a V L domain comprising: i. an LCDR1 consisting of ESNIGAGYR (SEQ ID NO:606); ii. an LCDR2 consisting of GRS; and iii. an LCDR3 consisting of QSYDSSLFDPHWV (SEQ ID NO:44).
- a polypeptide comprises: a) a V H domain comprising: i. an HCDR1 consisting of GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 consisting of IILLSGYG (SEQ ID NO:607); iii. an HCDR3 consisting of ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and - 53 - 3839034.v1 5708.1076005 b) a V L domain comprising: i. an LCDR1 consisting of SSNIGAGYR (SEQ ID NO:37); ii. an LCDR2 consisting of GRS; and iii.
- a polypeptide comprises: a) a V H domain comprising: i. an HCDR1 consisting of GDYSDVYT (SEQ ID NO:609); ii. an HCDR2 consisting of IILLLGYA (SEQ ID NO:610); and iii. an HCDR3 consisting of ARGFNGDYYGWGDDDAFDF (SEQ ID NO:33); and b) a V L domain comprising: i. an LCDR1 consisting of SSNIGAGYY (SEQ ID NO:611); ii. an LCDR2 consisting of GRS; and iii.
- a polypeptide comprises: a) a V H domain comprising: i. an HCDR1 consisting of GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 consisting of IILLSGYT (SEQ ID NO:612); and iii. an HCDR3 consisting of ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a V L domain comprising: i. an LCDR1 consisting of LSNIGAGYR (SEQ ID NO:613); ii. an LCDR2 consisting of GRS; and iii.
- a polypeptide comprises: a) a V H domain comprising: i. an HCDR1 consisting of GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 consisting of IILLSGYS (SEQ ID NO:614); and iii. an HCDR3 consisting of ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a V L domain comprising: i. an LCDR1 consisting of ESNIGAGYD (SEQ ID NO:615); ii.
- a polypeptide comprises: a) a V H domain comprising: i. an HCDR1 consisting of GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 consisting of IILLSGYA (SEQ ID NO:28); and iii. an HCDR3 consisting of ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a V L domain comprising: i.
- a polypeptide comprises: a) a V H domain comprising: i. an HCDR1 consisting of GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 consisting of IILLSDYT (SEQ ID NO:609); and iii. an HCDR3 consisting of ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a V L domain comprising: i.
- a polypeptide comprises: a) a V H domain comprising: i. an HCDR1 consisting of GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 consisting of IILLSGYA (SEQ ID NO:28); and iii. an HCDR3 consisting of ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a V L domain comprising: i.
- a polypeptide comprises: a) a V H domain comprising: - 55 - 3839034.v1 5708.1076005 i. an HCDR1 consisting of GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 consisting of IILLSGYA (SEQ ID NO:28); and iii.
- a polypeptide comprises: a) a V H domain comprising: i. an HCDR1 consisting of GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 consisting of IILLSGYT (SEQ ID NO:612); and iii.
- a polypeptide comprises: a) a V H domain comprising: i. an HCDR1 consisting of GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 consisting of IILLSGYA (SEQ ID NO:28); and iii.
- a polypeptide comprises: a) a V H domain comprising: i. an HCDR1 consisting of GDTSDIYT (SEQ ID NO:617); ii.
- a polypeptide comprises: a) a V H domain comprising: i.
- a polypeptide comprises: a) a V H domain comprising: i.
- a polypeptide comprises: a) a V H domain comprising: i.
- an HCDR1 consisting of GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 consisting of IILLSGYV (SEQ ID NO:619); and iii. an HCDR3 consisting of ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a V L domain comprising: - 57 - 3839034.v1 5708.1076005 i. an LCDR1 consisting of SSNIGAGYD (SEQ ID NO:36); ii. an LCDR2 consisting of GRS; iii. an LCDR3 consisting of QSYDSSSFDPHWV (SEQ ID NO:620).
- a polypeptide comprises: a) a V H domain comprising: i. an HCDR1 consisting of GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 consisting of IILLSGYA (SEQ ID NO:28); and iii. an HCDR3 consisting of ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a V L domain comprising: i. an LCDR1 consisting of SSNIGAGYR (SEQ ID NO:37); ii. an LCDR2 consisting of GRS; and iii. an LCDR3 consisting of QSYDSSYFDPHWV (SEQ ID NO:610).
- a polypeptide comprises: a) a V H domain comprising: i. an HCDR1 consisting of GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 consisting of IILLSGYA (SEQ ID NO:28); and iii. an HCDR3 consisting of ARGFNYDYYGWGDDDAFDF (SEQ ID NO:621); and b) a V L domain comprising: i. an LCDR1 consisting of VSNIGAGYR (SEQ ID NO:618); ii. an LCDR2 consisting of GRS; and iii. an LCDR3 consisting of QSYDSSLFDPHWV (SEQ ID NO:44).
- a polypeptide comprises: a) a V H domain comprising: i. an HCDR1 consisting of GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 consisting of IILLSGYS (SEQ ID NO:614); and iii. an HCDR3 consisting of ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a V L domain comprising: i. an LCDR1 consisting of SSNIGAGYD (SEQ ID NO:36); ii. an LCDR2 consisting of GRS; iii. an LCDR3 consisting of QSYDSSLFDPHWV (SEQ ID NO:44).
- a polypeptide comprises: a) a V H domain comprising: i. an HCDR1 consisting of GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 consisting of IILLSGYG (SEQ ID NO:607); and iii. an HCDR3 consisting of ARGFNGDYYGWGDDDAFDF (SEQ ID NO:33); and b) a V L domain comprising: i. an LCDR1 consisting of ESNIGAGYR (SEQ ID NO:606); ii. an LCDR2 consisting of GRS; and iii.
- a polypeptide binds to a SARS-CoV-2 Spike protein (e.g., SEQ ID NO:1 or SEQ ID NO:46) and comprises an immunoglobulin light chain variable domain, an immunoglobulin heavy chain variable domain, or an immunoglobulin light chain variable domain and an immunoglobulin heavy chain variable domain, wherein the polypeptide does not comprise SEQ ID NO:3 or SEQ ID NO:8 or both SEQ ID NO:3 and SEQ ID NO:8.
- SARS-CoV-2 Spike protein e.g., SEQ ID NO:1 or SEQ ID NO:46
- a polypeptide binds to one or more epitope residues of a wildtype SARS-CoV-2 Spike protein (e.g., one or more epitope residues in the SARS-CoV-2 S1 subunit).
- a polypeptide e.g., an antibody or antigen-binding fragment thereof
- a polypeptide comprises a V H domain having less than 100% sequence identity to the amino acid sequence of SEQ ID NO:3, a V L domain having less than 100% sequence identity to the amino acid sequence of SEQ ID NO:8, or both.
- a polypeptide comprises a V H (e.g., a mammalian V H such as a rodent (e.g., mouse) V H , a primate (e.g., a human) V H ) domain.
- a polypeptide comprises a V H domain that is humanized (e.g., at least about: 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99% humanized), contains human framework regions, or both.
- a polypeptide comprises a V H domain that has less than 100% sequence identity to the amino acid sequence of SEQ ID NO:3.
- a polypeptide comprises a V H domain that has at least about 70% sequence identity to the amino acid sequence of SEQ ID NO:3.
- a - 59 - 3839034.v1 5708.1076005 polypeptide comprises a V H domain that has at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of SEQ ID NO:3.
- a polypeptide comprises a V H domain that has at least about 85% sequence identity to the amino acid sequence of SEQ ID NO:3. In some embodiments, a polypeptide comprises a V H domain that has at least about 90% sequence identity to the amino acid sequence of SEQ ID NO:3. [00229] In some embodiments, a polypeptide comprises a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative substitution) relative to the amino acid sequence of SEQ ID NO:3.
- the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5- 14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11.
- a polypeptide comprises a V H domain that comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of SEQ ID NO:3.
- the at least one amino acid substitution replaces only an HCDR1, an HCDR2, and/or an HCDR3 residue, of SEQ ID NO:3.
- a polypeptide comprises a V H domain that has 100% sequence identity to the amino acid sequence of SEQ ID NO:3. In some embodiments, a polypeptide comprises a V H domain that comprises the amino acid sequence of SEQ ID NO:3. [00231] In some embodiments, a polypeptide comprises a V H domain that has at least about 70% sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6).
- a polypeptide comprises a V H domain that has at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6).
- a polypeptide comprises a V H domain that has at least about 85% sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6). In some embodiments, a polypeptide comprises a V H domain that has at least about 90% sequence - 60 - 3839034.v1 5708.1076005 identity to the amino acid sequence of any one or more of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6).
- a polypeptide comprises a V H domain that comprises at least one amino acid substitution relative to the amino acid sequence of any one or more of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6).
- the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7- 12, 8-12, 8-11 or 9-11.
- a polypeptide comprises a V H domain that comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of any one or more of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6).
- an amino acid substitution is a conservative substitution.
- an amino acid substitution is a highly conservative substitution.
- a polypeptide comprises a V H domain that has 100% sequence identity to the amino acid sequence of any one of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6).
- a polypeptide comprises a V H domain that comprises the amino acid sequence of any one of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6).
- a polypeptide comprises a V L (e.g., a mammalian V L such as a rodent (e.g., mouse) V L , a primate (e.g., a human) V L ) domain.
- a polypeptide comprises a V L domain that is humanized (e.g., at least about: 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99% humanized), contains human framework regions, or both. [00237] In some embodiments, a polypeptide comprises a V L domain that has less than 100% sequence identity to the amino acid sequence of SEQ ID NO:8. [00238] In some embodiments, a polypeptide comprises a V L domain that has at least about 70% sequence identity to the amino acid sequence of SEQ ID NO:8.
- a polypeptide comprises a V L domain that has at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of SEQ ID NO:8.
- a polypeptide comprises a V L domain that has at least about 85% sequence identity to the amino acid sequence of SEQ ID NO:8.
- a polypeptide comprises a V L domain that has at least about 90% sequence identity to the amino acid sequence of SEQ ID NO:8. - 61 - 3839034.v1 5708.1076005 [00239] In some embodiments, a polypeptide comprises a V L domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative substitution) relative to the amino acid sequence of SEQ ID NO:8.
- the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5- 14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11.
- a polypeptide comprises a V L domain that comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of SEQ ID NO:8.
- the at least one amino acid substitution replaces only an LCDR1, an LCDR2, and/or an LCDR3 residue, of SEQ ID NO:8.
- the at least one amino acid substitution replaces only a non-CDR residue (e.g., within a framework region), of SEQ ID NO:8.
- an amino acid substitution is a conservative substitution.
- an amino acid substitution is a highly conservative substitution.
- a polypeptide comprises a V L domain that has 100% sequence identity to the amino acid sequence of SEQ ID NO:8.
- a polypeptide comprises a V L domain [00243] that comprises the amino acid sequence of SEQ ID NO:8.
- a polypeptide comprises a V L domain that has at least about 70% sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:9-20, 91, and 92 (e.g., SEQ ID NOs:9-20).
- SEQ ID NOs:9-20, 91, and 92 e.g., SEQ ID NOs:9-20
- Table 2 which correspond to human V L domains.
- a polypeptide comprises a V L that has at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:9-20, 91, and 92 (e.g., SEQ ID NOs:9-20).
- a polypeptide comprises a V L domain that has at least about 85% sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:20-30. In some embodiments, a polypeptide comprises a V L domain that has at least about 90% sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:9-20, 91, and 92 (e.g., SEQ ID NOs:9-20).
- a polypeptide comprises a V L domain that comprises at least one amino acid substitution relative to the amino acid sequence of any one or more of SEQ ID - 62 - 3839034.v1 5708.1076005 NOs:9-20, 91, and 92 (e.g., SEQ ID NOs:9-20).
- the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7- 12, 8-12, 8-11 or 9-11.
- a polypeptide comprises a V L domain that comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of any one or more of SEQ ID NOs:9-20, 91, and 92 (e.g., SEQ ID NOs:9-20).
- an amino acid substitution is a conservative substitution.
- an amino acid substitution is a highly conservative substitution.
- a polypeptide comprises a V L domain that has 100% sequence identity to the amino acid sequence of any one of SEQ ID NOs:9-20, 91, and 92 (e.g., SEQ ID NOs:9-20).
- a polypeptide comprises a V L domain that comprises the amino acid sequence of any one of SEQ ID NOs:9-20, 91, and 92 (e.g., SEQ ID NOs:9-20).
- a polypeptide comprises a V H (e.g., a mammalian V H such as a rodent (e.g., mouse) V H , a primate (e.g., a human) V H ) domain and a V L (e.g., a mammalian V L such as a rodent (e.g., mouse) V L , a primate (e.g., a human) V L ) domain.
- V H e.g., a mammalian V H such as a rodent (e.g., mouse) V H
- a primate e.g., a human
- a polypeptide comprises a V H domain and V L domain that are humanized (e.g., at least about: 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99% humanized), contain human framework regions, or both.
- a polypeptide comprises: a) a V H domain that has less than 100% sequence identity to the amino acid sequence of SEQ ID NO:3; b) a V L domain that has less than 100% sequence identity to the amino acid sequence of SEQ ID NO:8; or both a) and b).
- a polypeptide comprises: a) a V H domain that has less than 100% sequence identity to the amino acid sequence of SEQ ID NO:3; and b) a V L domain that has less than 100% sequence identity to the amino acid sequence of SEQ ID NO:8.
- a polypeptide comprises: - 63 - 3839034.v1 5708.1076005 a) a V H domain that has at least about 55% (e.g., at least about: 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99%) sequence identity to the amino acid sequence of SEQ ID NO:3; b) a V L domain that has at least about 55% (e.g., at least about: 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99%) sequence identity to the amino acid sequence of SEQ ID NO:8; or both a) and b), wherein the polypeptide does not comprise all 6 CDRs of an antibody comprising a V H amino acid sequence of SEQ ID NO:3 and a V L amino acid sequence of SEQ ID NO:8.
- a polypeptide comprises: a) a V H domain that has at least about 55% (e.g., at least about: 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99%) sequence identity to the amino acid sequence of SEQ ID NO:3; and b) a V L domain that has at least about 55% (e.g., at least about: 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99%) sequence identity to the amino acid sequence of SEQ ID NO:8, wherein the polypeptide does not comprise all 6 CDRs of an antibody comprising a V H amino acid sequence of SEQ ID NO:3 and a V L amino acid sequence of SEQ ID NO:8.
- a polypeptide comprises: a) a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative substitution) relative to the amino acid sequence of SEQ ID NO:3; b) a V L domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative substitution) relative to the amino acid sequence of SEQ ID NO:8; or both a) and b).
- a polypeptide comprises: a) a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) relative to the amino acid sequence of SEQ ID NO:3; and b) a V L domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) relative to the amino acid sequence of SEQ ID NO:8.
- a polypeptide comprises: a) a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a HCDR1, a HCDR2 and/or a HCDR3 residue, of SEQ ID NO:3; b) a V L domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a LCDR1, a LCDR2 and/or a LCDR3 residue, of SEQ ID NO:8; or both a) and b).
- a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a HCDR1, a HCDR2 and/or a HCDR3 residue, of SEQ ID NO:3
- a V L domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a LCDR1, a
- a polypeptide comprises: a) a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a HCDR1, a HCDR2 and/or a HCDR3 residue, of SEQ ID NO:3; and b) a V L domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a LCDR1, a LCDR2 and/or a LCDR3 residue, of SEQ ID NO:8.
- a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a HCDR1, a HCDR2 and/or a HCDR3 residue, of SEQ ID NO:3
- a V L domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a LCDR1, a LCDR2 and/or a
- a polypeptide comprises: a) a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of SEQ ID NO:3; b) a V L domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of SEQ ID NO:8; or both a) and b).
- a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of SEQ ID NO:3
- V L domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region
- a polypeptide comprises: a) a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of SEQ ID NO:3; and b) a V L domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of SEQ ID NO:8.
- V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of SEQ ID NO:3
- V L domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of SEQ ID NO:8.
- a polypeptide comprises: - 65 - 3839034.v1 5708.1076005 a) a V H domain that has at least about 70% (e.g., at least about: 75, 80, 85, 90, 95, 98, or 99%) sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6); b) a V L domain that has at least about 70% (e.g., at least about: 75, 80, 85, 90, 95, 98, or 99%) sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:9-20, 91, and 92 (e.g., SEQ ID NOs:9-20); or both a) and b).
- a V H domain that has at least about 70% (e.g., at least about: 75, 80, 85, 90, 95, 98, or 99%) sequence identity to the amino acid sequence of any one or more of SEQ
- a polypeptide comprises: a) a V H domain that has at least about 70% (e.g., at least about: 75, 80, 85, 90, 95, 98, or 99%) sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6); and b) a V L domain that has at least about 70% (e.g., at least about: 75, 80, 85, 90, 95, 98, or 99%) sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:9-20, 91, and 92 (e.g., SEQ ID NOs:9-20).
- a polypeptide comprises: a) a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) relative to the amino acid sequence of any one or more of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6); b) a V L domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) relative to the amino acid sequence of any one or more of SEQ ID NOs:9-20, 91, and 92 (e.g., SEQ ID NOs:9-20); or both a) and b).
- a polypeptide comprises: a) a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) relative to the amino acid sequence of any one or more of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6); and b) a V L domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) relative to the amino acid sequence of any one or more of SEQ ID NOs:9-20, 91, and 92 (e.g., SEQ ID NOs:9-20).
- a polypeptide comprises: a) a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a HCDR1, a HCDR2 and/or a HCDR3 residue, of any one or more of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6); b) a V L domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a LCDR1, a LCDR2 and/or a LCDR3 residue, of any one or more of SEQ ID NOs:9-20, 91, and 92 (e.g., SEQ ID NOs:9-20); or both a) and b).
- a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a HCDR1, a HCDR2 and/or a HC
- a polypeptide comprises: a) a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a HCDR1, a HCDR2 and/or a HCDR3 residue, of any one or more of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6); and b) a V L domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a LCDR1, a LCDR2 and/or a LCDR3 residue, of any one or more of SEQ ID NOs:9-20, 91, and 92 (e.g., SEQ ID NOs:9-20).
- a polypeptide comprises: a) a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of any one or more of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6); b) a V L domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of any one or more of SEQ ID NOs:9-20, 91, and 92 (e.g., SEQ ID NOs:9-20); or both a) and b).
- a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of any one or more
- a polypeptide comprises: a) a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a - 67 - 3839034.v1 5708.1076005 non-CDR residue (e.g., within a framework region), of any one or more of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6); and b) a V L domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of any one or more of SEQ ID NOs:9-20, 91, and 92 (e.g., SEQ ID NOs:9-20).
- a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a - 67 - 3839034.
- a polypeptide comprises: a) a V H domain comprising the amino acid sequence of any one of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6); and b) a V L domain comprising the amino acid sequence of any one of SEQ ID NOs:9- 20, 91, and 92 (e.g., SEQ ID NOs:9-20).
- a polypeptide comprises: a) a V H domain comprising the amino acid sequence of any one of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6); and b) a V L domain comprising the amino acid sequence of SEQ ID NO:8.
- a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:3; and b) a V L domain comprising the amino acid sequence of any one of SEQ ID NOs:9- 20, 91, and 92 (e.g., SEQ ID NOs:9-20).
- a polypeptide comprises: a) a V H domain that has at least about 70% (e.g., at least about: 75, 80, 85, 90, 95, 98, or 99%) sequence identity to the amino acid sequence of SEQ ID NO:5; b) a V L domain that has at least about 70% (e.g., at least about: 75, 80, 85, 90, 95, 98, or 99%) sequence identity to the amino acid sequence of SEQ ID NO:14; or both a) and b).
- a polypeptide comprises: a) a V H domain that has at least about 70% (e.g., at least about: 75, 80, 85, 90, 95, 98, or 99%) sequence identity to the amino acid sequence of SEQ ID NO:5; and b) a V L domain that has at least about 70% (e.g., at least about: 75, 80, 85, 90, 95, 98, or 99%) sequence identity to the amino acid sequence of SEQ ID NO:14.
- a polypeptide comprises: - 68 - 3839034.v1 5708.1076005 a) a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) relative to the amino acid sequence of SEQ ID NO:5; b) a V L domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) relative to the amino acid sequence of SEQ ID NO:14; or both a) and b).
- a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) relative to the amino acid sequence of SEQ ID NO:5
- a V L domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) relative to the amino acid sequence of SEQ ID NO:14; or both a) and b).
- a polypeptide comprises: a) a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) relative to the amino acid sequence of SEQ ID NO:5; and b) a V L domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) relative to the amino acid sequence of SEQ ID NO:14.
- a polypeptide comprises: a) a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a HCDR1, a HCDR2 and/or a HCDR3 residue, of SEQ ID NO:5; b) a V L domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a LCDR1, a LCDR2 and/or a LCDR3 residue, of SEQ ID NO:14; or both a) and b).
- an amino acid substitution is a conservative substitution.
- an amino acid substitution is a highly conservative substitution.
- a polypeptide comprises: a) a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a HCDR1, a HCDR2 and/or a HCDR3 residue, of SEQ ID NO:5; and b) a V L domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a LCDR1, a LCDR2 and/or a LCDR3 residue, of SEQ ID NO:14.
- a polypeptide comprises: - 69 - 3839034.v1 5708.1076005 a) a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of SEQ ID NO:5; b) a V L domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of SEQ ID NO:14; or both a) and b).
- a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of SEQ ID NO:5
- a polypeptide comprises: a) a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of SEQ ID NO:5; and b) a V L domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of SEQ ID NO:14.
- a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of SEQ ID NO:5
- V L domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of SEQ ID NO:14
- a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:5, and b) a V L domain comprising the amino acid sequence of SEQ ID NO:14 (AB-2b).
- a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:4; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:9 (AB-1a).
- a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:4; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:10 (AB-1b).
- a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:4; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:11 (AB-1c).
- a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:4; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:12 (AB-1d).
- a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:5; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:13 (AB-2a).
- a polypeptide comprises: - 70 - 3839034.v1 5708.1076005 a) a V H domain comprising the amino acid sequence of SEQ ID NO:5; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:15 (AB-2c). [00288] In some embodiments, a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:5; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:16 (AB-2d).
- a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:6; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:17 (AB-3a).
- a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:6; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:18 (AB-3b).
- a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:6; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:19 (AB-3c). [00292] In some embodiments, a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:6; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:20 (AB-3d).
- a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:89; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:91 (AB-4a).
- a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:90; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:92 (AB-7a).
- a polypeptide comprises a V H domain that comprises an HCDR1, an HCDR2, and an HCDR3 that are substantially similar in amino acid sequence to an HCDR1, an HCDR2, and an HCDR3, respectively, of a V H amino acid sequence set forth in any of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6).
- a polypeptide comprises a V L domain that comprises an LCDR1, an LCDR2, and an LCDR3 that are substantially similar in amino acid sequence to an LCDR1, an LCDR2, and an LCDR3, respectively, of a V L amino acid sequence set forth in any of SEQ ID NOs:9-20, 91, and 92 (e.g., SEQ ID NOs:9-20).
- a polypeptide comprises a V H domain that comprises an HCDR1, an HCDR2, and an HCDR3 that are identical in amino acid sequence to an HCDR1, an - 71 - 3839034.v1 5708.1076005 HCDR2, and an HCDR3, respectively, of a V H amino acid sequence set forth in any of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6).
- a polypeptide comprises a V L domain that comprises an LCDR1, an LCDR2, and an LCDR3 that are identical in amino acid sequence to an LCDR1, an LCDR2, and an LCDR3, respectively, of a V L amino acid sequence set forth in any of SEQ ID NOs:9-20, 91, and 92 (e.g., SEQ ID NOs:9-20).
- a polypeptide comprises a V H domain that has at least about 70% sequence identity to the amino acid sequence of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:89, SEQ ID NO:90, or any combination of the foregoing.
- a V H domain can have at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:89, SEQ ID NO:90, or any combination of the foregoing.
- a V H domain has at least about 85% or at least about 90% sequence identity to the amino acid sequence of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:89, SEQ ID NO:90, or any combination of the foregoing.
- a polypeptide comprises a V L domain that has at least about 70% sequence identity to the amino acid sequence of SEQ ID NO:8.
- the V L domain can have at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO:8.
- the V L domain has at least about 85% or at least about 90% sequence identity to the amino acid sequence of SEQ ID NO:8.
- the sequence identified as SEQ ID NO:8 is shown in Table 2, which corresponds to a human V L domain.
- a polypeptide comprises a V L domain that has at least about 70% sequence identity to the amino acid sequence of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:91, SEQ ID NO:92, or any combination of the foregoing.
- the V L domain can have at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, - 72 - 3839034.v1 5708.1076005 SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:91, SEQ ID NO:92, or any combination of the foregoing.
- the V L domain has at least about 85% or at least about 90% sequence identity to the amino acid sequence of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:91, SEQ ID NO:92, or any combination of the foregoing.
- a polypeptide comprises a V H domain that comprises at least 1 amino acid substitution (e.g., at least 1 conservative substitution such as highly conservative amino acid substitution) relative to the amino acid sequence of SEQ ID NO:3.
- the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5- 14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11, or 9-11.
- a V H domain comprises about 1-10 amino acid substitutions relative to the amino acid sequence of SEQ ID NO:3.
- the at least 1 amino acid substitution replaces only an HCDR1, an HCDR2, and/or an HCDR3 residue of SEQ ID NO:3. In some embodiments, the at least 1 amino acid substitution replaces only a non-CDR residue (e.g., within a framework region) of SEQ ID NO:3.
- a polypeptide comprises a V H domain that comprises at least 1 amino acid substitution relative to the amino acid sequence of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:89, SEQ ID NO:90, or any combination of the foregoing.
- the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11, or 9-11.
- a V H domain comprises about 1-10 amino acid substitutions relative to the amino acid sequence of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:89, SEQ ID NO:90, or any combination of the foregoing.
- the at least 1 amino acid substitution replaces only an HCDR1, an HCDR2, and/or an HCDR3 residue of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:89, SEQ ID NO:90, or any combination of the foregoing.
- the at least 1 amino acid substitution replaces only a non-CDR residue (e.g., within a framework region) of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:89, SEQ ID NO:90,or any combination of the foregoing.
- a polypeptide comprises a V L domain that comprises at least 1 amino acid substitution relative to the amino acid sequence of SEQ ID NO:8.
- the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5- 14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11, or 9-11.
- the V L domain comprises about 1-10 amino acid substitutions relative to the amino acid sequence of SEQ ID NO:8.
- the at least 1 amino acid substitution replaces only an LCDR1, an LCDR2, and/or an LCDR3 residue of SEQ ID NO:8. In particular embodiments, the at least 1 amino acid substitution replaces only a non-CDR residue (e.g., within a framework region) of SEQ ID NO:8.
- a polypeptide comprises a V L domain that comprises at least 1 amino acid substitution relative to the amino acid sequence of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:91, SEQ ID NO:92, or any combination of the foregoing.
- the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7- 12, 8-12, 8-11, or 9-11.
- a V L domain comprises about 1-10 amino acid substitutions relative to the amino acid sequence of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:91, SEQ ID NO:92, or any combination of the foregoing.
- the at least 1 amino acid substitution replaces only an LCDR1, an LCDR2, and/or an LCDR3 residue of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:91, SEQ ID NO:92, or any combination of the foregoing.
- a polypeptide comprises a V H domain that comprises the amino acid sequence of SEQ ID NO:3.
- a polypeptide comprises a V H - 74 - 3839034.v1 5708.1076005 domain that comprises the amino acid sequence of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:89, or SEQ ID NO:90. [00309] In some embodiments, a polypeptide comprises a V L domain that comprises the amino acid sequence of SEQ ID NO:8.
- a polypeptide comprises a V L domain that comprises SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:91, SEQ ID NO:92.
- a polypeptide comprises a V L domain that comprises the amino acid sequence of SEQ ID NO:22.
- a polypeptide comprises a V L domain that comprises SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:91, SEQ ID NO:92.
- a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:8.
- a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:3; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, or SEQ ID NO:20.
- a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:8.
- a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, or SEQ ID NO:20.
- V H and V L domains may be linked together via a linker (e.g., a synthetic linker) to form various types of single-chain antibody designs in which the V H /V L domains pair intramolecularly, or intermolecularly in those cases when the V H and V L domains are expressed by separate chains, to form a monovalent antigen binding site.
- a linker e.g., a synthetic linker
- a polypeptide comprises a V H domain that has at least about 70% sequence identity to one or more V H amino acid sequences set forth in Table 1 and Table 4 herein.
- a polypeptide comprises a V H domain that has at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to one or more V H amino acid sequences set forth in Table 1 and Table 4 herein.
- a polypeptide comprises a V H domain that has at least about 85% sequence identity to one or more V H amino acid sequences set forth in Table 1 and Table 4 herein.
- a polypeptide comprises a V H domain that has at least about 90% sequence identity to one or more V H amino acid sequences set forth in Table 1 and Table 4 herein.
- a polypeptide comprises a V H domain that comprises at least one amino acid substitution relative to one or more V H amino acid sequences set forth in Table 1 and Table 4 herein.
- the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2- 17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11.
- a polypeptide comprises a V H domain that comprises about 1-10 amino acid substitutions, relative to one or more V H amino acid sequences set forth in Table 1 and Table 4 herein. [00318] In some embodiments, an amino acid substitution is a conservative substitution. [00319] In some embodiments, an amino acid substitution is a highly conservative substitution. [00320] In some embodiments, a polypeptide comprises a V H domain that has 100% sequence identity to any one of V H amino acid sequences set forth in Table 1 and Table 4 herein. In some embodiments, a polypeptide comprises a V H domain that comprises any one of V H amino acid sequences set forth in Table 1 and Table 4 herein.
- a polypeptide comprises a V L domain that has at least about 70% sequence identity to one or more V L amino acid sequences set forth in Table 2 and Table 4 herein.
- a polypeptide comprises a V L that has at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, - 76 - 3839034.v1 5708.1076005 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to one or more V L amino acid sequences set forth in Table 2 and Table 4 herein.
- a polypeptide comprises a V L domain that has at least about 85% sequence identity to one or more V L amino acid sequences set forth in Table 2 and Table 4 herein. In some embodiments, a polypeptide comprises a V L domain that has at least about 90% sequence identity to one or more V L amino acid sequences set forth in Table 2 and Table 4 herein. [00322] In some embodiments, a polypeptide comprises a V L domain that comprises at least one amino acid substitution relative to one or more V L amino acid sequences set forth in Table 2 and Table 4 herein.
- the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2- 17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11.
- a polypeptide comprises a V L domain that comprises about 1-10 amino acid substitutions, relative to one or more V L amino acid sequences set forth in Table 2 and Table 4 herein.
- an amino acid substitution is a conservative substitution.
- an amino acid substitution is a highly conservative substitution.
- a polypeptide comprises a V L domain that has 100% sequence identity to any one of V L amino acid sequences set forth in Table 2 and Table 4 herein. In some embodiments, a polypeptide comprises a V L domain that comprises the amino acid sequence of any one of V L amino acid sequences set forth in Table 2 and Table 4 herein.
- a polypeptide comprises: a) a V H domain that has at least about 70% (e.g., at least about: 75, 80, 85, 90, 95, 98, or 99%) sequence identity to one or more V H amino acid sequences set forth in Table 1 and Table 4 herein; b) a V L domain that has at least about 70% (e.g., at least about: 75, 80, 85, 90, 95, 98, or 99%) sequence identity to one or more V L amino acid sequences set forth in Table 2 and Table 4 herein; or both a) and b).
- a polypeptide comprises: a) a V H domain that has at least about 70% (e.g., at least about: 75, 80, 85, 90, 95, 98, or 99%) sequence identity to one or more V H amino acid sequences set forth in Table 1 and Table 4 herein; and - 77 - 3839034.v1 5708.1076005 b) a V L domain that has at least about 70% (e.g., at least about: 75, 80, 85, 90, 95, 98, or 99%) sequence identity to one or more V L amino acid sequences set forth in Table 2 and Table 4 herein.
- a polypeptide comprises: a) a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) relative to one or more V H amino acid sequences set forth in Table 1 and Table 4 herein; b) a V L domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) relative to one or more V L amino acid sequences set forth in Table 2 and Table 4 herein; or both a) and b).
- a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) relative to one or more V H amino acid sequences set forth in Table 1 and Table 4 herein
- a V L domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) relative to one or more V L amino acid sequences set forth in Table 2 and Table 4 herein; or both a) and b).
- a polypeptide comprises: a) a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) relative to one or more V H amino acid sequences set forth in Table 1 and Table 4 herein; and b) a V L domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) relative to one or more V L amino acid sequences set forth in Table 2 and Table 4 herein.
- a polypeptide comprises: a) a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a HCDR1, a HCDR2 and/or a HCDR3 residue, of any one or more V H amino acid sequences set forth in Table 1 and Table 4 herein; b) a V L domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a LCDR1, a LCDR2 and/or a LCDR3 residue, of any one or more V L amino acid sequences set forth in Table 2 and Table 4 herein; or both a) and b).
- a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a HCDR1, a HCDR2 and/or a HCDR3 residue, of any one or more V H amino acid sequences set forth in Table 1 and Table 4 herein
- a polypeptide comprises: - 78 - 3839034.v1 5708.1076005 a) a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a HCDR1, a HCDR2 and/or a HCDR3 residue, of any one or more V H amino acid sequences set forth in Table 1 and Table 4 herein; and b) a V L domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a LCDR1, a LCDR2 and/or a LCDR3 residue, of any one or more V L amino acid sequences set forth in Table 2 and Table 4 herein.
- a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a HCDR1, a HCDR2 and/or a HCDR3 residue, of any one or more V L amino acid sequence
- a polypeptide comprises: a) a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of any one or more V H amino acid sequences set forth in Table 1 and Table 4 herein; b) a V L domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of any one or more V L amino acid sequences set forth in Table 2 and Table 4 herein; or both a) and b).
- a polypeptide comprises: a) a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of any one or more V H amino acid sequences set forth in Table 1 and Table 4 herein; and b) a V L domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of any one or more V L amino acid sequences set forth in Table 2 and Table 4 herein.
- a V H domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of any one or more V L amino acid sequences set forth in Table 2 and Table 4 herein.
- a polypeptide comprises: a) a V H domain comprising any one of V H amino acid sequences set forth in Table 1 and Table 4 herein; and b) a V L domain comprising any one of V L amino acid sequences set forth in Table 2 and Table 4 herein.
- a polypeptide comprises: - 79 - 3839034.v1 5708.1076005 a) a V H domain comprising any one of V H amino acid sequences set forth in Table 1 and Table 4 herein; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:8.
- a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:3; and b) a V L domain comprising any one of V L amino acid sequences set forth in Table 2 and Table 4 herein. [00337] In some embodiments, a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:255; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:14.
- a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:292; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:477. [00339] In some embodiments, a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:206; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:14. [00340] In some embodiments, a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:202; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:434.
- a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:140; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:472.
- a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:240; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:449.
- a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:213; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:472.
- a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:258; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:477. [00345] In some embodiments, a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:213; and - 80 - 3839034.v1 5708.1076005 b) a V L domain comprising the amino acid sequence of SEQ ID NO:477.
- a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:5; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:512. [00347] In some embodiments, a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:158; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:469. [00348] In some embodiments, a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:213; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:452.
- a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:232; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:469.
- a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:140; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:449.
- a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:213; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:484.
- a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:204; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:455.
- a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:213; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:461.
- a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:137; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:426.
- a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:240; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:424.
- a polypeptide comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:130; and - 81 - 3839034.v1 5708.1076005 b) a V L domain comprising the amino acid sequence of SEQ ID NO:477.
- Paratopes [00357] Amino acid residues of a paratope contribute to an antibody’s interaction with an epitope of its target protein.
- An interaction can be a hydrogen bond, a salt bridge, a van der Waals interaction, an electrostatic interaction, a hydrophobic interaction, pi-interaction effects, an ionic bond, and/or any combination thereof.
- An interaction can be direct, or indirect, e.g., via a coordinated intermediate molecule, such as an ion or water.
- the residues of a paratope in some embodiments, comprise only residues that are part of a defined CDR. In some embodiments, the residues of a paratope further comprise one or more residues that are not part of a defined CDR (e.g., residues within a defined framework region).
- a paratope is oriented less than about 5.0 angstroms from an epitope on a target antigen when a polypeptide is bound to the target antigen, e.g., less than about: 4.5, 4.0, 3.5, 3.0, 2.5, 2.4, 2.3, 2.2, 2.1, 2.0, 1.9, 1.8, 1.7, 1.6, 1.5, 1.4, 1.3, 1.2, 1.1, 1.0, or 0.9 angstroms, or about: 0.9-5.0, 0.9-4.8.1.0-5, 1.0-4.5, 1.0-4.0, 1.0-3.5, 1.1-3.5, 1.1-3.0, 1.2-3.0, 1.2-2.5, 1.3-2.5, 1.3-2.4, 1.4-2.4, 1.4-2.3, 1.5-2.3, 1.5-2.2, 1.6-2.2, 1.6-2.1, 1.7-2.1, 1.7-2.0, or 1.8-2.0 angstroms, from the epitope.
- less than all of the amino acid residues constituting a paratope (e.g., about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% of the amino acid residues) in the paratope are oriented less than about 5.0 angstroms from an epitope on a target antigen when a polypeptide is bound to the target antigen.
- a polypeptide e.g., an antibody or antigen-binding fragment thereof
- a paratope comprises a V H domain and a V L domain.
- paratope residues are contained within a V H and V L of a polypeptide.
- a polypeptide comprises a paratope that differs from a paratope of an antibody comprising a V H/ V L combination of SEQ ID NO:3/SEQ ID NO:8.
- a polypeptide comprises a V H domain that has at least about 70% sequence identity to the amino acid sequence of SEQ ID NO:3.
- a V H can have at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO:3.
- a V H has at least about 85% or at least about 90% sequence identity to the amino acid sequence of SEQ ID NO:3.
- the sequence identified as SEQ ID NO:3 is shown in Table 1, which corresponds to a human V H domain.
- a polypeptide comprises a paratope that is substantially similar (e.g., having at least about 90% sequence identity) to a paratope of an antibody comprising a V H/ V L combination of SEQ ID NO:3/SEQ ID NO:8.
- a polypeptide comprises a paratope that is substantially similar (e.g., having at least about 90% sequence identity) to, and substantially preserves one or more functional properties of, a paratope of an antibody comprising a V H/ V L combination of SEQ ID NO:3/SEQ ID NO:8.
- a polypeptide comprises a paratope that has 100% sequence identity to a paratope of an antibody comprising a V H/ V L combination of SEQ ID NO:3/SEQ ID NO:8.
- a polypeptide comprises a paratope that differs from a paratope of an antibody comprising a V H/ V L combination of SEQ ID NO:3/SEQ ID NO:8, by substitution (e.g., conservative substitution such as highly conservative substitution) of from 1 to 3 (e.g., 1, 2 or 3) residues.
- a polypeptide comprises a paratope that differs from a paratope of a V H/ V L combination selected from: SEQ ID NO:4/SEQ ID NO:9 (AB-1a), SEQ ID NO:4/SEQ ID NO:10 (AB-1b), SEQ ID NO:4/SEQ ID NO:11 (AB-1c), SEQ ID NO:4/SEQ ID NO:12 (AB-1d), SEQ ID NO:5/SEQ ID NO:13 (AB-2a), SEQ ID NO:5/SEQ ID NO:14 (AB- 2b), SEQ ID NO:5/SEQ ID NO:15 (AB-2c), SEQ ID NO:5/SEQ ID NO:16 (AB-2d), SEQ ID NO:6/SEQ ID NO:17 (AB-3a), SEQ ID NO:6/SEQ ID NO:18 (AB-3b), SEQ ID NO:6/SEQ ID NO:19 (AB-3c), or SEQ ID NO:6/SEQ ID NO:20 (AB-1a), SEQ ID NO
- a polypeptide comprises a paratope that is substantially similar (e.g., having at least about 90% sequence identity) to a paratope of an antibody comprising a V H /V L pair selected from: SEQ ID NO:4 and SEQ ID NO:9 (AB-1a); SEQ ID NO:4 and SEQ ID NO:10 (AB-1b); SEQ ID NO:4 and SEQ ID NO:11 (AB-1c); SEQ ID NO:4 and SEQ ID NO:12 (AB-1d); SEQ ID NO:5 and SEQ ID NO:13 (AB-2a); SEQ ID NO:5 and SEQ ID NO:14 (AB-2b); SEQ ID NO:5 and SEQ ID NO:15 (AB-2c); SEQ ID NO:5 and SEQ ID NO:16 (AB-2d); - 83 - 3839034.v1 5708.1076005 SEQ ID NO:6
- a polypeptide comprises a paratope that is substantially similar (e.g., having at least about 90% sequence identity) to, and substantially preserves one or more functional properties of, a paratope of an antibody comprising a V H /V L pair selected from: SEQ ID NO:4 and SEQ ID NO:9 (AB-1a); SEQ ID NO:4 and SEQ ID NO:10 (AB-1b); SEQ ID NO:4 and SEQ ID NO:11 (AB-1c); SEQ ID NO:4 and SEQ ID NO:12 (AB-1d); SEQ ID NO:5 and SEQ ID NO:13 (AB-2a); SEQ ID NO:5 and SEQ ID NO:14 (AB-2b); SEQ ID NO:5 and SEQ ID NO:15 (AB-2c); SEQ ID NO:5 and SEQ ID NO:16 (AB-2d); SEQ ID NO:6 and SEQ ID NO:17 (AB-3a); SEQ ID NO:6 and SEQ ID NO:18 (AB-3b); SEQ ID NO:6 and SEQ ID
- a polypeptide comprises a paratope comprising only one or more conservative substitutions (e.g., only one or more highly conservative substitutions) relative a paratope of an antibody comprising a V H /V L pair selected from: SEQ ID NO:4 and SEQ ID NO:9 (AB-1a); SEQ ID NO:4 and SEQ ID NO:10 (AB-1b); SEQ ID NO:4 and SEQ ID NO:11 (AB-1c); SEQ ID NO:4 and SEQ ID NO:12 (AB-1d); SEQ ID NO:5 and SEQ ID NO:13 (AB-2a); SEQ ID NO:5 and SEQ ID NO:14 (AB-2b); SEQ ID NO:5 and SEQ ID NO:15 (AB-2c); SEQ ID NO:5 and SEQ ID NO:16 (AB-2d); SEQ ID NO:6 and SEQ ID NO:17 (AB-3a); - 84 - 3839034.v1 5708.1076005 SEQ ID NO:6
- the disclosure provides a polypeptide that specifically binds SARS-CoV-2-Spike, wherein the polypeptide comprises a paratope that has 100% sequence identity to a paratope of an antibody comprising a V H /V L pair selected from: SEQ ID NO:4 and SEQ ID NO:9 (AB-1a); SEQ ID NO:4 and SEQ ID NO:10 (AB-1b); SEQ ID NO:4 and SEQ ID NO:11 (AB-1c); SEQ ID NO:4 and SEQ ID NO:12 (AB-1d); SEQ ID NO:5 and SEQ ID NO:13 (AB-2a); SEQ ID NO:5 and SEQ ID NO:14 (AB-2b); SEQ ID NO:5 and SEQ ID NO:15 (AB-2c); SEQ ID NO:5 and SEQ ID NO:16 (AB-2d); SEQ ID NO:6 and SEQ ID NO:17 (AB-3a); SEQ ID NO:6 and SEQ ID NO:18 (AB-3b); SEQ ID NO:6 and SEQ ID
- a polypeptide comprises a paratope that is substantially similar to a paratope of a polypeptide selected from any one of AB-1a, AB-1b, AB-1c, AB-1d, AB-2a, AB-2b, AB-2c, AB-2d, AB-3a, AB-3b, AB-3c, and AB-3d.
- a polypeptide comprises a paratope comprising only conservative substitutions (e.g., only highly conservative substitutions) relative a paratope of a polypeptide selected from any one of AB-1a, AB-1b, AB- 1c, AB-1d, AB-2a, AB-2b, AB-2c, AB-2d, AB-3a, AB-3b, AB-3c, and AB-3d.
- a polypeptide comprises a paratope comprising up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 conservative substitutions (e.g., up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 highly conservative substitutions), relative a paratope of a polypeptide selected from any one of AB-1a, AB-1b, AB-1c, AB-1d, AB-2a, AB-2b, AB-2c, AB-2d, AB-3a, AB-3b, AB- 3c, and AB-3d.
- a polypeptide comprises a paratope having 100% sequence identity to a paratope of a polypeptide selected from any one of AB-1a, AB-1b, AB-1c, AB-1d, AB-2a, AB-2b, AB-2c, AB-2d, AB-3a, AB-3b, AB-3c, and AB-3d.
- a polypeptide comprises a paratope that is substantially similar to a paratope of a V H/ V L combination selected from: SEQ ID NO:4/SEQ ID NO:9 (AB-1a), SEQ ID NO:4/SEQ ID NO:10 (AB-1b), SEQ ID NO:4/SEQ ID NO:11 (AB-1c), SEQ ID NO:4/SEQ ID NO:12 (AB-1d), SEQ ID NO:5/SEQ ID NO:13 (AB-2a), SEQ ID NO:5/SEQ ID NO:14 (AB- 2b), SEQ ID NO:5/SEQ ID NO:15 (AB-2c), SEQ ID NO:5/SEQ ID NO:16 (AB-2d), SEQ ID NO:6/SEQ ID NO:17 (AB-3a), SEQ ID NO:6/SEQ ID NO:18 (AB-3b), SEQ ID NO:6/SEQ ID NO:19
- a polypeptide comprises a paratope that is identical to a paratope of a V H/ V L combination selected from: SEQ ID NO:4/SEQ ID NO:9 (AB-1a), SEQ ID NO:4/SEQ ID NO:10 (AB-1b), SEQ ID NO:4/SEQ ID NO:11 (AB-1c), SEQ ID NO:4/SEQ ID NO:12 (AB-1d), SEQ ID NO:5/SEQ ID NO:13 (AB-2a), SEQ ID NO:5/SEQ ID NO:14 (AB- 2b), SEQ ID NO:5/SEQ ID NO:15 (AB-2c), SEQ ID NO:5/SEQ ID NO:16 (AB-2d), SEQ ID NO:6/SEQ ID NO:17 (AB-3a), SEQ ID NO:6/SEQ ID NO:18 (AB-3b), SEQ ID NO:6/SEQ ID NO:19 (AB-3c), or SEQ ID NO:6/SEQ ID NO:20
- a polypeptide (e.g., an antibody or antigen-binding fragment thereof) comprises a V H comprising the amino acid sequence of SEQ ID NO:2, wherein: X 1 is not G; X 2 is not I; X 3 is not F; X 4 is not N; X 5 is not M; X 6 is not S; X 7 is not M; X 8 is not N; X 9 is not G; X 10 is not N; X 11 is not I; or any combination of the foregoing.
- SEQ ID NO:2 The sequence identified as SEQ ID NO:2 is shown in Table 1, which is a consensus V H sequence for SEQ ID Nos:3-6 herein.
- X 1 is G or D; - 86 - 3839034.v1 5708.1076005
- X 2 is I, T or Y;
- X 3 is F, S or D;
- X 4 is N or D;
- X 5 is M or L;
- X 6 is S or F;
- X 7 is M, Y or A;
- X 8 is N or H;
- X 9 is G or P;
- X 10 is N or D;
- X 11 is I or F; or any combination of the foregoing.
- X 1 is D; X 2 is T or Y; X 3 is S or D; X 4 is D; X 5 is L; X 6 is F; X 7 is Y or A; X 8 is H; X 9 is P; X 10 is D; X 11 is F; or any combination of the foregoing.
- X 1 is not G. In some embodiments, X 1 is G or D. In some embodiments, X 1 is G. In some embodiments, X 1 is D. [00378] In some embodiments, X 2 is not I. In some embodiments, X 2 is I, T or Y. In some embodiments, X 2 is T or Y.
- X 2 is I. In some embodiments, X 2 is T. In some embodiments, X 2 is Y. [00379] In some embodiments, X 3 is not F. In some embodiments, X 3 is F, S or D. In some embodiments, X 3 is S or D. In some embodiments, X 3 is F. In some embodiments, X 3 is S. In some embodiments, X 3 is D. - 87 - 3839034.v1 5708.1076005 [00380] In some embodiments, X 4 is not N. In some embodiments, X 4 is N or D. In some embodiments, X 4 is N. In some embodiments, X 4 is D.
- X 5 is not M. In some embodiments, X 5 is M or L. In some embodiments, X 5 is M. In some embodiments, X 5 is L. [00382] In some embodiments, X 6 is not S. In some embodiments, X 6 is S or F. In some embodiments, X 6 is S. In some embodiments, X 6 is F. [00383] In some embodiments, X 7 is not M. In some embodiments, X 7 is M, Y or A. In some embodiments, X 7 is Y or A. In some embodiments, X 7 is M. In some embodiments, X 7 is Y. In some embodiments, X 7 is A.
- X 8 is not N. In some embodiments, X 8 is N or H. In some embodiments, X 8 is N. In some embodiments, X 8 is H. [00385] In some embodiments, X 9 is not G. In some embodiments, X 9 is G or P. In some embodiments, X 9 is G. In some embodiments, X 9 is P. [00386] In some embodiments, X 10 is not N. In some embodiments, X 10 is N or D. In some embodiments, X 10 is N. In some embodiments, X 10 is D. [00387] In some embodiments, X 11 is not I. In some embodiments, X 11 is I or F.
- X 11 is I. In some embodiments, X 11 is F.
- a polypeptide e.g., an antibody or antigen-binding fragment thereof
- the sequence identified as SEQ ID NO:7 is shown in Table 2, which is a consensus V L sequence for SEQ ID Nos:8-20 herein.
- X 12 is N or S; - 88 - 3839034.v1 5708.1076005
- X 13 is D or R;
- X 14 is C, A, S, or Y;
- X 15 is N or R;
- X 16 is S or D;
- X 17 is L or S;
- X 18 is S or F;
- X 19 is G or D;
- X 20 is N or H; or any combination of the foregoing.
- X 12 is S; X 13 is R; X 14 is A, S, or Y; X 15 is R; X 16 is D; X 17 is S; X 18 is F; X 19 is D; X 20 is H; or any combination of the foregoing.
- X 12 is not N. In some embodiments, X 12 is N or S. In some embodiments, X 12 is N. In some embodiments, X 12 is S. [00393] In some embodiments, X 13 is not D. In some embodiments, X 13 is D or R. In some embodiments, X 13 is D. In some embodiments, X 13 is R.
- X 14 is not C. In some embodiments, X 14 is C, A, S, or Y. In some embodiments, X 14 is A, S, or Y. In some embodiments, X 14 is C. In some embodiments, X 14 is A. In some embodiments, X 14 is S. In some embodiments, X 14 is Y. [00395] In some embodiments, X 15 is not N. In some embodiments, X 15 is N or R. In some embodiments, X 15 is N. In some embodiments, X 15 is R. [00396] In some embodiments, X 16 is not S. In some embodiments, X 16 is S or D. In some embodiments, X 16 is S.
- X 16 is D. [00397] In some embodiments, X 17 is not L. In some embodiments, X 17 is L or S. In some embodiments, X 17 is L. In some embodiments, X 17 is S. - 89 - 3839034.v1 5708.1076005 [00398] In some embodiments, X 18 is not S. In some embodiments, X 18 is S or F. In some embodiments, X 18 is S. In some embodiments, X 18 is F. [00399] In some embodiments, X 19 is not G. In some embodiments, X 19 is G or D. In some embodiments, X 19 is G. In some embodiments, X 19 is D.
- X 20 is not N. In some embodiments, X 20 is N or H. In some embodiments, X 20 is N. In some embodiments, X 20 is H. [00401] In some embodiments, a) X 1 is G, X 2 is Y, X 3 is D, X 4 is N, X 5 is L, X 6 is F, X 7 is A, X 8 is H, X 9 is P, X 10 is D, X 11 is F, X 12 is S, X 13 is D, X 14 is C, X 15 is R, X 16 is D, X 17 is S, X 18 is S, X 19 is G, X 20 is H, or a combination thereof (AB-1a); b) X 1 is G, X 2 is Y, X 3 is D, X 4 is N, X 5 is L, X 6 is F, X 7 is A, X 8 is H, X 9 is P, X 10
- X 1 is D
- X 2 is T
- X 3 is S
- X 4 is D
- X 5 is L
- X 6 is S
- X 7 is Y
- X 8 is N
- X 9 is G
- X 10 is D
- X 11 is F
- X 12 is S
- X 13 is R
- X 14 is A
- X 15 is R
- X 16 is S
- X 17 is L
- X 18 is F
- X 19 is D
- X 20 is H, or a combination thereof (AB-2b).
- a polypeptide (e.g., an antibody or antigen-binding fragment thereof) comprises: a) an antibody heavy chain constant domain sequence; b) an antibody light chain constant domain sequence; or c) both an antibody heavy chain constant domain sequence and an antibody light chain constant domain sequence.
- a polypeptide comprises an antibody heavy chain constant domain sequence.
- an antibody heavy chain constant domain is selected from the group consisting of an IgA constant domain, an IgD constant domain, an IgE constant domain, an IgG constant domain, and an IgM constant domain.
- an IgG constant domain is an IgG1 constant domain (e.g., SEQ ID NO:576 or SEQ ID NO:50), an IgG2 constant domain, an IgG3 constant domain, or an IgG4 constant domain.
- the IgG2 constant domain is an IgG2a constant domain, an IgG2b constant domain or an IgG2c constant domain.
- the IgA constant domain is an IgA1 constant domain or an IgA2 constant domain.
- the antibody heavy chain constant domain is an IgG1 constant domain (e.g., IGHV1-5 or IGHV5-51).
- a polypeptide comprises an antibody heavy chain constant domain sequence that has at least about 60% sequence identity to the amino acid sequence of SEQ ID NO:576.
- a polypeptide can comprise an antibody heavy chain constant domain sequence that has at least about: 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO:576.
- a polypeptide comprises an antibody heavy chain constant domain sequence that has at least about 70% or at least about 80% sequence identity to the amino acid sequence of SEQ ID NO:576.
- a polypeptide comprises an antibody heavy chain constant domain sequence that comprises at least one amino acid substitution relative to the amino acid sequence of SEQ ID NO:576.
- the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11.
- a polypeptide comprises an antibody heavy chain constant domain sequence that comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of SEQ ID NO:576. [00409] In some embodiments, a polypeptide comprises an antibody heavy chain constant domain sequence that has 100% sequence identity to the amino acid sequence of SEQ ID NO:576.
- a polypeptide comprises an antibody heavy chain constant domain sequence that has at least about 60% sequence identity to the amino acid sequence of SEQ ID NO:50.
- a polypeptide can comprise an antibody heavy chain constant domain sequence that has at least about: 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO:50.
- a polypeptide comprises an antibody heavy chain constant domain sequence that has at least about 70% or at least about 80% sequence identity to the amino acid sequence of SEQ ID NO:50.
- a polypeptide comprises an antibody heavy chain constant domain sequence that comprises at least one amino acid substitution relative to the amino acid sequence of SEQ ID NO:50.
- the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11.
- a polypeptide comprises an antibody heavy chain constant domain sequence that comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of SEQ ID NO:50. [00413] In some embodiments, a polypeptide comprises an antibody heavy chain constant domain sequence that has 100% sequence identity to the amino acid sequence of SEQ ID NO:50. [00414] In some embodiments, a polypeptide comprises an Fc polypeptide, or Fc domain (e.g., an IgG1 domain, an IgG2 domain or an IgG4 domain).
- an Fc domain comprises one or more mutations that, for example, decreases (e.g., inhibits, ablates) an effector function of the Fc domain, increases half-life of an antibody or antibody fragment that comprises the Fc domain, or a combination thereof.
- decreases e.g., inhibits, ablates
- an effector function of the Fc domain increases half-life of an antibody or antibody fragment that comprises the Fc domain, or a combination thereof.
- an Fc domain comprises a LS modification (i.e., M428L/N434S substitutions with numbering determined by Kabat) or a YTE modification (i.e., M252Y/S254T/T256E substitutions as determined by Kabat numbering).
- an Fc domain comprises a LS modification.
- a polypeptide e.g., an antibody or antigen-binding fragment thereof
- a polypeptide comprises an antibody light chain constant domain sequence that is a ⁇ constant domain (e.g., SEQ ID NO:577 or SEQ ID NO:52).
- GQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAG VETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO:577).
- a polypeptide comprises an antibody light chain constant domain sequence that has at least about 60% sequence identity to the amino acid sequence of SEQ ID NO:557 or SEQ ID NO:52.
- a polypeptide can comprise an antibody light chain constant domain sequence that has at least about: 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of SEQ ID NO:557 or SEQ ID NO:52.
- a polypeptide comprises an antibody light chain constant domain sequence that has at least about 70% or at least about 80% sequence identity to SEQ ID NO:557 or SEQ ID NO:52. [00420] In some embodiments, a polypeptide comprises an antibody light chain constant domain sequence that comprises at least one amino acid substitution relative to the amino acid sequence of SEQ ID NO:557 or SEQ ID NO:52.
- the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7- 12, 8-12, 8-11 or 9-11.
- a polypeptide comprises an antibody light chain constant domain sequence that comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of SEQ ID NO:557 or SEQ ID NO:52.
- the at least one amino acid substitution is a conservative substitution.
- the at least one amino acid substitution is a highly conservative substitution.
- a polypeptide comprises an antibody light chain constant domain sequence that has 100% sequence identity to the amino acid sequence of SEQ ID NO:557 or SEQ ID NO:52. [00422] In some embodiments, a polypeptide comprises an antibody light chain constant domain sequence that has at least about 60% sequence identity to the amino acid sequence of - 94 - 3839034.v1 5708.1076005 SEQ ID NO:557.
- a polypeptide can comprise an antibody light chain constant domain sequence that has at least about: 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of SEQ ID NO:557.
- a polypeptide comprises an antibody light chain constant domain sequence that has at least about 70% or at least about 80% sequence identity to SEQ ID NO:557. [00423] In some embodiments, a polypeptide comprises an antibody light chain constant domain sequence that comprises at least one amino acid substitution relative to the amino acid sequence of SEQ ID NO:557.
- the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11.
- a polypeptide comprises an antibody light chain constant domain sequence that comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of SEQ ID NO:557. In some embodiments, the at least one amino acid substitution is a conservative substitution. In some embodiments, the at least one amino acid substitution is a highly conservative substitution. [00424] In some embodiments, a polypeptide comprises an antibody light chain constant domain sequence that has 100% sequence identity to the amino acid sequence of SEQ ID NO:557. [00425] In some embodiments, a polypeptide comprises an antibody light chain constant domain sequence that is a ⁇ constant domain (e.g., SEQ ID NO:51).
- a polypeptide comprises an antibody light chain constant domain sequence that has at least about 60% sequence identity to the amino acid sequence of SEQ ID NO:557, SEQ ID NO:52, or SEQ ID NO:51.
- a polypeptide can comprise an antibody light chain constant domain sequence that has at least about: 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of SEQ ID NO:557, SEQ ID NO:52, or SEQ ID NO:51.
- a polypeptide comprises an antibody light - 95 - 3839034.v1 5708.1076005 chain constant domain sequence that has at least about 70% or at least about 80% sequence identity to SEQ ID NO:557, SEQ ID NO:52, or SEQ ID NO:51. [00428] In some embodiments, a polypeptide comprises an antibody light chain constant domain sequence that comprises at least one amino acid substitution relative to the amino acid sequence of SEQ ID NO:557, SEQ ID NO:52, or SEQ ID NO:51.
- the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6- 13, 7-13, 7-12, 8-12, 8-11 or 9-11.
- a polypeptide comprises an antibody light chain constant domain sequence that comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of SEQ ID NO:557, SEQ ID NO:52, or SEQ ID NO:51.
- the at least one amino acid substitution is a conservative substitution.
- the at least one amino acid substitution is a highly conservative substitution.
- a polypeptide comprises an antibody light chain constant domain sequence that has 100% sequence identity to the amino acid sequence of SEQ ID NO:557, SEQ ID NO:52, or SEQ ID NO:51.
- a polypeptide comprises: a) an antibody heavy chain constant domain sequence; and b) an antibody light chain constant domain sequence.
- a polypeptide comprises an antibody heavy chain constant domain that is an IgG1 constant domain (e.g., SEQ ID NO:576 or SEQ ID NO:50), and an antibody light chain constant domain that is a ⁇ constant domain (e.g., SEQ ID NO:577 or SEQ ID NO:52).
- a polypeptide comprises: a) an antibody heavy chain constant domain comprising SEQ ID NO:576; b) an antibody light chain constant domain comprising SEQ ID NO:577; or both a) and b).
- a polypeptide comprises: a) an antibody heavy chain constant domain comprising SEQ ID NO:576; and b) an antibody light chain constant domain comprising SEQ ID NO:577.
- a polypeptide comprises: a) an antibody heavy chain constant domain comprising SEQ ID NO:50; b) an antibody light chain constant domain comprising SEQ ID NO:577; or both a) and b).
- a polypeptide comprises: a) an antibody heavy chain constant domain comprising SEQ ID NO:50; and [00436] an antibody light chain constant domain comprising SEQ ID NO:577. [00437] In some embodiments, a polypeptide comprises: a) an antibody heavy chain constant domain comprising SEQ ID NO:576; b) an antibody light chain constant domain comprising SEQ ID NO:52; or both a) and b).
- a polypeptide comprises: a) an antibody heavy chain constant domain comprising SEQ ID NO:576; and b) an antibody light chain constant domain comprising SEQ ID NO:52.
- Antibodies and Antigen Binding Fragments [00439] In some embodiments, a polypeptide specifically binds a spike receptor-binding domain (RBD) class 4 epitope of a betacoronavirus Spike glycoprotein (SARS-CoV-2-Spike).
- a polypeptide is an immunoglobulin molecule, such as an antibody (e.g., a whole antibody, an intact antibody) or an antigen-binding fragment of an antibody.
- a polypeptide is an antibody.
- the term “antibody” refers to an immunoglobulin molecule capable of specific binding to a target, such as a carbohydrate, polynucleotide, lipid, polypeptide, etc., through at least one antigen recognition site, located in the variable domain of the immunoglobulin molecule.
- the term “antibody” refers to a full-length antibody.
- a polypeptide is an antibody comprising two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds or multimers thereof (for example, IgM).
- Each heavy chain comprises a VH and a heavy chain constant domain (comprising domains CH1, hinge CH2 and CH3).
- Each light chain comprises a VL and a light chain constant domain (CL).
- VH and VL regions may be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed within framework regions (FRs).
- CDRs complementarity determining regions
- FRs framework regions
- VH and VL each comprises three CDRs and four FRs, arranged from the amino-terminus to the carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.
- An antibody can be of any species, such as a murine antibody, a human antibody, or a humanized antibody.
- a polypeptide comprises a heavy chain amino acid sequence that has at least about 60% sequence identity to the amino acid sequence of any one or more of - 97 - 3839034.v1 5708.1076005 SEQ ID NOs:578-591.
- a polypeptide can comprise a heavy chain amino acid sequence that has at least about: 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:578-591.
- a polypeptide comprises a heavy chain amino acid sequence that has at least about 70% or at least about 80% sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:578-591.
- a polypeptide comprises a heavy chain amino acid sequence that comprises at least one amino acid substitution relative to the amino acid sequence of any one or more of SEQ ID NOs:578-591.
- the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11.
- a polypeptide comprises a heavy chain amino acid sequence that comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of any one or more of SEQ ID NOs:578-591. [00459] In some embodiments, a polypeptide comprises a heavy chain amino acid sequence that has 100% sequence identity to the amino acid sequence of any one of SEQ ID NOs:578-591. [00460] In some embodiments, a polypeptide comprises a heavy chain amino acid sequence that has at least about 60% sequence identity to the amino acid sequence of SEQ ID NO:578.
- a polypeptide can comprise a heavy chain amino acid sequence that has at least about: 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of SEQ ID NO:578.
- a polypeptide comprises a heavy chain amino acid sequence that has at least about 70% or at least about 80% sequence identity to the amino acid sequence of SEQ ID NO:578.
- a polypeptide comprises a heavy chain amino acid sequence that comprises at least one amino acid substitution relative to the amino acid sequence of SEQ ID NO:578.
- the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11.
- a polypeptide comprises a heavy chain amino acid sequence that comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of SEQ ID NO:578. [00462] In some embodiments, a polypeptide comprises a heavy chain amino acid sequence that has 100% sequence identity to the amino acid sequence of SEQ ID NO:578. [00463] In some embodiments, a polypeptide comprises a heavy chain amino acid sequence that has at least about 60% sequence identity to the amino acid sequence of SEQ ID NO:579.
- a polypeptide can comprise a heavy chain amino acid sequence that has at least about: 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of SEQ ID NO:579.
- a polypeptide comprises a heavy chain amino acid sequence that has at least about 70% or at least about 80% sequence identity to the amino acid sequence of SEQ ID NO:579. [00464] In some embodiments, a polypeptide comprises a heavy chain amino acid sequence that comprises at least one amino acid substitution relative to the amino acid sequence of SEQ ID NO:579.
- the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11.
- a polypeptide comprises a heavy chain amino acid sequence that comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of SEQ ID NO:579. [00465] In some embodiments, a polypeptide comprises a heavy chain amino acid sequence that has 100% sequence identity to the amino acid sequence of SEQ ID NO:579. [00466] In some embodiments, a polypeptide comprises a light chain amino acid sequence that has at least about 60% sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:592-603.
- a polypeptide can comprise a light chain amino acid sequence that has at least about: 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:592-603.
- a polypeptide comprises a light chain amino acid sequence that has at least about 70% or at least about 80% sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:592-603.
- QTVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYRVHWYQQLPGTAPKLLIAGR SNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLFDPHWVFGGGTKLTV LGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPS KQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO:592).
- a polypeptide comprises a light chain amino acid sequence that comprises at least one amino acid substitution relative to the amino acid sequence of any one or more of SEQ ID NOs:592-603.
- the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11.
- a polypeptide comprises a light chain amino acid sequence that comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of any one or more of SEQ ID NOs:592-603. [00481] In some embodiments, a polypeptide comprises a light chain amino acid sequence that has 100% sequence identity to the amino acid sequence of any one of SEQ ID NOs:592-603. [00482] In some embodiments, a polypeptide comprises a light chain amino acid sequence that has at least about 60% sequence identity to the amino acid sequence of SEQ ID NO:592.
- a polypeptide can comprise a light chain amino acid sequence that has at least about: 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of SEQ ID NO:592.
- a polypeptide comprises a light chain amino acid sequence - 105 - 3839034.v1 5708.1076005 that has at least about 70% or at least about 80% sequence identity to the amino acid sequence of SEQ ID NO:592. [00483] In some embodiments, a polypeptide comprises a light chain amino acid sequence that comprises at least one amino acid substitution relative to the amino acid sequence of SEQ ID NO:592.
- the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11.
- a polypeptide comprises a light chain amino acid sequence that comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of SEQ ID NO:592. [00484] In some embodiments, a polypeptide comprises a light chain amino acid sequence that has 100% sequence identity to the amino acid sequence of SEQ ID NO:592.
- a polypeptide comprises: a) a heavy chain amino acid sequence that has at least about 60% sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:578-591; or b) a light chain amino acid sequence that has at least about 60% sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:592-603; or both a) and b).
- a polypeptide comprises: a) a heavy chain amino acid sequence that has at least about 60% sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:578-591; and b) a light chain amino acid sequence that has at least about 60% sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:592-603.
- a polypeptide comprises: a) a heavy chain amino acid sequence comprising at least one amino acid substitution relative to the amino acid sequence of any one or more of SEQ ID NOs:578-591; or b) a light chain amino acid sequence comprising at least one amino acid substitution relative to the amino acid sequence of any one or more of SEQ ID NOs:592-603; or both a) and b).
- a polypeptide comprises: - 106 - 3839034.v1 5708.1076005 a) a heavy chain amino acid sequence comprising at least one amino acid substitution relative to the amino acid sequence of any one or more of SEQ ID NOs:578-591; and b) a light chain amino acid sequence comprising at least one amino acid substitution relative to the amino acid sequence of any one or more of SEQ ID NOs:592-603.
- a polypeptide comprises: a) a heavy chain amino acid sequence comprising about 1-10 amino acid substitutions, relative to the amino acid sequence of any one or more of SEQ ID NOs:578-591; or b) a light chain amino acid sequence comprising about 1-10 amino acid substitutions, relative to the amino acid sequence of any one or more of SEQ ID NOs:592-603; or both a) and b).
- a polypeptide comprises: a) a heavy chain amino acid sequence comprising about 1-10 amino acid substitutions, relative to the amino acid sequence of any one or more of SEQ ID NOs:578-591; and b) a light chain amino acid sequence comprising about 1-10 amino acid substitutions, relative to the amino acid sequence of any one or more of SEQ ID NOs:592-603.
- a polypeptide comprises: a) a heavy chain amino acid sequence that has 100% sequence identity to the amino acid sequence of any one of SEQ ID NOs:578-591; or b) a light chain amino acid sequence that has 100% sequence identity to the amino acid sequence of any one of SEQ ID NOs:592-603; or both a) and b).
- a polypeptide comprises: a) a heavy chain amino acid sequence that has 100% sequence identity to the amino acid sequence of any one of SEQ ID NOs:578-591; and b) a light chain amino acid sequence that has 100% sequence identity to the amino acid sequence of any one of SEQ ID NOs:592-603.
- a polypeptide comprises: a) a heavy chain amino acid sequence that has at least about 60% sequence identity to the amino acid sequence of SEQ ID NO:578; or b) a light chain amino acid sequence that has at least about 60% sequence identity to the amino acid sequence of SEQ ID NO:592; or both a) and b).
- a polypeptide comprises: a) a heavy chain amino acid sequence that has at least about 60% sequence identity to the amino acid sequence of SEQ ID NO:578; and b) a light chain amino acid sequence that has at least about 60% sequence identity to the amino acid sequence of SEQ ID NO:592.
- a polypeptide comprises: a) a heavy chain amino acid sequence comprising at least one amino acid substitution relative to the amino acid sequence of SEQ ID NO:578; or b) a light chain amino acid sequence comprising about 1-10 amino acid substitutions, relative to the amino acid sequence of SEQ ID NO:592; or both a) and b).
- a polypeptide comprises: a) a heavy chain amino acid sequence comprising at least one amino acid substitution relative to the amino acid sequence of SEQ ID NO:578; and b) a light chain amino acid sequence comprising about 1-10 amino acid substitutions, relative to the amino acid sequence of SEQ ID NO:592.
- a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:578; and b) a light chain comprising the amino acid sequence of SEQ ID NO:592 (AB-2b).
- a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:579; and b) a light chain comprising the amino acid sequence of SEQ ID NO:592.
- a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:580; and b) a light chain comprising the amino acid sequence of SEQ ID NO:593.
- a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:581; and - 108 - 3839034.v1 5708.1076005 b) a light chain comprising the amino acid sequence of SEQ ID NO:592.
- a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:582; and b) a light chain comprising the amino acid sequence of SEQ ID NO:594.
- a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:583; and b) a light chain comprising the amino acid sequence of SEQ ID NO:594.
- a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:584; and b) a light chain comprising the amino acid sequence of SEQ ID NO:595.
- a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:585; and b) a light chain comprising the amino acid sequence of SEQ ID NO:594.
- a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:586; and b) a light chain comprising the amino acid sequence of SEQ ID NO:593.
- a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:585; and b) a light chain comprising the amino acid sequence of SEQ ID NO:593.
- a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:578; and b) a light chain comprising the amino acid sequence of SEQ ID NO:596.
- a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:587; and b) a light chain comprising the amino acid sequence of SEQ ID NO:597.
- a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:585; and b) a light chain comprising the amino acid sequence of SEQ ID NO:598.
- a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:588; and b) a light chain comprising the amino acid sequence of SEQ ID NO:597.
- a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:583; and - 109 - 3839034.v1 5708.1076005 b) a light chain comprising the amino acid sequence of SEQ ID NO:595.
- a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:585; and b) a light chain comprising the amino acid sequence of SEQ ID NO:599.
- a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:589; and b) a light chain comprising the amino acid sequence of SEQ ID NO:600.
- a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:585; and b) a light chain comprising the amino acid sequence of SEQ ID NO:601.
- a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:590; and b) a light chain comprising the amino acid sequence of SEQ ID NO:602.
- a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:584; and b) a light chain comprising the amino acid sequence of SEQ ID NO:603. [00517] In some embodiments, a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:591; and b) a light chain comprising the amino acid sequence of SEQ ID NO:603. [00518] In some embodiments, a polypeptide is a single-domain antibody or an antigen- binding fragment thereof.
- single-domain antibody refers to an immunoglobulin molecule consisting of a single monomeric variable antibody domain and capable of specific binding to a target.
- a single-domain antibody can be of any species, such as a murine antibody, a human antibody or a humanized single-domain antibody.
- a V H domain and a V L domain may be linked together via a linker (e.g., a synthetic linker) to form various types of single-chain antibody designs in which the V H /V L domains pair intramolecularly, or intermolecularly in those cases when the V H and V L domains are expressed by separate chains, to form a monovalent antigen binding site.
- a linker e.g., a synthetic linker
- a polypeptide is a heavy-chain antibody comprising two or more heavy chains, but lacking light chain, or an antigen-binding fragment thereof.
- Non-limiting examples of heavy chain antibodies include camelid Vhh (also referred to as VHH or VHH) - 110 - 3839034.v1 5708.1076005 antibodies.
- Camelid antibodies are antibodies from the Camelidae family of mammals that include llamas, camels, and alpacas.
- a polypeptide is an antibody mimetic.
- antibody mimetic refers to polypeptides capable of mimicking an antibody’s ability to bind an antigen, but structurally differ from native antibody structures.
- Non-limiting examples of antibody mimetics include Adnectins, Affibodies, Affilins, Affimers, Affitins, Alphabodies, Anticalins, Avimers, DARPins, Fynomers, Kunitz domain peptides, monobodies, nanobodies, nanoCLAMPs, and Versabodies.
- a polypeptide is an antigen-binding fragment of an antibody.
- the term “antigen-binding fragment” refers to a portion of an immunoglobulin molecule (e.g., antibody) that retains the antigen binding properties of the full-length Reference Antibody.
- Non- limiting examples of antigen-binding fragments include a VH region, a VL region, an Fab fragment, an F(ab’)2 fragment, an Fd fragment, an Fv fragment, and a domain antibody (dAb) consisting of one VH domain or one VL domain, etc.
- VH and VL domains may be linked together via a synthetic linker to form various types of single-chain antibody designs in which the VH/VL domains pair intramolecularly, or intermolecularly in those cases when the VH and VL domains are expressed by separate chains, to form a monovalent antigen binding site, such as single chain Fv (scFv) or diabody.
- a polypeptide disclosed herein is an antigen binding fragment selected from Fab, F(ab’)2, Fab’, scFv, or Fv. In some embodiments, a polypeptide is a scFv.
- a polypeptide e.g., an antibody or antigen-binding fragment
- a polypeptide is incorporated into a cell-based therapy.
- a polypeptide is an engineered T cell receptor.
- a polypeptide is a chimeric antigen receptor (CAR) (e.g., expressed on a T (CAR-T) cell, natural killer (CAR-NK) cell, or macrophage (CAR-M) cell).
- CAR chimeric antigen receptor
- a CAR comprises a transmembrane domain and an antigen-recognition moiety, wherein the antigen-recognition moiety binds SARS-CoV-2 (e.g., an epitope within RBD such as RBD class 4 epitope).
- a polypeptide is an antibody mimetic.
- a polypeptide competes with a comparator antibody for binding to the wildtype SARS-CoV-2-Spike, a SARS-CoV-2-Spike variant, or a combination thereof, wherein the reference antibody specifically binds the wildtype SARS-CoV-2-Spike (e.g., RBD).
- a polypeptide is an isolated polypeptide.
- a polypeptide e.g., an isolated polypeptide
- a polypeptide is recombinantly produced.
- a polypeptide e.g., an isolated polypeptide
- a polypeptide is synthetically produced.
- a polypeptide is linked to a second polypeptide.
- the term “linked” means attached, via a covalent or noncovalent interaction. Conjugation can employ a suitable linking agent. Non-limiting examples include peptide linkers, compound linkers, and chemical cross-linking agents. In some embodiments, the linker is a disulfide bond. [00528] In some embodiments, a polypeptide is conjugated to a heterologous moiety. The term “conjugated” refers to attached, via a covalent or noncovalent interaction. Conjugation can employ any one or more of suitable linking agents. Non-limiting examples include peptide linkers, compound linkers, and chemical cross-linking agents. [00529] In some embodiments, a heterologous moiety comprises a therapeutic agent, a diagnostic agent, or both.
- a heterologous moiety is selected from polyethylene glycol (PEG), hexadecanoic acid, hydrogels, nanoparticles, multimerization domains and carrier peptides.
- PEG polyethylene glycol
- a nanoparticle is a lipid nanoparticle.
- a nanoparticle is a polymer nanoparticle.
- a polymer is an amphiphilic polymer.
- a polymer is a hydrophobic or hydrophilic polymer.
- Non- limiting examples of polymers include poly(lactic acid)-poly(ethylene glycol), poly(lactic-co- glycolic acid)-poly(ethylene glycol), poly(lactic-co-glycolic) acid (PLGA), poly(lactic-co- glycolic acid)-d- ⁇ -tocopheryl polyethylene glycol succinate, poly(lactic-co-glycolic acid)- ethylene oxide fumarate, poly(glycolic acid)-poly(ethylene glycol), polycaprolactone- poly(ethylene glycol), or any salts thereof.
- a polymer nanoparticle comprises poly(lactic-co-glycolic acid) (PLGA).
- a carrier polypeptide is albumin or an Fc polypeptide.
- a polypeptide a) is capable of binding to an epitope in the RBD of SARS-CoV-2-Spike; b) binds SARS-CoV-1 and/or SARS-CoV-2 with a K D of 10 ⁇ M or less; c) neutralizes SARS-CoV-1 and/or SARS-CoV-2 infection of human host cells; d) has a weaker non-specific binding than the Reference Antibody; e) has a weaker self-association than the Reference Antibody; - 112 - 3839034.v1 5708.1076005 or a combination of any of the foregoing.
- a polypeptide is capable of binding to one or more epitope residues in RBD of SARS-CoV-2-Spike, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 residues of the RBD.
- a polypeptide is capable of binding to one or more epitope residues (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or all 16 residues) of SEQ ID NO:1.
- a polypeptide binds SARS-CoV-2-Spike with a binding constant (K D ) of about 10 ⁇ M or less.
- a polypeptide binds SARS-CoV-1-Spike (e.g., of CoV-1 and/or WIV1) and/or SARS-CoV-2-Spike (e.g., of Alpha, Beta, Gamma, Delta, Kappa, Epsilon, Eta, Iota, Lambda, Mu, and/or Omicron, for example, B.1, B.1.1, B.1.1.1, B.1.1.529, B.1.1.7, B.1.177, B.1.2, B.1.351, B.1.427/429, B.1.525, B.1.526, B.1.617.1,B.1.617.2, B.1.621, BA.1, BA.1.1, BA.2, BA.2.12.1, BA.2.75, BA.2.75.2, BA.3, BA.4, BA.4/5, BA.4/5+K444T, BA.4.6, BA.5, BA.5.2.6, BF.7, BF.11, BN.1, BQ.1, BQ
- a polypeptide binds SARS-CoV-1-Spike (e.g., of CoV-1 and/or WIV1) and/or SARS-CoV-2-Spike (e.g., of Alpha, Beta, Gamma, Delta, Kappa, Epsilon, Eta, Iota, Lambda, Mu, and/or Omicron, for example, B.1, B.1.1, B.1.1.1, B.1.1.529, B.1.1.7, B.1.177, B.1.2, B.1.351, B.1.427/429, B.1.525, B.1.526, B.1.617.1,B.1.617.2, B.1.621, BA.1, BA.1.1, BA.2, BA.2.12.1, BA.2.75, BA.2.75.2, BA.3, BA.4, BA.4/5, BA.4/5+K444T, BA.4.6, BA.5, BA.5.2.6, BF.7, BF.11, BN.1, BQ.1, BQ.1.1, C.
- a polypeptide binds SARS-CoV-1-Spike (e.g., of CoV-1 and/or WIV1) and/or SARS-CoV-2-Spike (e.g., of Alpha, Beta, Gamma, Delta, Kappa, Epsilon, Eta, Iota, Lambda, Mu, and/or Omicron, for example, B.1, B.1.1, B.1.1.1, B.1.1.529, B.1.1.7, B.1.177, B.1.2, B.1.351, B.1.427/429, B.1.525, B.1.526, B.1.617.1,B.1.617.2, B.1.621, BA.1, BA.1.1, BA.2, BA.2.12.1, BA.2.75, BA.2.75.2, BA.3, BA.4, BA.4/5, BA.4/5+K444T, BA.4.6, BA.5, BA.5.2.6, BF.7, BF.11, BN.1, BQ.1, BQ
- a polypeptide binds SARS- CoV-1-Spike (e.g., of CoV-1 and/or WIV1) and/or SARS-CoV-2-Spike (e.g., of Alpha, Beta, Gamma, Delta, Kappa, Epsilon, Eta, Iota, Lambda, Mu, and/or Omicron, for example, B.1, B.1.1, B.1.1.1, B.1.1.529, B.1.1.7, B.1.177, B.1.2, B.1.351, B.1.427/429, B.1.525, B.1.526, B.1.617.1,B.1.617.2, B.1.621, BA.1, BA.1.1, BA.2, BA.2.12.1, BA.2.75, BA.2.75.2, BA.3, BA.4, BA.4/5, BA.4/5+K444
- SARS- CoV-1-Spike e.g., of CoV-1 and/or WIV1
- SARS-CoV-2-Spike e.
- a polypeptide competes with the Reference Antibody for binding to a SARS-CoV-2-Spike (e.g., RBD such as RBD class 4 epitope).
- SARS-CoV-2-Spike e.g., RBD such as RBD class 4 epitope.
- a polypeptide neutralizes SARS-CoV-1 (e.g., CoV-1 and/or WIV1) and/or SARS-CoV-2 (e.g., of Alpha, Beta, Gamma, Delta, Kappa, Epsilon, Eta, Iota, Lambda, Mu, and/or Omicron, for example, B.1, B.1.1, B.1.1.1, B.1.1.529, B.1.1.7, B.1.177, B.1.2, B.1.351, B.1.427/429, B.1.525, B.1.526, B.1.617.1,B.1.617.2, B.1.621, BA.1, BA.1.1, BA.2, BA.2.12.1, BA.2.75, BA.2.75.2, BA.3, BA.4, BA.4/5, BA.4/5+K444T, BA.4.6, BA.5, BA.5.2.6, BF.7, BF.11, BN.1, BQ.1, BQ.1.1, C.37, D.
- SARS-CoV-1
- a polypeptide neutralizes SARS-CoV-2 (e.g. of Alpha, Beta, Gamma, Delta, Kappa, Epsilon, Eta, Iota, Lambda, Mu, and/or Omicron, for example, B.1, B.1.1, B.1.1.1, B.1.1.529, B.1.1.7, B.1.177, B.1.2, B.1.351, B.1.427/429, B.1.525, B.1.526, B.1.617.1,B.1.617.2, B.1.621, BA.1, BA.1.1, BA.2, BA.2.12.1, BA.2.75, BA.2.75.2, BA.3, BA.4, BA.4/5, BA.4/5+K444T, BA.4.6, BA.5, BA.5.2.6, BF.7, BF.11, BN.1, BQ.1, BQ.1.1, C.37, D.2, GA.5, GR/484A, P
- host cells are selected from the group consisting of lung type II pneumocytes, ileal absorptive enterocytes, nasal goblet secretory cells, and combinations thereof.
- a polypeptide neutralizes SARS-CoV-2 (e.g., of Alpha, Beta, Gamma, Delta, Kappa, Epsilon, Eta, Iota, Lambda, Mu, and/or Omicron, for example, B.1, B.1.1, B.1.1.1, B.1.1.529, B.1.1.7, B.1.177, B.1.2, B.1.351, B.1.427/429, B.1.525, B.1.526, B.1.617.1,B.1.617.2, B.1.621, BA.1, BA.1.1, BA.2, BA.2.12.1, BA.2.75, BA.2.75.2, BA.3, BA.4, BA.4/5, BA.4/5+K444T, BA.4.6, BA.5, BA.5.2.6, BF.7, BF.11, BN.1, BQ.1, BQ.1.1, C.37, D.2, GA.5, GR/484A
- SARS-CoV-2 e.g., of Alpha, Beta, Gamma, Delta
- a polypeptide neutralizes SARS-CoV-1 (e.g., CoV-1 and/or WIV1) infection of human host cells with an IC 50 of about 25,000 ng/mL or less, e.g., about: 20,000 ng/mL, 15,000 ng/mL, 10,000 ng/mL, 5,000 ng/mL, 2,500 ng/mL, 1,000 ng/mL, 750 ng/mL, 500 ng/mL, 250 ng/mL, 100 ng/mL, 75 ng/mL, 50 ng/mL, 25 ng/mL, or 10 ng/mL or less; e.g., about: 10-25,000 ng/mL, 10-20,000 ng/mL, 25- 20,000 ng/mL, 25-15,000 ng/mL, 50-15,000 ng/mL, 50-10,000 ng/mL, 75-10,000 ng/mL, 75-10,000 ng/mL, 50-15,000 ng/mL, 50
- a polypeptide neutralizes SARS-CoV-1 (e.g., CoV-1 and/or WIV1) infection of human host cells with an IC 80 of about 50,000 ng/mL or less, e.g., about: 25,000 ng/mL, 15,000 ng/mL, 10,000 ng/mL, 5,000 ng/mL, 2,500 ng/mL, 1,000 ng/mL, 750 ng/mL, 500 ng/mL, 250 ng/mL, 100 ng/mL, 75 ng/mL, 50 ng/mL, 25 ng/mL, or 10 ng/mL or less; e.g., about: 10-50,000 ng/mL, 10-25,000 ng/mL, 25- 25,000 ng/mL, 25-15,000 ng/mL, 50-15,000 ng/mL, 50-10,000 ng/mL, 75-10,000 ng/mL, 50-15,000 ng/mL, 50-10,000 ng/mL, 75
- a polypeptide reduces betacoronavirus (e.g., SARS-CoV-2) infectivity of host cells (e.g., human host cells).
- a polypeptide reduces - 115 - 3839034.v1 5708.1076005 betacoronavirus (e.g., SARS-CoV-2) infectivity of host cells (e.g., human host cells) by at least about 10%, e.g., by at least about: 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.
- a polypeptide reduces betacoronavirus (e.g., SARS-CoV-2) infectivity of human cells by at least about 30%.
- a polypeptide reduces betacoronavirus (such as SARS-CoV-2 (e.g., of Alpha, Beta, Gamma, Delta, Kappa, Epsilon, Eta, Iota, Lambda, Mu, and/or Omicron, for example, B.1, B.1.1, B.1.1.1, B.1.1.529, B.1.1.7, B.1.177, B.1.2, B.1.351, B.1.427/429, B.1.525, B.1.526, B.1.617.1,B.1.617.2, B.1.621, BA.1, BA.1.1, BA.2, BA.2.12.1, BA.2.75, BA.2.75.2, BA.3, BA.4, BA.4/5, BA.4/5+K444T, BA.4.6, BA.5, BA.5.2.6, BF.7
- SARS-CoV-2 e.g
- a polypeptide reduces betacoronavirus (such as SARS- CoV-2 (e.g., Alpha, Beta, Gamma, Delta, Kappa, Epsilon, Eta, Iota, Lambda, Mu, and/or Omicron, for example, B.1, B.1.1, B.1.1.1, B.1.1.529, B.1.1.7, B.1.177, B.1.2, B.1.351, B.1.427/429, B.1.525, B.1.526, B.1.617.1,B.1.617.2, B.1.621, BA.1, BA.1.1, BA.2, BA.2.12.1, BA.2.75, BA.2.75.2, BA.3, BA.4, BA.4/5, BA.4/5+K444T, BA.4.6, BA.5, BA.5.2.6, BF.7, BF.11, BN.1, BQ.1, BQ.1.1, C.37, D.2, GA.5, GR/484A, P.1, P.3, and/or XBB)
- a polypeptide reduces betacoronavirus (such as SARS-CoV-2 (e.g., of Alpha, Beta, Gamma, Delta, Kappa, Epsilon, Eta, Iota, Lambda, Mu, and/or Omicron, for example, B.1, B.1.1, B.1.1.1, B.1.1.529, B.1.1.7, B.1.177, B.1.2, B.1.351, B.1.427/429, B.1.525, B.1.526, B.1.617.1,B.1.617.2, B.1.621, BA.1, BA.1.1, BA.2, BA.2.12.1, BA.2.75, BA.2.75.2, BA.3, BA.4, BA.4/5, BA.4/5+K444T, BA.4.6, BA.5, BA.5.2.6, BF.7, BF.11, BN.1, BQ.1, BQ.1.1, C.37, D.2, GA.5, GR/484A, P.1, P.3, and/or XBB
- Infectivity or re-infection can be measured using techniques such as a pseudovirus neutralization assay or a live virus neutralization assay (see, e.g., Pinto et al., Cross- neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody, Nature 583: 290-95 (2020), the contents of which are incorporated herein by reference).
- a kit for example, the GenScript cPassTM SARS-CoV-2 neutralization antibody detection kit, can be used according to manufacturer's protocol.
- a polypeptide reduces SARS-CoV-1 (e.g., CoV-1 and/or WIV1) infectivity of host cells (e.g., human host cells).
- SARS-CoV-1 e.g., CoV-1 and/or WIV1
- host cells e.g., human host cells
- a polypeptide reduces SARS-CoV-1 (e.g., CoV-1 and/or WIV1) infectivity of host cells (e.g., human host cells) by at least about 10%, e.g., by at least about: 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. In some embodiments, a polypeptide reduces SARS-CoV-1 (e.g., CoV-1 and/or WIV1) infectivity of human cells by at least about 30%.
- SARS-CoV-1 e.g., CoV-1 and/or WIV1
- a polypeptide reduces SARS-CoV-1 (e.g., CoV-1 and/or WIV1) re-infection of host cells (e.g., human host cells).
- a polypeptide reduces SARS-CoV-1 (e.g., CoV-1 and/or WIV1) re-infection of host cells (e.g., human host cells) by at least about 10%, e.g., by at least about: 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.
- a polypeptide reduces SARS-CoV-1 (e.g., CoV-1 and/or WIV1) re- infection of human cells by at least about 30%.
- a polypeptide has a weaker self-association than the Reference Antibody, for example, as determined by an affinity-capture self-interaction nanoparticle spectroscopy (AC-SINS) value.
- AC-SINS value is the change in maximum absorbance wavelength in the coated-nanoparticle absorption spectra compared to the spectra of the nanoparticle alone. Thus, the greater the change in maximum absorbance wavelength, the more self-interaction of the antibody coated on the nanoparticle.
- a polypeptide has a weaker self-association than the Reference Antibody.
- a polypeptide has an AC-SINS value of no more than about: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 18, 20, 21, 22, 23, 24, or 25.
- a polypeptide has an AC-SINS value of no more than about 14. In some embodiments, a polypeptide has an AC-SINS value of no more than about 8. In some embodiments, a polypeptide has an AC-SINS value of about: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 18, 20, 21, 22, 23, 24, or 25. In some embodiments, a polypeptide has an AC-SINS value of about 0-25, e.g., 0-20, 0-15, 0-10, 0-8, 0-5, 2-20, 2-15, 2-10, 2-8, 2-5, 5-20, 5- 15, 5-10, 5-8, 7-8, or 13-15.
- a polypeptide has an AC-SINS value of - 117 - 3839034.v1 5708.1076005 about 13-14, 13-15, 7-9, or 7-8. In some embodiments, a polypeptide has an AC-SINS value of about: 8 or 14. [00552] In some embodiments, a polypeptide has an improved developability (e.g., reduced AC-SINS) relative to the Reference Antibody.
- self-association of a polypeptide is at least about 10% lower than that of the Reference Antibody, for example, by at least about: 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% lower than that of the Reference Antibody. In some embodiments, self-association of a polypeptide is at least about 30% lower than that of the Reference Antibody.
- self-association of a polypeptide is less than about 90% of that of the Reference Antibody, for example, less than about: 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% of that of the Reference Antibody.
- self-association of a polypeptide is about 1-90% relative to that of the Reference Antibody, for example, about: 2-90%, 2-85%, 3-85%, 3-80%, 4-80%, 4- 75%, 5-75%, 5-70%, 6-70%, 6-65%, 7-65%, 7-60%, 8-60%, 8-55%, 9-55%, 9-50%, 10-50%, 10-45%, 15-45%, 15-40%, 20-40%, 20-35%, 25-35%, or 25-30%, relative to that of the Reference Antibody.
- reduction in self-association relative to the Reference Antibody is at least about 10%, for example, by at least about: 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.
- Fusion Proteins [00556] The disclosure also provides, among other things, a fusion protein comprising one or more of the polypeptides disclosed herein. [00557]
- fusion protein refers to a synthetic, semi-synthetic or recombinant single protein molecule.
- a fusion protein can comprise all or a portion of two or more different proteins and/or polypeptides that are attached by covalent bonds (e.g., peptide bonds).
- a fusion protein can comprise a full-length polypeptide disclosed herein (e.g., a whole antibody), or a fragment thereof (e.g., an antigen-binding fragment of an antibody).
- the heterologous partner can be a full-length protein or a fragment thereof (e.g., a truncated protein).
- Fusion proteins of the disclosure can be produced recombinantly or synthetically, using routine methods and reagents that are well known in the art.
- a fusion protein - 118 - 3839034.v1 5708.1076005 of the disclosure can be produced recombinantly in a suitable host cell (e.g., bacteria) according to methods known in the art. See, e.g., Current Protocols in Molecular Biology, Second Edition, Ausubel et al. eds., John Wiley & Sons, 1992; and Molecular Cloning: a Laboratory Manual, 2nd edition, Sambrook et al., 1989, Cold Spring Harbor Laboratory Press.
- a nucleic acid molecule comprising a nucleotide sequence encoding a fusion protein described herein can be introduced and expressed in suitable host cell (e.g., E.
- the expressed fusion protein can be isolated/purified from the host cell (e.g., in inclusion bodies) using routine methods and readily available reagents.
- DNA fragments coding for different protein sequences e.g., a light-responsive domain, a heterologous peptide component
- the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers.
- PCR amplification of nucleic acid fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive nucleic acid fragments that can subsequently be annealed and re-amplified to generate a chimeric nucleic acid sequence (see Ausubel et al., Current Protocols in Molecular Biology, 1992).
- the disclosure also provides, among other things, one or more polynucleotides (e.g., DNA, RNA, or analogs of either, e.g., optionally including one or more modified nucleotides; a polynucleotide may be linear or circular, e.g., a linear or circular RNA) encoding any one of the polypeptides or fusion proteins described herein.
- a polypeptide or fusion protein disclosed herein is encoded by a single polynucleotide.
- a polypeptide or fusion protein disclosed herein is encoded by multiple polynucleotides.
- a polynucleotide comprises a nucleotide sequence that is codon-optimized for a chosen host cell.
- the disclosure also provides, among other things, a vector (e.g., an expression vector, including a viral-delivery vector) comprising any one or more of the polynucleotides disclosed herein.
- a vector e.g., an expression vector, including a viral-delivery vector
- expression vector refers to a replicable nucleic acid from which one or more proteins can be expressed when the expression vector is transformed into a suitable expression host cell.
- a vector (e.g., expression vector) further comprises an expression control polynucleotide sequence operably linked to the polynucleotide, a polynucleotide sequence encoding a selectable marker, or both.
- an - 119 - 3839034.v1 5708.1076005 expression control polynucleotide sequence comprises a promoter sequence, an enhancer sequence, or both.
- an expression control polynucleotide sequence comprises an inducible promoter sequence.
- promoter refers to a region of DNA to which RNA polymerase binds and initiates the transcription of a gene.
- operably linked means that the nucleic acid is positioned in the recombinant polynucleotide, e.g., vector, in such a way that enables expression of the nucleic acid under control of the element (e.g., promoter) to which it is linked.
- element e.g., promoter
- selectable marker element is an element that confers a trait suitable for artificial selection. Selectable marker elements can be negative or positive selection markers.
- the disclosure also provides, among other things, an expression host cell comprising any one or more of the polynucleotides or expression vectors disclosed herein.
- expression host cell refers to a cell useful for receiving, maintaining, reproducing and/or amplifying a vector.
- Non-limiting examples of expression host cells include mammalian cells such as hybridoma cells, Chinese hamster ovary (CHO) cells, COS cells, human embryonic kidney (HEK), yeast cells such as Pichia pastoris cells, or bacterial cells such as E. coli, including DH5 ⁇ , etc.
- Compositions [00566] The disclosure also provides, among other things, a composition comprising any one of the polypeptides, the polynucleotides, or fusion proteins disclosed herein. In some embodiments, a composition is a pharmaceutical composition.
- a composition (e.g., pharmaceutical composition) further comprises pharmaceutically acceptable carriers, excipients, stabilizers, diluents or tonifiers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)). Suitable pharmaceutically acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed.
- Non-limiting examples of pharmaceutically acceptable carriers, excipients, stabilizers, diluents or tonifiers include buffers (e.g., phosphate, citrate, histidine), antioxidants (e.g., ascorbic acid or methionine), preservatives, proteins (e.g., serum albumin, gelatin or immunoglobulins); hydrophilic polymers, amino acids, carbohydrates (e.g., monosaccharides, disaccharides, glucose, mannose or dextrins); chelating agents (e.g., EDTA), sugars (e.g., sucrose, mannitol, trehalose or sorbitol), salt-forming counter-ions (e.g., sodium), metal complexes (e.g., Zn-protein complexes); non-ionic surfactants (e.g., Tween), PLURONICSTM and polyethylene glycol (PEG).
- buffers e.g., phosphate, citrate, his
- a composition (e.g., a pharmaceutical composition) is formulated for a suitable administration schedule and route.
- administration routes include oral, rectal, mucosal, intravenous, intramuscular, subcutaneous, and topical, etc.
- a composition e.g., a pharmaceutical composition
- a composition is stored in the form of an aqueous solution or a dried formulation (e.g., lyophilized).
- a composition is formulated to be administered by infusion (e.g., intravenous infusion).
- a composition is formulated for subcutaneous administration.
- a composition is provided in a dosage form, e.g., in a prefilled syringe or autoinjector.
- a pharmaceutical composition comprises from about 50 mg to about 300 mg of a polypeptide or fusion protein disclosed herein, for example, about: 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 120 mg, 140 mg, 150 mg, 160 mg, 180 mg, 200 mg, 220 mg, 240 mg, 250 mg, 260 mg, 280 mg, or 300 mg.
- a pharmaceutical composition comprises from about 60 mg to about 300 mg of a polypeptide or fusion protein disclosed herein, for example, about: 60-280 mg, 80-280 mg, 80-260 mg, 100-260 mg, 100-250 mg, 120-250 mg, 120-240 mg, 140-240 mg, 140-220 mg, 150-250 mg, 150-200 mg, 160-220 mg, 160-200 mg, or 180-200 mg.
- a pharmaceutical composition comprises from about 50 mg/ml to about 200 mg/ml of a polypeptide or fusion protein disclosed herein, for example, about: 50 mg/ml, 60 mg/ml, 70 mg/ml, 80 mg/ml, 90 mg/ml, 100 mg/ml, 120 mg/ml, 140 mg/ml, 150 mg/ml, 160 mg/ml, 180 mg/ml, or 200 mg/ml of a polypeptide or fusion protein disclosed herein.
- a pharmaceutical composition comprises from about 60 mg/ml to about 200 mg/ml of a polypeptide or fusion protein disclosed herein, for example, about: 60-180 mg/ml, 80-180 mg/ml, 80-160 mg/ml, 100-160 mg/ml, 100-150 mg/ml, 120-150 mg/ml or 120- 140 mg/ml.
- a composition is formulated to be administered with at least one additional therapeutic agent as a combination therapy.
- a composition further comprises at least one additional therapeutic agent.
- At least one additional therapeutic agent comprises any one of the polypeptides described herein (e.g., the Reference Antibody, a different RBD 4 binder, a S2 binder, or any combination thereof).
- at least one additional therapeutic - 121 - 3839034.v1 5708.1076005 agent comprises bamlanivimab, etesevimab, casirivimab, imdevimab, Cilgavimab, Tixagevimab, AZD7442 (Tixagevimab-Cilgavimab), Regdanvimab, or Sotrovimab.
- a second therapeutic agent comprises Sotrovimab.
- At least one additional therapeutic agent comprises: a) an antibody or an antigen-binding fragment thereof that specifically binds SARS- CoV-2-Spike; b) a polynucleotide comprising a nucleotide sequence encoding the antibody or the antigen-binding fragment thereof of a); c) an antiviral agent; d) an ACE2 inhibitor; e) an antibiotic; f) an antimalarial agent; g) a vaccine; or any combination of a) to g).
- an antibody or an antigen-binding fragment thereof that specifically binds SARS- CoV-2-Spike comprises bamlanivimab, etesevimab, bebtelovimab, casirivimab, imdevimab, Cilgavimab, Tixagevimab, AZD7442 (Tixagevimab-Cilgavimab), Regdanvimab, Sotrovimab, or a combination thereof;
- an antibody or an antigen-binding fragment thereof that specifically binds SARS- CoV-2-Spike binds an S2 domain of SARS-CoV-2-Spike;
- an antiviral agent comprises oseltamivir (Tamiflu), favipiravir, amantadine, remdesivir, rimantadine, pleconaril, an anti-sense RNA to SARS-CoV-2, a
- Non-limiting examples of additional therapeutic agents include antibiotics (e.g., azithromycin), antibodies or antigen-binding fragments thereof (e.g., other SARS-CoV-2- - 122 - 3839034.v1 5708.1076005 binding antibodies or antigen-binding fragments), antimalarial agents (e.g., chloroquine or hydroxychloroquine), antiviral agents (e.g., Molnupiravir (LAGEVRIO, Merck), PF-07817883 (Pfizer), STI-1558 (Sorrento Therapeutics), PBI-0451 (Pardes Biosciences), EDP-235 (Enanta Pharmaceuticals), favipiravir, lopinavir, and/or ritonavir), cytokines (e.g., type 1 interferons such as interferon beta-1a), nucleotide analogs (e.g., remdesivir), protease inhibitors (e.g.,
- an antiviral agent comprises amantadine, Molnupiravir (LAGEVRIO, Merck), PF-07817883 (Pfizer), STI-1558 (Sorrento Therapeutics), PBI-0451 (Pardes Biosciences), EDP-235 (Enanta Pharmaceuticals), favipiravir, lopinavir, oseltamivir (Tamiflu), pleconaril, rimantadine, ritonavir, an anti-sense RNA to SARS-CoV-2, an siRNA to SARS-CoV-2, an additional anti-SARS-CoV-2 monoclonal antibody, or any combination thereof.
- an antiviral agent comprises Molnupiravir (LAGEVRIO, Merck), PF-07817883 (Pfizer), STI-1558 (Sorrento Therapeutics), PBI-0451 (Pardes Biosciences), EDP-235 (Enanta Pharmaceuticals), or any combination thereof.
- an anti-SARS-CoV-2 antibody targets S1 domain of a Spike protein of SARS-CoV-2.
- an anti-SARS-CoV-2 antibody targets class 4 region of a S1 domain.
- an anti-SARS-CoV-2 monoclonal antibody targets RBD (e.g., RBD class 1, 2, or 3 epitopes) of S1 domain of SARS-CoV-2.
- RBD e.g., RBD class 1, 2, or 3 epitopes
- an anti-SARS-CoV-2 antibody targets class 3 region of S1 domain.
- an anti-SARS-CoV-2 antibody targets the N-terminal domain (NTD)-nonsupersite region of S1 domain.
- an anti-SARS-CoV-2 antibody targets SD1 region of S1 domain.
- an anti-SARS-CoV-2 monoclonal antibody targets (e.g., binds) S2 domain of a Spike protein of SARS-CoV-2.
- an anti-SARS- CoV-2 monoclonal antibody comprises a neutralizing monoclonal antibody (e.g., as determined using a neutralization assay described herein or otherwise known in the art).
- anti-SARS-CoV-2 monoclonal antibodies include Bamlanivimab (LY-CoV555 or LY3819253), Etesevimab (LY-CoV016 or LY3832479), Bebtelovimab (LY-CoV1404, LY3853113), Casirivimab (REGN10933), Imdevimab (REGN10987), Cilgavimab, Tixagevimab, AZD7442/ EVUSHELD® (Tixagevimab-Cilgavimab), Regdanvimab, Sotrovimab (Vir Biotechnology, Inc.), ADG20 (Adagio Therapeutics, Inc.), Ensovibep (MP0420) (DARPin, Nov
- At least one additional therapeutic agent comprises an antibody or an antigen-binding fragment thereof that specifically binds an S2 domain of SARS-CoV-2- Spike.
- an antibody or an antigen-binding fragment thereof that specifically binds an S2 domain of SARS-CoV-2-Spike comprises a V H domain comprising an HCDR1, an HCDR2, and an HCDR3, and a V L domain comprising an LCDR1, an LCDR2, and an LCDR3 of an antibody comprising a V H amino acid sequence and a V L amino acid sequence, respectively, of: SEQ ID NO:53 and SEQ ID NO:75 (S2_AB-1); SEQ ID NO:57 and SEQ ID NO:76 (S2_AB-2); SEQ ID NO:58 and SEQ ID NO:77 (S2_AB-3); SEQ ID NO:59 and SEQ ID NO:78 (S2_AB-4); SEQ ID NO:60 and SEQ ID NO:75 (S2_AB-5); SEQ ID NO:61 and SEQ ID NO:79 (S2_AB-6); SEQ ID NO:62 and SEQ ID NO:80 (S2_AB-7); SEQ ID NO:53 and SEQ ID NO:75
- an antibody or an antigen-binding fragment thereof that specifically binds an S2 domain of SARS-CoV-2-Spike comprises an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2, and an LCDR3 of an antibody comprising a V H amino acid sequence of SEQ ID NO:53 and a V L amino acid sequence of SEQ ID NO:75 (S2_AB-1).
- an antibody or an antigen-binding fragment thereof that specifically binds an S2 domain of SARS-CoV-2-Spike comprises: a) an HCDR1 comprising GYTFTRYW (SEQ ID NO:557); - 125 - 3839034.v1 5708.1076005 b) an HCDR2 comprising IYPGDSDV (SEQ ID NO:558); c) an HCDR3 comprising ARLPQYCSKGVCYRWFDP (SEQ ID NO:559); d) an LCDR1 comprising QGISSW (SEQ ID NO:560); e) an LCDR2 comprising AAS; and f) an LCDR3 comprising QQGHSFPYT (SEQ ID NO:561).
- an antibody or an antigen-binding fragment thereof that specifically binds an S2 domain of SARS-CoV-2-Spike comprises: a) an HCDR1 consisting of GYTFTRYW (SEQ ID NO:557); b) an HCDR2 consisting of IYPGDSDV (SEQ ID NO:558); c) an HCDR3 consisting of ARLPQYCSKGVCYRWFDP (SEQ ID NO:559); d) an LCDR1 consisting of QGISSW (SEQ ID NO:560); e) an LCDR2 consisting of AAS; and f) an LCDR3 consisting of QQGHSFPYT (SEQ ID NO:561).
- an antibody or an antigen-binding fragment thereof that specifically binds an S2 domain of SARS-CoV-2-Spike comprises: a V H domain comprising the amino acid sequence of SEQ ID NO:53 and a V L domain comprising the amino acid sequence of SEQ ID NO:75 (S2_AB-1); a V H domain comprising the amino acid sequence of SEQ ID NO:57 and a V L domain comprising the amino acid sequence of SEQ ID NO:76 (S2_AB-2); a V H domain comprising the amino acid sequence of SEQ ID NO:58 and a V L domain comprising the amino acid sequence of SEQ ID NO:77 (S2_AB-3); a V H domain comprising the amino acid sequence of SEQ ID NO:59 and a V L domain comprising the amino acid sequence of SEQ ID NO:78 (S2_AB-4); a V H domain comprising the amino acid sequence of SEQ ID NO:60 and a V L domain comprising the amino acid sequence of SEQ ID NO:
- an antibody or an antigen-binding fragment thereof that specifically binds an S2 domain of SARS-CoV-2-Spike comprises: a) a V H domain comprising the amino acid sequence of SEQ ID NO:53; and b) a V L domain comprising the amino acid sequence of SEQ ID NO:75.
- a composition e.g., a pharmaceutical composition
- V H domain comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO:24, an HCDR2 comprising the amino acid sequence of SEQ ID NO:28, and an HCDR3 comprising the amino acid sequence of SEQ ID NO:33; and ii. a V L domain comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO:37, an LCDR2 comprising the amino acid sequence of - 129 - 3839034.v1 5708.1076005 SEQ ID NO:40; and an LCDR3 comprising the amino acid sequence of SEQ ID NO:44; and b) an antibody or an antigen-binding fragment thereof comprising: i.
- a V H domain comprising an HCDR1 comprising GYTFTRYW (SEQ ID NO:557), an HCDR2 comprising IYPGDSDV (SEQ ID NO:558), and an HCDR3 comprising ARLPQYCSKGVCYRWFDP (SEQ ID NO:559); and ii. a V L domain comprising an LCDR1 comprising QGISSW (SEQ ID NO:560), an LCDR2 comprising AAS, and an LCDR3 comprising QQGHSFPYT (SEQ ID NO:561).
- a composition e.g., a pharmaceutical composition
- V H domain comprising an HCDR1 consisting of the amino acid sequence of SEQ ID NO:24, an HCDR2 consisting of the amino acid sequence of SEQ ID NO:28, and an HCDR3 consisting of the amino acid sequence of SEQ ID NO:33; and ii. a V L domain comprising an LCDR 1 consisting of the amino acid sequence of SEQ ID NO:37, an LCDR2 consisting of the amino acid sequence of SEQ ID NO:40, and an LCDR3 consisting of the amino acid sequence of SEQ ID NO:44; and b) an antibody or an antigen-binding fragment thereof comprising: i.
- V H domain comprising an HCDR1 consisting of GYTFTRYW (SEQ ID NO:557), an HCDR2 consisting of IYPGDSDV (SEQ ID NO:558), and an HCDR3 consisting of ARLPQYCSKGVCYRWFDP (SEQ ID NO:559); and ii. a V L domain comprising an LCDR1 consisting of QGISSW (SEQ ID NO:560), an LCDR2 consisting of AAS, and an LCDR3 consisting of QQGHSFPYT (SEQ ID NO:561).
- a composition (e.g., a pharmaceutical composition) comprises: a) an antibody or an antigen-binding fragment thereof comprising a V H domain comprising the amino acid sequence of SEQ ID NO:5 and a V L domain comprising the amino acid sequence of SEQ ID NO:14; and - 130 - 3839034.v1 5708.1076005 b) an antibody or an antigen-binding fragment thereof comprising a V H domain comprising the amino acid sequence of SEQ ID NO:53 and a V L domain comprising the amino acid sequence of SEQ ID NO:75.
- a composition (e.g., a pharmaceutical composition) comprises: a) an antibody or an antigen-binding fragment thereof comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:578 and a light chain comprising the amino acid sequence of SEQ ID NO:592; and b) an antibody or an antigen-binding fragment thereof comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:622 and a light chain comprising the amino acid sequence of SEQ ID NO:623.
- S2_AB-1 heavy chain sequence EVQLVESGAEVKKPGESLKISCKGSGYTFTRYWIGWVRQMPGKGLEWMGIIYPGDSD VRYSPSFQGHVTISADKSISTAYLQWNSLKASDTAMYYCARLPQYCSKGVCYRWFDP WGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHT CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ PREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD
- S2_AB-1 light chain sequence [00596] EIVLTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASS LQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGHSFPYTFGQGTNLEIKRTVAAP SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:623).
- the disclosure also provides, among other things, a method of neutralizing a SARS- CoV-2 protein in a subject, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and, wherein as an active ingredient, any one of the polypeptides, polynucleotides, fusion proteins, or compositions disclosed herein.
- the disclosure also provides, among other things, a method of treating a subject in need thereof, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and, wherein as an active - 131 - 3839034.v1 5708.1076005 ingredient, any one of the polypeptides, polynucleotides, fusion proteins, or compositions disclosed herein.
- the disclosure also provides, among other things, a method of treating a SARS-CoV- 2 infection in a subject, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and, wherein as an active ingredient, any one of the polypeptides, polynucleotides, fusion proteins, or compositions disclosed herein.
- a method of reducing viral load of SARS-CoV-2 in a subject comprising administering to the subject an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and, wherein as an active ingredient, any one of the polypeptides, polynucleotides, fusion proteins, or compositions disclosed herein.
- the disclosure also provides, among other things, a method of reducing (e.g., preventing) a SARS-CoV-2 infection in a subject, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and, wherein as an active ingredient, any one of the polypeptides, polynucleotides, fusion proteins, or compositions disclosed herein.
- the disclosure also provides, among other things, a method of reducing (e.g., preventing) a SARS-CoV-2 infection in a subject, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and, wherein as an active ingredient, any one of the polypeptides, polynucleotides, fusion proteins, or compositions disclosed herein.
- a method disclosed herein comprises administering to the subject an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an antibody or an antigen- binding fragment thereof comprising: a) a V H domain comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO:24, an HCDR2 comprising the amino acid sequence of SEQ ID NO:28, and an HCDR3 comprising the amino acid sequence of SEQ ID NO:33; and - 132 - 3839034.v1 5708.1076005 b)
- a method disclosed herein comprises administering to the subject an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and: a) an antibody or an antigen-binding fragment thereof comprising: i.
- V H domain comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO:24, an HCDR2 comprising the amino acid sequence of SEQ ID NO:28, and an HCDR3 comprising the amino acid sequence of SEQ ID NO:33; and ii. a V L domain comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO:37, an LCDR2 comprising the amino acid sequence of SEQ ID NO:40; and an LCDR3 comprising the amino acid sequence of SEQ ID NO:44; and b) an antibody or an antigen-binding fragment thereof comprising: i.
- V H domain comprising an HCDR1 comprising GYTFTRYW (SEQ ID NO:557), an HCDR2 comprising IYPGDSDV (SEQ ID NO:558), and an HCDR3 comprising ARLPQYCSKGVCYRWFDP (SEQ ID NO:559); and ii. a V L domain comprising an LCDR1 comprising QGISSW (SEQ ID NO:560), an LCDR2 comprising AAS, and an LCDR3 comprising QQGHSFPYT (SEQ ID NO:561).
- a method disclosed herein comprises administering to the subject an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an antibody or an antigen- binding fragment thereof comprising: - 133 - 3839034.v1 5708.1076005 a) a V H domain comprising an HCDR1 consisting of the amino acid sequence of SEQ ID NO:24, an HCDR2 consisting of the amino acid sequence of SEQ ID NO:28, and an HCDR3 consisting of the amino acid sequence of SEQ ID NO:33; and
- a method disclosed herein comprises administering to the subject an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and: a) an antibody or an antigen-binding fragment thereof comprising: i.
- V H domain comprising an HCDR1 consisting of the amino acid sequence of SEQ ID NO:24, an HCDR2 consisting of the amino acid sequence of SEQ ID NO:28, and an HCDR3 consisting of the amino acid sequence of SEQ ID NO:33; and ii. a V L domain comprising an LCDR 1 consisting of the amino acid sequence of SEQ ID NO:37, an LCDR2 consisting of the amino acid sequence of SEQ ID NO:40, and an LCDR3 consisting of the amino acid sequence of SEQ ID NO:44; and b) an antibody or an antigen-binding fragment thereof comprising: i.
- V H domain comprising an HCDR1 consisting of GYTFTRYW (SEQ ID NO:557), an HCDR2 consisting of IYPGDSDV (SEQ ID NO:558), and an HCDR3 consisting of ARLPQYCSKGVCYRWFDP (SEQ ID NO:559); and ii. a V L domain comprising an LCDR1 consisting of QGISSW (SEQ ID NO:560), an LCDR2 consisting of AAS, and an LCDR3 consisting of QQGHSFPYT (SEQ ID NO:561).
- a method disclosed herein comprises administering to the subject an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an antibody or an antigen- binding fragment thereof comprising a V H domain comprising the amino acid sequence of SEQ ID NO:5 and a V L domain comprising the amino acid sequence of SEQ ID NO:14.
- a method disclosed herein comprises administering to the subject an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and: a) an antibody or an antigen-binding fragment thereof comprising a V H domain comprising the amino acid sequence of SEQ ID NO:5 and a V L domain comprising the amino acid sequence of SEQ ID NO:14; and b) an antibody or an antigen-binding fragment thereof comprising a V H domain comprising the amino acid sequence of SEQ ID NO:53 and a V L domain comprising the amino acid sequence of S
- a method disclosed herein comprises administering to the subject an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an antibody or an antigen- binding fragment thereof comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:578 and a light chain comprising the amino acid sequence of SEQ ID NO:592.
- a method disclosed herein comprises administering to the subject an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and: - 135 - 3839034.v1 5708.1076005 a) an antibody or an antigen-binding fragment thereof comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:578 and a light chain comprising the amino acid sequence of SEQ ID NO:592; and b) an antibody or an antigen-binding fragment thereof comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:
- the disclosure also provides, among other things, a method of reducing infectivity of SARS-CoV-2 of a cell in a subject, comprising contacting the cell with any one of the polypeptides, polynucleotides, fusion proteins, or compositions disclosed herein.
- a method of reducing (e.g., inhibiting) binding of SARS-CoV-2 to a target cell comprising contacting the target cell with any one of the polypeptides, polynucleotides, fusion proteins, or compositions disclosed herein.
- the disclosure also provides, among other things, a method of reducing (e.g., inhibiting) binding of SARS-CoV-2 to a target protein on a target cell, comprising contacting the target cell with any one of the polypeptides, polynucleotides, fusion proteins, or compositions disclosed herein.
- a method of reducing (e.g., inhibiting) virus mediated fusion with a target cell comprising contacting the target cell with any one of the polypeptides, polynucleotides, fusion proteins, or compositions disclosed herein.
- a method disclosed herein comprises contacting the target cell with an antibody or an antigen-binding fragment thereof comprising: a) a V H domain comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO:24, an HCDR2 comprising the amino acid sequence of SEQ ID NO:28, and an HCDR3 comprising the amino acid sequence of SEQ ID NO:33; and b) a V L domain comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO:37, an LCDR2 comprising the amino acid sequence of SEQ ID NO:
- a method disclosed herein e.g., reducing infectivity of SARS- CoV-2 of a cell in a subject, reducing (e.g., inhibiting) binding of SARS-CoV-2 to a target cell, reducing (e.g., inhibiting) binding of SARS-CoV-2 to a target protein on a target cell, or - 136 - 3839034.v1 5708.1076005 reducing (e.g., inhibiting) virus mediated fusion with a target cell), comprises contacting the target cell with: a) an antibody or an antigen-binding fragment thereof comprising: i.
- V H domain comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO:24, an HCDR2 comprising the amino acid sequence of SEQ ID NO:28, and an HCDR3 comprising the amino acid sequence of SEQ ID NO:33; and ii. a V L domain comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO:37, an LCDR2 comprising the amino acid sequence of SEQ ID NO:40; and an LCDR3 comprising the amino acid sequence of SEQ ID NO:44; and b) an antibody or an antigen-binding fragment thereof comprising: i.
- V H domain comprising an HCDR1 comprising GYTFTRYW (SEQ ID NO:557), an HCDR2 comprising IYPGDSDV (SEQ ID NO:558), and an HCDR3 comprising ARLPQYCSKGVCYRWFDP (SEQ ID NO:559); and ii. a V L domain comprising an LCDR1 comprising QGISSW (SEQ ID NO:560), an LCDR2 comprising AAS, and an LCDR3 comprising QQGHSFPYT (SEQ ID NO:561).
- a method disclosed herein comprises contacting the target cell with an antibody or an antigen-binding fragment thereof comprising: a) a V H domain comprising an HCDR1 consisting of the amino acid sequence of SEQ ID NO:24, an HCDR2 consisting of the amino acid sequence of SEQ ID NO:28, and an HCDR3 consisting of the amino acid sequence of SEQ ID NO:33; and b) a V L domain comprising an LCDR 1 consisting of the amino acid sequence of SEQ ID NO:37, an LCDR2 consisting of the amino acid sequence of
- a method disclosed herein comprises contacting the target cell with: a) an antibody or an antigen-binding fragment thereof comprising: i.
- V H domain comprising an HCDR1 consisting of the amino acid sequence of SEQ ID NO:24, an HCDR2 consisting of the amino acid sequence of SEQ ID NO:28, and an HCDR3 consisting of the amino acid sequence of SEQ ID NO:33; and ii. a V L domain comprising an LCDR 1 consisting of the amino acid sequence of SEQ ID NO:37, an LCDR2 consisting of the amino acid sequence of SEQ ID NO:40, and an LCDR3 consisting of the amino acid sequence of SEQ ID NO:44; and b) an antibody or an antigen-binding fragment thereof comprising: i.
- V H domain comprising an HCDR1 consisting of GYTFTRYW (SEQ ID NO:557), an HCDR2 consisting of IYPGDSDV (SEQ ID NO:558), and an HCDR3 consisting of ARLPQYCSKGVCYRWFDP (SEQ ID NO:559); and ii. a V L domain comprising an LCDR1 consisting of QGISSW (SEQ ID NO:560), an LCDR2 consisting of AAS, and an LCDR3 consisting of QQGHSFPYT (SEQ ID NO:561).
- a method disclosed herein comprises contacting the target cell with an antibody or an antigen-binding fragment thereof comprising a V H domain comprising the amino acid sequence of SEQ ID NO:5 and a V L domain comprising the amino acid sequence of SEQ ID NO:14.
- a method disclosed herein comprises contacting the target cell with: - 138 - 3839034.v1 5708.1076005 a) an antibody or an antigen-binding fragment thereof comprising a V H domain comprising the amino acid sequence of SEQ ID NO:5 and a V L domain comprising the amino acid sequence of SEQ ID NO:14; and b) an antibody or an antigen-binding fragment thereof comprising a V H domain comprising the amino acid sequence of SEQ ID NO:53 and a V L domain comprising the amino acid sequence of SEQ ID NO:75
- a method disclosed herein e.g., reducing infectivity of SARS- CoV-2 of a cell in a subject, reducing (e.g., inhibiting) binding of SARS-CoV-2 to a target cell, reducing (e.g., inhibiting) binding of SARS-CoV-2 to a target protein on a target cell, or reducing (e.g., inhibiting) virus mediated fusion with a target cell
- a method disclosed herein comprises contacting the target cell with: a) an antibody or an antigen-binding fragment thereof comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:578 and a light chain comprising the amino acid sequence of SEQ ID NO:592; and b) an antibody or an antigen-binding fragment thereof comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:622 and a light chain comprising the amino acid sequence of SEQ ID NO:623.
- a likelihood of SARS-CoV-2 infection in a subject is reduced by at least about 10%, e.g., by at least about: 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.
- the likelihood of SARS-CoV-2 infection in a subject in the presence of a polypeptide is about 1-90% relative to the likelihood in the absence of the polypeptide, for example, about: 2-90%, 2-85%, 3-85%, 3-80%, 4-80%, 4-75%, 5-75%, 5-70%, 6-70%, 6-65%, 7-65%, 7-60%, 8-60%, 8-55%, 9-55%, 9-50%, 10-50%, 10-45%, 15-45%, 15- 40%, 20-40%, 20-35%, 25-35%, or 25-30%.
- a subject has (e.g., confirmed by testing, such as by PCR or rapid test), or is suspected of having, COVID-19. In some embodiments, a subject has COVID- 19. In some embodiments, a subject has been diagnosed with COVID-19. In some embodiments, a subject is at risk of developing COVID-19. [00626] In some embodiments, a subject is a mammal.
- a subject is a mammal selected from the group consisting of a dog, a cat, a mouse, a rat, a hamster, a guinea pig, a horse, a pig, a sheep, a cow, a chimpanzee, a macaque, a cynomolgus, and a human.
- a subject is a primate.
- a subject is a human.
- a subject has a heart disease.
- a subject has a heart disease selected from the group consisting of a congenital heart disease, a coronary artery disease, a hypertensive heart disease, an inflammatory heart disease, a pulmonary heart disease, a rheumatic heart disease, a valvular heart disease, a cardiomyopathy, heart failure, and combinations thereof.
- a subject has a congestive heart failure.
- a subject has an inflammatory heart disease selected from the group consisting of endocarditis, cardiomegaly, myocarditis, and combinations thereof.
- a subject has diabetes.
- a subject has a lung disease.
- Non-limiting examples of lung diseases include acute respiratory distress syndromes, asthma, bronchitis, COPD, emphysema, lung tumors, pleural cavity diseases (e.g., pleural mesothelioma or tension pneumothorax), pulmonary vascular diseases (e.g., embolisms, edema, arterial hypertension or hemorrhage), or respiratory tract infections (e.g., pneumonia or other upper or lower respiratory tract infections).
- a subject is a tobacco smoker.
- a subject is immune-compromised (e.g., has an underlying disorder or is on immunosuppressive therapy).
- a subject is 40 years or older, e.g., at least: 45, 50, 55, 60, 65, 70, 75, 80, 85, or 90 years old.
- a method is used for prophylactic therapy.
- an effective dosage is sufficient to prevent the subject of being infected by SARS- CoV-2.
- a method is used for treating SARS-CoV-2 infection.
- an effective dosage is sufficient to reduce viral load in a subject.
- reduction in viral load is by at least about 10%, e.g., by at least about: 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, - 140 - 3839034.v1 5708.1076005 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.
- reduction in viral load is about 10-99%, e.g., about: 10-98%, 15-98%, 15-97%, 20-97%, 20-96%, 25-96%, 25-95%, 30-95%, 30-94%, 35-94%, 35-93%, 40-93%, 40-92%, 45-92%, 45-91%, 50-91%, 50- 90%, 55-90%, 55-85%, 60-85%, 60-80%, 65-80%, 65-75%, or 70-75%.
- an effective dosage is sufficient to inhibit binding of a virus to its target proteins, target cells, or both.
- reduction in binding is by at least about 10%, e.g., by at least about: 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.
- reduction in binding is about 10-99%, e.g., about: 10-98%, 15-98%, 15- 97%, 20-97%, 20-96%, 25-96%, 25-95%, 30-95%, 30-94%, 35-94%, 35-93%, 40-93%, 40-92%, 45-92%, 45-91%, 50-91%, 50-90%, 55-90%, 55-85%, 60-85%, 60-80%, 65-80%, 65-75%, or 70-75%.
- an effective dosage is sufficient to inhibit virus-mediated fusion with a target cell.
- reduction in fusion is by at least about 10%, e.g., by at least about: 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.
- reduction in fusion is about 10-99%, e.g., about: 10-98%, 15-98%, 15-97%, 20-97%, 20-96%, 25-96%, 25-95%, 30-95%, 30-94%, 35-94%, 35-93%, 40-93%, 40-92%, 45-92%, 45-91%, 50- 91%, 50-90%, 55-90%, 55-85%, 60-85%, 60-80%, 65-80%, 65-75%, or 70-75%.
- an effective dosage is sufficient to interfere with conformational changes in a viral envelope protein necessary for cell infectivity.
- a therapeutic agent described herein can be administered via a variety of routes of administration, including, for example, oral, dietary, topical, transdermal, rectal, parenteral (e.g., intra-arterial, intravenous, intramuscular, subcutaneous injection, intradermal injection), intravenous infusion, and inhalation (e.g., intrabronchial, intranasal or oral inhalation, intranasal drops) routes of administration, depending on the compound and the particular disease to be treated. Administration can be local or systemic as indicated. A preferred mode of administration can vary depending on the particular compound chosen.
- a polypeptide, polynucleotide, fusion protein, composition is administered to a subject as a monotherapy.
- a polypeptide, c polynucleotide, fusion protein, composition is administered to a subject in combination with at least one additional therapeutic agent (e.g., concurrently or sequentially with at least one additional - 141 - 3839034.v1 5708.1076005 therapeutic agent) or prophylactic agent (e.g., concurrently or sequentially with at least one additional prophylactic agent).
- a subject has been previously treated with at least one additional therapeutic agent prior to being administered a polypeptide, polynucleotide, fusion protein, composition (e.g., pharmaceutical composition) disclosed herein.
- a method disclosed herein comprises administering a therapeutically effective amount of at least one additional therapeutic agent to a subject at the same time as, or following administration of a polypeptide, polynucleotide, fusion protein, composition (e.g., pharmaceutical composition) disclosed herein.
- a method disclosed herein comprises administering a therapeutically effective amount of at least one prophylactic agent to a subject before, at the same time as, or following administration of a polypeptide, polynucleotide, fusion protein, composition (e.g., pharmaceutical composition) disclosed herein.
- a subject previously received a therapeutic or prophylactic agent.
- a subject was previously infected with a betacoronavirus, such as SARS-CoV-2.
- a subject is further treated (previously, concurrently, or sequentially) with (e.g., an effective amount of) one or more SARS-CoV-2 spike S2-specific antibodies or antigen-binding fragments thereof, such as CV3-25 or a variant thereof.
- SARS-CoV-2 spike S2-specific antibodies or antigen-binding fragments thereof include, for example, those described herein as S2_AB-1, S2_AB-2, S2_AB-3, S2_AB-4, S2_AB-5, S2_AB-6, S2_AB-7 ⁇ S2_AB-8 ⁇ S2_AB-9 ⁇ S2_AB-10, S2_AB-11, S2_AB-12, S2_AB-13, S2_AB-14, S2_AB-15, S2_AB-16, S2_AB-17, S2_AB-18, S2_AB-19, S2_AB-20, S2_AB-21, S2_AB-22, S2_AB-23, S2_AB-24, S2_AB-25, S2_AB-26, S2_AB-27, S2_AB-28, S2_AB-29, S2_AB-30, S2_AB-31, S2_AB-32, S2_AB-33, S2_AB-34, S2_AB-35
- Patent Application Nos.63/364,331 (filed on May 6, 2022), 63/364,328 (filed on May 6, 2022), 63/381,131 (filed on October 26, 2022), 63/381,132 (filed on October 26, 2022), 63/424,945 (filed on November 13, 2022), 63/383,695 (filed on November 14, 2022), 63/385,957 (filed on December 2, 2022), 63/478,650 (filed on January 5, 2023), 63/480,903 (filed on January 20, 2023), 63/492,206 (filed on March 24, 2023), 18/313,306 (filed on May 05, 2023), and Patent Cooperation Treaty Application No.
- a subject is further treated (previously, concurrently, or sequentially) with one or more SARS-CoV-2 RBD-class 3 antibodies (or antigen-binding fragments thereof), such as, for example, one or more of Sotrovimab, Bebtelovimab, AZD1061, P2G3, and EVUSHELD®.
- the subject is further treated (previously, concurrently, or sequentially) with one or more SARS-CoV-2 N-terminal domain (NTD)-nonsupersite antibodies (or antigen-binding fragments thereof).
- NTD N-terminal domain
- the subject is further treated (previously, concurrently, or sequentially) with one or more SARS-CoV-2 SD1 antibodies (or antigen-binding fragments thereof).
- the ACE2 inhibitor is selected from the group consisting of an RNAi to ACE2, an siRNA to ACE2, a CRISPR-based inhibitor of ACE2, a soluble ACE2, a soluble ACE2 variant, an anti-ACE2 antibody, a vaccine, and combinations thereof.
- the antibiotic is azithromycin.
- the antimalarial agent comprises chloroquine or hydroxychloroquine.
- the vaccine is a nucleic acid vaccine or an inactivated virus vaccine.
- the vaccine is mrna-1273, BNT162, INO-4800, AZD1222, Ad5-nCoV, PiCoVacc, NVX-CoV2373, JNJ-78436735, or a combination thereof.
- Administration of the two or more therapeutic agents encompasses co-administration of the therapeutic agents in a substantially simultaneous manner, such as in a pharmaceutical combination.
- such administration encompasses co-administration in multiple containers, or separate containers (e.g., capsules, powders, and liquids) for each therapeutic agent.
- Such administration also encompasses use of each type of therapeutic agent in a sequential manner, either at approximately the same time or at different times.
- Embodiment 1 comprising an immunoglobulin heavy chain variable domain (V H ) and an immunoglobulin light chain variable domain (V L ). 4.
- a polypeptide that specifically binds a severe acute respiratory syndrome coronavirus 2 Spike glycoprotein comprising: a) an immunoglobulin heavy chain variable domain (V H ) amino acid sequence comprising a heavy chain complementarity determining region 1 (HCDR1), a heavy chain complementarity determining region 2 (HCDR2) and a heavy chain complementarity determining region 3 (HCDR3) that are substantially similar to an HCDR1, HCDR2, and HCDR3, respectively, of the amino acid sequence of SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6; and b) an immunoglobulin light chain variable domain (V L ) amino acid sequence comprising a light chain complementarity determining region 1 (LCDR1), a light chain complementarity determining region 2 (LCDR2), and a light chain complementarity determining region 3 (LCDR3) that are substantially similar to an LCDR1, LCDR2 and LCDR3, respectively, of the amino acid sequence of SEQ ID NO:
- V H immunoglobulin heavy chain variable
- polypeptide of any one of Embodiments 1-4 comprising the HCDR1, HCDR2, and HCDR3, and LCDR1, LCDR2, and LCDR3, of an antibody comprising an amino acid sequence selected from: SEQ ID NO:4 and SEQ ID NO:9 (AB-1a); SEQ ID NO:4 and SEQ ID NO:10 (AB-1b); SEQ ID NO:4 and SEQ ID NO:11 (AB-1c); SEQ ID NO:4 and SEQ ID NO:12 (AB-1d); SEQ ID NO:5 and SEQ ID NO:13 (AB-2a); SEQ ID NO:5 and SEQ ID NO:14 (AB-2b); SEQ ID NO:5 and SEQ ID NO:15 (AB-2c); SEQ ID NO:5 and SEQ ID NO:16 (AB-2d); SEQ ID NO:6 and SEQ ID NO:17 (AB-3a); SEQ ID NO:6 and SEQ ID NO:18 (AB-3b); SEQ ID NO:6 and SEQ ID NO:19 (AB-3c); or
- the polypeptide of Embodiment 4 or 5, comprising a paratope that is identical to a paratope of an antibody comprising an amino acid sequence selected from: SEQ ID NO:4 and SEQ ID NO:9 (AB-1a); SEQ ID NO:4 and SEQ ID NO:10 (AB-1b); SEQ ID NO:4 and SEQ ID NO:11 (AB-1c); SEQ ID NO:4 and SEQ ID NO:12 (AB-1d); SEQ ID NO:5 and SEQ ID NO:13 (AB-2a); SEQ ID NO:5 and SEQ ID NO:14 (AB-2b); SEQ ID NO:5 and SEQ ID NO:15 (AB-2c); SEQ ID NO:5 and SEQ ID NO:16 (AB-2d); SEQ ID NO:6 and SEQ ID NO:17 (AB-3a); SEQ ID NO:6 and SEQ ID NO:18 (AB-3b); SEQ ID NO:6 and SEQ ID NO:19 (AB-3c); or SEQ ID NO:6 and SEQ ID NO:20 (AB
- SARS-CoV-2-Spike severe acute respiratory syndrome coronavirus 2 Spike glycoprotein
- V H immunoglobulin heavy chain variable domain
- V L immunoglobulin light chain variable domain
- SARS-CoV-2-Spike severe acute respiratory syndrome coronavirus 2 Spike glycoprotein
- V H immunoglobulin heavy chain variable domain
- X 1 is D
- X 2 is T or Y
- X 3 is S or D
- X 4 is D
- X 5 is L
- X 6 is F
- X 7 is Y or A
- X 8 is H
- X 9 is P
- X 10 is D
- X 11 is F; or any combination of the foregoing. 11.
- the polypeptide of Embodiment 9 or 10 comprising an immunoglobulin light chain variable domain (V L ) comprising the amino acid sequence of SEQ ID NO:7, wherein: X 12 is N or S; X 13 is D or R; X 14 is C, A, S, or Y; X 15 is N or R; X 16 is S or D; X 17 is L or S; X 18 is S or F; X 19 is G or D; X 20 is N or H; or any combination of the foregoing. 12.
- V L immunoglobulin light chain variable domain
- V H comprises a heavy chain complementarity determining region 1 (HCDR1), a heavy chain complementarity determining region 2 (HCDR2) and a heavy chain complementarity - 148 - 3839034.v1 5708.1076005 determining region 3 (HCDR3) that are identical in amino acid sequence to the HCDR1, HCDR2 and HCDR3, respectively, of SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6. 14.
- HCDR1 heavy chain complementarity determining region 1
- HCDR2 heavy chain complementarity determining region 2
- HCDR3 heavy chain complementarity - 148 - 3839034.v1 5708.1076005 determining region 3
- V L comprises a light chain complementarity determining region 1 (LCDR1), light chain complementarity determining region 2 (LCDR2) and light chain complementarity determining region 3 (LCDR3) that are identical in amino acid sequence to the LCDR1, LCDR2 and LCDR3, respectively, of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19 or SEQ ID NO:20.
- LCDR1 light chain complementarity determining region 1
- LCDR2 light chain complementarity determining region 2
- LCDR3 light chain complementarity determining region 3
- polypeptide of any one of Embodiments 1-5 and 7-14 wherein the polypeptide comprises a paratope that is identical to a paratope of a V H/ V L combination selected from the amino acid sequence of: SEQ ID NO:4 and SEQ ID NO:9 (AB-1a); SEQ ID NO:4 and SEQ ID NO:10 (AB-1b); SEQ ID NO:4 and SEQ ID NO:11 (AB-1c); SEQ ID NO:4 and SEQ ID NO:12 (AB-1d); SEQ ID NO:5 and SEQ ID NO:13 (AB-2a); SEQ ID NO:5 and SEQ ID NO:14 (AB-2b); SEQ ID NO:5 and SEQ ID NO:15 (AB-2c); SEQ ID NO:5 and SEQ ID NO:16 (AB-2d); SEQ ID NO:6 and SEQ ID NO:17 (AB-3a); SEQ ID NO:6 and SEQ ID NO:18 (AB-3b); SEQ ID NO:6 and SEQ ID NO:19 (AB-3c); or
- V H has at least 85% sequence identity to the amino acid sequence of SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6, or any combination of the foregoing.
- V H comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6, or any combination of the foregoing.
- - 149 - 3839034.v1 5708.1076005 18.
- V L has at least 85% sequence identity to the amino acid sequence of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19 or SEQ ID NO:20, or any combination of the foregoing. 19.
- V L comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19 or SEQ ID NO:20, or any combination of the foregoing.
- the polypeptide of any one of Embodiments 1-20 wherein: a) the V H comprises the amino acid sequence of SEQ ID NO:4; and b) the V L comprises the amino acid sequence of SEQ ID NO:11 (AB-1c). 25. The polypeptide of any one of Embodiments 1-20, wherein: a) the V H comprises the amino acid sequence of SEQ ID NO:4; and b) the V L comprises the amino acid sequence of SEQ ID NO:12 (AB-1d). 26. The polypeptide of any one of Embodiments 1-20, wherein: a) the V H comprises the amino acid sequence of SEQ ID NO:5; and b) the V L comprises the amino acid sequence of SEQ ID NO:13 (AB-2a).
- the polypeptide of any one of Embodiments 1-20 wherein: a) the V H comprises the amino acid sequence of SEQ ID NO:5; and b) the V L comprises the amino acid sequence of SEQ ID NO:16 (AB-2d).
- the polypeptide of any one of Embodiments 1-20 wherein: a) the V H comprises the amino acid sequence of SEQ ID NO:6; and b) the V L comprises the amino acid sequence of SEQ ID NO:17 (AB-3a).
- the polypeptide of any one of Embodiments 1-20 wherein: a) the V H comprises the amino acid sequence of SEQ ID NO:6; and b) the V L comprises the amino acid sequence of SEQ ID NO:19 (AB-3c). 33. The polypeptide of any one of Embodiments 1-20, wherein: a) the V H comprises the amino acid sequence of SEQ ID NO:6; and b) the V L comprises the amino acid sequence of SEQ ID NO:20 (AB-3d). 34. The polypeptide of any one of Embodiments 3-21, wherein the V H and V L are humanized, contain human framework regions, or a combination thereof. 35.
- the polypeptide of Embodiment 35 comprising an antibody heavy chain constant domain sequence, an antibody light chain constant domain sequence, or both an antibody heavy chain constant domain sequence and an antibody light chain constant domain sequence. 38.
- the polypeptide of Embodiment 37, wherein the antibody heavy chain constant domain is selected from the group consisting of an IgA constant domain, an IgD constant domain, an IgE constant domain, an IgG constant domain and an IgM constant domain.
- the polypeptide of Embodiment 38, wherein the antibody heavy chain constant domain is an IgG1 heavy chain constant domain.
- 40. The polypeptide of any one of Embodiments 37-39, comprising an antibody light chain constant domain selected from the group consisting of a ⁇ constant domain or a ⁇ constant domain.
- the polypeptide of Embodiment 42, wherein the heterologous moiety is selected from the group consisting of polyethylene glycol (PEG), hexadecanoic acid, a hydrogel, a lipid nanoparticle, a polymer nanoparticle, and a heterologous polypeptide sequence, or a combination thereof.
- polypeptide of Embodiment 42 wherein the heterologous polypeptide sequence comprises a carrier polypeptide.
- the carrier polypeptide is albumin or an Fc polypeptide. - 152 - 3839034.v1 5708.1076005 48.
- polypeptide of any one of Embodiments 1-47 wherein the polypeptide: a) binds SARS-CoV-2 with a K D of 1 ⁇ M or less; b) neutralizes SARS-CoV-2 infection of human host cells with an IC 50 of about 25,000 ng/mL or less; c) reduces infectivity of SARS-CoV-2 in human cells, or any combination of the foregoing, optionally, wherein SARS-CoV-2 is of a strain set forth in FIGs.6, 12 and/or 13, such as SARS CoV-2 Omicron BQ.1, SARS CoV-2 Omicron XBB (+K444T, L452R, F486V, R493Q, N658S), or SARS CoV-2 XBB.
- SARS-CoV-2 is of a strain set forth in FIGs.6, 12 and/or 13, such as SARS CoV-2 Omicron BQ.1, SARS CoV-2 Omicron XBB (+K444T, L45
- the polypeptide of Embodiment 48, wherein the SARS-CoV-2 is a variant comprising T19R, 156del, 157del, R158G, L452R, T478K, D614G, P681R and D950N, and optionally comprising G142D. 50.
- the polypeptide of Embodiment 48 or 49, wherein the polypeptide binds SARS-CoV-2 with a K D of 100 nM or less.
- a fusion protein comprising the polypeptide of any one of Embodiments 1-52.
- a polynucleotide e.g., DNA or RNA; linear or circular; optionally containing one or more modified nucleotides
- a vector e.g., an expression vector, including a viral-delivery vector comprising the polynucleotide of Embodiment 54.
- a host cell comprising the polynucleotide of Embodiment 54 or the vector of Embodiment 55.
- a composition comprising the polypeptide of any one of Embodiments 1-52 or the fusion protein of Embodiment 53 or the polynucleotide of Embodiment 54. - 153 - 3839034.v1 5708.1076005 58.
- the composition of Embodiment 57 comprising one or more pharmaceutical excipients, diluents, or carriers.
- a method of reducing infectivity of a betacoronavirius, such as SARS-CoV-2, of a cell in a subject comprising contacting the cell with an effective amount of the composition of Embodiment 57 or 58, optionally, wherein the betacoronavirius is one set forth in FIGs. 6, 12 and/or 13, such as SARS CoV-2 Omicron BQ.1, SARS CoV-2 Omicron XBB (+K444T, L452R, F486V, R493Q, N658S), or SARS CoV-2 XBB. 61.
- Embodiment 59 or 60 wherein the subject has (e.g., confirmed by testing, such as by PCR or rapid test), or is suspected of having, COVID-19.
- 63. The method of any one of Embodiments 59-62, wherein the subject is a human.
- Embodiment 64 wherein the heart disease is selected from the group consisting of a congestive heart disease, a coronary artery disease, a hypertensive heart disease, an inflammatory heart disease, a pulmonary heart disease, a rheumatic heart disease, a valvular heart disease, a cardiomyopathy, heart failure, and combinations thereof.
- the heart failure is a congestive heart failure.
- the inflammatory heart disease is selected from the group consisting of endocarditis, cardiomegaly, myocarditis, and combinations thereof.
- 68 The method of any one of Embodiments 59-67, wherein the subject has diabetes.
- Embodiments 59-68 The method of any one of Embodiments 59-68, wherein the subject has a lung disease. - 154 - 3839034.v1 5708.1076005 70.
- the lung disease is selected from the group consisting of acute respiratory distress syndrome, asthma, bronchitis, COPD, emphysema, a lung tumor, a pleural cavity disease, a pulmonary vascular disease, a respiratory tract infection, and combinations thereof.
- the lung disease is selected from the group consisting of acute respiratory distress syndrome, asthma, bronchitis, COPD, emphysema, a lung tumor, a pleural cavity disease,
- Embodiment 70 wherein: a) the respiratory tract infection is an upper respiratory tract infection, a lower respiratory tract infection, or pneumonia; b) the pleural cavity disease is pleural mesothelioma or tension pneumothorax; c) the pulmonary vascular disease is embolisms, edema, arterial hypertension or hemorrhages; or d) a combination thereof.
- 73. The method of any one of Embodiments 59-72, wherein the subject is immune- compromised.
- the additional SARS-CoV-2-Spike-binding antibody is selected from the group consisting of bamlanivimab, etesevimab, bebtelovimab, casirivimab, imdevimab, Cilgavimab, Tixagevimab, AZD7442 (Tixagevimab-Cilgavimab), Regdanvimab, Sotrovimab and combinations thereof; - 155 - 3839034.v1 5708.1076005
- the antiviral agent is selected from the group consisting of oseltamivir (Tamiflu), favipiravir, amantadine, remdesivir, rimantadine, pleconaril, an anti-sense RNA to SARS-CoV-2, a siRNA to SARS-CoV-2, and combinations thereof;
- the ACE2 inhibitor is selected from the group consisting of bamlanivimab, etese
- Embodiment 78 The method of Embodiment 78, wherein the vaccine is mrna-1273, BNT162, INO-4800, AZD1222, Ad5-nCoV, PiCoVacc, NVX-CoV2373, JNJ-78436735, or a combination thereof.
- 80 The method of any one of Embodiments 59-79, wherein the subject is further treated (previously, concurrently, or sequentially) with one or more S2 antibodies (or antigen- binding fragments thereof), such as CV3-25 or a variant thereof (e.g., one or more polypeptides disclosed in U.S.
- 81. The method of any one of Embodiments 59-80, wherein the subject previously received a therapeutic or prophylactic agent.
- 82. The method of any one of Embodiments 59-81, wherein the subject was previously infected with a betacoronavirus, such as SARS-CoV-2. *** [00648] Headings used in this application are for convenience only and do not affect the interpretation of this application.
- each of the various individual and collective combinations and permutations of these compounds may not be explicitly disclosed, each is specifically contemplated and described herein.
- a class of elements A, B, and C are disclosed as well as a class of elements D, E, and F and an example of a combination of elements A-D is disclosed, then, even if each is not individually recited, each is individually and collectively contemplated.
- each of the combinations A-E, A-F, B-D, B-E, B-F, C-D, C-E, and C-F are specifically contemplated and should be considered disclosed from disclosure of A, B, and C; D, E, and F; and the example combination A-D.
- any subset or combination of these is also specifically contemplated and disclosed.
- the sub-groups of A-E, B-F, and C-E are specifically contemplated and should be considered disclosed from disclosure of A, B, and C; D, E, and F; and the example combination A-D.
- This concept applies to all aspects of this application, including elements of a composition of matter and steps of method of making or using the compositions.
- Binding Assay (DELFIA) [00652] Polystyrene MaxiSorp plates (ThermoFisher, Waltham, MA, Cat # 460372) were coated with phosphate buffered saline (PBS)-diluted Spike proteins at 5 ⁇ g/ml and incubated overnight at 4°C. Plates were washed with Tris-buffered saline Tween ® 20 buffer (TBS-T) (ThermoFisher, Waltham, MA, Cat # 28360) and blocked with an assay diluent (BioLegend, San Diego, CA, Cat # 421205) for 1 hour at room temperature.
- PBS phosphate buffered saline
- TBS-T Tris-buffered saline Tween ® 20 buffer
- Serial dilutions (1:4) of the antibodies were made in PBS/bovine serum albumin (BSA) starting from 4.5 ⁇ g/ml. After one wash with - 157 - 3839034.v1 5708.1076005 TBS-T, the serially diluted antibodies were transferred to the pre-coated plates and incubated for 1 hour at room temperature. Next, the plates were washed 3 times with TBS-T, and a Europium- labeled secondary antibody (PerkinElmer, Waltham, MA, Cat # 1244-330) was added for 30 minutes at room temperature. Following the incubation, the plates were washed 3 times in TBS- T, and an enhancement solution (PerkinElmer, Waltham, MA, Cat # 4001-0010) was applied.
- BSA PBS/bovine serum albumin
- the antibodies were 3-, 4- , or 6-fold serially diluted in PBS/0.2% BSA/1x Penicillin-Streptomycin (Pen-Strep) buffer, starting from 72 ⁇ g/ml, 18 ⁇ g/ml or 4 ⁇ g/ml (4x final concentration), in round bottom 96-well plates (ThermoFisher, Waltham, MA, Cat # 268200).
- the antibodies were mixed with equal volumes of diluted SARS-CoV-2 pseudoviruses (lentiviruses pseudotyped with SARS-CoV-2 Delta, BA.1, SARS-CoV-1 or WIV1 Spike, and VSV-dG pseudotyped with SARS-CoV-2 D614G, Delta, BA.2, BA.2.12.1, BA.4/5, BA.4/5 + K444T, BQ.1, BQ.1.1, XBB.1, XBB.1.5, XBB.1.5.10, EG.5.1, SARS-CoV-1 or WIV1 Spike).
- Antibody-virus mixtures were incubated at 37 o C, 5% CO 2 for 30 - 60 minutes.
- a volume of 20 ⁇ l of antibody-virus mixture was then transferred to 384 well plates pre-seeded with Vero-TMPRSS2 cells.
- the 384-well plates were briefly centrifuged at ⁇ 50 ⁇ g and incubated at 37 o C, 5% CO 2 for 24 (VSV-dG) or 72 (lentiviruses) hours.
- 40 ⁇ l of luciferase detection buffer BPS Bioscience ONE-STEPSTM Luciferase Assay System, BPS Bioscience, San Diego, CA Cat # 60690-3 was added to each well of the cell culture plates. The plates were centrifuged for ⁇ 5 seconds at 50 ⁇ g, then incubated for 15 minutes with gentle rocking.
- AUC Area under the curve
- % Infection Sample is the percentage infection of any given dilution of test article
- % Infection Uninfected Control is the percentage infection measured in untreated wells that have not been infected (background signal)
- the aim of the project learning campaign was to improve antibody binding profile and function and reduce the number of sequence liabilities.
- the generation campaign chose a human IgG1 antibody isolated from a convalescent donor and targeting the RBD class 4 epitope as a Reference Antibody.
- the RBD class 4 epitope is poorly immunogenic.
- Variant sets of antibodies were generated, and the following datasets were acquired: (1) developability: HPLC-SEC (see, e.g., FIG.6 “% SEC Mono”), AC-SINS (see, e.g., FIG.6 “AC-SINS”), polyspecificity (see, e.g., FIG.6 “PSR-DNA and PSR-Insulin”); (2) binding of RBD proteins expressed on yeast and representative of SARS-CoV-2-related clade 1b, SARS- CoV-related clade 1, Asia non-ACE2 bat Sarbecovirus clade 2, Africa+Europe bat Sarbecovirus clade 3 (see, e.g., FIGs.8A-8B); (3) neutralization of pseudotyped lentiviruses or VSV-dG: SARS-CoV-2 Delta, SARS-CoV-2 Omicron BA.1, SARS-CoV-2 Omicron BA.2, SARS-CoV-2 Omicron BA.2.12.1, SARS-CoV-2 Omicron BA.
- AB-2b, AB-4a and AB-3a bound RBDs of all SARS-CoV-2 variants tested so far, including pre-Omicron lineages and Omicron sublineages.
- AB-4a and AB-3a robustly bound to emerging Omicron variants (XBB, BQ.1) while other clinical-stage antibodies (Sotrovimab, AZD1061, Bebtelovimab) showed low-to-no binding (FIGs.8A-8B).
- AB-2b robustly binds to prevalent Omicron variants (e.g., XBB1.5), while other clinical-stage antibodies (e.g., Bebtelovimab) show low-to-no binding (FIG.13A).
- AB-2b, AB-4a and AB-3a also bound RBDs of several SARS-CoV-2-related sarbecoviruses (FIGs.8A-8B and FIG.13A). Binding to RBDs was assessed through yeast surface display. Many generated class 4 anti-RBD antibodies also - 160 - 3839034.v1 5708.1076005 showed robust binding to RBDs of several non-SARS-CoV-2 Sarbecoviruses (FIG.8B and FIG. 13B). Overall, the unique binding profiles of Generate class 4 anti-RBD antibodies support their potential use for pandemic response and preparedness. [00664] As part of the screening campaigns, antibodies able to neutralize pseudoviruses not included in the training set were identified.
- BA.2 see, e.g., FIGs.3A-3B
- BA.4/5 see, e.g., FIGs.4A-4B
- BA.4/5 neutralization only partially correlated with binding to BA.4/5 Spike and was observed with antibodies having 9 or more amino acid mutations compared to the reference antibody (FIGs.5A-5B).
- class 4 anti- RBD screening hits with robust neutralization of SARS-CoV-2 BA.4/5 were identified (FIGs. 7A-7B).
- RBD sequences representative of SARS-CoV-2 variants, SARS-CoV-2-related Sarbecoviruses clade 1b, SARS-CoV-related Sarbecoviruses clade 1a, and Sarbecoviruses clades 2 and 3 were expressed on yeast to assess binding to selected class 4 anti-RBD screening hits (AB-3a and AB-4a) as well as clinical-stage antibodies Sotrovimab, AZD1061 and Bebtelovimab.
- AB-3a and AB-4a showed robust binding to all RBDs of SARS-CoV-2 variants including the emerging variants XBB and BQ.1, as well as several non-SARS-CoV-2 Sarbecoviruses, while clinical-stage antibodies showed more limited binding profiles (FIGs.8A- 8B).
- AB-4a was further tested for neutralization of a BA.4/5 pseudovirus harboring the escape mutation K444T observed in emerging SARS-CoV-2 variants.
- AB-4a neutralizes the BA.4/5+K444T pseudovirus and further enhances the neutralization profile of an anti-S2 antibody (FIG.9; see also Table 6 and Table 7 for V H and V L sequences of anti-S2 antibodies, respectively).
- AB-3a was tested for neutralization of the BA.4/5+K444T pseudovirus. AB-3a neutralizes the BA.4/5+K444T pseudovirus and further enhanced the neutralization profile of an anti-S2 antibody. Of note, enhancement of the anti-S2 antibody neutralization profile is observed in combination with clinical-stage antibodies as well (Sotrovimab, Bebtelovimab) (FIGs.10A- 10B). AB-3a was also tested for neutralization of the BQ.1.1 pseudovirus. AB-3a neutralizes the BQ.1.1 pseudovirus and further enhanced the neutralization profile of an anti-S2 antibody (FIGs. 11A-11D).
- AB-2b was tested for neutralization of the D614G, Delta, BQ1.1 or XBB.1.5 pseudovirus.
- AB-2b neutralized the D614G, Delta, BQ1.1 and XBB.1.5 pseudovirus (FIG.14A- - 161 - 3839034.v1 5708.1076005 14B).
- AB-2b also improved neutralization of Omicron BQ1.1 and XBB.1.5 by S2_AB-1, an anti-S2 antibody (FIGs.14A-14B).
- S2_AB-1 S2_AB-1
- an anti-S2 antibody FIGs.14A-14B
- AB-2b As shown in FIGs.15A-15B, AB-2b, alone or combined with S2_AB-1, potently neutralizes VSV-dG pseudoviruses representative of D614G, SARS-CoV-1 and WIV1. Neutralization of additional variants by AB-2b, alone or in combination with different amounts of S2_AB-1, is shown in FIGs.15C-15D. [00670] AB-4a was also tested for neutralization of the Delta and BA.5 live viruses. AB-4a neutralizes the Delta and BA.5 live viruses and further enhanced the neutralization profile of an anti-S2 antibody (FIGs.12A-12C). Example 3.
- AB-2b has comparable activity to sotrovimab V H /V L - hIgG1-LS in terms of lung viral titer reduction (as measured by TCID 50 ).
- TCID 50 median tissue culture infectious dose
- SARS-CoV-2 BA.1 spike trimer and AB-2b Fab were expressed in EXPI293® cells following the Gibco ® EXPI293® Expression System protocol. In brief, three million cells were transfected with approximately 1 ⁇ g of plasmid DNA. The cells were incubated at 37°C with 80% relative humidity and 8% CO 2 on an orbital shaker at 150 RPM. Four days post- - 162 - 3839034.v1 5708.1076005 transfection, the cells were harvested and pelleted at 3,900 ⁇ g for 30 mins at 4°C.
- the supernatant was decanted into 0.22 ⁇ m filter units and stored at 4°C until purification.
- the SARS-CoV-2 BA.1 spike trimer was purified using Nickel Sepharose Excel resin (Cytiva, Marlborough, MA).
- the AB-2b Fab was purified using the LambdaFabSelect resin (Cytiva).
- [00674] Complexation of BA.1 with AB-2b Fab [00675] SARS-CoV-2 BA.1 spike trimer was incubated with AB-2b Fab at a 1:2 molar ratio at 4°C overnight with gentle mixing.
- the complex was purified by size exclusion chromatography on a SUPEROSE® 6 Increase 10/300 GL column equilibrated in 50 mM HEPES (pH8.0), 150 mM NaCl. Each fraction was analyzed by aSEC (absolute size exclusion chromatography) and SDS-PAGE (electrophoresis) to confirm complex formation between the BA.1 spike protein and AB-2b Fab. Fractions containing the complex were pooled and vitrified on the Vitrobot Mark IV (Thermo Fisher Scientific). [00676] Cryo-EM Data Collection [00677] Cryo-EM images were acquired on a Krios G4 cryo-TEM using EPU software (v3.2).
- the Krios was operated at 300 kV with a Falcon4i direct electron detector and a Selectris energy filter with a zero-loss slit width of 10 eV.
- a total of 6587 movies were collected at 165,000x magnification at a pixel size of 0.730 ⁇ .
- the total dose per movie was 51.05 electrons per square angstrom.
- the targeted defocus range was between 0.5-2.4 ⁇ m.
- Cryo-EM Processing [00679] Following collection, all processing was performed using cryoSPARC. First, movies were corrected for beam-induced motion using a patch motion correction. Next, the contrast transfer function parameters of micrographs were estimated using the patch CTF estimation. Individual particles were auto-picked and then clustered into distinct class averages.
- the class averages with highest resolution features were selected for a homogeneous refinement with C3 symmetry, owing to the three-fold rotational symmetry of the SARS-CoV-2 spike.
- a mask around this region was generated in ChimeraX (v1.6.1) and used for a local-refinement in cryoSPARC.
- Model building [00681] Initial models were built as a homology model of the initial design. Each component of the structure (RBD, FAB, Spike main chain) was individually docked into the composite density map. The structure was then computationally reassembled followed by energy minimization using the GROMACS (v2023.1) molecular dynamics software. The minimized structure then underwent real-space refinement using PHENIX (v1.20.1), with secondary- structure and torsion restrains present. [00682] FIGs.17A-17B depict structural analysis of AB-2b Fab binding to SARS-CoV-2 BA.1 RBD and related contact residues.
- FIG.17C shows a low-pass filtered Cryo-EM map of the SARS-CoV-2 BA.1 spike trimer with AB-3a Fab binding the RBD and an anti-S2 antibody, S2_AB-1, binding the S2 stem helix. The map is shown from a side profile (top panel) and from below (bottom panel). Each of the presumptive Fabs is labeled.
- FIG.17D shows a density-docked atomic model of the SARS- CoV-2 spike assembly with bound RBD-binding (AB-3a) and S2-binding (S2_AB-1) Fabs.
- a high-resolution structure of the SARS-CoV-2 spike trimer with the S2 stem helix is resolved.
- the bottom panel of FIG.17D depicts three anti-S2 Fabs (S2_AB-1) docked into the propeller shaped density around the S2 stem helix.
- Table 8 represents epitope mapping (amino acid contacts) of: Reference Ab with spike of SARS-CoV-2 ancestral strain; lead molecule AB-2b with spike of SARS-CoV-2 Omicron BA.1, both predicted from the design and experimentally determined through cryo-EM. The table also report amino acid differences between SARS-CoV-2 ancestral strain and Omicron BA.1 spike proteins that fall within Reference Ab or AB-2b epitopes.
- Tables 9-10 represent paratope mapping (amino acid contacts) of lead molecule AB- 2b light chain (Table 9) and heavy chain (Table 10) with spike of SARS-CoV-2 Omicron BA.1, both predicted from the design and experimentally determined through cryo-EM.
- V H & V L SEQ ID Numbers (Part 1) - 185 - 3839034.v1 5708.1076005 Table 5.
- V H & V L SEQ ID Numbers (Part 2) - 186 - 3839034.v1 5708.1076005 Table 5.
- V H & V L SEQ ID Numbers (Part 3) - 187 - 3839034.v1 5708.1076005 Table 5.
- V H Amino Acid Sequences of anti-S2 polypeptides e.g., monoclonal antibodies
- anti-S2 polypeptides e.g., monoclonal antibodies
- V L Amino Acid Sequences of anti-S2 polypeptides e.g., monoclonal antibodies
- Neutralization potencies of novel anti-RBD class 4 hits optimized from AB-2b Neutralization data of screening hits identified from optimization of AB-2b. Results with the reference antibody Reference Ab are also reported for comparison.
- Pseudoviruses representative of the following SARS-CoV-2 variants have been tested: ancestral strain (D614G), BQ.1.1, XBB.1, XBB.1.5.10, EG.5.1.
- Neutralization data are expressed as EC 50 values for individual pseudoviruses and also as composite score (a metric that summarize neutralization data across all pseudoviruses [the higher the better]).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
Abstract
The disclosure provides, in various embodiments, polypeptides (e.g, antibodies and antigen binding fragments thereof) that specifically bind to receptor binding domains (RBDs) of betacoronavirus Spike glycoproteins, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoproteins. The disclosure also provides, in various embodiments, fusion proteins comprising one or more of polypeptides, polynucleotides encoding polypeptides, vectors and host cells suitable for expressing polypeptides, and methods for treating viral infections (e.g., COVID-19).
Description
5708.1076005 ANTIGEN BINDING MOLECULES TARGETING SARS-COV-2 RELATED APPLICATION(S) [0001] This application claims the benefit of U.S. Provisional Application No.63/424,947, filed on November 13, 2022, U.S. Provisional Application No.63/383,699, filed on November 14, 2022, U.S. Provisional Application No.63/480,919, filed on January 20, 2023, U.S. Provisional Application No.63/492,211, filed on March 24, 2023, and U.S. Provisional Application No 63/520,549, filed on August 18, 2023. The entire teachings of the above applications are incorporated herein by reference. INCORPORATION BY REFERENCE OF MATERIAL IN XML [0002] This application incorporates by reference the Sequence Listing contained in the following eXtensible Markup Language (XML) file being submitted concurrently herewith: a) File name: 5708_1076-005_SL.xml; created November 1, 2023, 584,835 Bytes in size. BACKGROUND [0003] The SARS-Coronavirus-2 (SARS-CoV-2), a novel coronavirus, first caused a cluster of pneumonia cases (COVID-19) in Wuhan, China. As of March 1, 2020, 79,968 patients in China had tested positive for COVID-19, 2,873 deaths had occurred, equivalent to a mortality rate of 3.6% (95% CI 3.5-3.7) (Baud et al. Real estimates of mortality following COVID-19 infection, Lancet Infect Dis.20(7):773 (2020)). This figure, however, may be an underestimate of the potential threat of COVID-19 in symptomatic patients (Id.). [0004] COVID-19 has been spreading rapidly throughout the world, resulting in a pandemic. The Coronavirus disease (COVID-2019) situation report released from the World Health Organization on April 21, 2020 reported 2,397,216 confirmed infections and 162,956 deaths. Among them, 83,006 new cases and 5,109 deaths were added within the previous 24 hours. Quarantine, isolation, and infection-control measures have been relied on to prevent disease spread, and supportive care for those who become ill (Baden & Rubin, Covid-19 - The Search for Effective Therapy, N Engl J Med.382(19):1851-52 (2020)). [0005] Despite development and use of vaccines and therapeutics, SARS-CoV-2 outbreaks continue and mutants of SARS-CoV-2 continue to develop and evade these prophylactics and treatments. Accordingly, a need exists for additional therapeutics that can be rapidly deployed, - 1 - 3839034.v1
5708.1076005 preferably therapeutics that counter escape mutants and retain therapeutic efficacy, e.g., through broadly neutralizing activity. SUMMARY [0006] There is a critical need to develop specific antiviral therapeutic agents for preventing transmission of COVID-19 as well as treating COVID-19 patients, preferably where such therapeutic agents retain activity against new and emerging variants, with broadly neutralizing activity. The disclosure provides such therapeutics. [0007] The disclosure provided herein is based, in part, on the discovery that polypeptides disclosed herein specifically bind to the spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2-Spike). Accordingly, the disclosure generally relates to compositions (e.g., polypeptides, pharmaceutical compositions) and methods that are useful for reducing Spike (e.g., SARS-CoV-2-Spike) mediated viral entry into a cell. [0008] Provided herein, among other things, are polypeptides (e.g., antibodies and antigen binding fragments thereof) that specifically bind an RBD of a betacoronavirus Spike glycoprotein (e.g., an RBD of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoprotein). In some embodiments, the polypeptides have one or more properties selected from: a broadly neutralizing activity against a plurality of known and predicted betacoronaviruses (e.g., past, present, emergent, and future betacoronaviruses), and a binding affinity for an RBD epitope (e.g., RBD class 4 epitope) that is highly conserved across a plurality of betacoronaviruses. In some embodiments, a polypeptide has a broadly neutralizing activity against a plurality of known and predicted betacoronaviruses, and a binding affinity for an RBD domain epitope (e.g., RBD class 4 epitope) that is highly conserved across a plurality of betacoronaviruses. [0009] The disclosure provides, among other things, polypeptides that specifically bind SARS-CoV-2-Spike, wherein the polypeptide comprises a paratope that is substantially similar to a paratope of an antibody comprising a VH/VL pair selected from: SEQ ID NO:4 and SEQ ID NO:9 (AB-1a); SEQ ID NO:4 and SEQ ID NO:10 (AB-1b); SEQ ID NO:4 and SEQ ID NO:11 (AB-1c); SEQ ID NO:4 and SEQ ID NO:12 (AB-1d); SEQ ID NO:5 and SEQ ID NO:13 (AB-2a); SEQ ID NO:5 and SEQ ID NO:14 (AB-2b); SEQ ID NO:5 and SEQ ID NO:15 (AB-2c); - 2 - 3839034.v1
5708.1076005 SEQ ID NO:5 and SEQ ID NO:16 (AB-2d); SEQ ID NO:6 and SEQ ID NO:17 (AB-3a); SEQ ID NO:6 and SEQ ID NO:18 (AB-3b); SEQ ID NO:6 and SEQ ID NO:19 (AB-3c); SEQ ID NO:6 and SEQ ID NO:20 (AB-3d); or any combination of the foregoing. [0010] The disclosure provides, among other things, polypeptides that specifically bind SARS-CoV-2-Spike, wherein the polypeptide comprises a paratope that is substantially similar to a paratope of an antibody comprising a VH/VL pair selected from: SEQ ID NO:4 and SEQ ID NO:9 (AB-1a); SEQ ID NO:4 and SEQ ID NO:10 (AB-1b); SEQ ID NO:4 and SEQ ID NO:11 (AB-1c); SEQ ID NO:4 and SEQ ID NO:12 (AB-1d); SEQ ID NO:5 and SEQ ID NO:13 (AB-2a); SEQ ID NO:5 and SEQ ID NO:14 (AB-2b); SEQ ID NO:5 and SEQ ID NO:15 (AB-2c); SEQ ID NO:5 and SEQ ID NO:16 (AB-2d); SEQ ID NO:6 and SEQ ID NO:17 (AB-3a); SEQ ID NO:6 and SEQ ID NO:18 (AB-3b); SEQ ID NO:6 and SEQ ID NO:19 (AB-3c); SEQ ID NO:6 and SEQ ID NO:20 (AB-3d); SEQ ID NO:89 and SEQ ID NO:91 (AB-4a); SEQ ID NO:90 and SEQ ID NO:92 (AB-7a); or any combination of the foregoing. [0011] The disclosure also provides, among other things, a polypeptide that specifically binds SARS-CoV-2-Spike, wherein the polypeptide comprises: an immunoglobulin heavy chain variable domain (VH) amino acid sequence comprising a heavy chain complementarity determining region 1 (HCDR1), a heavy chain complementarity determining region 2 (HCDR2) and a heavy chain complementarity determining region 3 (HCDR3) that are substantially similar to an HCDR1, an HCDR2 and an HCDR3, respectively, of SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6; and an immunoglobulin light chain variable domain (VL) amino acid sequence comprising a light chain complementarity determining region 1 (LCDR1), a light chain complementarity - 3 - 3839034.v1
5708.1076005 determining region 2 (LCDR2) and a light chain complementarity determining region 3 (LCDR3) that are substantially similar to an LCDR1, an LCDR2 and an LCDR3, respectively, of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19 or SEQ ID NO:20. [0012] The disclosure also provides, among other things, a polypeptide that specifically binds SARS-CoV-2-Spike, wherein the polypeptide comprises: an immunoglobulin heavy chain variable domain (VH) amino acid sequence comprising a heavy chain complementarity determining region 1 (HCDR1), a heavy chain complementarity determining region 2 (HCDR2) and a heavy chain complementarity determining region 3 (HCDR3) that are substantially similar to an HCDR1, an HCDR2 and an HCDR3, respectively, of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:89 or SEQ ID NO:90; and an immunoglobulin light chain variable domain (VL) amino acid sequence comprising a light chain complementarity determining region 1 (LCDR1), a light chain complementarity determining region 2 (LCDR2) and a light chain complementarity determining region 3 (LCDR3) that are substantially similar to an LCDR1, an LCDR2 and an LCDR3, respectively, of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:91 or SEQ ID NO:92. [0013] In some embodiments, a polypeptide disclosed herein comprises an HCDR1, HCDR2 and HCDR3, and an LCDR1, LCDR2 and LCDR3, of an antibody comprising an amino acid sequence selected from: SEQ ID NO:4 and SEQ ID NO:9 (AB-1a); SEQ ID NO:4 and SEQ ID NO:10 (AB-1b); SEQ ID NO:4 and SEQ ID NO:11 (AB-1c); SEQ ID NO:4 and SEQ ID NO:12 (AB-1d); SEQ ID NO:5 and SEQ ID NO:13 (AB-2a); SEQ ID NO:5 and SEQ ID NO:14 (AB-2b); SEQ ID NO:5 and SEQ ID NO:15 (AB-2c); SEQ ID NO:5 and SEQ ID NO:16 (AB-2d); SEQ ID NO:6 and SEQ ID NO:17 (AB-3a); SEQ ID NO:6 and SEQ ID NO:18 (AB-3b); SEQ ID NO:6 and SEQ ID NO:19 (AB-3c); or - 4 - 3839034.v1
5708.1076005 SEQ ID NO:6 and SEQ ID NO:20 (AB-3d). [0014] In some embodiments, a polypeptide disclosed herein comprises an HCDR1, HCDR2 and HCDR3, and an LCDR1, LCDR2 and LCDR3, of an antibody comprising an amino acid sequence selected from: SEQ ID NO:4 and SEQ ID NO:9 (AB-1a); SEQ ID NO:4 and SEQ ID NO:10 (AB-1b); SEQ ID NO:4 and SEQ ID NO:11 (AB-1c); SEQ ID NO:4 and SEQ ID NO:12 (AB-1d); SEQ ID NO:5 and SEQ ID NO:13 (AB-2a); SEQ ID NO:5 and SEQ ID NO:14 (AB-2b); SEQ ID NO:5 and SEQ ID NO:15 (AB-2c); SEQ ID NO:5 and SEQ ID NO:16 (AB-2d); SEQ ID NO:6 and SEQ ID NO:17 (AB-3a); SEQ ID NO:6 and SEQ ID NO:18 (AB-3b); SEQ ID NO:6 and SEQ ID NO:19 (AB-3c); SEQ ID NO:6 and SEQ ID NO:20 (AB-3d); SEQ ID NO:89 and SEQ ID NO:91 (AB-4a); or SEQ ID NO:90 and SEQ ID NO:92 (AB-7a). [0015] In some embodiments, a polypeptide disclosed herein comprises a paratope that is identical to a paratope of an antibody comprising an amino acid sequence selected from: SEQ ID NO:4 and SEQ ID NO:9 (AB-1a); SEQ ID NO:4 and SEQ ID NO:10 (AB-1b); SEQ ID NO:4 and SEQ ID NO:11 (AB-1c); SEQ ID NO:4 and SEQ ID NO:12 (AB-1d); SEQ ID NO:5 and SEQ ID NO:13 (AB-2a); SEQ ID NO:5 and SEQ ID NO:14 (AB-2b); SEQ ID NO:5 and SEQ ID NO:15 (AB-2c); SEQ ID NO:5 and SEQ ID NO:16 (AB-2d); SEQ ID NO:6 and SEQ ID NO:17 (AB-3a); SEQ ID NO:6 and SEQ ID NO:18 (AB-3b); SEQ ID NO:6 and SEQ ID NO:19 (AB-3c); or SEQ ID NO:6 and SEQ ID NO:20 (AB-3d). - 5 - 3839034.v1
5708.1076005 [0016] In some embodiments, a polypeptide disclosed herein comprises a paratope that is identical to a paratope of an antibody comprising an amino acid sequence selected from: SEQ ID NO:4 and SEQ ID NO:9 (AB-1a); SEQ ID NO:4 and SEQ ID NO:10 (AB-1b); SEQ ID NO:4 and SEQ ID NO:11 (AB-1c); SEQ ID NO:4 and SEQ ID NO:12 (AB-1d); SEQ ID NO:5 and SEQ ID NO:13 (AB-2a); SEQ ID NO:5 and SEQ ID NO:14 (AB-2b); SEQ ID NO:5 and SEQ ID NO:15 (AB-2c); SEQ ID NO:5 and SEQ ID NO:16 (AB-2d); SEQ ID NO:6 and SEQ ID NO:17 (AB-3a); SEQ ID NO:6 and SEQ ID NO:18 (AB-3b); SEQ ID NO:6 and SEQ ID NO:19 (AB-3c); SEQ ID NO:6 and SEQ ID NO:20 (AB-3d); SEQ ID NO:89 and SEQ ID NO:91 (AB-4a); or SEQ ID NO:90 and SEQ ID NO:92 (AB-7a). [0017] The disclosure further provides, among other things, a polypeptide that comprises a VH comprising SEQ ID NO:2, wherein: X1 is not G; X2 is not I; X3 is not F; X4 is not N; X5 is not M; X6 is not S; X7 is not M; X8 is not N; X9 is not G; X10 is not N; X11 is not I; or any combination of the foregoing. [0018] In some embodiments, a polypeptide disclosed herein comprises a VL comprising SEQ ID NO:7, wherein: X12 is not N; - 6 - 3839034.v1
5708.1076005 X13 is not D; X14 is not C; X15 is not N; X16 is not S; X17 is not L; X18 is not S; X19 is not G; X20 is not N; or any combination of the foregoing. [0019] In some embodiments, the disclosure provides a polypeptide that specifically binds SARS-CoV-2-Spike, comprising: a VH sequence that has at least 70% sequence identity to SEQ ID NO:3; or a VL sequence that has at least 70% sequence identity to SEQ ID NO:8; or a combination thereof, wherein the VH sequence does not comprise SEQ ID NO:3, the VL sequence does not comprise SEQ ID NO:8, or both. [0020] In some embodiments, a polypeptide disclosed herein is a fusion protein. [0021] In some embodiments, the disclosure provides a polynucleotide encoding a polypeptide disclosed herein, a vector comprising such polynucleotide, and a host cell comprising such polynucleotide and/or vector. [0022] In some embodiments, the disclosure provides methods of treating a patient and/or subject in need thereof (e.g., a subject having a SARS-CoV infection, such as COVID-19), comprising administering to the subject an effective amount (e.g., a therapeutically effective amount) of one or more polypeptides disclosed herein and/or a composition (e.g., pharmaceutical composition) comprising one or more polypeptides disclosed herein. [0023] In some embodiments, the disclosure provides uses of one or more polypeptides disclosed herein in the manufacture of a medicament for treating a patient and/or subject in need thereof (e.g., a subject having a SARS-CoV infection, such as COVID-19). [0024] In some embodiments, the disclosure provides pharmaceutical compositions for use in a method of treating an infection (e.g., a SARS-CoV infection, such as a COVID-19 infection) in a subject, comprising one or more polypeptides disclosed herein and/or a composition (e.g., pharmaceutical composition) comprising one or more polypeptides disclosed herein, the method comprising administering an effective amount (e.g., a therapeutically effective amount) of one or - 7 - 3839034.v1
5708.1076005 more polypeptides disclosed herein and/or a composition (e.g., pharmaceutical composition) comprising one or more polypeptides disclosed herein (e.g., for a time sufficient to treat the infection). [0025] In some embodiments, the disclosure provides methods of neutralizing SARS-CoV-2 variants in a cell (e.g., a cell in a subject), comprising contacting the cell with an effective amount of a composition comprising a polypeptide disclosed herein or a composition (e.g., pharmaceutical composition) comprising a polypeptide disclosed herein. BRIEF DESCRIPTION OF THE DRAWINGS [0026] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee. [0027] The foregoing will be apparent from the following more particular description of example embodiments, as illustrated in the accompanying drawings in which like reference characters refer to the same parts throughout the different views. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating embodiments. [0028] FIG.1 depicts an alignment of non-limiting examples of heavy chain variable domain (VH) amino acid sequences that are useful in polypeptides as disclosed herein. The heavy chain complementarity determining region (HCDR) amino acid sequences (indicated using boxes) are determined by ImMunoGeneTics (IMGT) numbering (www.imgt.org/IMGTScientificChart/Nomenclature/IMGT-FRCDRdefinition.html, also accessible at www.imgt.org/). Identical residues are represented by dots, and variable residues are represented by letters (designated throughout this disclosure by “Xn”) in the depicted sequences. Also see VH consensus sequence (SEQ ID NO:2) in Table 1. The antibody sequences were computationally generated using information from the sequence and structure of a reference polypeptide (Reference). [0029] FIG.2 depicts an alignment of non-limiting examples of light chain variable domain (VL) amino acid sequences that are useful in polypeptides as disclosed herein. The light chain complementarity determining region (LCDR) amino acid sequences (indicated using boxes) are determined by IMGT numbering. Identical residues are represented by dots, and variable residues are represented by letters (designated throughout this disclosure by “Xn”) in the depicted sequences. Also see VL consensus sequence (SEQ ID NO:7) in Table 2. The antibody sequences were computationally generated using information from the sequence and structure of a reference polypeptide (Reference). - 8 - 3839034.v1
5708.1076005 [0030] FIGs.3A-3B show pseudovirus neutralization data of each antibody (represented as dot) expressed as the Log fold change (FC) of IC50 values (i.e., log10(FC of IC50) over a reference polypeptide (Reference) (FIG.3A) or percentage neutralization versus concentration (FIG.3B) for the indicated viruses. [0031] FIGs.4A-4B show pseudovirus neutralization data expressed as normalized signal versus concentration of antibody. The term “Seeds” refers to test antibodies that have been selected for project learning. Sotrovimab is a clinical-stage antibody. [0032] FIG.5A shows binding (expressed as Log EC50 fold change over Sotrovimab) and pseudovirus neutralization data (expressed as percentage neutralization at 0.28 µg/ml) for BA.4/5, where each dot represents an antibody. FIG.5B shows neutralization data for BA.4/5 (expressed as percentage neutralization at 0.28 µg/ml) as a function of Hamming distance from Reference. [0033] FIG.6 shows developability of the top VS-341 hits (i.e., antibodies selected from Project Learning results). Benchmark comparison ranges: 1 (Tm1 >60 ℃ acceptable, Tm150-60 ℃ may be acceptable, Tm1 <50℃ outside acceptable range); 2(SEC monomer level >95% acceptable, SEC monomer level 95%~90% not applicable; SEC monomer level <90% outside acceptable range); 3(relative to PRO-18404, Z-score <1 acceptable, Z-score 1~1.5 not applicable, Z-score >2 outside acceptable range; c.f.9.5 ± 0.3 and 7.5 ± 1.0 for PSR-DNA and PSR-Insulin of Bococizumab ctrl); 4( ^^ shift <10nm acceptable, ^^ shift 10~15 nm not applicable, ^^ shift >15 nm outside acceptable range); and 5 (∆% >-5% acceptable, ∆% -5~ -10% not applicable, ∆% <- 10% outside acceptable range). Ranges, based on TSLP developability studies where appropriate, are arbitrary and separated at least by averaged std errors or SDs. Additional notes are as follows: a (Method optimization ongoing), *(Melting curve suggestive of the compromised Fab thermal stability), †(acceptable), (may be acceptable), **(outside acceptable range), and N/A (not applicable). Value +/- ranges are standard deviations for at least duplicates where available. [0034] FIGs.7A-7B show pseudovirus neutralization profiles of selected class 4 anti-RBD screening hits (AB-1a, AB-2a, AB-3a, AB-4a, AB-7) and Reference antibody for BA.4/5. [0035] FIGs.8A-8B show binding profiles of selected class 4 anti-RBD screening hits (AB- 3a, AB-4a) and clinical-stage antibodies (Sotrovimab, Bebtelovimab, AZD1061) to RBDs representative of Sarbecovirus clades expressed on yeasts. FIG.8C shows neutralization of a VSV-dG pseudovirus representative of SARS-CoV-2 BQ.1.1 by the class 4 anti-RBD screening hits AB-3a and clinical-stage antibodies (Sotrovimab, Bebtelovimab, AZD1061). SYNAGIS® was used as isotype control. - 9 - 3839034.v1
5708.1076005 [0036] FIGs.9A-9C shows pseudovirus neutralization profiles of AB-4a, a class 4 anti-RBD antibody identified in the variant set VS-341, and an anti-S2 monoclonal antibody alone and in combination, as well as clinical-stage antibodies Sotrovimab, Bebtelovimab, Cilgavimab + Tixagevimab (EVUSHELD®) for BA.4/5 (FIG.9A) and BA.4/5 + K444T (FIG.9B). SYNAGIS® was used as isotype control. FIG.9C reports respective EC50 and EC90 values as ng/ml. [0037] FIG.10A shows pseudovirus neutralization profiles of the class 4 anti-RBD hits AB- 3a, Sotrovimab and Bebtelovimab alone or combined with an anti-S2 monoclonal antibody (also tested alone) for BA.4/5 and BA.4/5 + K444T. SYNAGIS® was used as isotype control. FIG. 10B shows results of the neutralization profiles shown in FIG.10A reported as Area Under the Curve (AUC) and efficacy (% max neutralization). [0038] FIGs.11A is two graphs, and FIG.11B is a chart, showing that AB-3a combined with an anti-S2 antibody (“S2_AB-1”) demonstrates improved neutralization potency and efficacy against Omicron BQ.1.1 pseudovirus. FIGs.11A-11B show neutralization profiles. SYNAGIS® was used as isotype control. Standard deviation (SD) is applied as error bars in FIG.11A. FIG. 11C reports results shown in FIG.11A as EC50 (95% confidence interval (CI)) and % median neutralization at 18 µg/ml (95% CI) values. FIG.11D is two graphs showing that an anti-S2 antibody (S2_AB-1) combined with class 4 anti-RBD antibody 3a (“RBD Class 4 mAb-3a” or “AB-3a”) demonstrates improved neutralization potency and efficacy against Omicron BQ.1.1 pseudovirus. The graphs are neutralization profiles. Synagis was used as isotype control. Standard error of the mean (SEM) is applied as error bars. [0039] FIGs.12A and 12B are graphs, and FIG.12C is a chart, showing that AB-4a combined with an anti-S2 antibody (“S2_AB-1”) demonstrates improved neutralization potency and efficacy against Delta and Omicron BA.5 live viruses. FIGs.12A and 12B show neutralization profiles against SARS-CoV-2 Delta and BA.5 live viruses, respectively. SYNAGIS® was used as isotype control. Standard deviation (SD) is applied as error bars in FIGs.12A and 12B. FIG.12C reports results shown in FIG.12A-12B as EC50 (95% CI) and % median neutralization at 18 µg/ml (95% CI) values. [0040] FIGs.13A-13B show binding profiles of the class 4 anti-RBD molecule AB-2b and a clinical-stage antibody Bebtelovimab to RBDs representative of Sarbecovirus clades expressed on yeast. SYNAGIS® was used as isotype control. [0041] FIG.14A shows neutralization profiles of the class 4 anti-RBD molecule AB-2b in combination with an anti-S2 monoclonal antibody (S2_AB-1) or an isotype control, for SARS- - 10 - 3839034.v1
5708.1076005 CoV-2 D614G, Delta, BQ.1.1, or XBB.1.5. Also shown are neutralization profiles of S2_AB-1 or a clinical-stage antibody Bebtelovimab, in combination with the isotype control. SYNAGIS® was used as the isotype control. FIG.14B reports corresponding EC50 values, EC90 values, and 95% confidence intervals (95% CI) against the indicated pseudoviruses. [0042] FIG.15A shows neutralization profiles of the class 4 anti-RBD molecule AB-2b in combination with an anti-S2 monoclonal antibody (S2_AB-1) or an isotype control, for SARS- CoV-2 D614G, SARS-CoV-1, or WIV1. Also shown are neutralization profiles of S2_AB-1 or a clinical-stage antibody Bebtelovimab, in combination with the isotype control. SYNAGIS® was used as the isotype control. FIG.15B reports corresponding EC90 values and 95% confidence intervals (95% CI) against the indicated pseudoviruses. FIGs. 15C-15D. Neutralization of SARS-CoV-2 variants by Anti-S2 in combination with AB-2b. Neutralization profiles of Anti-S2 + AB-2b (tested at two different ratios), Anti-S2, AB-2b, and bebtelovimab as single agents, and isotype control antibody against pseudoviruses representative of the indicated SARS-CoV-2 variants using TMPRSS2-Vero E6 (FIG.15C) or Vero E6 (FIG.15D) cells. The anti-spike antibodies tested as single agents were combined with isotype at the same concentrations to control for overall mass of anti-spike antibodies tested as combinations. The x-axis indicates the concentration of each individual antibody in the combinations, or of the antibody with the highest concentration if the concentrations differ. The results are reported as % neutralization and shown as mean ± standard deviation (representative of three or four independent experiments, four technical replicates each). [0043] FIG.16 shows that AB-2b has comparable activity to sotrovimab VH/VL - hIgG1-LS in terms of lung viral titer reduction (as measured by TCID50) in a hamster challenge model with SARS-CoV-2 BA.2. However, a combination of AB-2b and S2_AB-1 achieved a much greater reduction in lung viral titer. [0044] FIGs.17A-17B depict structural analysis of AB-2b Fab binding to SARS-CoV-2 BA.1 RBD and related contact residues. FIG.17C is a low-pass filtered Cryo-EM map of the SARS-CoV-2 BA.1 spike trimer with AB-3a Fab binding RBD and anti-S2 antibody (S2_AB-1) binding S2 stem helix. Map is shown from a side profile and from below. Each of the presumptive Fabs is labeled. FIG.17D is a density-docked atomic model of the SARS-CoV-2 spike assembly with bound Fabs. Spike trimer: a high-resolution structure of the SARS-CoV-2 spike with the S2 stem helix resolved. AB-3a: the designed model for AB-3a Fab. Bottom: three anti-S2 Fabs docked into the propeller shaped density around the S2 stem helix. - 11 - 3839034.v1
5708.1076005 [0045] FIGs.18A-18B show neutralization of SARS-CoV-2 live virus variants by AB-2b in combination with S2_AB-1. Neutralization profiles of AB-2b + S2_AB-1 combination, as well as AB-2b, S2_AB-1, and bebtelovimab as single agents, and isotype control antibody against SARS-CoV-2 ancestral strain (Eng20 (WT)), Delta, BQ.1.1, XBB.1.1) live viruses are shown. The anti-Spike antibodies tested as single agents were combined with isotype at the same concentrations to control for overall mass of anti-Spike antibodies tested as combinations. The x- axis indicates the concentration of each individual antibody in the combinations, or of the antibody with the highest concentration if the concentrations differ. The results are reported as % neutralization and shown as mean ± standard deviation (representative of one experiment, two to three technical replicates). AB-2b combined with S2_AB-1 demonstrates improved neutralization of SARS-CoV-2 Omicron BQ1.1 and XBB.1.1 live viruses. DETAILED DESCRIPTION [0046] A description of example embodiments follows. [0047] Several aspects of the disclosure are described below, with reference to examples for illustrative purposes only. It should be understood that numerous specific details, relationships, and methods are set forth to provide a full understanding of the disclosure. One having ordinary skill in the relevant art, however, will readily recognize that the disclosure can be practiced without one or more of the specific details or practiced with other methods, protocols, reagents, cell lines and animals. The disclosure is not limited by the illustrated ordering of acts or events, as some acts may occur in different orders and/or concurrently with other acts or events. Furthermore, not all illustrated acts, steps or events are required to implement a methodology in accordance with the disclosure. Definitions [0048] Unless otherwise defined, all terms of art, notations and other scientific terms or terminology used herein are intended to have the meanings commonly understood by those of skill in the art to which this disclosure pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and/or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a substantial difference over what is generally understood in the art. It will be further understood that terms, such as those defined in commonly-used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the relevant art and/or as otherwise defined herein. - 12 - 3839034.v1
5708.1076005 [0049] The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. [0050] When introducing elements disclosed herein, the articles “a,” “an,” “the,” and “said” are intended to mean that there are one or more of the elements. Further, the one or more elements may be the same or different. For example, unless the context clearly indicates otherwise, “a polypeptide” includes a single polypeptide, and two or more polypeptides. [0051] Throughout this specification and the claims which follow, unless the context requires otherwise, the term “comprise,” and variations such as “comprises” and “comprising”, will be understood to imply the inclusion of, e.g., a stated integer or step or group of integers or steps, but not the exclusion of any other integer or step or group of integer or step. When used herein, the term “comprising” can be substituted with the term “containing” or “including.” [0052] As used herein, the term “consisting of” excludes any element, step, or ingredient not specified in the claim element. When used herein, the term “consisting essentially of” does not exclude materials or steps that do not materially affect the basic and novel characteristics of the claim. [0053] Also provided herein are corresponding embodiments for each and every embodiment featuring the term “comprising,” “containing,” “including,” or “having,” wherein those terms are replaced by the term “consisting of” and/or “consisting essentially of”. [0054] As used herein, the conjunctive term “and/or” between multiple recited elements is understood as encompassing both individual and combined options. For instance, where two elements are conjoined by “and/or,” a first option refers to the applicability of the first element without the second. A second option refers to the applicability of the second element without the first. A third option refers to the applicability of the first and second elements together. Any one of these options is understood to fall within the meaning, and, therefore, satisfy the requirement of the term “and/or” as used herein. Concurrent applicability of more than one of the options is also understood to fall within the meaning, and, therefore, satisfy the requirement of the term “and/or.” [0055] It should be understood that for all numerical bounds describing some parameter in this application, such as “about,” “at least,” “less than,” “fewer than,” and “more than,” the description also necessarily encompasses any range bounded by the recited values. Accordingly, for example, the description “at least 1, 2, 3, 4, or 5” also describes, inter alia, the ranges 1-2, 1- 3, 1-4, 1-5, 2-3, 2-4, 2-5, 3-4, 3-5, and 4-5, et cetera. - 13 - 3839034.v1
5708.1076005 [0056] When a list is presented, unless stated otherwise, it is to be understood that each individual element of that list, and every combination of that list, is a separate embodiment. For example, a list of embodiments presented as “A, B, or C” is to be interpreted as including the embodiments, “A,” “B,” “C,” “A or B,” “A or C,” “B or C,” or “A, B, or C.” [0057] As used herein, the term “about” means within an acceptable error range for a particular value, as determined by one of ordinary skill in the art. Typically, an acceptable error range for a particular value depends, at least in part, on how the value is measured or determined, e.g., the limitations of the measurement system. For example, “about” can mean within an acceptable standard deviation, per the practice in the art. Alternatively, “about” can mean a range of ± 20%, e.g., ± 10%, ± 5% or ± 1% of a given value. It is to be understood that the term “about” can precede any particular value specified herein, except for particular values used in the Exemplification. When “about” precedes a range, as in “90-99.9%,” the term “about” should be read as applying to both given values of the range, such that “about 90-99.9%” means about 90% repeats to about 99.9%. [0058] As used herein, the term “polypeptide” refers to a polymer of at least two amino acids covalently linked by an amide bond, regardless of length or post-translational modification (e.g., glycosylation or phosphorylation). A polypeptide can comprise any suitable L-and/or D-amino acid, for example, common ^-amino acids (e.g., alanine, glycine, valine), non- ^-amino acids (e.g., ^-alanine, 4-aminobutyric acid, 6-aminocaproic acid, sarcosine, statine), and unusual amino acids (e.g., citrulline, homocitruline, homoserine, norleucine, norvaline, ornithine). The amino, carboxyl, and/or other functional groups on a polypeptide can be free (e.g., unmodified) or protected with a suitable protecting group. Suitable protecting groups for amino and carboxyl groups, and methods for adding or removing protecting groups are known in the art and are disclosed in, for example, Green and Wuts, “Protecting Groups in Organic Synthesis,” John Wiley and Sons, 1991. The functional groups of a polypeptide can also be derivatized (e.g., alkylated) or labeled (e.g., with a detectable label, such as a fluorogen or a hapten) using methods known in the art. A polypeptide can comprise one or more modifications (e.g., amino acid linkers, acylation, acetylation, amidation, methylation, terminal modifiers (e.g., cyclizing modifications), N-methyl- ^-amino group substitution), if desired. In addition, a polypeptide can be an analog of a known and/or naturally-occurring peptide, for example, a peptide analog having conservative amino acid residue substitution(s). [0059] As used herein, a “polynucleotide” is defined as a plurality of nucleotides and/or nucleotide analogs linked together in a single molecule. In some embodiments, a polynucleotide - 14 - 3839034.v1
5708.1076005 disclosed herein comprises deoxyribonucleotides. In some embodiments, the polynucleotide comprises ribonucleotides. Non-limiting examples of polynucleotides include single-, double- or multi-stranded DNA or RNA, DNA-RNA hybrids (e.g., each “T” position may be independently substituted by a “U” or vice versa), or a polymer comprising purine and pyrimidine bases, or other natural, chemically, or biochemically modified, non-natural, or derivatized nucleotide bases. The backbone of the polynucleotide can comprise sugars and phosphate groups, modified or substituted sugar or phosphate groups, a polymer of synthetic subunits such as phosphoramidates, or a combination thereof. [0060] As used herein, the term “sequence identity” refers to the extent to which two nucleotide sequences have the same residues at the same positions when the sequences are aligned to achieve a maximal level of identity, expressed as a percentage. For sequence alignment and comparison, typically one sequence is designated as a reference sequence, to which test sequences are compared. Sequence identity between reference and test sequences is expressed as a percentage of positions across the entire length of the reference sequence where the reference and test sequences share the same nucleotide or amino acid upon alignment of the reference and test sequences to achieve a maximal level of identity. As an example, two sequences are considered to have 70% sequence identity when, upon alignment to achieve a maximal level of identity, the test sequence has the same nucleotide residue at 70% of the same positions over the entire length of the reference sequence. [0061] Alignment of sequences for comparison to achieve maximal levels of identity can be readily performed by a person of ordinary skill in the art using an appropriate alignment method or algorithm. In some instances, alignment can include introduced gaps to provide for the maximal level of identity. Examples include the local homology algorithm of Smith & Waterman, Adv. Appl. Math.2:482 (1981), the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol.48:443 (1970), the search for similarity method of Pearson & Lipman, Proc. Nat’l. Acad. Sci. USA 85:2444 (1988), computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), and visual inspection (see generally Ausubel et al., Current Protocols in Molecular Biology). [0062] When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequent coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the - 15 - 3839034.v1
5708.1076005 designated program parameters. A commonly used tool for determining percent sequence identity is Protein Basic Local Alignment Search Tool (BLASTP) available through National Center for Biotechnology Information, National Library of Medicine, of the United States National Institutes of Health. (Altschul et al., 1990). [0063] As used herein, the term “substantially similar to” refers to a polypeptide disclosed herein that is substantially similar in amino acid sequence (e.g., has at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% of the amino acid residues amino acid sequence identity) and substantially preserves one or more functional properties of a specified polypeptide disclosed herein (e.g., AB-1). In some embodiments, the one or more functional properties are selected from, without limitation, a substantially similar binding affinity, a substantially similar binding specificity, a substantially similar inhibitory activity, a substantially similar neutralization activity, and a substantially similar self-association property. [0064] As used herein, a “complementarity determining region (CDR)” encompasses any CDR defined by an art-recognized method for identifying the CDR residues on an antibody. See, e.g., Kabat, E.A., et al., (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No.91-3242, Chothia et al., (1989) Nature 342:877; Chothia, C. et al., (1987) J. Mol. Biol.196:901-917; Al-lazikani et al., (1997) J. Molec. Biol.273:927-948; and Almagro, J. Mol. Recognit.17:132-143 (2004). See also hgmp.mrc.ac.uk and bioinf.org.uk/abs. Two antibodies are determined to have the same CDR as one another with respect to an HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and/or LCDR3, when the identity of that CDR is determined for both antibodies using the same method. [0065] The extent of the framework region and the CDRs of an antibody can be identified using one of several suitable methodologies that are well known in the art, for example, by the Kabat definition, the Chothia definition, the AbM definition, and/or the contact definition. Publicly and/or commercially available tools for identifying framework and/or CDR regions include, IgBlast (accessible at www.ncbi.nlm.nih.gov/igblast/), Scaligner (available from drugdesigntech at www.scaligner.com/), IMGT rules and/or tools (see, for example, www.imgt.org/IMGTScientificChart/Nomenclature/IMGT-FRCDRdefinition.html, also accessible at www.imgt.org/), Chothia Canonical Assignment (accessible at www.bioinf.org.uk/abs/chothia.html), Antigen receptor Numbering And Receptor CalssificatiIon (ANARCI, accessible at opig.stats.ox.ac.uk/webapps/newsabdab/sabpred/anarci/), or the - 16 - 3839034.v1
5708.1076005 Paratome web server (see Vered Kunik, et al, Nucleic Acids Research, Volume 40, Issue W1, 1 July 2012, Pages W521-W524). [0066] As used herein, the term “paratope” refers to a set of amino acid residues in an antibody or an antigen-binding fragment thereof that contribute to a binding interaction with an epitope of a target protein. The binding interaction can be a hydrogen bond, a salt bridge, a van der Waal interaction, an ionic bond or a combination thereof. A binding interaction may be direct, or indirect, e.g., via a coordinated intermediate molecule, such as an ion or water. The residues of a paratope, in some embodiments, comprise only residues that are part of a defined CDR. In other embodiments, the residues of a paratope further comprise one or more residues that are not part of a defined CDR. [0067] As used herein, the term “antibody mimetic” refers to polypeptides capable of mimicking an antibody’s ability to bind an antigen, but structurally differ from native antibody structures. Examples of antibody mimetics include, but not limited to, Adnectins, Affibodies, Affilins, Affimers, Affitins, Alphabodies, Anticalins, Avimers, DARPins, Fynomers, Kunitz domain peptides, monobodies, nanobodies, nanoCLAMPs, and Versabodies. [0068] As used herein the term “KD,” also referred to as “binding constant,” “equilibrium dissociation constant” or “affinity constant,” is a measure of the extent of a reversible association between two molecular species (e.g., antibody and target protein) and includes both the actual binding affinity as well as the apparent binding affinity. Binding affinity can be determined using methods known in the art including, for example, by measurement of surface plasmon resonance, e.g., using a Biolayer interferometry (Octet, ForteBio) or a surface plasmon resonance (Biacore) system and assay. A reference that compares various surface technologies for measuring binding affinity and kinetics is Yang, D., Singh, A., Wu, H., & Kroe-Barrett, R., Comparison of biosensor platforms in the evaluation of high affinity antibody-antigen binding kinetics, Analytical Biochemistry 508: 78-96 (2016), the contents of which are incorporated by reference herein in their entirety. [0069] The term “subject” and “patient” are used herein interchangeably to refer to an animal (e.g., a mammal, such as a human) to be treated according to a method disclosed herein. A subject to be treated according to methods described herein may be one who has been diagnosed with a particular condition (e.g., COVID-19), or one at risk of developing such conditions. Diagnosis may be performed by any method or technique known in the art. One skilled in the art will understand that a subject to be treated according to the present disclosure may have been - 17 - 3839034.v1
5708.1076005 subjected to standard tests or may have been identified, without examination, as one at risk due to the presence of one or more risk factors associated with the disease or condition. [0070] The phrase “pharmaceutically acceptable” means that the substance or composition the phrase modifies is, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, and are commensurate with a reasonable benefit/risk ratio. [0071] As used herein, the term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of mammals without undue toxicity, irritation, allergic response, and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, the relevant teachings of which are incorporated herein by reference in their entirety. Pharmaceutically acceptable salts of the agents/compounds described herein include salts derived from suitable inorganic and organic acids, and suitable inorganic and organic bases. [0072] Examples of salts derived from suitable acids include salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid, or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art, such as ion exchange. Other pharmaceutically acceptable salts derived from suitable acids include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, cinnamate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, glutarate, glycolate, hemisulfate, heptanoate, hexanoate, hydroiodide, hydroxybenzoate, 2-hydroxy-ethanesulfonate, hydroxymaleate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 2-phenoxybenzoate, phenylacetate, 3-phenylpropionate, phosphate, pivalate, propionate, pyruvate, salicylate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. [0073] Either the mono-, di- or tri-acid salts can be formed, and such salts can exist in either a hydrated, solvated or substantially anhydrous form. - 18 - 3839034.v1
5708.1076005 [0074] Salts derived from appropriate bases include salts derived from inorganic bases, such as alkali metal, alkaline earth metal, and ammonium bases, and salts derived from aliphatic, alicyclic or aromatic organic amines, such as methylamine, trimethylamine and picoline, or N+((C1-C4)alkyl)4 salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, barium and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxyl, sulfate, phosphate, nitrate, lower alkyl sulfonate and aryl sulfonate. [0075] “Pharmaceutically acceptable carrier” refers to a non-toxic carrier or excipient that does not destroy the pharmacological activity of the agent with which it is formulated and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the agent. Pharmaceutically acceptable carriers that may be used in the compositions described herein include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat. [0076] “Treating” or “treatment,” as used herein, refers to taking steps to deliver a therapy to a subject, such as a mammal, in need thereof (e.g., as by administering to a mammal one or more therapeutic agents). “Treating” or “treatment” includes inhibiting the disease or condition (e.g., as by slowing or stopping its progression or causing regression of the disease or condition) and relieving the symptoms resulting from the disease or condition. [0077] The term “treating,” or “treatment” refers to the medical management of a subject with the intent to improve, ameliorate, stabilize (i.e., not worsen), prevent, or cure a disease, pathological condition, or disorder—such as the particular indications exemplified herein. This term includes active treatment (treatment directed to improve the disease, pathological condition, or disorder), causal treatment (treatment directed to the cause of the associated disease, pathological condition, or disorder), palliative treatment (treatment designed for the relief of symptoms), preventative treatment (treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder); and - 19 - 3839034.v1
5708.1076005 supportive treatment (treatment employed to supplement another therapy). Treatment also includes diminishment of the extent of the disease or condition; preventing spread of the disease or condition; delay or slowing the progress of the disease or condition; amelioration or palliation of the disease or condition; and remission (whether partial or total), whether detectable or undetectable. “Ameliorating” or “palliating” a disease or condition means that the extent and/or undesirable clinical manifestations of the disease, disorder, or condition are lessened and/or time course of the progression is slowed or lengthened, as compared to the extent or time course in the absence of treatment. “Treatment” can also mean prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already with the condition or disorder, as well as those prone to have the condition or disorder or those in which the condition or disorder is to be prevented. [0078] A “pharmaceutical composition” refers to a formulation of one or more therapeutic agents and a medium generally accepted in the art for delivery of a biologically active agent to subjects, e.g., humans. In some embodiments, a pharmaceutical composition may include one or more pharmaceutically acceptable excipients, diluents, or carriers. In some embodiments, a pharmaceutical composition suitable for use in methods disclosed herein further comprises one or more pharmaceutically acceptable carriers. [0079] “Pharmaceutically acceptable carrier, diluent, or excipient” includes any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals. [0080] “Pharmaceutically acceptable carrier” refers to an ingredient in a pharmaceutical composition, other than an active ingredient, which is nontoxic to a subject. A pharmaceutically acceptable carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative. In some embodiments, the carrier may be a diluent, adjuvant, excipient, or vehicle with which the agent (e.g., polynucleotide) is administered. Such vehicles may be liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like. For example, 0.4% saline and 0.3% glycine can be used. These solutions are sterile and generally free of particulate matter. They may be sterilized by conventional, well-known sterilization techniques (e.g., filtration). The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, stabilizing, - 20 - 3839034.v1
5708.1076005 thickening, lubricating, and coloring agents, etc. The concentration of the agent in such pharmaceutical formulation may vary widely, i.e., from less than about 0.5%, to at least about 1%, or to as much as 15% or 20%, 25%, 30%, 35%, 40%, 45% or 50% by weight. The concentration will be selected primarily based on required dose, fluid volumes, viscosities, etc., according to the mode of administration. Suitable vehicles and formulations, inclusive of other human proteins, e.g., human serum albumin, are described, for example, in Remington: The Science and Practice of Pharmacy, 21st Edition, Troy, D.B. ed., Lipincott Williams and Wilkins, Philadelphia, PA 2006, Part 5, Pharmaceutical Manufacturing: 691-1092 (e.g., pages 958-89). [0081] Non-limiting examples of pharmaceutically acceptable carriers are solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible, such as salts, buffers, antioxidants, saccharides, aqueous or non-aqueous carriers, preservatives, wetting agents, surfactants or emulsifying agents, or combinations thereof. [0082] Non-limiting examples of buffers are acetic acid, citric acid, formic acid, succinic acid, phosphoric acid, carbonic acid, malic acid, aspartic acid, histidine, boric acid, Tris buffers, HEPPSO, and HEPES. [0083] Non-limiting examples of antioxidants are ascorbic acid, methionine, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite, lecithin, citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, and tartaric acid. [0084] Non-limiting examples of amino acids are histidine, isoleucine, methionine, glycine, arginine, lysine, L-leucine, tri-leucine, alanine, glutamic acid, L-threonine, and 2-phenylamine. [0085] Non-limiting examples of surfactants are polysorbates (e.g., polysorbate-20 or polysorbate-80); polyoxamers (e.g., poloxamer 188); Triton; sodium octyl glycoside; lauryl-, myristyl-, linoleyl-, or stearyl-sulfobetaine; lauryl-, myristyl-, linoleyl- or stearyl-sarcosine; linoleyl-, myristyl-, or cetyl-betaine; lauroamidopropyl-, cocamidopropyl-, linoleamidopropyl-, myristamidopropyl-, palmidopropyl-, or isostearamidopropyl-betaine (e.g., lauroamidopropyl); myristamidopropyl-, palmidopropyl-, or isostearamidopropyl-dimethylamine; sodium methyl cocoyl-, or disodium methyl oleyl-taurate; and the MONAQUA™ series (Mona Industries, Inc., Paterson, N.J.), polyethyl glycol, polypropyl glycol, and copolymers of ethylene and propylene glycol (e.g., PLURONICS™, PF68, etc.). [0086] Non-limiting examples of preservatives are phenol, m-cresol, p-cresol, o-cresol, chlorocresol, benzyl alcohol, phenylmercuric nitrite, phenoxyethanol, formaldehyde, chlorobutanol, magnesium chloride, alkylparaben (methyl, ethyl, propyl, butyl, and the like), - 21 - 3839034.v1
5708.1076005 benzalkonium chloride, benzethonium chloride, sodium dehydroacetate, and thimerosal, or mixtures thereof. [0087] Non-limiting examples of saccharides are monosaccharides, disaccharides, trisaccharides, polysaccharides, sugar alcohols, reducing sugars, nonreducing sugars such as glucose, sucrose, trehalose, lactose, fructose, maltose, dextran, glycerin, dextran, erythritol, glycerol, arabitol, sylitol, sorbitol, mannitol, mellibiose, melezitose, raffinose, mannotriose, stachyose, maltose, lactulose, maltulose, glucitol, maltitol, lactitol, or iso-maltulose. [0088] Non-limiting examples of salts are acid addition salts and base addition salts. Acid addition salts include those derived from nontoxic inorganic acids, such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydroiodic, phosphorous, and the like, as well as from nontoxic organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, aromatic acids, aliphatic and aromatic sulfonic acids, and the like. Base addition salts include those derived from alkaline earth metals, such as sodium, potassium, magnesium, calcium, and the like, as well as from nontoxic organic amines, such as N,N’-dibenzylethylenediamine, N-methylglucamine, chloroprocaine, choline, diethanolamine, ethylenediamine, procaine, and the like. In some embodiments, the salt is sodium chloride (NaCl). [0089] Agents (e.g., polynucleotides) described herein may be prepared in accordance with standard procedures and are administered at dosages that are selected to reduce, prevent, or eliminate, or to slow or halt progression of, a condition being treated (see, e.g., Remington’s Pharmaceutical Sciences, Mack Publishing Company, Easton, PA, and Goodman and Gilman’s The Pharmaceutical Basis of Therapeutics, McGraw-Hill, New York, N.Y., the contents of which are incorporated herein by reference, for a general description of methods for administering various agents for human therapy). [0090] “Administering” or “administration,” as used herein, refers to providing a compound, composition, or pharmaceutically acceptable salt thereof described herein to a subject in need of treatment or prevention. Administering can be performed, for example, once, a plurality of times, and/or over one or more extended periods. Administration includes both direct administration (including self-administration), and indirect administration (including an act of prescribing a drug or directing a subject to consume an agent). For example, as used herein, one (e.g., a physician) who instructs a subject (e.g., a human patient) to self-administer an agent (e.g., a drug), or to have an agent administered by another and/or who provides a patient with a prescription for a drug is administering an agent to a subject. - 22 - 3839034.v1
5708.1076005 [0091] “A therapeutically effective amount,” “an effective amount” or “an effective dosage” refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic result (e.g., treatment, healing, inhibition or amelioration of physiological response or condition, etc.). A full therapeutic effect does not necessarily occur by administration of one dose and may occur only after administration of a series of doses. Thus, a therapeutically effective amount may be administered in one or more administrations. A therapeutically effective amount may vary according to factors such as the disease state, age, sex, and weight of a mammal (e.g., a human patient), mode of administration, and the ability of a therapeutic or a combination of therapeutics to elicit a desired response. [0092] An effective amount of an agent to be administered can be determined by a clinician of ordinary skill using the guidance provided herein and other methods known in the art. Relevant factors include the given agent, the pharmaceutical formulation, the route of administration, the type of disease or disorder, the identity of the subject (e.g., age, sex, weight) or host being treated, and the like. For example, suitable dosages can be from about 0.001 mg/kg to about 100 mg/kg, from about 0.01 mg/kg to about 100 mg/kg, from about 0.01 mg/kg to about 10 mg/kg, from about 0.01 mg/kg to about 1 mg/kg body weight per treatment. Determining the dosage for a particular agent, subject and disease is well within the abilities of one of skill in the art. Preferably, the dosage does not cause or produces minimal adverse side effects. [0093] Desired response or desired results include effects at the cellular level, tissue level, or clinical results. As such, “a therapeutically effective amount” or synonym thereto depends upon the context in which it is being applied. For example, in some embodiments it is an amount of the composition sufficient to achieve a treatment response as compared to the response obtained without administration of the composition. In other embodiments, it is an amount that results in a beneficial or desired result in a subject as compared to a control. As defined herein, a therapeutically effective amount of a composition (e.g., a pharmaceutical composition) disclosed herein may be readily determined by one of ordinary skill by routine methods known in the art. Dosage regimen and route of administration may be adjusted to provide the optimum therapeutic response. [0094] Preferred features of each of the aspects or embodiments provided by the invention are applicable to all of the other aspects or embodiments of the invention mutatis mutandis and, without limitation, are exemplified by the dependent claims and also encompass combinations and permutations of individual features (e.g., elements, including numerical ranges and exemplary embodiments) of particular embodiments and aspects of the invention, including the - 23 - 3839034.v1
5708.1076005 working examples. For example, particular experimental parameters exemplified in the working examples can be adapted for use in the claimed invention piecemeal without departing from the invention. For example, for materials that are disclosed, while specific reference of each of the various individual and collective combinations and permutations of these compounds may not be explicitly disclosed, each is specifically contemplated and described herein. Thus, if a class of elements A, B, and C are disclosed as well as a class of elements D, E, and F and an example of a combination of elements A-D is disclosed, then, even if each is not individually recited, each is individually and collectively contemplated. Thus, in this example, each of the combinations A-E, A-F, B-D, B-E, B-F, C-D, C-E, and C-F are specifically contemplated and should be considered disclosed from disclosure of A, B, and C; D, E, and F; and the example combination A-D. Likewise, any subset or combination of these is also specifically contemplated and disclosed. Thus, for example, the sub-groups of A-E, B-F, and C-E are specifically contemplated and should be considered disclosed from disclosure of A, B, and C; D, E, and F; and the example combination A-D. This concept applies to all aspects of this application, including elements of a composition of matter and steps of method of making or using the compositions. The forgoing aspects of the invention, as recognized by the person having ordinary skill in the art following the teachings of the specification, can be claimed in any combination or permutation to the extent that they are novel and non-obvious over the prior art—thus, to the extent an element is described in one or more references known to the person having ordinary skill in the art, they may be excluded from the claimed invention by, inter alia, a negative proviso or disclaimer of the feature or combination of features. Polypeptides that Specifically Bind Betacoronavirus Spike Proteins [0095] Provided herein, among other things, are polypeptides that specifically bind to receptor-binding domain (RBD) of betacoronavirus Spike glycoprotein. In some embodiments, a polypeptide has one or more properties selected from: a broadly neutralizing activity against a plurality of known and predicted betacoronaviruses (e.g., past, present, emergent, and future betacoronaviruses), a binding affinity for an RBD domain epitope (e.g., RBD class 4 epitope) that is highly conserved across a plurality of betacoronaviruses, and an inhibitory activity against potential emerging betacoronavirus escape variants. In some embodiments, a polypeptide specifically binds the RBD of a sarbecovirus (e.g., a SARS-CoV-1 virus, a SARS-CoV-2 virus) Spike protein. In some embodiments, a polypeptide specifically binds the RBD of a SARS-CoV- 1 virus (e.g., a plurality of SARS-CoV-1 variants) Spike protein. In some embodiments, a polypeptide specifically binds the RBD of a SARS-CoV-2 virus (e.g., a plurality of SARS-CoV- - 24 - 3839034.v1
5708.1076005 2 variants) Spike protein. In some embodiments, a polypeptide specifically binds the RBD of a SARS-CoV-1 virus (e.g., a plurality of SARS-CoV-1 variants) Spike protein and the RBD of a SARS-CoV-2 virus (e.g., a plurality of SARS-CoV-2 variants) spike protein. [0096] In some embodiments, a polypeptide has a broadly neutralizing activity (e.g., as measured using a neutralization assay described herein or otherwise known to those of ordinary skill the art) against a plurality of betacoronaviruses. In some embodiments, a polypeptide has neutralizing activity against a plurality of sarbecoviruses (e.g., SARS-CoV-1 viruses, SARS- CoV-2 viruses). In some embodiments, a polypeptide has neutralizing activity against a plurality of SARS-CoV-1 viruses (e.g., a plurality of SARS-CoV-1 variants). In some embodiments, a polypeptide has neutralizing activity against a plurality of SARS-CoV-2 viruses (e.g., a plurality of SARS-CoV-2 variants). In some embodiments, a polypeptide has neutralizing activity against a plurality of SARS-CoV-1 viruses (e.g., a plurality of SARS-CoV-1 variants) and a plurality of SARS-CoV-2 viruses (e.g., a plurality of SARS-CoV-2 variants). [0097] In some embodiments, a polypeptide has a binding affinity for an RBD epitope (e.g., RBD class 4 epitope) that is conserved (e.g., highly conserved) across a plurality of betacoronaviruses. In some embodiments, an RBD epitope is highly conserved across a plurality of sarbecoviruses (e.g., SARS-CoV-1 viruses, SARS-CoV-2 viruses). In some embodiments, an RBD epitope is highly conserved across a plurality of SARS-CoV-1 viruses (e.g., a plurality of SARS-CoV-1 variants). In some embodiments, an RBD epitope is highly conserved across a plurality of SARS-CoV-2 viruses (e.g., a plurality of SARS-CoV-2 variants). In some embodiments, an RBD epitope is highly conserved across a plurality of SARS-CoV-1 viruses (e.g., a plurality of SARS-CoV-1 variants) and a plurality of SARS-CoV-2 viruses (e.g., a plurality of SARS-CoV-2 variants). [0098] SARS-CoV-2 is the causative agent of COVID-19. The genome of SARS-CoV-2 encodes the nucleoprotein (N), the membrane glycoprotein (M), the small envelope glycoprotein (E), and the spike protein (S), in addition to 16 non-structural proteins (Song et al., Cytokine storm induced by SARS-CoV-2, Clin Chim Acta.509:280-7 (2020)). SARS-CoV-2-Spike, or S of the SARS-CoV-2, facilitates entry of the SARS-CoV-2 virus into a host cell, such as a human host cell. S is a trimer with protomers composed of S1 and S2 subunits. S1 contains an RBD that binds ACE2 receptors, and S2 is necessary for fusion of viral and host membranes. [0099] A non-limiting example of a wildtype SARS-CoV-2-Spike (S) sequence is NCBI RefSeq YP_009724390 (SEQ ID NO:1). - 25 - 3839034.v1
5708.1076005 [00100] MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQD LFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKT QSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVS QPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGI NITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCA LDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAW NRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPG QTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEI YQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKST NLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCS FGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGC LIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRARSVASQSIIAYTMSLGAENSVAYSNN SIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAV EQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGF IKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAA LQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVV NQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQL IRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPA QEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVI GIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVA KNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSC GSCCKFDEDDSEPVLKGVKLHYT (SEQ ID NO:1). [00101] As used herein, SARS-CoV-2-Spike includes wild-type SARS-CoV-2 Spike proteins (e.g., SEQ ID NO:1 (RefSeq YP_009724390) or homologs thereof) and truncated forms thereof, mutant and engineered versions of full-length and truncated SARS-CoV-2 Spike proteins, and modified forms (e.g., post-translationally modified forms) of full-length and truncated SARS- CoV-2 Spike proteins. [00102] In some embodiments, a polypeptide binds to a SARS-CoV-2 Spike protein comprising SEQ ID NO:1. [00103] In some embodiments, a polypeptide binds to a mutant, engineered and/or modified form of SARS-CoV-2-Spike. In some embodiments, a mutant, engineered or modified form of SARS-CoV-2-Spike comprises an amino acid sequence that has at least about 90% sequence identity to a wildtype SARS-CoV-2-Spike sequence (e.g., SEQ ID NO:1), for example, having at - 26 - 3839034.v1
5708.1076005 least about: 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity to a wildtype SARS-CoV-2-Spike sequence. In some embodiments, a mutant, engineered or modified form of SARS-CoV-2-Spike comprises an amino acid sequence that has about: 90-99.9%, 90-99.8%, 92-99.8%, 92-99.6%, 94-99.6%, 94-99.5%, 95-99.5%, 95-99.4%, 96-99.4%, 96-99.2%, 97-99.2%, or 97-99% sequence identity to a wildtype SARS-CoV-2-Spike sequence (e.g., SEQ ID NO:1). [00104] In some embodiments, a mutant, engineered, or modified form of SARS-CoV-2- Spike comprises, relative to SEQ ID NO:1, one or more mutations selected from: L5F, S13I, T19R, A67V, del69, del70, del69-70, D80G, T95I, G142D, del142-144, del144, Y145D, W152C, E154K, F157S, del211, L212I, ins214EPE, A222V, D253G, G261D, G339D, V367F, S371L, S371L, S373P, S375F, K417N, N439K, N440K, G446S, L452R, Y453F, S477N, T478K, E484A, E484K, E484Q, F486L, S494P, Q493R, G496S, Q498R, N501T, N501Y, Y505H, T547K, F565L, A570D, H655Y, D614G, Q677H, N679K, P681H, P681R, A701V, T716I, N764K, D796Y, T859N, N856K, F888L, D950N, Q954H, Q957R, N969K, L981F, S982A, Q1071H, V1176F, D1118H, K1191N, or a combination thereof, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, or more mutations. [00105] In some embodiments, a mutant, engineered, or modified form of SARS-CoV-2- Spike comprises, relative to SEQ ID NO:1, one or more mutations selected from: 69del, 70del, 144del, E484K, S494P, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H, or K1191N, or a combination thereof. In some embodiments, a mutant, engineered, or modified form of SARS-CoV-2-Spike comprises 69del, 70del, 144del, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H. In some embodiments, a mutant, engineered or modified form of SARS- CoV-2-Spike further comprises E484K, S494P, or K1191N, or a combination thereof. [00106] In some embodiments, a mutant, engineered, or modified form of SARS-CoV-2- Spike comprises, relative to SEQ ID NO:1, one or more mutations selected from: D80A, D215G, 241del, 242del, 243del, K417N, E484K, N501Y, D614G, or A701V, or a combination thereof. In some embodiments, a mutant, engineered or modified form of SARS-CoV-2-Spike comprises D80A, D215G, 241del, 242del, 243del, K417N, E484K, N501Y, D614G, and A701V. [00107] In some embodiments, a mutant, engineered, or modified form of SARS-CoV-2- Spike comprises, relative to SEQ ID NO:1, one or more mutations selected from: T19R, G142D, 156del, 157del, R158G, L452R, T478K, D614G, P681R, or D950N, or a combination thereof. In some embodiments, a mutant, engineered, or modified form of SARS-CoV-2-Spike comprises - 27 - 3839034.v1
5708.1076005 T19R, 156del, 157del, R158G, L452R, T478K, D614G, P681R, and D950N. In some embodiments, a mutant, engineered, or modified form of SARS-CoV-2-Spike further comprises G142D. [00108] In some embodiments, a mutant, engineered, or modified form of SARS-CoV-2- Spike comprises, relative to SEQ ID NO:1, one or more mutations selected from: 69del, 70del, 144del, A222V, G261D, V367F, K417N, N439K, Y453F, S477N, E484K, F486L, N501T, N501Y, A570D, or D614G, or a combination thereof. [00109] In some embodiments, a mutant, engineered, or modified form of SARS-CoV-2- Spike comprises, relative to SEQ ID NO:1, one or more mutations selected from: E484K, N501Y, or D614G, or a combination thereof. [00110] In some embodiments, a mutant, engineered, or modified form of SARS-CoV-2 Spike protein comprises, relative to SEQ ID NO:1, one or more mutations selected from: F817P, A892P, A899P, A942P, K986P, or V987P, or a combination thereof. [00111] In some embodiments, a mutant, engineered, or modified form of SARS-CoV-2 Spike protein comprises, relative to SEQ ID NO:1, one or more mutations selected from: L452R, F486V, or R493Q, or a combination thereof. [00112] In some embodiments, a mutant, engineered, or modified form of SARS-CoV-2 Spike protein comprises, relative to SEQ ID NO:1, one or more mutations selected from: A67V, del69-70, T95I, del142-144, Y145D, del211, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, or L981F, or a combination thereof. [00113] In some embodiments, the modified SARS-CoV-2 Spike protein comprises, relative to SEQ ID NO:1, one or more mutations selected from: T19I, del24-26, A27S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, or N969K, or a combination thereof. [00114] In some embodiments, the modified SARS-CoV-2 Spike protein comprises, relative to SEQ ID NO:1, one or more mutations selected from: T19I, del24-26, A27S, del69-70, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, or N969K, or a combination thereof. - 28 - 3839034.v1
5708.1076005 [00115] In some embodiments, the modified SARS-CoV-2 Spike protein comprises, relative to SEQ ID NO:1, one or more mutations selected from: T19I, del24-26, A27S, del69-70, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, K444T, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, or N969K, or a combination thereof. [00116] In some embodiments, a modified SARS-CoV-2 Spike protein comprises, relative to SEQ ID NO:1, one or more mutations selected from: T19I, del24-26, A27S, del69-70, G142D, V213G, G339D, R346T, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, K444T, L452R, N460K, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, or N969K, or a combination thereof. [00117] Additional modified SARS-CoV-2 Spike proteins can be found at https://covariants.org/shared-mutations, the contents of which are incorporated herein by reference. Non-limiting examples include Alpha, Beta, Gamma, Delta, Kappa, Epsilon, Eta, Iota, Lambda, Mu, and/or Omicron, for example, B.1, B.1.1, B.1.1.1, B.1.1.529, B.1.1.7, B.1.177, B.1.2, B.1.351, B.1.427/429, B.1.525, B.1.526, B.1.617.1,B.1.617.2, B.1.621, BA.1, BA.1.1, BA.2, BA.2.12.1, BA.2.75, BA.2.75.2, BA.3, BA.4, BA.4/5, BA.4/5+K444T, BA.4.6, BA.5, BA.5.2.6, BF.7, BF.11, BN.1, BQ.1, BQ.1.1, C.37, D.2, GA.5, GR/484A, P.1, P.3, and/or XBB. [00118] In some embodiments, a polypeptide binds to a RBD of a SARS-CoV-2 Spike (S) protein. As used herein, RBD includes full-length RBD (e.g., having the amino acid sequence of SEQ ID NO:46 or homologs thereof) and truncated forms thereof, mutant and engineered versions of full-length and truncated RBD (e.g., an epitope within the RBD (e.g., RBD class 4 epitope)), and modified forms (e.g., post-translationally modified forms) of full-length and truncated RBD. [00119] In some embodiments, a polypeptide binds SARS-CoV-1-Spike (e.g., of CoV-1 and/or WIV1) and/or SARS-CoV-2-Spike (e.g., of Alpha, Beta, Gamma, Delta, Kappa, Epsilon, Eta, Iota, Lambda, Mu, and/or Omicron, for example, AY.3, AY.4, AY.41, AY.44, AY.64, AY.103, B.1, B.1.1, B.1.1.1, B.1.1.529, B.1.1.7, B.1.177, B.1.2, B.1.351, B.1.427/429, B.1.525, B.1.526, B.1.533, B.1.617.1, B.1.617.2, B.1.621, BA.1, BA.1.1, BA.1.15, BA.1.17.2, BA.2, BA.2+P1162L, and BA.2+P1162S, BA.2.3.20, BA.2.10, BA.2.12.1, BA.2.75, BA.2.75.2, BA.3, BA.4, BA.4/5, BA.4/5+K444T, BA.4.6, BA.5, BA.5.2.6, BA.5.8, BF.7, BF.11, BN.1, BQ.1, BQ.1.1, C.37, CH.1.1, CH.1.1.1, D.2, GA.5, GR/484A, P.1, P.1.17, P.1.10, P.2, P.3, Q.3, Q.4, Q.7, XBB, XBB.1.1, XBB.1.16, XBB.1, XBB.1.5, XBB.1.5.10, XBB.1.9.1, and/or EG.5.1) or a fragment thereof (e.g., the S2 domain of SARS-CoV-2-Spike and/or the epitopes in FIG.1) with - 29 - 3839034.v1
5708.1076005 a KD of about: 5 µM, 2 µM, 1 µM, 500 nM, 200 nM, 100 nM, 50 nM, 20 nM, 10 nM, 5 nM, 2 nM, 1 nM, 0.5 nM, 0.2 nM or 0.1 nM or less. In some embodiments, a polypeptide binds SARS- CoV-1-Spike (e.g., of CoV-1 and/or WIV1) and/or SARS-CoV-2-Spike (e.g. of Alpha, Beta, Gamma, Delta, Kappa, Epsilon, Eta, Iota, Lambda, Mu, and/or Omicron, for example, AY.3, AY.4, AY.41, AY.44, AY.64, AY.103, B.1, B.1.1, B.1.1.1, B.1.1.529, B.1.1.7, B.1.177, B.1.2, B.1.351, B.1.427/429, B.1.525, B.1.526, B.1.533, B.1.617.1, B.1.617.2, B.1.621, BA.1, BA.1.1, BA.1.15, BA.1.17.2, BA.2, BA.2+P1162L, and BA.2+P1162S, BA.2.3.20, BA.2.10, BA.2.12.1, BA.2.75, BA.2.75.2, BA.3, BA.4, BA.4/5, BA.4/5+K444T, BA.4.6, BA.5, BA.5.2.6, BA.5.8, BF.7, BF.11, BN.1, BQ.1, BQ.1.1, C.37, CH.1.1, CH.1.1.1, D.2, GA.5, GR/484A, P.1, P.1.17, P.1.10, P.2, P.3, Q.3, Q.4, Q.7, XBB, XBB.1.1, XBB.1.16, XBB.1, XBB.1.5, XBB.1.5.10, XBB.1.9.1, and/or EG.5.1) or a fragment thereof (e.g., a RBD domain of SARS-CoV-2-Spike). [00120] RVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNS ASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTG CVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYF PLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNF (SEQ ID NO:46). [00121] In some embodiments, a polypeptide binds to a mutant, engineered, or modified form of an RBD. In some embodiments, a mutant, engineered, or modified form of an RBD comprises an amino acid sequence that has at least about 90% sequence identity to a wild-type full length RBD (e.g., SEQ ID NO:46), for example, having at least about: 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% sequence identity. In some embodiments, the sequence identity is about: 90-99.9%, 90-99.8%, 92-99.8%, 92-99.6%, 94-99.6%, 94-99.5%, 95-99.5%, 95-99.4%, 96-99.4%, 96-99.2%, 97- 99.2%, or 97-99%. In some embodiments, a mutant, engineered or modified form of SARS- CoV-2-Spike comprises an amino acid sequence that has about: 90-99.9%, 90-99.8%, 92-99.8%, 92-99.6%, 94-99.6%, 94-99.5%, 95-99.5%, 95-99.4%, 96-99.4%, 96-99.2%, 97-99.2%, or 97- 99% sequence identity to a wildtype full length RBD (e.g., SEQ ID NO:46). Comparator Polypeptides [00122] As used herein, the term “comparator” or “comparator polypeptide” refers to a polypeptide (e.g., immunoglobulin molecule) that specifically binds to a SARS-CoV-2-Spike and is not a polypeptide of the disclosure. The sequence of a comparator polypeptide and a polypeptide of the disclosure may be compared to illustrate structural differences between them (e.g., differences at one or more amino acid positions, such as amino acid substitutions). - 30 - 3839034.v1
5708.1076005 Polypeptides of the disclosure have more than insubstantial differences (e.g., one or more substantial differences) in comparison to a comparator polypeptide, such that, polypeptides disclosed herein will, under controlled conditions, exhibit one or more (i.e., one, two, or all three) of: a different function, in a different way, to achieve a different result, in comparison to a comparator polypeptide. A comparator polypeptide may vary from a polypeptide of the disclosure by one or more amino acids, e.g., in some embodiments, by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more amino acids. In some embodiments, a comparator polypeptide diverges from a polypeptide of the disclosure by at least about: 0.4%, 0.8%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, or more amino acid percent identity. [00123] In some embodiments, a comparator polypeptide is an antibody comprising: a) an immunoglobulin heavy chain variable (VH) domain comprising a heavy chain complementarity determining region 1 (HCDR1), an HCDR2, and an HCDR3 amino acid sequences of SEQ ID NO:22, SEQ ID NO:26, and SEQ ID NO:31, respectively; b) an immunoglobulin light chain variable (VL) domain comprising a light chain complementarity determining region 1 (LCDR1), an LCDR2, and an LCDR3 amino acid sequences of SEQ ID NO:35, SEQ ID NO:38, and SEQ ID NO:42, respectively; or both a) and b). [00124] In some embodiments, a comparator polypeptide is an antibody comprising: a) a VH domain comprising an HCDR1, an HCDR2, and an HCDR3 sequences of SEQ ID NO:22, SEQ ID NO:26, and SEQ ID NO:31, respectively; and b) a VL domain comprising an LCDR1, an LCDR2, and an LCDR3 sequences of SEQ ID NO:35, SEQ ID NO:38, and SEQ ID NO:42, respectively. [00125] See Table 3 and FIGs.1-2 for SEQ ID NOs:22, 26, 31, 35, 38, 42. [00126] In some embodiments, a comparator polypeptide is an antibody comprising: a) a VH domain comprising the amino acid sequence of SEQ ID NO:3; b) a VL domain comprising the amino acid sequence of SEQ ID NO:8, or both a) and b). [00127] In some embodiments, a comparator polypeptide is an antibody comprising: a) a VH domain comprising the amino acid sequence of SEQ ID NO:3; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:8. - 31 - 3839034.v1
5708.1076005 [00128] See Table 1 and FIG.1 for SEQ ID NO:3. See Table 2 and FIG.2 for SEQ ID NO:8. [00129] In some embodiments, a comparator polypeptide is an antibody referred to herein as the “Reference Antibody”, which comprises a VH domain comprising the amino acid sequence of SEQ ID NO:3, a VL domain comprising the amino acid sequence of SEQ ID NO:8, a heavy chain comprising the amino acid sequence of SEQ ID NO:47 and/or SEQ ID NO:48, and a light chain comprising the amino acid sequence of SEQ ID NO:49. The Reference Antibody binds SARS-CoV-2 RBD and neutralizes SARS-CoV-2 variants. [00130] QVQLVQSGAEVKKPGSSVKVSCKASGGIFNTYTISWVRQAPGQGLEWMGRII LMSGMANYAQKIQGRVTITADKSTSTAYMELTSLRSDDTAVYYCARGFNGNYYGWGD DDAFDIWGQGTLVTVYSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKS C (SEQ ID NO:47). [00131] QVQLVQSGAEVKKPGSSVKVSCKASGGIFNTYTISWVRQAPGQGLEWMGRII LMSGMANYAQKIQGRVTITADKSTSTAYMELTSLRSDDTAVYYCARGFNGNYYGWGD DDAFDIWGQGTLVTVYSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO:48). [00132] QTVLTQPPSVSGAPGQRVTISCTGSNSNIGAGYDVHWYQQLPGTAPKLLICG NSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGPNWVFGGGTKLT VLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTT PSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO:49). Complementarity Determining Regions (CDRs) [00133] A CDR (e.g., HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and/or LCDR3) can be a CDR defined by any art-recognized method for identifying CDR residues of an antibody, as described further herein (e.g., a CDR as defined by Kabat, a CDR as defined by Chothia, or a CDR as defined by IMGT). [00134] In some embodiments, a polypeptide (e.g., an antibody or antigen-binding fragment thereof) does not comprise all six CDRs of an antibody that comprises a VH amino acid sequence - 32 - 3839034.v1
5708.1076005 of SEQ ID NO:3 and a VL amino acid sequence of SEQ ID NO:8. In some embodiments, a polypeptide does not comprise all six sequences of SEQ ID NO:22, SEQ ID NO:26, SEQ ID NO:31, SEQ ID NO:35, SEQ ID NO:38, and SEQ ID NO:42. See Table 3 for SEQ ID NO:22, SEQ ID NO:26, SEQ ID NO:31, SEQ ID NO:35, SEQ ID NO:38, and SEQ ID NO:42. [00135] In some embodiments, a polypeptide comprises fewer than six (e.g., 1, 2, 3, 4 or 5) CDRs of an antibody that comprises a VH amino acid sequence of SEQ ID NO:3 and a VL amino acid sequence of SEQ ID NO:8. In some embodiments, a polypeptide comprises 1, 2, 3, 4 or 5 sequences, but not all 6 sequences, selected from SEQ ID NO:22, SEQ ID NO:26, SEQ ID NO:31, SEQ ID NO:35, SEQ ID NO:38, and SEQ ID NO:42. [00136] In some embodiments, a polypeptide comprises all six CDRs of a specific polypeptide disclosed herein. In some embodiments, a polypeptide comprises fewer than six (e.g., 1, 2, 3, 4 or 5) of CDRs of a specific polypeptide disclosed herein. [00137] In some embodiments, a polypeptide comprises: a) a VH domain comprising a heavy chain complementarity determining region 1 (HCDR1), an HCDR2, and an HCDR3 that are substantially similar (e.g., having at least about 90% sequence identity) in amino acid sequence to an HCDR1, an HCDR2, and an HCDR3, respectively, of a VH amino acid sequence set forth in any of SEQ ID NOs:4-6; b) a VL domain comprising a light chain complementarity determining region 1 (LCDR1), an LCDR2, and an LCDR3 that are substantially similar (e.g., having at least about 90% sequence identity) in amino acid sequence to an LCDR1, an LCDR2, and an LCDR3, respectively, of a VL amino acid sequence set forth in any of SEQ ID NOs:9-20; or both a) and b). [00138] See Table 3 and FIGs.1-2 for non-limiting examples of corresponding HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 sequences. [00139] In some embodiments, a polypeptide comprises: a) a VH domain comprising a heavy chain complementarity determining region 1 (HCDR1), an HCDR2, and an HCDR3 that are substantially similar (e.g., having at least about 90% sequence identity) in amino acid sequence to an HCDR1, an HCDR2, and an HCDR3, respectively, of a VH amino acid sequence set forth in any of SEQ ID NOs:4-6; - 33 - 3839034.v1
5708.1076005 b) a VL domain comprising a light chain complementarity determining region 1 (LCDR1), an LCDR2, and an LCDR3 that are substantially similar (e.g., having at least about 90% sequence identity) in amino acid sequence to an LCDR1, an LCDR2, and an LCDR3, respectively, of a VL amino acid sequence set forth in any of SEQ ID NOs:9-20; or both a) and b). [00140] In some embodiments, a polypeptide comprises: a) a VH domain comprising an HCDR1, an HCDR2, and an HCDR3 that substantially preserve one or more functional properties of an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence of any one or more of SEQ ID NOs:4-6; b) a VL domain comprising an LCDR1, an LCDR2, and an LCDR3 that substantially preserve one or more functional properties of an LCDR1, an LCDR2 and an LCDR3, respectively, of a VL amino acid sequence of any one or more of SEQ ID NOs:9-20; or both a) and b). [00141] In some embodiments, a polypeptide comprises: a) a VH domain comprising an HCDR1, an HCDR2, and an HCDR3 that substantially preserve one or more functional properties of an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence of any one or more of SEQ ID NOs:4-6; and b) a VL domain comprising an LCDR1, an LCDR2, and an LCDR3 that substantially preserve one or more functional properties of an LCDR1, an LCDR2 and an LCDR3, respectively, of a VL amino acid sequence of any one or more of SEQ ID NOs:9-20. [00142] In some embodiments, a polypeptide comprises an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2, and an LCDR3 that substantially preserve one or more functional properties of an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2, and an LCDR3 of a polypeptide selected from any one of AB-1a, AB-1b, AB-1c, AB-1d, AB-2a, AB-2b, AB-2c, AB-2d, AB-3a, AB-3b, AB-3c, and AB-3d. [00143] In some embodiments, a polypeptide comprises: a) a VH domain that comprises an HCDR1, an HCDR2, and an HCDR3 comprising only one or more conservative substitutions (e.g., only one or more highly - 34 - 3839034.v1
5708.1076005 conservative substitutions), relative to an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence of any one or more of SEQ ID NOs:4- 6; or b) a VL domain that comprises an LCDR1, an LCDR2, and an LCDR3 comprising only one or more conservative substitutions (e.g., only one or more highly conservative substitutions), relative to an LCDR1, an LCDR2 and an LCDR3, respectively, of a VL amino acid sequence of any one or more of SEQ ID NOs:9- 20, or both a) and b). [00144] In some embodiments, an amino acid substitution is a conservative substitution. The term “a conservative amino acid substitution” or “a conservative substitution” refers to an amino acid substitution having a value of 0 or greater in BLOSUM62. [00145] In some embodiments, an amino acid substitution is a highly conservative substitution. The term “a highly conservative amino acid substitution” or “a highly conservative substitution” refers to an amino acid substitution having a value of at least 1 (e.g., at least 2) in BLOSUM62. [00146] In some embodiments, a polypeptide comprises: a) a VH domain that comprises an HCDR1, an HCDR2, and an HCDR3 comprising only one or more conservative substitutions (e.g., only one or more highly conservative substitutions), relative to an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence of any one or more of SEQ ID NOs:4- 6; and b) a VL domain that comprises an LCDR1, an LCDR2, and an LCDR3 comprising only one or more conservative substitutions (e.g., only one or more highly conservative substitutions), relative to an LCDR1, an LCDR2 and an LCDR3, respectively, of a VL amino acid sequence of any one or more of SEQ ID NOs:9- 20. [00147] In some embodiments, a polypeptide comprises: a) a VH domain that comprises an HCDR1, an HCDR2, and an HCDR3 comprising up to 1, 2, or 3 conservative substitutions (e.g., up to 1, 2, or 3 highly conservative substitutions), relative to an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence of any one or more of SEQ ID NOs:4-6; or - 35 - 3839034.v1
5708.1076005 b) a VL domain that comprises an LCDR1, an LCDR2, and an LCDR3 comprising up to 1, 2, or 3 conservative substitutions (e.g., up to 1, 2, or 3 highly conservative substitutions), relative to an LCDR1, an LCDR2 and an LCDR3, respectively, of a VL amino acid sequence of any one or more of SEQ ID NOs:9-20, or both a) and b). [00148] In some embodiments, a polypeptide comprises: a) a VH domain that comprises an HCDR1, an HCDR2, and an HCDR3 comprising up to 1, 2, or 3 conservative substitutions (e.g., up to 1, 2, or 3 highly conservative substitutions), relative to an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence of any one or more of SEQ ID NOs:4-6; and b) a VL domain that comprises an LCDR1, an LCDR2, and an LCDR3 comprising up to 1, 2, or 3 conservative substitutions (e.g., up to 1, 2, or 3 highly conservative substitutions), relative to an LCDR1, an LCDR2 and an LCDR3, respectively, of a VL amino acid sequence of any one or more of SEQ ID NOs:9-20. [00149] In some embodiments, a polypeptide comprises: a) a VH domain that comprises an HCDR1, an HCDR2, and an HCDR3 having 100% sequence identity to an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence of any one or more of SEQ ID NOs:4-6; or b) a VL domain that comprises an LCDR1, an LCDR2, and an LCDR3 having 100% sequence identity to an LCDR1, an LCDR2 and an LCDR3, respectively, of a VL amino acid sequence of any one or more of SEQ ID NOs:9-20, or both a) and b). [00150] In some embodiments, a polypeptide comprises: a) a VH domain that comprises an HCDR1, an HCDR2, and an HCDR3 having 100% sequence identity to an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence of any one or more of SEQ ID NOs:4-6; and b) a VL domain that comprises an LCDR1, an LCDR2, and an LCDR3 having 100% sequence identity to an LCDR1, an LCDR2 and an LCDR3, respectively, of a VL amino acid sequence of any one or more of SEQ ID NOs:9-20. [00151] In some embodiments, a polypeptide comprises an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2, and an LCDR3, of an antibody comprising a VH/VL pair selected from: SEQ ID NO:4 and SEQ ID NO:9 (AB-1a); SEQ ID NO:4 and SEQ ID NO:10 (AB-1b); - 36 - 3839034.v1
5708.1076005 SEQ ID NO:4 and SEQ ID NO:11 (AB-1c); SEQ ID NO:4 and SEQ ID NO:12 (AB-1d); SEQ ID NO:5 and SEQ ID NO:13 (AB-2a); SEQ ID NO:5 and SEQ ID NO:14 (AB-2b); SEQ ID NO:5 and SEQ ID NO:15 (AB-2c); SEQ ID NO:5 and SEQ ID NO:16 (AB-2d); SEQ ID NO:6 and SEQ ID NO:17 (AB-3a); SEQ ID NO:6 and SEQ ID NO:18 (AB-3b); SEQ ID NO:6 and SEQ ID NO:19 (AB-3c); or SEQ ID NO:6 and SEQ ID NO:20 (AB-3d). [00152] In some embodiments, a polypeptide comprises: a) a VH domain comprising an HCDR1, an HCDR2, and an HCDR3 that are substantially similar (e.g., having at least about 90% sequence identity) in amino acid sequence to an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence of SEQ ID NO:5; b) a VL domain comprising an LCDR1, an LCDR2 and an LCDR3 that are substantially similar (e.g., having at least about 90% sequence identity) in amino acid sequence to an LCDR1, an LCDR2 and an LCDR3, respectively, of a VL amino acid sequence of SEQ ID NO:14, or both a) and b). [00153] In some embodiments, a polypeptide comprises: a) a VH domain comprising an HCDR1, an HCDR2, and an HCDR3 that are substantially similar (e.g., having at least about 90% sequence identity) in amino acid sequence to an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence of SEQ ID NO:5; and b) a VL domain comprising an LCDR1, an LCDR2 and an LCDR3 that are substantially similar (e.g., having at least about 90% sequence identity) in amino acid sequence to an LCDR1, an LCDR2 and an LCDR3, respectively, of a VL amino acid sequence of SEQ ID NO:14. [00154] In some embodiments, a polypeptide comprises: a) a VH domain comprising an HCDR1, an HCDR2, and an HCDR3 that substantially preserve one or more functional properties of an HCDR1, an - 37 - 3839034.v1
5708.1076005 HCDR2 and an HCDR3, respectively, of a VH amino acid sequence of SEQ ID NO:5; or b) a VL domain comprising an LCDR1, an LCDR2, and an LCDR3 that substantially preserve one or more functional properties of an LCDR1, an LCDR2 and an LCDR3, respectively, of a VL amino acid sequence of SEQ ID NO:14, or both a) and b). [00155] In some embodiments, a polypeptide comprises: a) a VH domain comprising an HCDR1, an HCDR2, and an HCDR3 that substantially preserve one or more functional properties of an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence of SEQ ID NO:5; and b) a VL domain comprising an LCDR1, an LCDR2, and an LCDR3 that substantially preserve one or more functional properties of an LCDR1, an LCDR2 and an LCDR3, respectively, of a VL amino acid sequence of SEQ ID NO:14. [00156] In some embodiments, a polypeptide comprises: a) a VH domain that comprises an HCDR1, an HCDR2, and an HCDR3 comprising only one or more conservative substitutions (e.g., only one or more highly conservative substitutions), relative to an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence of SEQ ID NO:5; or b) a VL domain that comprises an LCDR1, an LCDR2, and an LCDR3 comprising only one or more conservative substitutions (e.g., only one or more highly conservative substitutions), relative to an LCDR1, an LCDR2 and an LCDR3, respectively, of a VL amino acid sequence of SEQ ID NO:14, or both a) and b). [00157] In some embodiments, a polypeptide comprises: a) a VH domain that comprises an HCDR1, an HCDR2, and an HCDR3 comprising only one or more conservative substitutions (e.g., only one or more highly conservative substitutions), relative to an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence of SEQ ID NO:5; and b) a VL domain that comprises an LCDR1, an LCDR2, and an LCDR3 comprising only one or more conservative substitutions (e.g., only one or more highly conservative substitutions), relative to an LCDR1, an LCDR2 and an LCDR3, respectively, of a VL amino acid sequence of SEQ ID NO:14. - 38 - 3839034.v1
5708.1076005 [00158] In some embodiments, a polypeptide comprises: a) a VH domain that comprises an HCDR1, an HCDR2, and an HCDR3 having 100% sequence identity to an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence of SEQ ID NO:5; or b) a VL domain that comprises an LCDR1, an LCDR2, and an LCDR3 having 100% sequence identity to an LCDR1, an LCDR2 and an LCDR3, respectively, of a VL amino acid sequence of SEQ ID NO:14, or both a) and b). [00159] In some embodiments, a polypeptide comprises: a) a VH domain that comprises an HCDR1, an HCDR2, and an HCDR3 having 100% sequence identity to an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence of SEQ ID NO:5; and b) a VL domain that comprises an LCDR1, an LCDR2, and an LCDR3 having 100% sequence identity to an LCDR1, an LCDR2 and an LCDR3, respectively, of a VL amino acid sequence of SEQ ID NO:14. [00160] In some embodiments, a polypeptide comprises: a) an HCDR1 comprising at least one amino acid substitution relative to at least one amino acid sequence set forth in SEQ ID NOs:22-24 (e.g., at least one amino acid sequence set forth in SEQ ID NO:23 or SEQ ID NO:24); b) an HCDR2 comprising at least one amino acid substitution relative to at least one amino acid sequence set forth in SEQ ID NOs:26-29 (e.g., at least one amino acid sequence set forth in SEQ ID NOs:27-29); c) an HCDR3 comprising at least one amino acid substitution relative to at least one amino acid sequence set forth in SEQ ID NOs:31-33 (e.g., at least one amino acid sequence set forth in SEQ ID NO:32 or SEQ ID NO:33); d) an LCDR1 comprising at least one amino acid substitution relative to at least one amino acid sequence set forth in SEQ ID NOs:35-37 (e.g., at least one amino acid sequence set forth in SEQ ID NO:36 or SEQ ID NO:37); e) an LCDR2 comprising at least one amino acid substitution relative to at least one amino acid sequence set forth in SEQ ID NOs:38-40 (e.g., at least one amino acid sequence set forth in SEQ ID NOs:39-40); - 39 - 3839034.v1
5708.1076005 f) an LCDR3 comprising at least one amino acid substitution relative to at least one amino acid sequence set forth in SEQ ID NOs:42-45 (e.g., at least one amino acid sequence set forth in SEQ ID NOs:43-45); or any combination of the foregoing. [00161] In some embodiments, a polypeptide comprises an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2, and an LCDR3 comprising only one or more conservative substitutions (e.g., only one or more highly conservative substitutions), relative an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2, and an LCDR3 of a polypeptide selected from any one of AB- 1a, AB-1b, AB-1c, AB-1d, AB-2a, AB-2b, AB-2c, AB-2d, AB-3a, AB-3b, AB-3c, and AB-3d. [00162] In some embodiments, a polypeptide comprises an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2, and an LCDR3 comprising up to 1, 2, or 3 conservative substitutions (e.g., up to 1, 2, or 3 highly conservative substitutions), relative an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2, and an LCDR3 of a polypeptide selected from any one of AB- 1a, AB-1b, AB-1c, AB-1d, AB-2a, AB-2b, AB-2c, AB-2d, AB-3a, AB-3b, AB-3c, and AB-3d. [00163] In some embodiments, a polypeptide comprises an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2, and an LCDR3 having 100% sequence identity to an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2, and an LCDR3 of a polypeptide selected from any one of AB-1a, AB-1b, AB-1c, AB-1d, AB-2a, AB-2b, AB-2c, AB-2d, AB-3a, AB-3b, AB-3c, and AB-3d. [00164] In some embodiments, a polypeptide comprises: a) an HCDR1 comprising the amino acid sequence of SEQ ID NO:24; b) an HCDR2 comprising the amino acid sequence of SEQ ID NO:28; c) an HCDR3 comprising the amino acid sequence of SEQ ID NO:33; d) an LCDR1 comprising the amino acid sequence of SEQ ID NO:37; e) an LCDR2 comprising the amino acid sequence of SEQ ID NO:40; f) an LCDR3 comprising the amino acid sequence of SEQ ID NO:44; or any combination of the foregoing. [00165] In some embodiments, a polypeptide comprises: a) an HCDR1 comprising the amino acid sequence of SEQ ID NO:24; b) an HCDR2 comprising the amino acid sequence of SEQ ID NO:28; c) an HCDR3 comprising the amino acid sequence of SEQ ID NO:33; d) an LCDR1 comprising the amino acid sequence of SEQ ID NO:37; e) an LCDR2 comprising the amino acid sequence of SEQ ID NO:40; and - 40 - 3839034.v1
5708.1076005 f) an LCDR3 comprising the amino acid sequence of SEQ ID NO:44. [00166] In some embodiments, a polypeptide comprises: a) an HCDR1 consisting of the amino acid sequence of SEQ ID NO:24; b) an HCDR2 consisting of the amino acid sequence of SEQ ID NO:28; c) an HCDR3 consisting of the amino acid sequence of SEQ ID NO:33; d) an LCDR1 consisting of the amino acid sequence of SEQ ID NO:37; e) an LCDR2 consisting of the amino acid sequence of SEQ ID NO:40; f) an LCDR3 consisting of the amino acid sequence of SEQ ID NO:44; or any combination of the foregoing. [00167] In some embodiments, a polypeptide comprises: a) an HCDR1 consisting of the amino acid sequence of SEQ ID NO:24; b) an HCDR2 consisting of the amino acid sequence of SEQ ID NO:28; c) an HCDR3 consisting of the amino acid sequence of SEQ ID NO:33; d) an LCDR1 consisting of the amino acid sequence of SEQ ID NO:37; e) an LCDR2 consisting of the amino acid sequence of SEQ ID NO:40; and f) an LCDR3 consisting of the amino acid sequence of SEQ ID NO:44. [00168] In some embodiments, a polypeptide comprises: a) a VH domain comprising an HCDR1, an HCDR2, and an HCDR3 having 100% sequence identity to an HCDR1, an HCDR2, and an HCDR3, respectively, of a VH amino acid sequence set forth in Table 1 or Table 4 herein; b) a VL domain comprising an LCDR1, an LCDR2, and an LCDR3 having 100% sequence identity to an LCDR1, an LCDR2, and an LCDR3, respectively, of a VL amino acid sequence set forth in Table 2 or Table 4 herein; or both a) and b), optionally wherein the VH amino acid sequence set forth in Table 1 or Table 4 herein and the VL amino acid sequence set forth in Table 2 or Table 4 herein are a sequence pair set forth in Table 5 herein. [00169] In some embodiments, a polypeptide comprises: a) a VH domain comprising an HCDR1, an HCDR2, and an HCDR3 having 100% sequence identity to an HCDR1, an HCDR2, and an HCDR3, respectively, of a VH amino acid sequence set forth in Table 1 or Table 4 herein; and - 41 - 3839034.v1
5708.1076005 b) a VL domain comprising an LCDR1, an LCDR2, and an LCDR3 having 100% sequence identity to an LCDR1, an LCDR2, and an LCDR3, respectively, of a VL amino acid sequence set forth in Table 2 or Table 4 herein, optionally wherein the VH amino acid sequence set forth in Table 1 or Table 4 herein and the VL amino acid sequence set forth in Table 2 or Table 4 herein are a sequence pair set forth in Table 5 herein. [00170] In some embodiments, a polypeptide comprises: a) a VH domain comprising an HCDR1, an HCDR2, and an HCDR3 that are substantially similar (e.g., having at least about 90% sequence identity) in amino acid sequence to an HCDR1, an HCDR2, and an HCDR3, respectively, of a VH amino acid sequence set forth in Table 1 or Table 4 herein; b) a VL domain comprising an LCDR1, an LCDR2, and an LCDR3 that are substantially similar (e.g., having at least about 90% sequence identity) in amino acid sequence to an LCDR1, an LCDR2, and an LCDR3, respectively, of a VL amino acid sequence set forth in Table 2 or Table 4 herein; or both a) and b), optionally wherein the VH amino acid sequence set forth in Table 1 or Table 4 herein and the VL amino acid sequence set forth in Table 2 or Table 4 herein are a sequence pair set forth in Table 5 herein. [00171] In some embodiments, a polypeptide comprises: a) a VH domain comprising an HCDR1, an HCDR2, and an HCDR3 that substantially preserve one or more functional properties of an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence set forth in Table 1 or Table 4 herein; b) a VL domain comprising an LCDR1, an LCDR2, and an LCDR3 that substantially preserve one or more functional properties of an LCDR1, an LCDR2 and an LCDR3, respectively, of a VL amino acid sequence set forth in Table 2 or Table 4 herein; or both a) and b), optionally wherein the VH amino acid sequence set forth in Table 1 or Table 4 herein and the VL amino acid sequence set forth in Table 2 or Table 4 herein are a sequence pair set forth in Table 5 herein. [00172] In some embodiments, a polypeptide comprises: - 42 - 3839034.v1
5708.1076005 a) a VH domain comprising an HCDR1, an HCDR2, and an HCDR3 that substantially preserve one or more functional properties of an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence set forth in Table 1 or Table 4 herein; and b) a VL domain comprising an LCDR1, an LCDR2, and an LCDR3 that substantially preserve one or more functional properties of an LCDR1, an LCDR2 and an LCDR3, respectively, of a VL amino acid sequence set forth in Table 2 or Table 4 herein, optionally wherein the VH amino acid sequence set forth in Table 1 or Table 4 herein and the VL amino acid sequence set forth in Table 2 or Table 4 herein are a sequence pair set forth in Table 5 herein. [00173] In some embodiments, a polypeptide comprises an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2, and an LCDR3 that substantially preserve one or more functional properties of an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2, and an LCDR3 of a polypeptide selected from any antibody set forth in Table 5 herein. [00174] In some embodiments, a polypeptide comprises: a) a VH domain that comprises an HCDR1, an HCDR2, and an HCDR3 comprising only one or more conservative substitutions (e.g., only one or more highly conservative substitutions), relative to an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence set forth in Table 1 or Table 4 herein; or b) a VL domain that comprises an LCDR1, an LCDR2, and an LCDR3 comprising only one or more conservative substitutions (e.g., only one or more highly conservative substitutions), relative to an LCDR1, an LCDR2 and an LCDR3, respectively, of a VL amino acid sequence set forth in Table 2 or Table 4 herein, or both a) and b), optionally wherein the VH amino acid sequence set forth in Table 1 or Table 4 herein and the VL amino acid sequence set forth in Table 2 or Table 4 herein are a sequence pair set forth in Table 5 herein. [00175] In some embodiments, a polypeptide comprises: a) a VH domain that comprises an HCDR1, an HCDR2, and an HCDR3 comprising only one or more conservative substitutions (e.g., only one or more highly - 43 - 3839034.v1
5708.1076005 conservative substitutions), relative to an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence set forth in Table 1 or Table 4 herein; and b) a VL domain that comprises an LCDR1, an LCDR2, and an LCDR3 comprising only one or more conservative substitutions (e.g., only one or more highly conservative substitutions), relative to an LCDR1, an LCDR2 and an LCDR3, respectively, of a VL amino acid sequence set forth in Table 2 or Table 4 herein, optionally wherein the VH amino acid sequence set forth in Table 1 or Table 4 herein and the VL amino acid sequence set forth in Table 2 or Table 4 herein are a sequence pair set forth in Table 5 herein. [00176] In some embodiments, a polypeptide comprises: a) a VH domain that comprises an HCDR1, an HCDR2, and an HCDR3 comprising up to 1, 2, or 3 conservative substitutions (e.g., up to 1, 2, or 3 highly conservative substitutions), relative to an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence set forth in Table 1 or Table 4 herein; or b) a VL domain that comprises an LCDR1, an LCDR2, and an LCDR3 comprising up to 1, 2, or 3 conservative substitutions (e.g., up to 1, 2, or 3 highly conservative substitutions), relative to an LCDR1, an LCDR2 and an LCDR3, respectively, of a VL amino acid sequence set forth in Table 2 or Table 4 herein, or both a) and b), optionally wherein the VH amino acid sequence set forth in Table 1 or Table 4 herein and the VL amino acid sequence set forth in Table 2 or Table 4 herein are a sequence pair set forth in Table 5 herein. [00177] In some embodiments, a polypeptide comprises: a) a VH domain that comprises an HCDR1, an HCDR2, and an HCDR3 comprising up to 1, 2, or 3 conservative substitutions (e.g., up to 1, 2, or 3 highly conservative substitutions), relative to an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence set forth in Table 1 or Table 4 herein; and b) a VL domain that comprises an LCDR1, an LCDR2, and an LCDR3 comprising up to 1, 2, or 3 conservative substitutions (e.g., up to 1, 2, or 3 highly conservative substitutions), relative to an LCDR1, an LCDR2 and an LCDR3, respectively, of a VL amino acid sequence set forth in Table 2 or Table 4 herein, - 44 - 3839034.v1
5708.1076005 optionally wherein the VH amino acid sequence set forth in Table 1 or Table 4 herein and the VL amino acid sequence set forth in Table 2 or Table 4 herein are a sequence pair set forth in Table 5 herein. [00178] In some embodiments, a polypeptide comprises: a) a VH domain that comprises an HCDR1, an HCDR2, and an HCDR3 having 100% sequence identity to an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence set forth in Table 1 or Table 4 herein; or b) a VL domain that comprises an LCDR1, an LCDR2, and an LCDR3 having 100% sequence identity to an LCDR1, an LCDR2 and an LCDR3, respectively, of a VL amino acid sequence set forth in Table 2 or Table 4 herein, or both a) and b), optionally wherein the VH amino acid sequence set forth in Table 1 or Table 4 herein and the VL amino acid sequence set forth in Table 2 or Table 4 herein are a sequence pair set forth in Table 5 herein. [00179] In some embodiments, a polypeptide comprises: a) a VH domain that comprises an HCDR1, an HCDR2, and an HCDR3 having 100% sequence identity to an HCDR1, an HCDR2 and an HCDR3, respectively, of a VH amino acid sequence set forth in Table 1 or Table 4 herein; and b) a VL domain that comprises an LCDR1, an LCDR2, and an LCDR3 having 100% sequence identity to an LCDR1, an LCDR2 and an LCDR3, respectively, of a VL amino acid sequence set forth in Table 2 or Table 4 herein, optionally wherein the VH amino acid sequence set forth in Table 1 or Table 4 herein and the VL amino acid sequence set forth in Table 2 or Table 4 herein are a sequence pair set forth in Table 5 herein. [00180] In some embodiments, a polypeptide comprises an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2, and an LCDR3, of an antibody comprising a VH/VL pair selected from Table 5 herein. [00181] In some embodiments, a) an HCDR1 amino acid sequence corresponds to positions 26-33 of a VH amino acid sequence set forth in Table 4; b) an HCDR2 amino acid sequence corresponds to positions 51-58 of a VH amino acid sequence set forth in Table 4; - 45 - 3839034.v1
5708.1076005 c) an HCDR3 amino acid sequence corresponds to positions 97-115 of a VH amino acid sequence set forth in Table 4; d) an LCDR1 amino acid sequence corresponds to positions 26-34 of a VL amino acid sequence set forth in Table 4; e) an LCDR2 amino acid sequence corresponds to positions 52-54 of a VL amino acid sequence set forth in Table 4; f) an LCDR3 amino acid sequence corresponds to positions 91-103 of a VL amino acid sequence set forth in Table 4. [00182] In some embodiments, a polypeptide comprises: a) an HCDR1 comprising at least one amino acid substitution relative to at least one amino acid sequence set forth in SEQ ID NOs:22-24 and (HCDR1 amino acid sequences set forth in) Table 4 (e.g., at least one amino acid sequence set forth in SEQ ID NOs:23-24 and Table 4); b) an HCDR2 comprising at least one amino acid substitution relative to at least one amino acid sequence set forth in SEQ ID NOs:26-29 and (HCDR2 amino acid sequences set forth in) Table 4 (e.g., at least one amino acid sequence set forth in SEQ ID NOs:27-29 and Table 4); c) an HCDR3 comprising at least one amino acid substitution relative to at least one amino acid sequence set forth in SEQ ID NOs:31-33 and (HCDR3 amino acid sequences set forth in) Table 4 (e.g., at least one amino acid sequence set forth in SEQ ID NOs:32-33 and Table 4); d) an LCDR1 comprising at least one amino acid substitution relative to at least one amino acid sequence set forth in SEQ ID NOs:35-37 and (LCDR1 amino acid sequences set forth in) Table 4 (e.g., at least one amino acid sequence set forth in SEQ ID NOs:36-37 and Table 4); e) an LCDR2 comprising at least one amino acid substitution relative to at least one amino acid sequence set forth in SEQ ID NOs:38-40 and (LCDR2 amino acid sequences set forth in) Table 4 (e.g., at least one amino acid sequence set forth in SEQ ID NOs:39-40 and Table 4); f) an LCDR3 comprising at least one amino acid substitution relative to at least one amino acid sequence set forth in SEQ ID NOs:42-45 and (LCDR3 amino acid sequences set forth in) Table 4 (e.g., at least one amino acid sequence set forth in SEQ ID NOs:43-45 and Table 4); - 46 - 3839034.v1
5708.1076005 or any combination of the foregoing, optionally wherein a VH amino acid sequence comprising the HCDR1, the HCDR2, and the HCDR3, and a VL amino acid sequence comprising the LCDR1, the LCDR2, and the LCDR3, are a sequence pair set forth in Table 5 herein. [00183] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 comprising GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 comprising IILLPGYA (SEQ ID NO:604); and iii. an HCDR3 comprising ARGFNRDYYGWGDDDAFDF (SEQ ID NO:605); and b) a VL domain comprising: i. an LCDR1 comprising SSNIGAGYR (SEQ ID NO:37); ii. an LCDR2 comprising GRS; and iii. an LCDR3 comprising QSYDSSLFDPHWV (SEQ ID NO:44). [00184] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 comprising GDTEDTYT (SEQ ID NO:606); ii. an HCDR2 comprising IILLSGYA (SEQ ID NO:28); and iii. an HCDR3 comprising ARGFNGDYYGWGDDDAFDF (SEQ ID NO:33); and b) a VL domain comprising: i. an LCDR1 comprising ESNIGAGYR (SEQ ID NO:606); ii. an LCDR2 comprising GRS; and iii. an LCDR3 comprising QSYDSSLFDPHWV (SEQ ID NO:44). [00185] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 comprising GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 comprising IILLSGYG (SEQ ID NO:607); iii. an HCDR3 comprising ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a VL domain comprising: i. an LCDR1 comprising SSNIGAGYR (SEQ ID NO:37); ii. an LCDR2 comprising GRS; and - 47 - 3839034.v1
5708.1076005 iii. an LCDR3 comprising QSYDSSLFDPHWV (SEQ ID NO:44). [00186] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 comprising GDYSDVYT (SEQ ID NO:609); ii. an HCDR2 comprising IILLLGYA (SEQ ID NO:610); and iii. an HCDR3 comprising ARGFNGDYYGWGDDDAFDF (SEQ ID NO:33); and b) a VL domain comprising: i. an LCDR1 comprising SSNIGAGYY (SEQ ID NO:611); ii. an LCDR2 comprising GRS; and iii. an LCDR3 comprising QSYDSSLFDPHWV (SEQ ID NO:44). [00187] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 comprising GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 comprising IILLSGYT (SEQ ID NO:612); and iii. an HCDR3 comprising ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a VL domain comprising: i. an LCDR1 comprising LSNIGAGYR (SEQ ID NO:613); ii. an LCDR2 comprising GRS; and iii. an LCDR3 comprising QSYDSSLFDPHWV (SEQ ID NO:44). [00188] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 comprising GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 comprising IILLSGYS (SEQ ID NO:614); and iii. an HCDR3 comprising ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a VL domain comprising: i. an LCDR1 comprising ESNIGAGYD (SEQ ID NO:615); ii. an LCDR2 comprising GRS; and iii. an LCDR3 comprising QSYDSSLFDPHWV (SEQ ID NO:44). [00189] In some embodiments, a polypeptide comprises: a) a VH domain comprising: - 48 - 3839034.v1
5708.1076005 i. an HCDR1 comprising GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 comprising IILLSGYA (SEQ ID NO:28); and iii. an HCDR3 comprising ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a VL domain comprising: i. an LCDR1 comprising LSNIGAGYR (SEQ ID NO:613); ii. an LCDR2 comprising GRS; and iii. an LCDR3 comprising QSYDSSLFDPHWV (SEQ ID NO:44). [00190] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 comprising GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 comprising IILLSDYT (SEQ ID NO:609); and iii. an HCDR3 comprising ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a VL domain comprising: i. an LCDR1 comprising ESNIGAGYR (SEQ ID NO:606); ii. an LCDR2 comprising GRS; and iii. an LCDR3 comprising QSYDSSLFDPHWV (SEQ ID NO:44). [00191] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 comprising GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 comprising IILLSGYA (SEQ ID NO:28); and iii. an HCDR3 comprising ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a VL domain comprising: i. an LCDR1 comprising ESNIGAGYR (SEQ ID NO:606); ii. an LCDR2 comprising GRS; and iii. an LCDR3 comprising QSYDSSLFDPHWV (SEQ ID NO:44). [00192] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 comprising GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 comprising IILLSGYA (SEQ ID NO:28); and - 49 - 3839034.v1
5708.1076005 iii. an HCDR3 comprising ARGFNGDYYGWGDDDAFDF (SEQ ID NO:33); and b) a VL domain comprising: i. an LCDR1 comprising SSNIGAGYD (SEQ ID NO:36); ii. an LCDR2 comprising GRS; and iii. an LCDR3 comprising QSYDSSYFDPHWV (SEQ ID NO:610). [00193] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 comprising GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 comprising IILLSGYT (SEQ ID NO:612); and iii. an HCDR3 comprising ARGFNEDYYGWGDDDAFDF (SEQ ID NO:614); and b) a VL domain comprising: i. an LCDR1 comprising VSNIGAGYD (SEQ ID NO:615); ii. an LCDR2 comprising GRS; and iii. an LCDR3 comprising QSYDSSLFDPHWV (SEQ ID NO:44). [00194] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 comprising GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 comprising IILLSGYA (SEQ ID NO:28); and iii. an HCDR3 comprising ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a VL domain comprising: i. an LCDR1 comprising PSNIGAGYR (SEQ ID NO:616); ii. an LCDR2 comprising GRS; and iii. an LCDR3 comprising QSYDSSLFDPHWV (SEQ ID NO:44). [00195] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 comprising GDTSDIYT (SEQ ID NO:617); ii. an HCDR2 comprising IILLSGYT (SEQ ID NO:612); and iii. an HCDR3 comprising ARGFNGDYYGWGDDDAFDF (SEQ ID NO:33); and b) a VL domain comprising: - 50 - 3839034.v1
5708.1076005 i. an LCDR1 comprising VSNIGAGYD (SEQ ID NO:615); ii. an LCDR2 comprising GRS; and iii. an LCDR3 comprising QSYDSSLFDPHWV (SEQ ID NO:44). [00196] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 comprising GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 comprising IILLSGYT (SEQ ID NO:612); and iii. an HCDR3 comprising ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a VL domain comprising: i. an LCDR1 comprising ESNIGAGYD (SEQ ID NO:615); ii. an LCDR2 comprising GRS; and iii. an LCDR3 comprising QSYDSSLFDPHWV (SEQ ID NO:44). [00197] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 comprising GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 comprising IILLSGYA (SEQ ID NO:28); and iii. an HCDR3 comprising ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a VL domain comprising: i. an LCDR1 comprising VSNIGAGYR (SEQ ID NO:618); ii. an LCDR2 comprising GSS; and iii. an LCDR3 comprising QSYDSSLFDPHWV (SEQ ID NO:44). [00198] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 comprising GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 comprising IILLSGYV (SEQ ID NO:619); and iii. an HCDR3 comprising ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a VL domain comprising: i. an LCDR1 comprising SSNIGAGYD (SEQ ID NO:36); ii. an LCDR2 comprising GRS; iii. an LCDR3 comprising QSYDSSSFDPHWV (SEQ ID NO:620). - 51 - 3839034.v1
5708.1076005 [00199] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 comprising GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 comprising IILLSGYA (SEQ ID NO:28); and iii. an HCDR3 comprising ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a VL domain comprising: i. an LCDR1 comprising SSNIGAGYR (SEQ ID NO:37); ii. an LCDR2 comprising GRS; and iii. an LCDR3 comprising QSYDSSYFDPHWV (SEQ ID NO:610). [00200] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 comprising GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 comprising IILLSGYA (SEQ ID NO:28); and iii. an HCDR3 comprising ARGFNYDYYGWGDDDAFDF (SEQ ID NO:621); and b) a VL domain comprising: i. an LCDR1 comprising VSNIGAGYR (SEQ ID NO:618); ii. an LCDR2 comprising GRS; and iii. an LCDR3 comprising QSYDSSLFDPHWV (SEQ ID NO:44). [00201] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 comprising GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 comprising IILLSGYS (SEQ ID NO:614); and iii. an HCDR3 comprising ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a VL domain comprising: i. an LCDR1 comprising SSNIGAGYD (SEQ ID NO:36); ii. an LCDR2 comprising GRS; iii. an LCDR3 comprising QSYDSSLFDPHWV (SEQ ID NO:44). [00202] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 comprising GDTSDTYT (SEQ ID NO:24); - 52 - 3839034.v1
5708.1076005 ii. an HCDR2 comprising IILLSGYG (SEQ ID NO:607); and iii. an HCDR3 comprising ARGFNGDYYGWGDDDAFDF (SEQ ID NO:33); and b) a VL domain comprising: i. an LCDR1 comprising ESNIGAGYR (SEQ ID NO:606); ii. an LCDR2 comprising GRS; and iii. an LCDR3 comprising QSYDSSLFDPHWV (SEQ ID NO:44). [00203] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 consisting of GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 consisting of IILLPGYA (SEQ ID NO:604); and iii. an HCDR3 consisting of ARGFNRDYYGWGDDDAFDF (SEQ ID NO:605); and b) a VL domain comprising: i. an LCDR1 consisting of SSNIGAGYR (SEQ ID NO:37); ii. an LCDR2 consisting of GRS; and iii. an LCDR3 consisting of QSYDSSLFDPHWV (SEQ ID NO:44). [00204] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 consisting of GDTEDTYT (SEQ ID NO:606); ii. an HCDR2 consisting of IILLSGYA (SEQ ID NO:28); and iii. an HCDR3 consisting of ARGFNGDYYGWGDDDAFDF (SEQ ID NO:33); and b) a VL domain comprising: i. an LCDR1 consisting of ESNIGAGYR (SEQ ID NO:606); ii. an LCDR2 consisting of GRS; and iii. an LCDR3 consisting of QSYDSSLFDPHWV (SEQ ID NO:44). [00205] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 consisting of GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 consisting of IILLSGYG (SEQ ID NO:607); iii. an HCDR3 consisting of ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and - 53 - 3839034.v1
5708.1076005 b) a VL domain comprising: i. an LCDR1 consisting of SSNIGAGYR (SEQ ID NO:37); ii. an LCDR2 consisting of GRS; and iii. an LCDR3 consisting of QSYDSSLFDPHWV (SEQ ID NO:44). [00206] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 consisting of GDYSDVYT (SEQ ID NO:609); ii. an HCDR2 consisting of IILLLGYA (SEQ ID NO:610); and iii. an HCDR3 consisting of ARGFNGDYYGWGDDDAFDF (SEQ ID NO:33); and b) a VL domain comprising: i. an LCDR1 consisting of SSNIGAGYY (SEQ ID NO:611); ii. an LCDR2 consisting of GRS; and iii. an LCDR3 consisting of QSYDSSLFDPHWV (SEQ ID NO:44). [00207] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 consisting of GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 consisting of IILLSGYT (SEQ ID NO:612); and iii. an HCDR3 consisting of ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a VL domain comprising: i. an LCDR1 consisting of LSNIGAGYR (SEQ ID NO:613); ii. an LCDR2 consisting of GRS; and iii. an LCDR3 consisting of QSYDSSLFDPHWV (SEQ ID NO:44). [00208] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 consisting of GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 consisting of IILLSGYS (SEQ ID NO:614); and iii. an HCDR3 consisting of ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a VL domain comprising: i. an LCDR1 consisting of ESNIGAGYD (SEQ ID NO:615); ii. an LCDR2 consisting of GRS; and - 54 - 3839034.v1
5708.1076005 iii. an LCDR3 consisting of QSYDSSLFDPHWV (SEQ ID NO:44). [00209] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 consisting of GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 consisting of IILLSGYA (SEQ ID NO:28); and iii. an HCDR3 consisting of ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a VL domain comprising: i. an LCDR1 consisting of LSNIGAGYR (SEQ ID NO:613); ii. an LCDR2 consisting of GRS; and iii. an LCDR3 consisting of QSYDSSLFDPHWV (SEQ ID NO:44). [00210] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 consisting of GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 consisting of IILLSDYT (SEQ ID NO:609); and iii. an HCDR3 consisting of ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a VL domain comprising: i. an LCDR1 consisting of ESNIGAGYR (SEQ ID NO:606); ii. an LCDR2 consisting of GRS; and iii. an LCDR3 consisting of QSYDSSLFDPHWV (SEQ ID NO:44). [00211] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 consisting of GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 consisting of IILLSGYA (SEQ ID NO:28); and iii. an HCDR3 consisting of ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a VL domain comprising: i. an LCDR1 consisting of ESNIGAGYR (SEQ ID NO:606); ii. an LCDR2 consisting of GRS; and iii. an LCDR3 consisting of QSYDSSLFDPHWV (SEQ ID NO:44). [00212] In some embodiments, a polypeptide comprises: a) a VH domain comprising: - 55 - 3839034.v1
5708.1076005 i. an HCDR1 consisting of GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 consisting of IILLSGYA (SEQ ID NO:28); and iii. an HCDR3 consisting of ARGFNGDYYGWGDDDAFDF (SEQ ID NO:33); and b) a VL domain comprising: i. an LCDR1 consisting of SSNIGAGYD (SEQ ID NO:36); ii. an LCDR2 consisting of GRS; and iii. an LCDR3 consisting of QSYDSSYFDPHWV (SEQ ID NO:610). [00213] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 consisting of GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 consisting of IILLSGYT (SEQ ID NO:612); and iii. an HCDR3 consisting of ARGFNEDYYGWGDDDAFDF (SEQ ID NO:614); and b) a VL domain comprising: i. an LCDR1 consisting of VSNIGAGYD (SEQ ID NO:615); ii. an LCDR2 consisting of GRS; and iii. an LCDR3 consisting of QSYDSSLFDPHWV (SEQ ID NO:44). [00214] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 consisting of GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 consisting of IILLSGYA (SEQ ID NO:28); and iii. an HCDR3 consisting of ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a VL domain comprising: i. an LCDR1 consisting of PSNIGAGYR (SEQ ID NO:616); ii. an LCDR2 consisting of GRS; and iii. an LCDR3 consisting of QSYDSSLFDPHWV (SEQ ID NO:44). [00215] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 consisting of GDTSDIYT (SEQ ID NO:617); ii. an HCDR2 consisting of IILLSGYT (SEQ ID NO:612); and - 56 - 3839034.v1
5708.1076005 iii. an HCDR3 consisting of ARGFNGDYYGWGDDDAFDF (SEQ ID NO:33); and b) a VL domain comprising: i. an LCDR1 consisting of VSNIGAGYD (SEQ ID NO:615); ii. an LCDR2 consisting of GRS; and iii. an LCDR3 consisting of QSYDSSLFDPHWV (SEQ ID NO:44). [00216] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 consisting of GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 consisting of IILLSGYT (SEQ ID NO:612); and iii. an HCDR3 consisting of ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a VL domain comprising: i. an LCDR1 consisting of ESNIGAGYD (SEQ ID NO:615); ii. an LCDR2 consisting of GRS; and iii. an LCDR3 consisting of QSYDSSLFDPHWV (SEQ ID NO:44). [00217] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 consisting of GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 consisting of IILLSGYA (SEQ ID NO:28); and iii. an HCDR3 consisting of ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a VL domain comprising: i. an LCDR1 consisting of VSNIGAGYR (SEQ ID NO:618); ii. an LCDR2 consisting of GSS; and iii. an LCDR3 consisting of QSYDSSLFDPHWV (SEQ ID NO:44). [00218] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 consisting of GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 consisting of IILLSGYV (SEQ ID NO:619); and iii. an HCDR3 consisting of ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a VL domain comprising: - 57 - 3839034.v1
5708.1076005 i. an LCDR1 consisting of SSNIGAGYD (SEQ ID NO:36); ii. an LCDR2 consisting of GRS; iii. an LCDR3 consisting of QSYDSSSFDPHWV (SEQ ID NO:620). [00219] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 consisting of GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 consisting of IILLSGYA (SEQ ID NO:28); and iii. an HCDR3 consisting of ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a VL domain comprising: i. an LCDR1 consisting of SSNIGAGYR (SEQ ID NO:37); ii. an LCDR2 consisting of GRS; and iii. an LCDR3 consisting of QSYDSSYFDPHWV (SEQ ID NO:610). [00220] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 consisting of GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 consisting of IILLSGYA (SEQ ID NO:28); and iii. an HCDR3 consisting of ARGFNYDYYGWGDDDAFDF (SEQ ID NO:621); and b) a VL domain comprising: i. an LCDR1 consisting of VSNIGAGYR (SEQ ID NO:618); ii. an LCDR2 consisting of GRS; and iii. an LCDR3 consisting of QSYDSSLFDPHWV (SEQ ID NO:44). [00221] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 consisting of GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 consisting of IILLSGYS (SEQ ID NO:614); and iii. an HCDR3 consisting of ARGFNPDYYGWGDDDAFDF (SEQ ID NO:608); and b) a VL domain comprising: i. an LCDR1 consisting of SSNIGAGYD (SEQ ID NO:36); ii. an LCDR2 consisting of GRS; iii. an LCDR3 consisting of QSYDSSLFDPHWV (SEQ ID NO:44). - 58 - 3839034.v1
5708.1076005 [00222] In some embodiments, a polypeptide comprises: a) a VH domain comprising: i. an HCDR1 consisting of GDTSDTYT (SEQ ID NO:24); ii. an HCDR2 consisting of IILLSGYG (SEQ ID NO:607); and iii. an HCDR3 consisting of ARGFNGDYYGWGDDDAFDF (SEQ ID NO:33); and b) a VL domain comprising: i. an LCDR1 consisting of ESNIGAGYR (SEQ ID NO:606); ii. an LCDR2 consisting of GRS; and iii. an LCDR3 consisting of QSYDSSLFDPHWV (SEQ ID NO:44). Variable Domains [00223] In some embodiments, a polypeptide binds to a SARS-CoV-2 Spike protein (e.g., SEQ ID NO:1 or SEQ ID NO:46) and comprises an immunoglobulin light chain variable domain, an immunoglobulin heavy chain variable domain, or an immunoglobulin light chain variable domain and an immunoglobulin heavy chain variable domain, wherein the polypeptide does not comprise SEQ ID NO:3 or SEQ ID NO:8 or both SEQ ID NO:3 and SEQ ID NO:8. [00224] In some embodiments, a polypeptide binds to one or more epitope residues of a wildtype SARS-CoV-2 Spike protein (e.g., one or more epitope residues in the SARS-CoV-2 S1 subunit). [00225] In some embodiments, a polypeptide (e.g., an antibody or antigen-binding fragment thereof) comprises a VH domain, a VL domain, or both. In some embodiments, a polypeptide comprises a VH domain having less than 100% sequence identity to the amino acid sequence of SEQ ID NO:3, a VL domain having less than 100% sequence identity to the amino acid sequence of SEQ ID NO:8, or both. [00226] In some embodiments, a polypeptide comprises a VH (e.g., a mammalian VH such as a rodent (e.g., mouse) VH, a primate (e.g., a human) VH) domain. In some embodiments, a polypeptide comprises a VH domain that is humanized (e.g., at least about: 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99% humanized), contains human framework regions, or both. [00227] In some embodiments, a polypeptide comprises a VH domain that has less than 100% sequence identity to the amino acid sequence of SEQ ID NO:3. [00228] In some embodiments, a polypeptide comprises a VH domain that has at least about 70% sequence identity to the amino acid sequence of SEQ ID NO:3. In some embodiments, a - 59 - 3839034.v1
5708.1076005 polypeptide comprises a VH domain that has at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of SEQ ID NO:3. In some embodiments, a polypeptide comprises a VH domain that has at least about 85% sequence identity to the amino acid sequence of SEQ ID NO:3. In some embodiments, a polypeptide comprises a VH domain that has at least about 90% sequence identity to the amino acid sequence of SEQ ID NO:3. [00229] In some embodiments, a polypeptide comprises a VH domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative substitution) relative to the amino acid sequence of SEQ ID NO:3. For example, the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5- 14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11. In some embodiments, a polypeptide comprises a VH domain that comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of SEQ ID NO:3. In some embodiments, the at least one amino acid substitution replaces only an HCDR1, an HCDR2, and/or an HCDR3 residue, of SEQ ID NO:3. In some embodiments, the at least one amino acid substitution replaces only a non-CDR residue (e.g., within a framework region), of SEQ ID NO:3. [00230] In some embodiments, a polypeptide comprises a VH domain that has 100% sequence identity to the amino acid sequence of SEQ ID NO:3. In some embodiments, a polypeptide comprises a VH domain that comprises the amino acid sequence of SEQ ID NO:3. [00231] In some embodiments, a polypeptide comprises a VH domain that has at least about 70% sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6). The sequences identified as SEQ ID NOs:4-6, 89, and 90 are shown in Table 1, which correspond to human VH domains. In some embodiments, a polypeptide comprises a VH domain that has at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6). In some embodiments, a polypeptide comprises a VH domain that has at least about 85% sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6). In some embodiments, a polypeptide comprises a VH domain that has at least about 90% sequence - 60 - 3839034.v1
5708.1076005 identity to the amino acid sequence of any one or more of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6). [00232] In some embodiments, a polypeptide comprises a VH domain that comprises at least one amino acid substitution relative to the amino acid sequence of any one or more of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6). For example, the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7- 12, 8-12, 8-11 or 9-11. In some embodiments, a polypeptide comprises a VH domain that comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of any one or more of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6). [00233] In some embodiments, an amino acid substitution is a conservative substitution. [00234] In some embodiments, an amino acid substitution is a highly conservative substitution. [00235] In some embodiments, a polypeptide comprises a VH domain that has 100% sequence identity to the amino acid sequence of any one of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6). In some embodiments, a polypeptide comprises a VH domain that comprises the amino acid sequence of any one of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6). [00236] In some embodiments, a polypeptide comprises a VL (e.g., a mammalian VL such as a rodent (e.g., mouse) VL, a primate (e.g., a human) VL) domain. In some embodiments, a polypeptide comprises a VL domain that is humanized (e.g., at least about: 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99% humanized), contains human framework regions, or both. [00237] In some embodiments, a polypeptide comprises a VL domain that has less than 100% sequence identity to the amino acid sequence of SEQ ID NO:8. [00238] In some embodiments, a polypeptide comprises a VL domain that has at least about 70% sequence identity to the amino acid sequence of SEQ ID NO:8. In some embodiments, a polypeptide comprises a VL domain that has at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of SEQ ID NO:8. In some embodiments, a polypeptide comprises a VL domain that has at least about 85% sequence identity to the amino acid sequence of SEQ ID NO:8. In some embodiments, a polypeptide comprises a VL domain that has at least about 90% sequence identity to the amino acid sequence of SEQ ID NO:8. - 61 - 3839034.v1
5708.1076005 [00239] In some embodiments, a polypeptide comprises a VL domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative substitution) relative to the amino acid sequence of SEQ ID NO:8. For example, the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5- 14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11. In some embodiments, a polypeptide comprises a VL domain that comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of SEQ ID NO:8. In some embodiments, the at least one amino acid substitution replaces only an LCDR1, an LCDR2, and/or an LCDR3 residue, of SEQ ID NO:8. In some embodiments, the at least one amino acid substitution replaces only a non-CDR residue (e.g., within a framework region), of SEQ ID NO:8. [00240] In some embodiments, an amino acid substitution is a conservative substitution. [00241] In some embodiments, an amino acid substitution is a highly conservative substitution. [00242] In some embodiments, a polypeptide comprises a VL domain that has 100% sequence identity to the amino acid sequence of SEQ ID NO:8. In some embodiments, a polypeptide comprises a VL domain [00243] that comprises the amino acid sequence of SEQ ID NO:8. [00244] In some embodiments, a polypeptide comprises a VL domain that has at least about 70% sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:9-20, 91, and 92 (e.g., SEQ ID NOs:9-20). The sequences identified as SEQ ID NOs:9-20, 91, and 92 (e.g., SEQ ID NOs:9-20) are shown in Table 2, which correspond to human VL domains. In some embodiments, a polypeptide comprises a VL that has at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:9-20, 91, and 92 (e.g., SEQ ID NOs:9-20). In some embodiments, a polypeptide comprises a VL domain that has at least about 85% sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:20-30. In some embodiments, a polypeptide comprises a VL domain that has at least about 90% sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:9-20, 91, and 92 (e.g., SEQ ID NOs:9-20). [00245] In some embodiments, a polypeptide comprises a VL domain that comprises at least one amino acid substitution relative to the amino acid sequence of any one or more of SEQ ID - 62 - 3839034.v1
5708.1076005 NOs:9-20, 91, and 92 (e.g., SEQ ID NOs:9-20). For example, the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7- 12, 8-12, 8-11 or 9-11. In some embodiments, a polypeptide comprises a VL domain that comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of any one or more of SEQ ID NOs:9-20, 91, and 92 (e.g., SEQ ID NOs:9-20). [00246] In some embodiments, an amino acid substitution is a conservative substitution. [00247] In some embodiments, an amino acid substitution is a highly conservative substitution. [00248] In some embodiments, a polypeptide comprises a VL domain that has 100% sequence identity to the amino acid sequence of any one of SEQ ID NOs:9-20, 91, and 92 (e.g., SEQ ID NOs:9-20). In some embodiments, a polypeptide comprises a VL domain that comprises the amino acid sequence of any one of SEQ ID NOs:9-20, 91, and 92 (e.g., SEQ ID NOs:9-20). [00249] In some embodiments, a polypeptide comprises a VH (e.g., a mammalian VH such as a rodent (e.g., mouse) VH, a primate (e.g., a human) VH) domain and a VL (e.g., a mammalian VL such as a rodent (e.g., mouse) VL, a primate (e.g., a human) VL) domain. In some embodiments, a polypeptide comprises a VH domain and VL domain that are humanized (e.g., at least about: 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99% humanized), contain human framework regions, or both. [00250] In some embodiments, a polypeptide comprises: a) a VH domain that has less than 100% sequence identity to the amino acid sequence of SEQ ID NO:3; b) a VL domain that has less than 100% sequence identity to the amino acid sequence of SEQ ID NO:8; or both a) and b). [00251] In some embodiments, a polypeptide comprises: a) a VH domain that has less than 100% sequence identity to the amino acid sequence of SEQ ID NO:3; and b) a VL domain that has less than 100% sequence identity to the amino acid sequence of SEQ ID NO:8. [00252] In some embodiments, a polypeptide comprises: - 63 - 3839034.v1
5708.1076005 a) a VH domain that has at least about 55% (e.g., at least about: 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99%) sequence identity to the amino acid sequence of SEQ ID NO:3; b) a VL domain that has at least about 55% (e.g., at least about: 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99%) sequence identity to the amino acid sequence of SEQ ID NO:8; or both a) and b), wherein the polypeptide does not comprise all 6 CDRs of an antibody comprising a VH amino acid sequence of SEQ ID NO:3 and a VL amino acid sequence of SEQ ID NO:8. [00253] In some embodiments, a polypeptide comprises: a) a VH domain that has at least about 55% (e.g., at least about: 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99%) sequence identity to the amino acid sequence of SEQ ID NO:3; and b) a VL domain that has at least about 55% (e.g., at least about: 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99%) sequence identity to the amino acid sequence of SEQ ID NO:8, wherein the polypeptide does not comprise all 6 CDRs of an antibody comprising a VH amino acid sequence of SEQ ID NO:3 and a VL amino acid sequence of SEQ ID NO:8. [00254] In some embodiments, a polypeptide comprises: a) a VH domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative substitution) relative to the amino acid sequence of SEQ ID NO:3; b) a VL domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative substitution) relative to the amino acid sequence of SEQ ID NO:8; or both a) and b). [00255] In some embodiments, a polypeptide comprises: a) a VH domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) relative to the amino acid sequence of SEQ ID NO:3; and b) a VL domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) relative to the amino acid sequence of SEQ ID NO:8. - 64 - 3839034.v1
5708.1076005 [00256] In some embodiments, a polypeptide comprises: a) a VH domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a HCDR1, a HCDR2 and/or a HCDR3 residue, of SEQ ID NO:3; b) a VL domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a LCDR1, a LCDR2 and/or a LCDR3 residue, of SEQ ID NO:8; or both a) and b). [00257] In some embodiments, a polypeptide comprises: a) a VH domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a HCDR1, a HCDR2 and/or a HCDR3 residue, of SEQ ID NO:3; and b) a VL domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a LCDR1, a LCDR2 and/or a LCDR3 residue, of SEQ ID NO:8. [00258] In some embodiments, a polypeptide comprises: a) a VH domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of SEQ ID NO:3; b) a VL domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of SEQ ID NO:8; or both a) and b). [00259] In some embodiments, a polypeptide comprises: a) a VH domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of SEQ ID NO:3; and b) a VL domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of SEQ ID NO:8. [00260] In some embodiments, a polypeptide comprises: - 65 - 3839034.v1
5708.1076005 a) a VH domain that has at least about 70% (e.g., at least about: 75, 80, 85, 90, 95, 98, or 99%) sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6); b) a VL domain that has at least about 70% (e.g., at least about: 75, 80, 85, 90, 95, 98, or 99%) sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:9-20, 91, and 92 (e.g., SEQ ID NOs:9-20); or both a) and b). [00261] In some embodiments, a polypeptide comprises: a) a VH domain that has at least about 70% (e.g., at least about: 75, 80, 85, 90, 95, 98, or 99%) sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6); and b) a VL domain that has at least about 70% (e.g., at least about: 75, 80, 85, 90, 95, 98, or 99%) sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:9-20, 91, and 92 (e.g., SEQ ID NOs:9-20). [00262] In some embodiments, a polypeptide comprises: a) a VH domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) relative to the amino acid sequence of any one or more of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6); b) a VL domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) relative to the amino acid sequence of any one or more of SEQ ID NOs:9-20, 91, and 92 (e.g., SEQ ID NOs:9-20); or both a) and b). [00263] In some embodiments, a polypeptide comprises: a) a VH domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) relative to the amino acid sequence of any one or more of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6); and b) a VL domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) relative to the amino acid sequence of any one or more of SEQ ID NOs:9-20, 91, and 92 (e.g., SEQ ID NOs:9-20). - 66 - 3839034.v1
5708.1076005 [00264] In some embodiments, a polypeptide comprises: a) a VH domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a HCDR1, a HCDR2 and/or a HCDR3 residue, of any one or more of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6); b) a VL domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a LCDR1, a LCDR2 and/or a LCDR3 residue, of any one or more of SEQ ID NOs:9-20, 91, and 92 (e.g., SEQ ID NOs:9-20); or both a) and b). [00265] In some embodiments, a polypeptide comprises: a) a VH domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a HCDR1, a HCDR2 and/or a HCDR3 residue, of any one or more of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6); and b) a VL domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a LCDR1, a LCDR2 and/or a LCDR3 residue, of any one or more of SEQ ID NOs:9-20, 91, and 92 (e.g., SEQ ID NOs:9-20). [00266] In some embodiments, a polypeptide comprises: a) a VH domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of any one or more of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6); b) a VL domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of any one or more of SEQ ID NOs:9-20, 91, and 92 (e.g., SEQ ID NOs:9-20); or both a) and b). [00267] In some embodiments, a polypeptide comprises: a) a VH domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a - 67 - 3839034.v1
5708.1076005 non-CDR residue (e.g., within a framework region), of any one or more of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6); and b) a VL domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of any one or more of SEQ ID NOs:9-20, 91, and 92 (e.g., SEQ ID NOs:9-20). [00268] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of any one of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6); and b) a VL domain comprising the amino acid sequence of any one of SEQ ID NOs:9- 20, 91, and 92 (e.g., SEQ ID NOs:9-20). [00269] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of any one of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6); and b) a VL domain comprising the amino acid sequence of SEQ ID NO:8. [00270] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:3; and b) a VL domain comprising the amino acid sequence of any one of SEQ ID NOs:9- 20, 91, and 92 (e.g., SEQ ID NOs:9-20). [00271] In some embodiments, a polypeptide comprises: a) a VH domain that has at least about 70% (e.g., at least about: 75, 80, 85, 90, 95, 98, or 99%) sequence identity to the amino acid sequence of SEQ ID NO:5; b) a VL domain that has at least about 70% (e.g., at least about: 75, 80, 85, 90, 95, 98, or 99%) sequence identity to the amino acid sequence of SEQ ID NO:14; or both a) and b). [00272] In some embodiments, a polypeptide comprises: a) a VH domain that has at least about 70% (e.g., at least about: 75, 80, 85, 90, 95, 98, or 99%) sequence identity to the amino acid sequence of SEQ ID NO:5; and b) a VL domain that has at least about 70% (e.g., at least about: 75, 80, 85, 90, 95, 98, or 99%) sequence identity to the amino acid sequence of SEQ ID NO:14. [00273] In some embodiments, a polypeptide comprises: - 68 - 3839034.v1
5708.1076005 a) a VH domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) relative to the amino acid sequence of SEQ ID NO:5; b) a VL domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) relative to the amino acid sequence of SEQ ID NO:14; or both a) and b). [00274] In some embodiments, a polypeptide comprises: a) a VH domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) relative to the amino acid sequence of SEQ ID NO:5; and b) a VL domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) relative to the amino acid sequence of SEQ ID NO:14. [00275] In some embodiments, a polypeptide comprises: a) a VH domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a HCDR1, a HCDR2 and/or a HCDR3 residue, of SEQ ID NO:5; b) a VL domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a LCDR1, a LCDR2 and/or a LCDR3 residue, of SEQ ID NO:14; or both a) and b). [00276] In some embodiments, an amino acid substitution is a conservative substitution. [00277] In some embodiments, an amino acid substitution is a highly conservative substitution. [00278] In some embodiments, a polypeptide comprises: a) a VH domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a HCDR1, a HCDR2 and/or a HCDR3 residue, of SEQ ID NO:5; and b) a VL domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a LCDR1, a LCDR2 and/or a LCDR3 residue, of SEQ ID NO:14. [00279] In some embodiments, a polypeptide comprises: - 69 - 3839034.v1
5708.1076005 a) a VH domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of SEQ ID NO:5; b) a VL domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of SEQ ID NO:14; or both a) and b). [00280] In some embodiments, a polypeptide comprises: a) a VH domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of SEQ ID NO:5; and b) a VL domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of SEQ ID NO:14. [00281] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:5, and b) a VL domain comprising the amino acid sequence of SEQ ID NO:14 (AB-2b). [00282] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:4; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:9 (AB-1a). [00283] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:4; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:10 (AB-1b). [00284] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:4; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:11 (AB-1c). [00285] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:4; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:12 (AB-1d). [00286] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:5; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:13 (AB-2a). [00287] In some embodiments, a polypeptide comprises: - 70 - 3839034.v1
5708.1076005 a) a VH domain comprising the amino acid sequence of SEQ ID NO:5; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:15 (AB-2c). [00288] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:5; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:16 (AB-2d). [00289] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:6; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:17 (AB-3a). [00290] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:6; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:18 (AB-3b). [00291] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:6; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:19 (AB-3c). [00292] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:6; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:20 (AB-3d). [00293] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:89; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:91 (AB-4a). [00294] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:90; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:92 (AB-7a). [00295] In some embodiments, a polypeptide comprises a VH domain that comprises an HCDR1, an HCDR2, and an HCDR3 that are substantially similar in amino acid sequence to an HCDR1, an HCDR2, and an HCDR3, respectively, of a VH amino acid sequence set forth in any of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6). [00296] In some embodiments, a polypeptide comprises a VL domain that comprises an LCDR1, an LCDR2, and an LCDR3 that are substantially similar in amino acid sequence to an LCDR1, an LCDR2, and an LCDR3, respectively, of a VL amino acid sequence set forth in any of SEQ ID NOs:9-20, 91, and 92 (e.g., SEQ ID NOs:9-20). [00297] In some embodiments, a polypeptide comprises a VH domain that comprises an HCDR1, an HCDR2, and an HCDR3 that are identical in amino acid sequence to an HCDR1, an - 71 - 3839034.v1
5708.1076005 HCDR2, and an HCDR3, respectively, of a VH amino acid sequence set forth in any of SEQ ID NOs:4-6, 89, and 90 (e.g., SEQ ID NOs:4-6). [00298] In some embodiments, a polypeptide comprises a VL domain that comprises an LCDR1, an LCDR2, and an LCDR3 that are identical in amino acid sequence to an LCDR1, an LCDR2, and an LCDR3, respectively, of a VL amino acid sequence set forth in any of SEQ ID NOs:9-20, 91, and 92 (e.g., SEQ ID NOs:9-20). [00299] In some embodiments, a polypeptide comprises a VH domain that has at least about 70% sequence identity to the amino acid sequence of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:89, SEQ ID NO:90, or any combination of the foregoing. For example, a VH domain can have at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:89, SEQ ID NO:90, or any combination of the foregoing. In some embodiments, a VH domain has at least about 85% or at least about 90% sequence identity to the amino acid sequence of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:89, SEQ ID NO:90, or any combination of the foregoing. [00300] In some embodiments, a polypeptide comprises a VL domain that has at least about 70% sequence identity to the amino acid sequence of SEQ ID NO:8. For example, the VL domain can have at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO:8. In some embodiments, the VL domain has at least about 85% or at least about 90% sequence identity to the amino acid sequence of SEQ ID NO:8. The sequence identified as SEQ ID NO:8 is shown in Table 2, which corresponds to a human VL domain. [00301] In some embodiments, a polypeptide comprises a VL domain that has at least about 70% sequence identity to the amino acid sequence of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:91, SEQ ID NO:92, or any combination of the foregoing. For example, the VL domain can have at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, - 72 - 3839034.v1
5708.1076005 SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:91, SEQ ID NO:92, or any combination of the foregoing. In some embodiments, the VL domain has at least about 85% or at least about 90% sequence identity to the amino acid sequence of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:91, SEQ ID NO:92, or any combination of the foregoing. [00302] In some embodiments, a polypeptide comprises a VH domain that comprises at least 1 amino acid substitution (e.g., at least 1 conservative substitution such as highly conservative amino acid substitution) relative to the amino acid sequence of SEQ ID NO:3. For example, the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5- 14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11, or 9-11. In some embodiments, a VH domain comprises about 1-10 amino acid substitutions relative to the amino acid sequence of SEQ ID NO:3. In some embodiments, the at least 1 amino acid substitution replaces only an HCDR1, an HCDR2, and/or an HCDR3 residue of SEQ ID NO:3. In some embodiments, the at least 1 amino acid substitution replaces only a non-CDR residue (e.g., within a framework region) of SEQ ID NO:3. [00303] In some embodiments, a polypeptide comprises a VH domain that comprises at least 1 amino acid substitution relative to the amino acid sequence of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:89, SEQ ID NO:90, or any combination of the foregoing. For example, the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11, or 9-11. In some embodiments, a VH domain comprises about 1-10 amino acid substitutions relative to the amino acid sequence of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:89, SEQ ID NO:90, or any combination of the foregoing. [00304] In some embodiments, the at least 1 amino acid substitution replaces only an HCDR1, an HCDR2, and/or an HCDR3 residue of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:89, SEQ ID NO:90, or any combination of the foregoing. In particular embodiments, the at least 1 amino acid substitution replaces only a non-CDR residue (e.g., within a framework region) of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:89, SEQ ID NO:90,or any combination of the foregoing. - 73 - 3839034.v1
5708.1076005 [00305] In some embodiments, a polypeptide comprises a VL domain that comprises at least 1 amino acid substitution relative to the amino acid sequence of SEQ ID NO:8. For example, the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5- 14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11, or 9-11. In some embodiments, the VL domain comprises about 1-10 amino acid substitutions relative to the amino acid sequence of SEQ ID NO:8. In some embodiments, the at least 1 amino acid substitution replaces only an LCDR1, an LCDR2, and/or an LCDR3 residue of SEQ ID NO:8. In particular embodiments, the at least 1 amino acid substitution replaces only a non-CDR residue (e.g., within a framework region) of SEQ ID NO:8. [00306] In some embodiments, a polypeptide comprises a VL domain that comprises at least 1 amino acid substitution relative to the amino acid sequence of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:91, SEQ ID NO:92, or any combination of the foregoing. For example, the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7- 12, 8-12, 8-11, or 9-11. In some embodiments, a VL domain comprises about 1-10 amino acid substitutions relative to the amino acid sequence of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:91, SEQ ID NO:92, or any combination of the foregoing. [00307] In some embodiments, the at least 1 amino acid substitution replaces only an LCDR1, an LCDR2, and/or an LCDR3 residue of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:91, SEQ ID NO:92, or any combination of the foregoing. In particular embodiments, the at least 1 amino acid substitution replaces only a non-CDR residue (e.g., within a framework region) of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:91, SEQ ID NO:92, or any combination of the foregoing. [00308] In some embodiments, a polypeptide comprises a VH domain that comprises the amino acid sequence of SEQ ID NO:3. In some embodiments, a polypeptide comprises a VH - 74 - 3839034.v1
5708.1076005 domain that comprises the amino acid sequence of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:89, or SEQ ID NO:90. [00309] In some embodiments, a polypeptide comprises a VL domain that comprises the amino acid sequence of SEQ ID NO:8. In some embodiments, a polypeptide comprises a VL domain that comprises SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:91, SEQ ID NO:92. [00310] In some embodiments, a polypeptide comprises a VL domain that comprises the amino acid sequence of SEQ ID NO:22. In some embodiments, a polypeptide comprises a VL domain that comprises SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:91, SEQ ID NO:92. [00311] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:8. [00312] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:3; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, or SEQ ID NO:20. [00313] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:8. [00314] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, or SEQ ID NO:20. - 75 - 3839034.v1
5708.1076005 [00315] In some embodiments, VH and VL domains may be linked together via a linker (e.g., a synthetic linker) to form various types of single-chain antibody designs in which the VH/VL domains pair intramolecularly, or intermolecularly in those cases when the VH and VL domains are expressed by separate chains, to form a monovalent antigen binding site. [00316] In some embodiments, a polypeptide comprises a VH domain that has at least about 70% sequence identity to one or more VH amino acid sequences set forth in Table 1 and Table 4 herein. In some embodiments, a polypeptide comprises a VH domain that has at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to one or more VH amino acid sequences set forth in Table 1 and Table 4 herein. In some embodiments, a polypeptide comprises a VH domain that has at least about 85% sequence identity to one or more VH amino acid sequences set forth in Table 1 and Table 4 herein. In some embodiments, a polypeptide comprises a VH domain that has at least about 90% sequence identity to one or more VH amino acid sequences set forth in Table 1 and Table 4 herein. [00317] In some embodiments, a polypeptide comprises a VH domain that comprises at least one amino acid substitution relative to one or more VH amino acid sequences set forth in Table 1 and Table 4 herein. For example, the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2- 17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11. In some embodiments, a polypeptide comprises a VH domain that comprises about 1-10 amino acid substitutions, relative to one or more VH amino acid sequences set forth in Table 1 and Table 4 herein. [00318] In some embodiments, an amino acid substitution is a conservative substitution. [00319] In some embodiments, an amino acid substitution is a highly conservative substitution. [00320] In some embodiments, a polypeptide comprises a VH domain that has 100% sequence identity to any one of VH amino acid sequences set forth in Table 1 and Table 4 herein. In some embodiments, a polypeptide comprises a VH domain that comprises any one of VH amino acid sequences set forth in Table 1 and Table 4 herein. [00321] In some embodiments, a polypeptide comprises a VL domain that has at least about 70% sequence identity to one or more VL amino acid sequences set forth in Table 2 and Table 4 herein. In some embodiments, a polypeptide comprises a VL that has at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, - 76 - 3839034.v1
5708.1076005 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to one or more VL amino acid sequences set forth in Table 2 and Table 4 herein. In some embodiments, a polypeptide comprises a VL domain that has at least about 85% sequence identity to one or more VL amino acid sequences set forth in Table 2 and Table 4 herein. In some embodiments, a polypeptide comprises a VL domain that has at least about 90% sequence identity to one or more VL amino acid sequences set forth in Table 2 and Table 4 herein. [00322] In some embodiments, a polypeptide comprises a VL domain that comprises at least one amino acid substitution relative to one or more VL amino acid sequences set forth in Table 2 and Table 4 herein. For example, the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2- 17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11. In some embodiments, a polypeptide comprises a VL domain that comprises about 1-10 amino acid substitutions, relative to one or more VL amino acid sequences set forth in Table 2 and Table 4 herein. [00323] In some embodiments, an amino acid substitution is a conservative substitution. [00324] In some embodiments, an amino acid substitution is a highly conservative substitution. [00325] In some embodiments, a polypeptide comprises a VL domain that has 100% sequence identity to any one of VL amino acid sequences set forth in Table 2 and Table 4 herein. In some embodiments, a polypeptide comprises a VL domain that comprises the amino acid sequence of any one of VL amino acid sequences set forth in Table 2 and Table 4 herein. [00326] In some embodiments, a polypeptide comprises: a) a VH domain that has at least about 70% (e.g., at least about: 75, 80, 85, 90, 95, 98, or 99%) sequence identity to one or more VH amino acid sequences set forth in Table 1 and Table 4 herein; b) a VL domain that has at least about 70% (e.g., at least about: 75, 80, 85, 90, 95, 98, or 99%) sequence identity to one or more VL amino acid sequences set forth in Table 2 and Table 4 herein; or both a) and b). [00327] In some embodiments, a polypeptide comprises: a) a VH domain that has at least about 70% (e.g., at least about: 75, 80, 85, 90, 95, 98, or 99%) sequence identity to one or more VH amino acid sequences set forth in Table 1 and Table 4 herein; and - 77 - 3839034.v1
5708.1076005 b) a VL domain that has at least about 70% (e.g., at least about: 75, 80, 85, 90, 95, 98, or 99%) sequence identity to one or more VL amino acid sequences set forth in Table 2 and Table 4 herein. [00328] In some embodiments, a polypeptide comprises: a) a VH domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) relative to one or more VH amino acid sequences set forth in Table 1 and Table 4 herein; b) a VL domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) relative to one or more VL amino acid sequences set forth in Table 2 and Table 4 herein; or both a) and b). [00329] In some embodiments, a polypeptide comprises: a) a VH domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) relative to one or more VH amino acid sequences set forth in Table 1 and Table 4 herein; and b) a VL domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) relative to one or more VL amino acid sequences set forth in Table 2 and Table 4 herein. [00330] In some embodiments, a polypeptide comprises: a) a VH domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a HCDR1, a HCDR2 and/or a HCDR3 residue, of any one or more VH amino acid sequences set forth in Table 1 and Table 4 herein; b) a VL domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a LCDR1, a LCDR2 and/or a LCDR3 residue, of any one or more VL amino acid sequences set forth in Table 2 and Table 4 herein; or both a) and b). [00331] In some embodiments, a polypeptide comprises: - 78 - 3839034.v1
5708.1076005 a) a VH domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a HCDR1, a HCDR2 and/or a HCDR3 residue, of any one or more VH amino acid sequences set forth in Table 1 and Table 4 herein; and b) a VL domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a LCDR1, a LCDR2 and/or a LCDR3 residue, of any one or more VL amino acid sequences set forth in Table 2 and Table 4 herein. [00332] In some embodiments, a polypeptide comprises: a) a VH domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of any one or more VH amino acid sequences set forth in Table 1 and Table 4 herein; b) a VL domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of any one or more VL amino acid sequences set forth in Table 2 and Table 4 herein; or both a) and b). [00333] In some embodiments, a polypeptide comprises: a) a VH domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of any one or more VH amino acid sequences set forth in Table 1 and Table 4 herein; and b) a VL domain that comprises at least one amino acid substitution (e.g., at least one conservative substitution such as highly conservative amino acid substitution) of a non-CDR residue (e.g., within a framework region), of any one or more VL amino acid sequences set forth in Table 2 and Table 4 herein. [00334] In some embodiments, a polypeptide comprises: a) a VH domain comprising any one of VH amino acid sequences set forth in Table 1 and Table 4 herein; and b) a VL domain comprising any one of VL amino acid sequences set forth in Table 2 and Table 4 herein. [00335] In some embodiments, a polypeptide comprises: - 79 - 3839034.v1
5708.1076005 a) a VH domain comprising any one of VH amino acid sequences set forth in Table 1 and Table 4 herein; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:8. [00336] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:3; and b) a VL domain comprising any one of VL amino acid sequences set forth in Table 2 and Table 4 herein. [00337] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:255; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:14. [00338] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:292; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:477. [00339] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:206; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:14. [00340] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:202; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:434. [00341] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:140; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:472. [00342] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:240; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:449. [00343] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:213; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:472. [00344] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:258; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:477. [00345] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:213; and - 80 - 3839034.v1
5708.1076005 b) a VL domain comprising the amino acid sequence of SEQ ID NO:477. [00346] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:5; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:512. [00347] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:158; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:469. [00348] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:213; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:452. [00349] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:232; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:469. [00350] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:140; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:449. [00351] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:213; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:484. [00352] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:204; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:455. [00353] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:213; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:461. [00354] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:137; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:426. [00355] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:240; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:424. [00356] In some embodiments, a polypeptide comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:130; and - 81 - 3839034.v1
5708.1076005 b) a VL domain comprising the amino acid sequence of SEQ ID NO:477. Paratopes [00357] Amino acid residues of a paratope contribute to an antibody’s interaction with an epitope of its target protein. An interaction can be a hydrogen bond, a salt bridge, a van der Waals interaction, an electrostatic interaction, a hydrophobic interaction, pi-interaction effects, an ionic bond, and/or any combination thereof. An interaction can be direct, or indirect, e.g., via a coordinated intermediate molecule, such as an ion or water. The residues of a paratope, in some embodiments, comprise only residues that are part of a defined CDR. In some embodiments, the residues of a paratope further comprise one or more residues that are not part of a defined CDR (e.g., residues within a defined framework region). [00358] In some embodiments, a paratope is oriented less than about 5.0 angstroms from an epitope on a target antigen when a polypeptide is bound to the target antigen, e.g., less than about: 4.5, 4.0, 3.5, 3.0, 2.5, 2.4, 2.3, 2.2, 2.1, 2.0, 1.9, 1.8, 1.7, 1.6, 1.5, 1.4, 1.3, 1.2, 1.1, 1.0, or 0.9 angstroms, or about: 0.9-5.0, 0.9-4.8.1.0-5, 1.0-4.5, 1.0-4.0, 1.0-3.5, 1.1-3.5, 1.1-3.0, 1.2-3.0, 1.2-2.5, 1.3-2.5, 1.3-2.4, 1.4-2.4, 1.4-2.3, 1.5-2.3, 1.5-2.2, 1.6-2.2, 1.6-2.1, 1.7-2.1, 1.7-2.0, or 1.8-2.0 angstroms, from the epitope. In some embodiments, less than all of the amino acid residues constituting a paratope (e.g., about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% of the amino acid residues) in the paratope are oriented less than about 5.0 angstroms from an epitope on a target antigen when a polypeptide is bound to the target antigen. [00359] In some embodiments, a polypeptide (e.g., an antibody or antigen-binding fragment thereof) comprising a paratope comprises a VH domain and a VL domain. In some embodiments, paratope residues are contained within a VH and VL of a polypeptide. [00360] In some embodiments, a polypeptide comprises a paratope that differs from a paratope of an antibody comprising a VH/VL combination of SEQ ID NO:3/SEQ ID NO:8. [00361] In some embodiments, a polypeptide comprises a VH domain that has at least about 70% sequence identity to the amino acid sequence of SEQ ID NO:3. For example, a VH can have at least about: 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO:3. In some embodiments, a VH has at least about 85% or at least about 90% sequence identity to the amino acid sequence of SEQ ID NO:3. The sequence identified as SEQ ID NO:3 is shown in Table 1, which corresponds to a human VH domain. - 82 - 3839034.v1
5708.1076005 [00362] In some embodiments, a polypeptide comprises a paratope that is substantially similar (e.g., having at least about 90% sequence identity) to a paratope of an antibody comprising a VH/VL combination of SEQ ID NO:3/SEQ ID NO:8. In some embodiments, a polypeptide comprises a paratope that is substantially similar (e.g., having at least about 90% sequence identity) to, and substantially preserves one or more functional properties of, a paratope of an antibody comprising a VH/VL combination of SEQ ID NO:3/SEQ ID NO:8. [00363] In some embodiments, a polypeptide comprises a paratope that has 100% sequence identity to a paratope of an antibody comprising a VH/VL combination of SEQ ID NO:3/SEQ ID NO:8. [00364] In some embodiments, a polypeptide comprises a paratope that differs from a paratope of an antibody comprising a VH/VL combination of SEQ ID NO:3/SEQ ID NO:8, by substitution (e.g., conservative substitution such as highly conservative substitution) of from 1 to 3 (e.g., 1, 2 or 3) residues. [00365] In some embodiments, a polypeptide comprises a paratope that differs from a paratope of a VH/VL combination selected from: SEQ ID NO:4/SEQ ID NO:9 (AB-1a), SEQ ID NO:4/SEQ ID NO:10 (AB-1b), SEQ ID NO:4/SEQ ID NO:11 (AB-1c), SEQ ID NO:4/SEQ ID NO:12 (AB-1d), SEQ ID NO:5/SEQ ID NO:13 (AB-2a), SEQ ID NO:5/SEQ ID NO:14 (AB- 2b), SEQ ID NO:5/SEQ ID NO:15 (AB-2c), SEQ ID NO:5/SEQ ID NO:16 (AB-2d), SEQ ID NO:6/SEQ ID NO:17 (AB-3a), SEQ ID NO:6/SEQ ID NO:18 (AB-3b), SEQ ID NO:6/SEQ ID NO:19 (AB-3c), or SEQ ID NO:6/SEQ ID NO:20 (AB-3d), by substitution (e.g., conservative such as highly conservative substitution) of from 1 to 3 (e.g., 1, 2 or 3) residues. See Table 1 for SEQ ID NOs:4-6 and Table 2 for SEQ ID NOs:9-20. [00366] In some embodiments, a polypeptide comprises a paratope that is substantially similar (e.g., having at least about 90% sequence identity) to a paratope of an antibody comprising a VH/VL pair selected from: SEQ ID NO:4 and SEQ ID NO:9 (AB-1a); SEQ ID NO:4 and SEQ ID NO:10 (AB-1b); SEQ ID NO:4 and SEQ ID NO:11 (AB-1c); SEQ ID NO:4 and SEQ ID NO:12 (AB-1d); SEQ ID NO:5 and SEQ ID NO:13 (AB-2a); SEQ ID NO:5 and SEQ ID NO:14 (AB-2b); SEQ ID NO:5 and SEQ ID NO:15 (AB-2c); SEQ ID NO:5 and SEQ ID NO:16 (AB-2d); - 83 - 3839034.v1
5708.1076005 SEQ ID NO:6 and SEQ ID NO:17 (AB-3a); SEQ ID NO:6 and SEQ ID NO:18 (AB-3b); SEQ ID NO:6 and SEQ ID NO:19 (AB-3c); SEQ ID NO:6 and SEQ ID NO:20 (AB-3d); or any combination thereof. [00367] In some embodiments, a polypeptide comprises a paratope that is substantially similar (e.g., having at least about 90% sequence identity) to, and substantially preserves one or more functional properties of, a paratope of an antibody comprising a VH/VL pair selected from: SEQ ID NO:4 and SEQ ID NO:9 (AB-1a); SEQ ID NO:4 and SEQ ID NO:10 (AB-1b); SEQ ID NO:4 and SEQ ID NO:11 (AB-1c); SEQ ID NO:4 and SEQ ID NO:12 (AB-1d); SEQ ID NO:5 and SEQ ID NO:13 (AB-2a); SEQ ID NO:5 and SEQ ID NO:14 (AB-2b); SEQ ID NO:5 and SEQ ID NO:15 (AB-2c); SEQ ID NO:5 and SEQ ID NO:16 (AB-2d); SEQ ID NO:6 and SEQ ID NO:17 (AB-3a); SEQ ID NO:6 and SEQ ID NO:18 (AB-3b); SEQ ID NO:6 and SEQ ID NO:19 (AB-3c); SEQ ID NO:6 and SEQ ID NO:20 (AB-3d); or any combination thereof. [00368] In some embodiments, a polypeptide comprises a paratope comprising only one or more conservative substitutions (e.g., only one or more highly conservative substitutions) relative a paratope of an antibody comprising a VH/VL pair selected from: SEQ ID NO:4 and SEQ ID NO:9 (AB-1a); SEQ ID NO:4 and SEQ ID NO:10 (AB-1b); SEQ ID NO:4 and SEQ ID NO:11 (AB-1c); SEQ ID NO:4 and SEQ ID NO:12 (AB-1d); SEQ ID NO:5 and SEQ ID NO:13 (AB-2a); SEQ ID NO:5 and SEQ ID NO:14 (AB-2b); SEQ ID NO:5 and SEQ ID NO:15 (AB-2c); SEQ ID NO:5 and SEQ ID NO:16 (AB-2d); SEQ ID NO:6 and SEQ ID NO:17 (AB-3a); - 84 - 3839034.v1
5708.1076005 SEQ ID NO:6 and SEQ ID NO:18 (AB-3b); SEQ ID NO:6 and SEQ ID NO:19 (AB-3c); SEQ ID NO:6 and SEQ ID NO:20 (AB-3d); or any combination thereof. [00369] In some embodiments, the disclosure provides a polypeptide that specifically binds SARS-CoV-2-Spike, wherein the polypeptide comprises a paratope that has 100% sequence identity to a paratope of an antibody comprising a VH/VL pair selected from: SEQ ID NO:4 and SEQ ID NO:9 (AB-1a); SEQ ID NO:4 and SEQ ID NO:10 (AB-1b); SEQ ID NO:4 and SEQ ID NO:11 (AB-1c); SEQ ID NO:4 and SEQ ID NO:12 (AB-1d); SEQ ID NO:5 and SEQ ID NO:13 (AB-2a); SEQ ID NO:5 and SEQ ID NO:14 (AB-2b); SEQ ID NO:5 and SEQ ID NO:15 (AB-2c); SEQ ID NO:5 and SEQ ID NO:16 (AB-2d); SEQ ID NO:6 and SEQ ID NO:17 (AB-3a); SEQ ID NO:6 and SEQ ID NO:18 (AB-3b); SEQ ID NO:6 and SEQ ID NO:19 (AB-3c); or SEQ ID NO:6 and SEQ ID NO:20 (AB-3d). [00370] In some embodiments, a polypeptide comprises a paratope that is substantially similar to a paratope of a polypeptide selected from any one of AB-1a, AB-1b, AB-1c, AB-1d, AB-2a, AB-2b, AB-2c, AB-2d, AB-3a, AB-3b, AB-3c, and AB-3d. In some embodiments, a polypeptide comprises a paratope comprising only conservative substitutions (e.g., only highly conservative substitutions) relative a paratope of a polypeptide selected from any one of AB-1a, AB-1b, AB- 1c, AB-1d, AB-2a, AB-2b, AB-2c, AB-2d, AB-3a, AB-3b, AB-3c, and AB-3d. In some embodiments, a polypeptide comprises a paratope comprising up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 conservative substitutions (e.g., up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 highly conservative substitutions), relative a paratope of a polypeptide selected from any one of AB-1a, AB-1b, AB-1c, AB-1d, AB-2a, AB-2b, AB-2c, AB-2d, AB-3a, AB-3b, AB- 3c, and AB-3d. In some embodiments, a polypeptide comprises a paratope having 100% sequence identity to a paratope of a polypeptide selected from any one of AB-1a, AB-1b, AB-1c, AB-1d, AB-2a, AB-2b, AB-2c, AB-2d, AB-3a, AB-3b, AB-3c, and AB-3d. - 85 - 3839034.v1
5708.1076005 [00371] In some embodiments, a polypeptide comprises a paratope that is substantially similar to a paratope of a VH/VL combination selected from: SEQ ID NO:4/SEQ ID NO:9 (AB-1a), SEQ ID NO:4/SEQ ID NO:10 (AB-1b), SEQ ID NO:4/SEQ ID NO:11 (AB-1c), SEQ ID NO:4/SEQ ID NO:12 (AB-1d), SEQ ID NO:5/SEQ ID NO:13 (AB-2a), SEQ ID NO:5/SEQ ID NO:14 (AB- 2b), SEQ ID NO:5/SEQ ID NO:15 (AB-2c), SEQ ID NO:5/SEQ ID NO:16 (AB-2d), SEQ ID NO:6/SEQ ID NO:17 (AB-3a), SEQ ID NO:6/SEQ ID NO:18 (AB-3b), SEQ ID NO:6/SEQ ID NO:19 (AB-3c), or SEQ ID NO:6/SEQ ID NO:20 (AB-3d). [00372] In some embodiments, a polypeptide comprises a paratope that is identical to a paratope of a VH/VL combination selected from: SEQ ID NO:4/SEQ ID NO:9 (AB-1a), SEQ ID NO:4/SEQ ID NO:10 (AB-1b), SEQ ID NO:4/SEQ ID NO:11 (AB-1c), SEQ ID NO:4/SEQ ID NO:12 (AB-1d), SEQ ID NO:5/SEQ ID NO:13 (AB-2a), SEQ ID NO:5/SEQ ID NO:14 (AB- 2b), SEQ ID NO:5/SEQ ID NO:15 (AB-2c), SEQ ID NO:5/SEQ ID NO:16 (AB-2d), SEQ ID NO:6/SEQ ID NO:17 (AB-3a), SEQ ID NO:6/SEQ ID NO:18 (AB-3b), SEQ ID NO:6/SEQ ID NO:19 (AB-3c), or SEQ ID NO:6/SEQ ID NO:20 (AB-3d). Consensus Sequences [00373] In some embodiments, a polypeptide (e.g., an antibody or antigen-binding fragment thereof) comprises a VH comprising the amino acid sequence of SEQ ID NO:2, wherein: X1 is not G; X2 is not I; X3 is not F; X4 is not N; X5 is not M; X6 is not S; X7 is not M; X8 is not N; X9 is not G; X10 is not N; X11 is not I; or any combination of the foregoing. [00374] The sequence identified as SEQ ID NO:2 is shown in Table 1, which is a consensus VH sequence for SEQ ID Nos:3-6 herein. [00375] In some embodiments: X1 is G or D; - 86 - 3839034.v1
5708.1076005 X2 is I, T or Y; X3 is F, S or D; X4 is N or D; X5 is M or L; X6 is S or F; X7 is M, Y or A; X8 is N or H; X9 is G or P; X10 is N or D; X11 is I or F; or any combination of the foregoing. [00376] In some embodiments: X1 is D; X2 is T or Y; X3 is S or D; X4 is D; X5 is L; X6 is F; X7 is Y or A; X8 is H; X9 is P; X10 is D; X11 is F; or any combination of the foregoing. [00377] In some embodiments, X1 is not G. In some embodiments, X1 is G or D. In some embodiments, X1 is G. In some embodiments, X1 is D. [00378] In some embodiments, X2 is not I. In some embodiments, X2 is I, T or Y. In some embodiments, X2 is T or Y. In some embodiments, X2 is I. In some embodiments, X2 is T. In some embodiments, X2 is Y. [00379] In some embodiments, X3 is not F. In some embodiments, X3 is F, S or D. In some embodiments, X3 is S or D. In some embodiments, X3 is F. In some embodiments, X3 is S. In some embodiments, X3 is D. - 87 - 3839034.v1
5708.1076005 [00380] In some embodiments, X4 is not N. In some embodiments, X4 is N or D. In some embodiments, X4 is N. In some embodiments, X4 is D. [00381] In some embodiments, X5 is not M. In some embodiments, X5 is M or L. In some embodiments, X5 is M. In some embodiments, X5 is L. [00382] In some embodiments, X6 is not S. In some embodiments, X6 is S or F. In some embodiments, X6 is S. In some embodiments, X6 is F. [00383] In some embodiments, X7 is not M. In some embodiments, X7 is M, Y or A. In some embodiments, X7 is Y or A. In some embodiments, X7 is M. In some embodiments, X7 is Y. In some embodiments, X7 is A. [00384] In some embodiments, X8 is not N. In some embodiments, X8 is N or H. In some embodiments, X8 is N. In some embodiments, X8 is H. [00385] In some embodiments, X9 is not G. In some embodiments, X9 is G or P. In some embodiments, X9 is G. In some embodiments, X9 is P. [00386] In some embodiments, X10 is not N. In some embodiments, X10 is N or D. In some embodiments, X10 is N. In some embodiments, X10 is D. [00387] In some embodiments, X11 is not I. In some embodiments, X11 is I or F. In some embodiments, X11 is I. In some embodiments, X11 is F. [00388] In some embodiments, a polypeptide (e.g., an antibody or antigen-binding fragment thereof) comprises a VL comprising the amino acid sequence of SEQ ID NO:7, wherein: X12 is not N; X13 is not D; X14 is not C; X15 is not N; X16 is not S; X17 is not L; X18 is not S; X19 is not G; X20 is not N; or any combination of the foregoing. [00389] The sequence identified as SEQ ID NO:7 is shown in Table 2, which is a consensus VL sequence for SEQ ID Nos:8-20 herein. [00390] In some embodiments: X12 is N or S; - 88 - 3839034.v1
5708.1076005 X13 is D or R; X14 is C, A, S, or Y; X15 is N or R; X16 is S or D; X17 is L or S; X18 is S or F; X19 is G or D; X20 is N or H; or any combination of the foregoing. [00391] In some embodiments: X12 is S; X13 is R; X14 is A, S, or Y; X15 is R; X16 is D; X17 is S; X18 is F; X19 is D; X20 is H; or any combination of the foregoing. [00392] In some embodiments, X12 is not N. In some embodiments, X12 is N or S. In some embodiments, X12 is N. In some embodiments, X12 is S. [00393] In some embodiments, X13 is not D. In some embodiments, X13 is D or R. In some embodiments, X13 is D. In some embodiments, X13 is R. [00394] In some embodiments, X14 is not C. In some embodiments, X14 is C, A, S, or Y. In some embodiments, X14 is A, S, or Y. In some embodiments, X14 is C. In some embodiments, X14 is A. In some embodiments, X14 is S. In some embodiments, X14 is Y. [00395] In some embodiments, X15 is not N. In some embodiments, X15 is N or R. In some embodiments, X15 is N. In some embodiments, X15 is R. [00396] In some embodiments, X16 is not S. In some embodiments, X16 is S or D. In some embodiments, X16 is S. In some embodiments, X16 is D. [00397] In some embodiments, X17 is not L. In some embodiments, X17 is L or S. In some embodiments, X17 is L. In some embodiments, X17 is S. - 89 - 3839034.v1
5708.1076005 [00398] In some embodiments, X18 is not S. In some embodiments, X18 is S or F. In some embodiments, X18 is S. In some embodiments, X18 is F. [00399] In some embodiments, X19 is not G. In some embodiments, X19 is G or D. In some embodiments, X19 is G. In some embodiments, X19 is D. [00400] In some embodiments, X20 is not N. In some embodiments, X20 is N or H. In some embodiments, X20 is N. In some embodiments, X20 is H. [00401] In some embodiments, a) X1 is G, X2 is Y, X3 is D, X4 is N, X5 is L, X6 is F, X7 is A, X8 is H, X9 is P, X10 is D, X11 is F, X12 is S, X13 is D, X14 is C, X15 is R, X16 is D, X17 is S, X18 is S, X19 is G, X20 is H, or a combination thereof (AB-1a); b) X1 is G, X2 is Y, X3 is D, X4 is N, X5 is L, X6 is F, X7 is A, X8 is H, X9 is P, X10 is D, X11 is F, X12 is S, X13 is D, X14 is A, X15 is R, X16 is D, X17 is S, X18 is S, X19 is G, X20 is H, or a combination thereof (AB-1b); c) X1 is G, X2 is Y, X3 is D, X4 is N, X5 is L, X6 is F, X7 is A, X8 is H, X9 is P, X10 is D, X11 is F, X12 is S, X13 is D, X14 is S, X15 is R, X16 is D, X17 is S, X18 is S, X19 is G, X20 is H, or a combination thereof (AB-1c); d) X1 is G, X2 is Y, X3 is D, X4 is N, X5 is L, X6 is F, X7 is A, X8 is H, X9 is P, X10 is D, X11 is F, X12 is S, X13 is D, X14 is Y, X15 is R, X16 is D, X17 is S, X18 is S, X19 is G, X20 is H, or a combination thereof (AB-1d); e) X1 is D, X2 is T, X3 is S, X4 is D, X5 is L, X6 is S, X7 is Y, X8 is N, X9 is G, X10 is D, X11 is F, X12 is S, X13 is R, X14 is C, X15 is R, X16 is S, X17 is L, X18 is F, X19 is D, X20 is H, or a combination thereof (AB-2a); f) X1 is D, X2 is T, X3 is S, X4 is D, X5 is L, X6 is S, X7 is Y, X8 is N, X9 is G, X10 is D, X11 is F, X12 is S, X13 is R, X14 is A, X15 is R, X16 is S, X17 is L, X18 is F, X19 is D, X20 is H, or a combination thereof (AB-2b); g) X1 is D, X2 is T, X3 is S, X4 is D, X5 is L, X6 is S, X7 is Y, X8 is N, X9 is G, X10 is D, X11 is F, X12 is S, X13 is R, X14 is S, X15 is R, X16 is S, X17 is L, X18 is F, X19 is D, X20 is H, or a combination thereof (AB-2c); h) X1 is D, X2 is T, X3 is S, X4 is D, X5 is L, X6 is S, X7 is Y, X8 is N, X9 is G, X10 is D, X11 is F, X12 is S, X13 is R, X14 is Y, X15 is R, X16 is S, X17 is L, X18 is F, X19 is D, X20 is H, or a combination thereof (AB-2d); - 90 - 3839034.v1
5708.1076005 i) X1 is D, X2 is T, X3 is S, X4 is D, X5 is M, X6 is S, X7 is Y, X8 is N, X9 is G, X10 is D, X11 is F, X12 is S, X13 is D, X14 is C, X15 is R, X16 is S, X17 is L, X18 is S, X19 is D, X20 is H, or a combination thereof (AB-3a); j) X1 is D, X2 is T, X3 is S, X4 is D, X5 is M, X6 is S, X7 is Y, X8 is N, X9 is G, X10 is D, X11 is F, X12 is S, X13 is D, X14 is A, X15 is R, X16 is S, X17 is L, X18 is S, X19 is D, X20 is H, or a combination thereof (AB-3b); k) X1 is D, X2 is T, X3 is S, X4 is D, X5 is M, X6 is S, X7 is Y, X8 is N, X9 is G, X10 is D, X11 is F, X12 is S, X13 is D, X14 is S, X15 is R, X16 is S, X17 is L, X18 is S, X19 is D, X20 is H, or a combination thereof (AB-3c); or l) X1 is D, X2 is T, X3 is S, X4 is D, X5 is M, X6 is S, X7 is Y, X8 is N, X9 is G, X10 is D, X11 is F, X12 is S, X13 is D, X14 is Y, X15 is R, X16 is S, X17 is L, X18 is S, X19 is D, X20 is H, or a combination thereof (AB-3d). [00402] In some embodiments, X1 is D, X2 is T, X3 is S, X4 is D, X5 is L, X6 is S, X7 is Y, X8 is N, X9 is G, X10 is D, X11 is F, X12 is S, X13 is R, X14 is A, X15 is R, X16 is S, X17 is L, X18 is F, X19 is D, X20 is H, or a combination thereof (AB-2b). Constant Domains [00403] In some embodiments, a polypeptide (e.g., an antibody or antigen-binding fragment thereof) comprises: a) an antibody heavy chain constant domain sequence; b) an antibody light chain constant domain sequence; or c) both an antibody heavy chain constant domain sequence and an antibody light chain constant domain sequence. [00404] In some embodiments, a polypeptide comprises an antibody heavy chain constant domain sequence. In some embodiments, an antibody heavy chain constant domain is selected from the group consisting of an IgA constant domain, an IgD constant domain, an IgE constant domain, an IgG constant domain, and an IgM constant domain. [00405] In some embodiments, an IgG constant domain is an IgG1 constant domain (e.g., SEQ ID NO:576 or SEQ ID NO:50), an IgG2 constant domain, an IgG3 constant domain, or an IgG4 constant domain. In some embodiments, the IgG2 constant domain is an IgG2a constant domain, an IgG2b constant domain or an IgG2c constant domain. In some embodiments, the IgA constant domain is an IgA1 constant domain or an IgA2 constant domain. In some embodiments, the antibody heavy chain constant domain is an IgG1 constant domain (e.g., IGHV1-5 or IGHV5-51). - 91 - 3839034.v1
5708.1076005 [00406] ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF PAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCP APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL YSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO:576). [00407] In some embodiments, a polypeptide comprises an antibody heavy chain constant domain sequence that has at least about 60% sequence identity to the amino acid sequence of SEQ ID NO:576. For example, a polypeptide can comprise an antibody heavy chain constant domain sequence that has at least about: 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO:576. In some embodiments, a polypeptide comprises an antibody heavy chain constant domain sequence that has at least about 70% or at least about 80% sequence identity to the amino acid sequence of SEQ ID NO:576. [00408] In some embodiments, a polypeptide comprises an antibody heavy chain constant domain sequence that comprises at least one amino acid substitution relative to the amino acid sequence of SEQ ID NO:576. For example, the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11. In some embodiments, a polypeptide comprises an antibody heavy chain constant domain sequence that comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of SEQ ID NO:576. [00409] In some embodiments, a polypeptide comprises an antibody heavy chain constant domain sequence that has 100% sequence identity to the amino acid sequence of SEQ ID NO:576. [00410] ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF PAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCP APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLY SKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:50). - 92 - 3839034.v1
5708.1076005 [00411] In some embodiments, a polypeptide comprises an antibody heavy chain constant domain sequence that has at least about 60% sequence identity to the amino acid sequence of SEQ ID NO:50. For example, a polypeptide can comprise an antibody heavy chain constant domain sequence that has at least about: 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO:50. In some embodiments, a polypeptide comprises an antibody heavy chain constant domain sequence that has at least about 70% or at least about 80% sequence identity to the amino acid sequence of SEQ ID NO:50. [00412] In some embodiments, a polypeptide comprises an antibody heavy chain constant domain sequence that comprises at least one amino acid substitution relative to the amino acid sequence of SEQ ID NO:50. For example, the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11. In some embodiments, a polypeptide comprises an antibody heavy chain constant domain sequence that comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of SEQ ID NO:50. [00413] In some embodiments, a polypeptide comprises an antibody heavy chain constant domain sequence that has 100% sequence identity to the amino acid sequence of SEQ ID NO:50. [00414] In some embodiments, a polypeptide comprises an Fc polypeptide, or Fc domain (e.g., an IgG1 domain, an IgG2 domain or an IgG4 domain). In some embodiments, an Fc domain comprises one or more mutations that, for example, decreases (e.g., inhibits, ablates) an effector function of the Fc domain, increases half-life of an antibody or antibody fragment that comprises the Fc domain, or a combination thereof. See, e.g., Dumet et al., Insights into the IgG heavy chain engineering patent landscape as applied to IgG4 antibody development, Mabs. 11(8):1341-50 (2019) (particularly Tables 1 and 2 therein) and WO02060919, the contents of which are incorporated by reference herein in their entirety. In some embodiments, an Fc domain comprises a LS modification (i.e., M428L/N434S substitutions with numbering determined by Kabat) or a YTE modification (i.e., M252Y/S254T/T256E substitutions as determined by Kabat numbering). In some embodiments, an Fc domain comprises a LS modification. [00415] In some embodiments, a polypeptide (e.g., an antibody or antigen-binding fragment thereof) comprises an antibody light chain constant domain sequence. - 93 - 3839034.v1
5708.1076005 [00416] In some embodiments, a polypeptide comprises an antibody light chain constant domain sequence that is a λ constant domain (e.g., SEQ ID NO:577 or SEQ ID NO:52). [00417] GQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAG VETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO:577). [00418] GQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAG VETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO:52). [00419] In some embodiments, a polypeptide comprises an antibody light chain constant domain sequence that has at least about 60% sequence identity to the amino acid sequence of SEQ ID NO:557 or SEQ ID NO:52. For example, a polypeptide can comprise an antibody light chain constant domain sequence that has at least about: 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of SEQ ID NO:557 or SEQ ID NO:52. In some embodiments, a polypeptide comprises an antibody light chain constant domain sequence that has at least about 70% or at least about 80% sequence identity to SEQ ID NO:557 or SEQ ID NO:52. [00420] In some embodiments, a polypeptide comprises an antibody light chain constant domain sequence that comprises at least one amino acid substitution relative to the amino acid sequence of SEQ ID NO:557 or SEQ ID NO:52. For example, the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7- 12, 8-12, 8-11 or 9-11. In some embodiments, a polypeptide comprises an antibody light chain constant domain sequence that comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of SEQ ID NO:557 or SEQ ID NO:52. In some embodiments, the at least one amino acid substitution is a conservative substitution. In some embodiments, the at least one amino acid substitution is a highly conservative substitution. [00421] In some embodiments, a polypeptide comprises an antibody light chain constant domain sequence that has 100% sequence identity to the amino acid sequence of SEQ ID NO:557 or SEQ ID NO:52. [00422] In some embodiments, a polypeptide comprises an antibody light chain constant domain sequence that has at least about 60% sequence identity to the amino acid sequence of - 94 - 3839034.v1
5708.1076005 SEQ ID NO:557. For example, a polypeptide can comprise an antibody light chain constant domain sequence that has at least about: 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of SEQ ID NO:557. In some embodiments, a polypeptide comprises an antibody light chain constant domain sequence that has at least about 70% or at least about 80% sequence identity to SEQ ID NO:557. [00423] In some embodiments, a polypeptide comprises an antibody light chain constant domain sequence that comprises at least one amino acid substitution relative to the amino acid sequence of SEQ ID NO:557. For example, the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11. In some embodiments, a polypeptide comprises an antibody light chain constant domain sequence that comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of SEQ ID NO:557. In some embodiments, the at least one amino acid substitution is a conservative substitution. In some embodiments, the at least one amino acid substitution is a highly conservative substitution. [00424] In some embodiments, a polypeptide comprises an antibody light chain constant domain sequence that has 100% sequence identity to the amino acid sequence of SEQ ID NO:557. [00425] In some embodiments, a polypeptide comprises an antibody light chain constant domain sequence that is a κ constant domain (e.g., SEQ ID NO:51). [00426] RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:51). [00427] In some embodiments, a polypeptide comprises an antibody light chain constant domain sequence that has at least about 60% sequence identity to the amino acid sequence of SEQ ID NO:557, SEQ ID NO:52, or SEQ ID NO:51. For example, a polypeptide can comprise an antibody light chain constant domain sequence that has at least about: 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of SEQ ID NO:557, SEQ ID NO:52, or SEQ ID NO:51. In some embodiments, a polypeptide comprises an antibody light - 95 - 3839034.v1
5708.1076005 chain constant domain sequence that has at least about 70% or at least about 80% sequence identity to SEQ ID NO:557, SEQ ID NO:52, or SEQ ID NO:51. [00428] In some embodiments, a polypeptide comprises an antibody light chain constant domain sequence that comprises at least one amino acid substitution relative to the amino acid sequence of SEQ ID NO:557, SEQ ID NO:52, or SEQ ID NO:51. For example, the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6- 13, 7-13, 7-12, 8-12, 8-11 or 9-11. In some embodiments, a polypeptide comprises an antibody light chain constant domain sequence that comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of SEQ ID NO:557, SEQ ID NO:52, or SEQ ID NO:51. In some embodiments, the at least one amino acid substitution is a conservative substitution. In some embodiments, the at least one amino acid substitution is a highly conservative substitution. [00429] In some embodiments, a polypeptide comprises an antibody light chain constant domain sequence that has 100% sequence identity to the amino acid sequence of SEQ ID NO:557, SEQ ID NO:52, or SEQ ID NO:51. [00430] In some embodiments, a polypeptide comprises: a) an antibody heavy chain constant domain sequence; and b) an antibody light chain constant domain sequence. [00431] In some embodiments, a polypeptide comprises an antibody heavy chain constant domain that is an IgG1 constant domain (e.g., SEQ ID NO:576 or SEQ ID NO:50), and an antibody light chain constant domain that is a λ constant domain (e.g., SEQ ID NO:577 or SEQ ID NO:52). [00432] In some embodiments, a polypeptide comprises: a) an antibody heavy chain constant domain comprising SEQ ID NO:576; b) an antibody light chain constant domain comprising SEQ ID NO:577; or both a) and b). [00433] In some embodiments, a polypeptide comprises: a) an antibody heavy chain constant domain comprising SEQ ID NO:576; and b) an antibody light chain constant domain comprising SEQ ID NO:577. [00434] In some embodiments, a polypeptide comprises: a) an antibody heavy chain constant domain comprising SEQ ID NO:50; b) an antibody light chain constant domain comprising SEQ ID NO:577; or both a) and b). - 96 - 3839034.v1
5708.1076005 [00435] In some embodiments, a polypeptide comprises: a) an antibody heavy chain constant domain comprising SEQ ID NO:50; and [00436] an antibody light chain constant domain comprising SEQ ID NO:577. [00437] In some embodiments, a polypeptide comprises: a) an antibody heavy chain constant domain comprising SEQ ID NO:576; b) an antibody light chain constant domain comprising SEQ ID NO:52; or both a) and b). [00438] In some embodiments, a polypeptide comprises: a) an antibody heavy chain constant domain comprising SEQ ID NO:576; and b) an antibody light chain constant domain comprising SEQ ID NO:52. Antibodies and Antigen Binding Fragments [00439] In some embodiments, a polypeptide specifically binds a spike receptor-binding domain (RBD) class 4 epitope of a betacoronavirus Spike glycoprotein (SARS-CoV-2-Spike). [00440] In some embodiments, a polypeptide is an immunoglobulin molecule, such as an antibody (e.g., a whole antibody, an intact antibody) or an antigen-binding fragment of an antibody. [00441] In some embodiments, a polypeptide is an antibody. As used herein, the term “antibody” refers to an immunoglobulin molecule capable of specific binding to a target, such as a carbohydrate, polynucleotide, lipid, polypeptide, etc., through at least one antigen recognition site, located in the variable domain of the immunoglobulin molecule. As used herein, the term “antibody” refers to a full-length antibody. [00442] In some embodiments, a polypeptide is an antibody comprising two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds or multimers thereof (for example, IgM). Each heavy chain comprises a VH and a heavy chain constant domain (comprising domains CH1, hinge CH2 and CH3). Each light chain comprises a VL and a light chain constant domain (CL). VH and VL regions may be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed within framework regions (FRs). VH and VL each comprises three CDRs and four FRs, arranged from the amino-terminus to the carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. An antibody can be of any species, such as a murine antibody, a human antibody, or a humanized antibody. [00443] In some embodiments, a polypeptide comprises a heavy chain amino acid sequence that has at least about 60% sequence identity to the amino acid sequence of any one or more of - 97 - 3839034.v1
5708.1076005 SEQ ID NOs:578-591. For example, a polypeptide can comprise a heavy chain amino acid sequence that has at least about: 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:578-591. In some embodiments, a polypeptide comprises a heavy chain amino acid sequence that has at least about 70% or at least about 80% sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:578-591. [00444] QVQLVQSGAEVKKPGSSVKVSCKASGDTSDTYTISWVRQAPGQGLEWMGRI ILLSGYANYAQKIQGRVTITADKSTSTAYMELTSLRSDDTAVYYCARGFNGDYYGWGD DDAFDFWGQGTLVTVYSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO:578). [00445] QVQLVQSGAEVKKPGSSVKVSCKASGDTSDTYTISWVRQAPGQGLEWMGRI ILLPGYANYAQKIQGRVTITADKSTSTAYMELTSLRSDDTAVYYCARGFNRDYYGWGD DDAFDFWGQGTLVTVYSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO:579). [00446] QVQLVQSGAEVKKPGSSVKVSCKASGDTEDTYTISWVRQAPGQGLEWMGRI ILLSGYANYAQKIQGRVTITADKSTSTAYMELTSLRSDDTAVYYCARGFNGDYYGWGD DDAFDFWGQGTLVTVYSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP - 98 - 3839034.v1
5708.1076005 VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO:580). [00447] QVQLVQSGAEVKKPGSSVKVSCKASGDTSDTYTISWVRQAPGQGLEWMGRI ILLSGYGNYAQKIQGRVTITADKSTSTAYMELTSLRSDDTAVYYCARGFNPDYYGWGD DDAFDFWGQGTLVTVYSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO:581). [00448] QVQLVQSGAEVKKPGSSVKVSCKASGDYSDVYTISWVRQAPGQGLEWMGRI ILLLGYANYAQKIQGRVTITADKSTSTAYMELTSLRSDDTAVYYCARGFNGDYYGWGD DDAFDFWGQGTLVTVYSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO:582). [00449] QVQLVQSGAEVKKPGSSVKVSCKASGDTSDTYTISWVRQAPGQGLEWMGRI ILLSGYTNYAQKIQGRVTITADKSTSTAYMELTSLRSDDTAVYYCARGFNPDYYGWGD DDAFDFWGQGTLVTVYSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO:583). [00450] QVQLVQSGAEVKKPGSSVKVSCKASGDTSDTYTISWVRQAPGQGLEWMGRI ILLSGYSNYAQKIQGRVTITADKSTSTAYMELTSLRSDDTAVYYCARGFNPDYYGWGD DDAFDFWGQGTLVTVYSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKS - 99 - 3839034.v1
5708.1076005 CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO:584). [00451] QVQLVQSGAEVKKPGSSVKVSCKASGDTSDTYTISWVRQAPGQGLEWMGRI ILLSGYANYAQKIQGRVTITADKSTSTAYMELTSLRSDDTAVYYCARGFNPDYYGWGD DDAFDFWGQGTLVTVYSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO:585). [00452] QVQLVQSGAEVKKPGSSVKVSCKASGDTSDTYTISWVRQAPGQGLEWMGRI ILLSDYTNYAQKIQGRVTITADKSTSTAYMELTSLRSDDTAVYYCARGFNPDYYGWGD DDAFDFWGQGTLVTVYSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO:586). [00453] QVQLVQSGAEVKKPGSSVKVSCKASGDTSDTYTISWVRQAPGQGLEWMGRI ILLSGYTNYAQKIQGRVTITADKSTSTAYMELTSLRSDDTAVYYCARGFNEDYYGWGD DDAFDFWGQGTLVTVYSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO:587). - 100 - 3839034.v1
5708.1076005 [00454] QVQLVQSGAEVKKPGSSVKVSCKASGDTSDIYTISWVRQAPGQGLEWMGRII LLSGYTNYAQKIQGRVTITADKSTSTAYMELTSLRSDDTAVYYCARGFNGDYYGWGDD DAFDFWGQGTLVTVYSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSC DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO:588). [00455] QVQLVQSGAEVKKPGSSVKVSCKASGDTSDTYTISWVRQAPGQGLEWMGRI ILLSGYVNYAQKIQGRVTITADKSTSTAYMELTSLRSDDTAVYYCARGFNPDYYGWGD DDAFDFWGQGTLVTVYSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO:589). [00456] QVQLVQSGAEVKKPGSSVKVSCKASGDTSDTYTISWVRQAPGQGLEWMGRI ILLSGYANYAQKIQGRVTITADKSTSTAYMELTSLRSDDTAVYYCARGFNYDYYGWGD DDAFDFWGQGTLVTVYSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO:590). [00457] QVQLVQSGAEVKKPGSSVKVSCKASGDTSDTYTISWVRQAPGQGLEWMGRI ILLSGYGNYAQKIQGRVTITADKSTSTAYMELTSLRSDDTAVYYCARGFNGDYYGWGD DDAFDFWGQGTLVTVYSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS - 101 - 3839034.v1
5708.1076005 KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO:591). [00458] In some embodiments, a polypeptide comprises a heavy chain amino acid sequence that comprises at least one amino acid substitution relative to the amino acid sequence of any one or more of SEQ ID NOs:578-591. For example, the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11. In some embodiments, a polypeptide comprises a heavy chain amino acid sequence that comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of any one or more of SEQ ID NOs:578-591. [00459] In some embodiments, a polypeptide comprises a heavy chain amino acid sequence that has 100% sequence identity to the amino acid sequence of any one of SEQ ID NOs:578-591. [00460] In some embodiments, a polypeptide comprises a heavy chain amino acid sequence that has at least about 60% sequence identity to the amino acid sequence of SEQ ID NO:578. For example, a polypeptide can comprise a heavy chain amino acid sequence that has at least about: 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of SEQ ID NO:578. In some embodiments, a polypeptide comprises a heavy chain amino acid sequence that has at least about 70% or at least about 80% sequence identity to the amino acid sequence of SEQ ID NO:578. [00461] In some embodiments, a polypeptide comprises a heavy chain amino acid sequence that comprises at least one amino acid substitution relative to the amino acid sequence of SEQ ID NO:578. For example, the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11. In some embodiments, a polypeptide comprises a heavy chain amino acid sequence that comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of SEQ ID NO:578. [00462] In some embodiments, a polypeptide comprises a heavy chain amino acid sequence that has 100% sequence identity to the amino acid sequence of SEQ ID NO:578. [00463] In some embodiments, a polypeptide comprises a heavy chain amino acid sequence that has at least about 60% sequence identity to the amino acid sequence of SEQ ID NO:579. For - 102 - 3839034.v1
5708.1076005 example, a polypeptide can comprise a heavy chain amino acid sequence that has at least about: 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of SEQ ID NO:579. In some embodiments, a polypeptide comprises a heavy chain amino acid sequence that has at least about 70% or at least about 80% sequence identity to the amino acid sequence of SEQ ID NO:579. [00464] In some embodiments, a polypeptide comprises a heavy chain amino acid sequence that comprises at least one amino acid substitution relative to the amino acid sequence of SEQ ID NO:579. For example, the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11. In some embodiments, a polypeptide comprises a heavy chain amino acid sequence that comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of SEQ ID NO:579. [00465] In some embodiments, a polypeptide comprises a heavy chain amino acid sequence that has 100% sequence identity to the amino acid sequence of SEQ ID NO:579. [00466] In some embodiments, a polypeptide comprises a light chain amino acid sequence that has at least about 60% sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:592-603. For example, a polypeptide can comprise a light chain amino acid sequence that has at least about: 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:592-603. In some embodiments, a polypeptide comprises a light chain amino acid sequence that has at least about 70% or at least about 80% sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:592-603. [00467] QTVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYRVHWYQQLPGTAPKLLIAGR SNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLFDPHWVFGGGTKLTV LGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPS KQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO:592). [00468] QTVLTQPPSVSGAPGQRVTISCTGSESNIGAGYRVHWYQQLPGTAPKLLIAGR SNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLFDPHWVFGGGTKLTV - 103 - 3839034.v1
5708.1076005 LGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPS KQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO:593). [00469] QTVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYYVHWYQQLPGTAPKLLIAGR SNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLFDPHWVFGGGTKLTV LGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPS KQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO:594). [00470] QTVLTQPPSVSGAPGQRVTISCTGSESNIGAGYDVHWYQQLPGTAPKLLIAGR SNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLFDPHWVFGGGTKLTV LGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPS KQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO:595). [00471] QTVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIAGR SNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSYFDPHWVFGGGTKLTV LGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPS KQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO:596). [00472] QTVLTQPPSVSGAPGQRVTISCTGSVSNIGAGYDVHWYQQLPGTAPKLLIAG RSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLFDPHWVFGGGTKLT VLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTT PSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO:597). [00473] QTVLTQPPSVSGAPGQRVTISCTGSPSNIGAGYRVHWYQQLPGTAPKLLIAGR SNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLFDPHWVFGGGTKLTV LGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPS KQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO:598). [00474] QTVLTQPPSVSGAPGQRVTISCTGSVSNIGAGYRVHWYQQLPGTAPKLLIAGS SNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLFDPHWVFGGGTKLTV LGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPS KQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO:599). [00475] QTVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIAGR SNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSSFDPHWVFGGGTKLTV LGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPS KQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO:600). [00476] QTVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYRVHWYQQLPGTAPKLLIAGR SNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSYFDPHWVFGGGTKLTV - 104 - 3839034.v1
5708.1076005 LGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPS KQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO:601). [00477] QTVLTQPPSVSGAPGQRVTISCTGSVSNIGAGYRVHWYQQLPGTAPKLLIAGR SNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLFDPHWVFGGGTKLTV LGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPS KQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO:602). [00478] QTVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIAGR SNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLFDPHWVFGGGTKLTV LGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPS KQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO:603). [00479] QTVLTQPPSVSGAPGQRVTISCTGSESNIGAGYRVHWYQQLPGTAPKLLIAGR SNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLFDPHWVFGGGTKLTV LGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPS KQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO:603). [00480] In some embodiments, a polypeptide comprises a light chain amino acid sequence that comprises at least one amino acid substitution relative to the amino acid sequence of any one or more of SEQ ID NOs:592-603. For example, the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11. In some embodiments, a polypeptide comprises a light chain amino acid sequence that comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of any one or more of SEQ ID NOs:592-603. [00481] In some embodiments, a polypeptide comprises a light chain amino acid sequence that has 100% sequence identity to the amino acid sequence of any one of SEQ ID NOs:592-603. [00482] In some embodiments, a polypeptide comprises a light chain amino acid sequence that has at least about 60% sequence identity to the amino acid sequence of SEQ ID NO:592. For example, a polypeptide can comprise a light chain amino acid sequence that has at least about: 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of SEQ ID NO:592. In some embodiments, a polypeptide comprises a light chain amino acid sequence - 105 - 3839034.v1
5708.1076005 that has at least about 70% or at least about 80% sequence identity to the amino acid sequence of SEQ ID NO:592. [00483] In some embodiments, a polypeptide comprises a light chain amino acid sequence that comprises at least one amino acid substitution relative to the amino acid sequence of SEQ ID NO:592. For example, the number of amino acid substitutions can be at least about: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or about: 1-20, 1-19, 2-19, 2-18, 2-17, 3-17, 3-16, 4-16, 4-15, 5-15, 5-14, 6-14, 6-13, 7-13, 7-12, 8-12, 8-11 or 9-11. In some embodiments, a polypeptide comprises a light chain amino acid sequence that comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of SEQ ID NO:592. [00484] In some embodiments, a polypeptide comprises a light chain amino acid sequence that has 100% sequence identity to the amino acid sequence of SEQ ID NO:592. [00485] In some embodiments, a polypeptide comprises: a) a heavy chain amino acid sequence that has at least about 60% sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:578-591; or b) a light chain amino acid sequence that has at least about 60% sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:592-603; or both a) and b). [00486] In some embodiments, a polypeptide comprises: a) a heavy chain amino acid sequence that has at least about 60% sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:578-591; and b) a light chain amino acid sequence that has at least about 60% sequence identity to the amino acid sequence of any one or more of SEQ ID NOs:592-603. [00487] In some embodiments, a polypeptide comprises: a) a heavy chain amino acid sequence comprising at least one amino acid substitution relative to the amino acid sequence of any one or more of SEQ ID NOs:578-591; or b) a light chain amino acid sequence comprising at least one amino acid substitution relative to the amino acid sequence of any one or more of SEQ ID NOs:592-603; or both a) and b). [00488] In some embodiments, a polypeptide comprises: - 106 - 3839034.v1
5708.1076005 a) a heavy chain amino acid sequence comprising at least one amino acid substitution relative to the amino acid sequence of any one or more of SEQ ID NOs:578-591; and b) a light chain amino acid sequence comprising at least one amino acid substitution relative to the amino acid sequence of any one or more of SEQ ID NOs:592-603. [00489] In some embodiments, a polypeptide comprises: a) a heavy chain amino acid sequence comprising about 1-10 amino acid substitutions, relative to the amino acid sequence of any one or more of SEQ ID NOs:578-591; or b) a light chain amino acid sequence comprising about 1-10 amino acid substitutions, relative to the amino acid sequence of any one or more of SEQ ID NOs:592-603; or both a) and b). [00490] In some embodiments, a polypeptide comprises: a) a heavy chain amino acid sequence comprising about 1-10 amino acid substitutions, relative to the amino acid sequence of any one or more of SEQ ID NOs:578-591; and b) a light chain amino acid sequence comprising about 1-10 amino acid substitutions, relative to the amino acid sequence of any one or more of SEQ ID NOs:592-603. [00491] In some embodiments, a polypeptide comprises: a) a heavy chain amino acid sequence that has 100% sequence identity to the amino acid sequence of any one of SEQ ID NOs:578-591; or b) a light chain amino acid sequence that has 100% sequence identity to the amino acid sequence of any one of SEQ ID NOs:592-603; or both a) and b). [00492] In some embodiments, a polypeptide comprises: a) a heavy chain amino acid sequence that has 100% sequence identity to the amino acid sequence of any one of SEQ ID NOs:578-591; and b) a light chain amino acid sequence that has 100% sequence identity to the amino acid sequence of any one of SEQ ID NOs:592-603. - 107 - 3839034.v1
5708.1076005 [00493] In some embodiments, a polypeptide comprises: a) a heavy chain amino acid sequence that has at least about 60% sequence identity to the amino acid sequence of SEQ ID NO:578; or b) a light chain amino acid sequence that has at least about 60% sequence identity to the amino acid sequence of SEQ ID NO:592; or both a) and b). [00494] In some embodiments, a polypeptide comprises: a) a heavy chain amino acid sequence that has at least about 60% sequence identity to the amino acid sequence of SEQ ID NO:578; and b) a light chain amino acid sequence that has at least about 60% sequence identity to the amino acid sequence of SEQ ID NO:592. [00495] In some embodiments, a polypeptide comprises: a) a heavy chain amino acid sequence comprising at least one amino acid substitution relative to the amino acid sequence of SEQ ID NO:578; or b) a light chain amino acid sequence comprising about 1-10 amino acid substitutions, relative to the amino acid sequence of SEQ ID NO:592; or both a) and b). [00496] In some embodiments, a polypeptide comprises: a) a heavy chain amino acid sequence comprising at least one amino acid substitution relative to the amino acid sequence of SEQ ID NO:578; and b) a light chain amino acid sequence comprising about 1-10 amino acid substitutions, relative to the amino acid sequence of SEQ ID NO:592. [00497] In some embodiments, a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:578; and b) a light chain comprising the amino acid sequence of SEQ ID NO:592 (AB-2b). [00498] In some embodiments, a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:579; and b) a light chain comprising the amino acid sequence of SEQ ID NO:592. [00499] In some embodiments, a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:580; and b) a light chain comprising the amino acid sequence of SEQ ID NO:593. [00500] In some embodiments, a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:581; and - 108 - 3839034.v1
5708.1076005 b) a light chain comprising the amino acid sequence of SEQ ID NO:592. [00501] In some embodiments, a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:582; and b) a light chain comprising the amino acid sequence of SEQ ID NO:594. [00502] In some embodiments, a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:583; and b) a light chain comprising the amino acid sequence of SEQ ID NO:594. [00503] In some embodiments, a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:584; and b) a light chain comprising the amino acid sequence of SEQ ID NO:595. [00504] In some embodiments, a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:585; and b) a light chain comprising the amino acid sequence of SEQ ID NO:594. [00505] In some embodiments, a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:586; and b) a light chain comprising the amino acid sequence of SEQ ID NO:593. [00506] In some embodiments, a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:585; and b) a light chain comprising the amino acid sequence of SEQ ID NO:593. [00507] In some embodiments, a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:578; and b) a light chain comprising the amino acid sequence of SEQ ID NO:596. [00508] In some embodiments, a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:587; and b) a light chain comprising the amino acid sequence of SEQ ID NO:597. [00509] In some embodiments, a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:585; and b) a light chain comprising the amino acid sequence of SEQ ID NO:598. [00510] In some embodiments, a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:588; and b) a light chain comprising the amino acid sequence of SEQ ID NO:597. [00511] In some embodiments, a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:583; and - 109 - 3839034.v1
5708.1076005 b) a light chain comprising the amino acid sequence of SEQ ID NO:595. [00512] In some embodiments, a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:585; and b) a light chain comprising the amino acid sequence of SEQ ID NO:599. [00513] In some embodiments, a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:589; and b) a light chain comprising the amino acid sequence of SEQ ID NO:600. [00514] In some embodiments, a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:585; and b) a light chain comprising the amino acid sequence of SEQ ID NO:601. [00515] In some embodiments, a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:590; and b) a light chain comprising the amino acid sequence of SEQ ID NO:602. [00516] In some embodiments, a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:584; and b) a light chain comprising the amino acid sequence of SEQ ID NO:603. [00517] In some embodiments, a polypeptide comprises: a) a heavy chain comprising the amino acid sequence of SEQ ID NO:591; and b) a light chain comprising the amino acid sequence of SEQ ID NO:603. [00518] In some embodiments, a polypeptide is a single-domain antibody or an antigen- binding fragment thereof. As used herein, the term “single-domain antibody (sdAb)” or “nanobody” refers to an immunoglobulin molecule consisting of a single monomeric variable antibody domain and capable of specific binding to a target. A single-domain antibody can be of any species, such as a murine antibody, a human antibody or a humanized single-domain antibody. [00519] In some embodiments, a VH domain and a VL domain may be linked together via a linker (e.g., a synthetic linker) to form various types of single-chain antibody designs in which the VH/VL domains pair intramolecularly, or intermolecularly in those cases when the VH and VL domains are expressed by separate chains, to form a monovalent antigen binding site. [00520] In some embodiments, a polypeptide is a heavy-chain antibody comprising two or more heavy chains, but lacking light chain, or an antigen-binding fragment thereof. Non-limiting examples of heavy chain antibodies include camelid Vhh (also referred to as VHH or VHH) - 110 - 3839034.v1
5708.1076005 antibodies. Camelid antibodies are antibodies from the Camelidae family of mammals that include llamas, camels, and alpacas. [00521] In some embodiments, a polypeptide is an antibody mimetic. The term “antibody mimetic” refers to polypeptides capable of mimicking an antibody’s ability to bind an antigen, but structurally differ from native antibody structures. Non-limiting examples of antibody mimetics include Adnectins, Affibodies, Affilins, Affimers, Affitins, Alphabodies, Anticalins, Avimers, DARPins, Fynomers, Kunitz domain peptides, monobodies, nanobodies, nanoCLAMPs, and Versabodies. [00522] In some embodiments, a polypeptide is an antigen-binding fragment of an antibody. The term “antigen-binding fragment” refers to a portion of an immunoglobulin molecule (e.g., antibody) that retains the antigen binding properties of the full-length Reference Antibody. Non- limiting examples of antigen-binding fragments include a VH region, a VL region, an Fab fragment, an F(ab’)2 fragment, an Fd fragment, an Fv fragment, and a domain antibody (dAb) consisting of one VH domain or one VL domain, etc. VH and VL domains may be linked together via a synthetic linker to form various types of single-chain antibody designs in which the VH/VL domains pair intramolecularly, or intermolecularly in those cases when the VH and VL domains are expressed by separate chains, to form a monovalent antigen binding site, such as single chain Fv (scFv) or diabody. In some embodiments, a polypeptide disclosed herein is an antigen binding fragment selected from Fab, F(ab’)2, Fab’, scFv, or Fv. In some embodiments, a polypeptide is a scFv. [00523] In some embodiments, a polypeptide (e.g., an antibody or antigen-binding fragment) is incorporated into a cell-based therapy. In some embodiments, a polypeptide is an engineered T cell receptor. In some embodiments, a polypeptide is a chimeric antigen receptor (CAR) (e.g., expressed on a T (CAR-T) cell, natural killer (CAR-NK) cell, or macrophage (CAR-M) cell). In some embodiments, a CAR comprises a transmembrane domain and an antigen-recognition moiety, wherein the antigen-recognition moiety binds SARS-CoV-2 (e.g., an epitope within RBD such as RBD class 4 epitope). [00524] In some embodiments, a polypeptide is an antibody mimetic. [00525] In some embodiments, a polypeptide competes with a comparator antibody for binding to the wildtype SARS-CoV-2-Spike, a SARS-CoV-2-Spike variant, or a combination thereof, wherein the reference antibody specifically binds the wildtype SARS-CoV-2-Spike (e.g., RBD). The term “specifically binding” or “specifically binds” refers to preferential interaction, - 111 - 3839034.v1
5708.1076005 i.e., significantly higher binding affinity, between an antibody, or an antigen-binding fragment thereof, and its epitope relative to other antigens or amino acid sequences. [00526] In some embodiments, a polypeptide is an isolated polypeptide. In some embodiments, a polypeptide (e.g., an isolated polypeptide) is recombinantly produced. In some embodiments, a polypeptide (e.g., an isolated polypeptide) is synthetically produced. [00527] In some embodiments, a polypeptide is linked to a second polypeptide. The term “linked” means attached, via a covalent or noncovalent interaction. Conjugation can employ a suitable linking agent. Non-limiting examples include peptide linkers, compound linkers, and chemical cross-linking agents. In some embodiments, the linker is a disulfide bond. [00528] In some embodiments, a polypeptide is conjugated to a heterologous moiety. The term “conjugated” refers to attached, via a covalent or noncovalent interaction. Conjugation can employ any one or more of suitable linking agents. Non-limiting examples include peptide linkers, compound linkers, and chemical cross-linking agents. [00529] In some embodiments, a heterologous moiety comprises a therapeutic agent, a diagnostic agent, or both. In some embodiments, a heterologous moiety is selected from polyethylene glycol (PEG), hexadecanoic acid, hydrogels, nanoparticles, multimerization domains and carrier peptides. [00530] In some embodiments, a nanoparticle is a lipid nanoparticle. In some embodiments, a nanoparticle is a polymer nanoparticle. In some embodiments, a polymer is an amphiphilic polymer. In some embodiments, a polymer is a hydrophobic or hydrophilic polymer. Non- limiting examples of polymers include poly(lactic acid)-poly(ethylene glycol), poly(lactic-co- glycolic acid)-poly(ethylene glycol), poly(lactic-co-glycolic) acid (PLGA), poly(lactic-co- glycolic acid)-d-α-tocopheryl polyethylene glycol succinate, poly(lactic-co-glycolic acid)- ethylene oxide fumarate, poly(glycolic acid)-poly(ethylene glycol), polycaprolactone- poly(ethylene glycol), or any salts thereof. In some embodiments, a polymer nanoparticle comprises poly(lactic-co-glycolic acid) (PLGA). [00531] In some embodiments, a carrier polypeptide is albumin or an Fc polypeptide. [00532] In some embodiments, a polypeptide: a) is capable of binding to an epitope in the RBD of SARS-CoV-2-Spike; b) binds SARS-CoV-1 and/or SARS-CoV-2 with a KD of 10 µM or less; c) neutralizes SARS-CoV-1 and/or SARS-CoV-2 infection of human host cells; d) has a weaker non-specific binding than the Reference Antibody; e) has a weaker self-association than the Reference Antibody; - 112 - 3839034.v1
5708.1076005 or a combination of any of the foregoing. [00533] In some embodiments, a polypeptide is capable of binding to one or more epitope residues in RBD of SARS-CoV-2-Spike, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 residues of the RBD. In some embodiments, a polypeptide is capable of binding to one or more epitope residues (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or all 16 residues) of SEQ ID NO:1. [00534] In some embodiments, a polypeptide binds SARS-CoV-2-Spike with a binding constant (KD) of about 10 µM or less. [00535] In some embodiments, a polypeptide binds SARS-CoV-1-Spike (e.g., of CoV-1 and/or WIV1) and/or SARS-CoV-2-Spike (e.g., of Alpha, Beta, Gamma, Delta, Kappa, Epsilon, Eta, Iota, Lambda, Mu, and/or Omicron, for example, B.1, B.1.1, B.1.1.1, B.1.1.529, B.1.1.7, B.1.177, B.1.2, B.1.351, B.1.427/429, B.1.525, B.1.526, B.1.617.1,B.1.617.2, B.1.621, BA.1, BA.1.1, BA.2, BA.2.12.1, BA.2.75, BA.2.75.2, BA.3, BA.4, BA.4/5, BA.4/5+K444T, BA.4.6, BA.5, BA.5.2.6, BF.7, BF.11, BN.1, BQ.1, BQ.1.1, C.37, D.2, GA.5, GR/484A, P.1, P.3, and/or XBB) or a fragment thereof (e.g., the RBD of SARS-CoV-2-Spike) with a KD of about: 5 µM, 2 µM, 1 µM, 500 nM, 200 nM, 100 nM, 50 nM, 20 nM, 10 nM, 5 nM, 2 nM, 1 nM, 0.5 nM, 0.2 nM, or 0.1 nM or less. In some embodiments, a polypeptide binds SARS-CoV-1-Spike (e.g., of CoV-1 and/or WIV1) and/or SARS-CoV-2-Spike (e.g., of Alpha, Beta, Gamma, Delta, Kappa, Epsilon, Eta, Iota, Lambda, Mu, and/or Omicron, for example, B.1, B.1.1, B.1.1.1, B.1.1.529, B.1.1.7, B.1.177, B.1.2, B.1.351, B.1.427/429, B.1.525, B.1.526, B.1.617.1,B.1.617.2, B.1.621, BA.1, BA.1.1, BA.2, BA.2.12.1, BA.2.75, BA.2.75.2, BA.3, BA.4, BA.4/5, BA.4/5+K444T, BA.4.6, BA.5, BA.5.2.6, BF.7, BF.11, BN.1, BQ.1, BQ.1.1, C.37, D.2, GA.5, GR/484A, P.1, P.3, and/or XBB) or a fragment thereof (e.g., the RBD of SARS-CoV-2-Spike) with a KD of 100 nM or less. [00536] In some embodiments, a polypeptide binds SARS-CoV-1-Spike (e.g., of CoV-1 and/or WIV1) and/or SARS-CoV-2-Spike (e.g., of Alpha, Beta, Gamma, Delta, Kappa, Epsilon, Eta, Iota, Lambda, Mu, and/or Omicron, for example, B.1, B.1.1, B.1.1.1, B.1.1.529, B.1.1.7, B.1.177, B.1.2, B.1.351, B.1.427/429, B.1.525, B.1.526, B.1.617.1,B.1.617.2, B.1.621, BA.1, BA.1.1, BA.2, BA.2.12.1, BA.2.75, BA.2.75.2, BA.3, BA.4, BA.4/5, BA.4/5+K444T, BA.4.6, BA.5, BA.5.2.6, BF.7, BF.11, BN.1, BQ.1, BQ.1.1, C.37, D.2, GA.5, GR/484A, P.1, P.3, and/or XBB) or a fragment thereof (e.g., the RBD of SARS-CoV-2-Spike) with a KD of about: 10-10-10- 5 M, 10-10-5x10-6 M, 2x10-10-5x10-6 M, 2x10-10-2x10-6 M, 5x10-10-2x10-6 M, 5x10-10-10-7 M, 10-9- 10-7 M, 10-9-5x10-8 M, 2x10-9-5x10-8 M, 2x10-9-2x10-8 M, 5x10-9-2x10-8 M, or 5x10-9-10-8 M. - 113 - 3839034.v1
5708.1076005 [00537] In some embodiments, a polypeptide (e.g., full-length IgG1 antibody) binds SARS- CoV-1-Spike (e.g., of CoV-1 and/or WIV1) and/or SARS-CoV-2-Spike (e.g., of Alpha, Beta, Gamma, Delta, Kappa, Epsilon, Eta, Iota, Lambda, Mu, and/or Omicron, for example, B.1, B.1.1, B.1.1.1, B.1.1.529, B.1.1.7, B.1.177, B.1.2, B.1.351, B.1.427/429, B.1.525, B.1.526, B.1.617.1,B.1.617.2, B.1.621, BA.1, BA.1.1, BA.2, BA.2.12.1, BA.2.75, BA.2.75.2, BA.3, BA.4, BA.4/5, BA.4/5+K444T, BA.4.6, BA.5, BA.5.2.6, BF.7, BF.11, BN.1, BQ.1, BQ.1.1, C.37, D.2, GA.5, GR/484A, P.1, P.3, and/or XBB) or a fragment thereof (e.g., the RBD of SARS-CoV-2-Spike) with a KD of about 10-6 M or less, e.g., about: 500 nM, 200 nM, 100 nM, 50 nM, 20 nM, 10 nM, 5 nM, 2 nM, 1 nM, 0.5 nM, 0.2 nM, or 0.1 nM or less; or about: 10-10-10- 6 M, 10-10-5x10-7 M, 2x10-10-5x10-7 M, 2x10-10-2x10-7 M, 5x10-10-2x10-7 M, 5x10-10-10-7 M, 10-9- 10-7 M, 10-9-5x10-8 M, 2x10-9-5x10-8 M, 2x10-9-2x10-8 M, 5x10-9-2x10-8 M, or 5x10-9-10-8 M. [00538] In some embodiments, a polypeptide competes with the Reference Antibody for binding to a SARS-CoV-2-Spike (e.g., RBD such as RBD class 4 epitope). Techniques and assays for assessing competition between antibodies are known in the art. [00539] In some embodiments, a polypeptide neutralizes SARS-CoV-1 (e.g., CoV-1 and/or WIV1) and/or SARS-CoV-2 (e.g., of Alpha, Beta, Gamma, Delta, Kappa, Epsilon, Eta, Iota, Lambda, Mu, and/or Omicron, for example, B.1, B.1.1, B.1.1.1, B.1.1.529, B.1.1.7, B.1.177, B.1.2, B.1.351, B.1.427/429, B.1.525, B.1.526, B.1.617.1,B.1.617.2, B.1.621, BA.1, BA.1.1, BA.2, BA.2.12.1, BA.2.75, BA.2.75.2, BA.3, BA.4, BA.4/5, BA.4/5+K444T, BA.4.6, BA.5, BA.5.2.6, BF.7, BF.11, BN.1, BQ.1, BQ.1.1, C.37, D.2, GA.5, GR/484A, P.1, P.3, and/or XBB) with an IC50 of 10 µM or less. [00540] In some embodiments, a polypeptide (e.g., full-length IgG1 antibody) neutralizes SARS-CoV-2 (e.g. of Alpha, Beta, Gamma, Delta, Kappa, Epsilon, Eta, Iota, Lambda, Mu, and/or Omicron, for example, B.1, B.1.1, B.1.1.1, B.1.1.529, B.1.1.7, B.1.177, B.1.2, B.1.351, B.1.427/429, B.1.525, B.1.526, B.1.617.1,B.1.617.2, B.1.621, BA.1, BA.1.1, BA.2, BA.2.12.1, BA.2.75, BA.2.75.2, BA.3, BA.4, BA.4/5, BA.4/5+K444T, BA.4.6, BA.5, BA.5.2.6, BF.7, BF.11, BN.1, BQ.1, BQ.1.1, C.37, D.2, GA.5, GR/484A, P.1, P.3, and/or XBB) infection of a human host cells with an IC50 of about 25,000 ng/mL or less, e.g., about: 20,000 ng/mL, 15,000 ng/mL, 10,000 ng/mL, 5,000 ng/mL, 2,500 ng/mL, 1,000 ng/mL, 750 ng/mL, 500 ng/mL, 250 ng/mL, 100 ng/mL, 75 ng/mL, 50 ng/mL, 25 ng/mL or 10 ng/mL or less; e.g., about: 10-25,000 ng/mL, 10-20,000 ng/mL, 25-20,000 ng/mL, 25-15,000 ng/mL, 50-15,000 ng/mL, 50-10,000 ng/mL, 75-10,000 ng/mL, 75-5,000 ng/mL, 100-5,000 ng/mL, 100-2,500 ng/mL, 250-2,500 ng/mL, 250-1,000 ng/mL, 500-1,000 ng/mL, or 500-750 ng/mL. - 114 - 3839034.v1
5708.1076005 [00541] In some embodiments, host cells are selected from the group consisting of lung type II pneumocytes, ileal absorptive enterocytes, nasal goblet secretory cells, and combinations thereof. [00542] In some embodiments, a polypeptide (e.g., full-length IgG1 antibody) neutralizes SARS-CoV-2 (e.g., of Alpha, Beta, Gamma, Delta, Kappa, Epsilon, Eta, Iota, Lambda, Mu, and/or Omicron, for example, B.1, B.1.1, B.1.1.1, B.1.1.529, B.1.1.7, B.1.177, B.1.2, B.1.351, B.1.427/429, B.1.525, B.1.526, B.1.617.1,B.1.617.2, B.1.621, BA.1, BA.1.1, BA.2, BA.2.12.1, BA.2.75, BA.2.75.2, BA.3, BA.4, BA.4/5, BA.4/5+K444T, BA.4.6, BA.5, BA.5.2.6, BF.7, BF.11, BN.1, BQ.1, BQ.1.1, C.37, D.2, GA.5, GR/484A, P.1, P.3, and/or XBB) infection of human host cells with an IC80 of about 50,000 ng/mL or less, e.g., about: 25,000 ng/mL, 15,000 ng/mL, 10,000 ng/mL, 5,000 ng/mL, 2,500 ng/mL, 1,000 ng/mL, 750 ng/mL, 500 ng/mL, 250 ng/mL, 100 ng/mL, 75 ng/mL, 50 ng/mL, 25 ng/mL or 10 ng/mL or less; e.g., about: 10-50,000 ng/mL, 10-25,000 ng/mL, 25-25,000 ng/mL, 25-15,000 ng/mL, 50-15,000 ng/mL, 50-10,000 ng/mL, 75-10,000 ng/mL, 75-5,000 ng/mL, 100-5,000 ng/mL, 100-2,500 ng/mL, 250-2,500 ng/mL, 250-1,000 ng/mL, 500-1,000 ng/mL, or 500-750 ng/mL. [00543] In some embodiments, a polypeptide (e.g., full-length IgG1 antibody) neutralizes SARS-CoV-1 (e.g., CoV-1 and/or WIV1) infection of human host cells with an IC50 of about 25,000 ng/mL or less, e.g., about: 20,000 ng/mL, 15,000 ng/mL, 10,000 ng/mL, 5,000 ng/mL, 2,500 ng/mL, 1,000 ng/mL, 750 ng/mL, 500 ng/mL, 250 ng/mL, 100 ng/mL, 75 ng/mL, 50 ng/mL, 25 ng/mL, or 10 ng/mL or less; e.g., about: 10-25,000 ng/mL, 10-20,000 ng/mL, 25- 20,000 ng/mL, 25-15,000 ng/mL, 50-15,000 ng/mL, 50-10,000 ng/mL, 75-10,000 ng/mL, 75- 5,000 ng/mL, 100-5,000 ng/mL, 100-2,500 ng/mL, 250-2,500 ng/mL, 250-1,000 ng/mL, 500- 1,000 ng/mL, or 500-750 ng/mL. [00544] In some embodiments, a polypeptide (e.g., full-length IgG1 antibody) neutralizes SARS-CoV-1 (e.g., CoV-1 and/or WIV1) infection of human host cells with an IC80 of about 50,000 ng/mL or less, e.g., about: 25,000 ng/mL, 15,000 ng/mL, 10,000 ng/mL, 5,000 ng/mL, 2,500 ng/mL, 1,000 ng/mL, 750 ng/mL, 500 ng/mL, 250 ng/mL, 100 ng/mL, 75 ng/mL, 50 ng/mL, 25 ng/mL, or 10 ng/mL or less; e.g., about: 10-50,000 ng/mL, 10-25,000 ng/mL, 25- 25,000 ng/mL, 25-15,000 ng/mL, 50-15,000 ng/mL, 50-10,000 ng/mL, 75-10,000 ng/mL, 75- 5,000 ng/mL, 100-5,000 ng/mL, 100-2,500 ng/mL, 250-2,500 ng/mL, 250-1,000 ng/mL, 500- 1,000 ng/mL, or 500-750 ng/mL. [00545] In some embodiments, a polypeptide reduces betacoronavirus (e.g., SARS-CoV-2) infectivity of host cells (e.g., human host cells). In some embodiments, a polypeptide reduces - 115 - 3839034.v1
5708.1076005 betacoronavirus (e.g., SARS-CoV-2) infectivity of host cells (e.g., human host cells) by at least about 10%, e.g., by at least about: 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. In some embodiments, a polypeptide reduces betacoronavirus (e.g., SARS-CoV-2) infectivity of human cells by at least about 30%. [00546] In some embodiments, a polypeptide reduces betacoronavirus (such as SARS-CoV-2 (e.g., of Alpha, Beta, Gamma, Delta, Kappa, Epsilon, Eta, Iota, Lambda, Mu, and/or Omicron, for example, B.1, B.1.1, B.1.1.1, B.1.1.529, B.1.1.7, B.1.177, B.1.2, B.1.351, B.1.427/429, B.1.525, B.1.526, B.1.617.1,B.1.617.2, B.1.621, BA.1, BA.1.1, BA.2, BA.2.12.1, BA.2.75, BA.2.75.2, BA.3, BA.4, BA.4/5, BA.4/5+K444T, BA.4.6, BA.5, BA.5.2.6, BF.7, BF.11, BN.1, BQ.1, BQ.1.1, C.37, D.2, GA.5, GR/484A, P.1, P.3, and/or XBB)) re-infection of host cells (e.g., human host cells). In some embodiments, a polypeptide reduces betacoronavirus (such as SARS- CoV-2 (e.g., Alpha, Beta, Gamma, Delta, Kappa, Epsilon, Eta, Iota, Lambda, Mu, and/or Omicron, for example, B.1, B.1.1, B.1.1.1, B.1.1.529, B.1.1.7, B.1.177, B.1.2, B.1.351, B.1.427/429, B.1.525, B.1.526, B.1.617.1,B.1.617.2, B.1.621, BA.1, BA.1.1, BA.2, BA.2.12.1, BA.2.75, BA.2.75.2, BA.3, BA.4, BA.4/5, BA.4/5+K444T, BA.4.6, BA.5, BA.5.2.6, BF.7, BF.11, BN.1, BQ.1, BQ.1.1, C.37, D.2, GA.5, GR/484A, P.1, P.3, and/or XBB)) re-infection of host cells (e.g., human host cells) by at least about 10%, e.g., by at least about: 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. In some embodiments, a polypeptide reduces betacoronavirus (such as SARS-CoV-2 (e.g., of Alpha, Beta, Gamma, Delta, Kappa, Epsilon, Eta, Iota, Lambda, Mu, and/or Omicron, for example, B.1, B.1.1, B.1.1.1, B.1.1.529, B.1.1.7, B.1.177, B.1.2, B.1.351, B.1.427/429, B.1.525, B.1.526, B.1.617.1,B.1.617.2, B.1.621, BA.1, BA.1.1, BA.2, BA.2.12.1, BA.2.75, BA.2.75.2, BA.3, BA.4, BA.4/5, BA.4/5+K444T, BA.4.6, BA.5, BA.5.2.6, BF.7, BF.11, BN.1, BQ.1, BQ.1.1, C.37, D.2, GA.5, GR/484A, P.1, P.3, and/or XBB)) re-infection of human cells by at least about 30%. [00547] Infectivity or re-infection can be measured using techniques such as a pseudovirus neutralization assay or a live virus neutralization assay (see, e.g., Pinto et al., Cross- neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody, Nature 583: 290-95 (2020), the contents of which are incorporated herein by reference). A kit, for example, the GenScript cPass™ SARS-CoV-2 neutralization antibody detection kit, can be used according to manufacturer's protocol. - 116 - 3839034.v1
5708.1076005 [00548] In some embodiments, a polypeptide reduces SARS-CoV-1 (e.g., CoV-1 and/or WIV1) infectivity of host cells (e.g., human host cells). In some embodiments, a polypeptide reduces SARS-CoV-1 (e.g., CoV-1 and/or WIV1) infectivity of host cells (e.g., human host cells) by at least about 10%, e.g., by at least about: 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. In some embodiments, a polypeptide reduces SARS-CoV-1 (e.g., CoV-1 and/or WIV1) infectivity of human cells by at least about 30%. [00549] In some embodiments, a polypeptide reduces SARS-CoV-1 (e.g., CoV-1 and/or WIV1) re-infection of host cells (e.g., human host cells). In some embodiments, a polypeptide reduces SARS-CoV-1 (e.g., CoV-1 and/or WIV1) re-infection of host cells (e.g., human host cells) by at least about 10%, e.g., by at least about: 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. In some embodiments, a polypeptide reduces SARS-CoV-1 (e.g., CoV-1 and/or WIV1) re- infection of human cells by at least about 30%. [00550] In some embodiments, a polypeptide has a weaker self-association than the Reference Antibody, for example, as determined by an affinity-capture self-interaction nanoparticle spectroscopy (AC-SINS) value. AC-SINS value is the change in maximum absorbance wavelength in the coated-nanoparticle absorption spectra compared to the spectra of the nanoparticle alone. Thus, the greater the change in maximum absorbance wavelength, the more self-interaction of the antibody coated on the nanoparticle. Self-association is an unwanted property that correlates with poor viscosity and poor PK properties. Techniques and assays for assessing self-association of proteins are known in the art. See, e.g., Patro & Przybycien, Biotechnol Bioeng.52(2):193-203 (1996), the contents of which are incorporated herein in their entirety. In some embodiments, a polypeptide has a weaker self-association than the Reference Antibody. [00551] In some embodiments, a polypeptide has an AC-SINS value of no more than about: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 18, 20, 21, 22, 23, 24, or 25. In some embodiments, a polypeptide has an AC-SINS value of no more than about 14. In some embodiments, a polypeptide has an AC-SINS value of no more than about 8. In some embodiments, a polypeptide has an AC-SINS value of about: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 18, 20, 21, 22, 23, 24, or 25. In some embodiments, a polypeptide has an AC-SINS value of about 0-25, e.g., 0-20, 0-15, 0-10, 0-8, 0-5, 2-20, 2-15, 2-10, 2-8, 2-5, 5-20, 5- 15, 5-10, 5-8, 7-8, or 13-15. In some embodiments, a polypeptide has an AC-SINS value of - 117 - 3839034.v1
5708.1076005 about 13-14, 13-15, 7-9, or 7-8. In some embodiments, a polypeptide has an AC-SINS value of about: 8 or 14. [00552] In some embodiments, a polypeptide has an improved developability (e.g., reduced AC-SINS) relative to the Reference Antibody. In some embodiments, self-association of a polypeptide is at least about 10% lower than that of the Reference Antibody, for example, by at least about: 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% lower than that of the Reference Antibody. In some embodiments, self-association of a polypeptide is at least about 30% lower than that of the Reference Antibody. [00553] In some embodiments, self-association of a polypeptide is less than about 90% of that of the Reference Antibody, for example, less than about: 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% of that of the Reference Antibody. [00554] In some embodiments, self-association of a polypeptide is about 1-90% relative to that of the Reference Antibody, for example, about: 2-90%, 2-85%, 3-85%, 3-80%, 4-80%, 4- 75%, 5-75%, 5-70%, 6-70%, 6-65%, 7-65%, 7-60%, 8-60%, 8-55%, 9-55%, 9-50%, 10-50%, 10-45%, 15-45%, 15-40%, 20-40%, 20-35%, 25-35%, or 25-30%, relative to that of the Reference Antibody. [00555] In some embodiments, reduction in self-association relative to the Reference Antibody is at least about 10%, for example, by at least about: 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. Fusion Proteins [00556] The disclosure also provides, among other things, a fusion protein comprising one or more of the polypeptides disclosed herein. [00557] The term “fusion protein” refers to a synthetic, semi-synthetic or recombinant single protein molecule. A fusion protein can comprise all or a portion of two or more different proteins and/or polypeptides that are attached by covalent bonds (e.g., peptide bonds). For example, a fusion protein can comprise a full-length polypeptide disclosed herein (e.g., a whole antibody), or a fragment thereof (e.g., an antigen-binding fragment of an antibody). The heterologous partner can be a full-length protein or a fragment thereof (e.g., a truncated protein). [00558] Fusion proteins of the disclosure can be produced recombinantly or synthetically, using routine methods and reagents that are well known in the art. For example, a fusion protein - 118 - 3839034.v1
5708.1076005 of the disclosure can be produced recombinantly in a suitable host cell (e.g., bacteria) according to methods known in the art. See, e.g., Current Protocols in Molecular Biology, Second Edition, Ausubel et al. eds., John Wiley & Sons, 1992; and Molecular Cloning: a Laboratory Manual, 2nd edition, Sambrook et al., 1989, Cold Spring Harbor Laboratory Press. For example, a nucleic acid molecule comprising a nucleotide sequence encoding a fusion protein described herein can be introduced and expressed in suitable host cell (e.g., E. coli), and the expressed fusion protein can be isolated/purified from the host cell (e.g., in inclusion bodies) using routine methods and readily available reagents. For example, DNA fragments coding for different protein sequences (e.g., a light-responsive domain, a heterologous peptide component) can be ligated together in-frame in accordance with conventional techniques. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of nucleic acid fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive nucleic acid fragments that can subsequently be annealed and re-amplified to generate a chimeric nucleic acid sequence (see Ausubel et al., Current Protocols in Molecular Biology, 1992). Nucleic Acids, Vectors, Host Cells [00559] The disclosure also provides, among other things, one or more polynucleotides (e.g., DNA, RNA, or analogs of either, e.g., optionally including one or more modified nucleotides; a polynucleotide may be linear or circular, e.g., a linear or circular RNA) encoding any one of the polypeptides or fusion proteins described herein. In some embodiments, a polypeptide or fusion protein disclosed herein is encoded by a single polynucleotide. In some embodiments, a polypeptide or fusion protein disclosed herein is encoded by multiple polynucleotides. [00560] In some embodiments, a polynucleotide comprises a nucleotide sequence that is codon-optimized for a chosen host cell. [00561] The disclosure also provides, among other things, a vector (e.g., an expression vector, including a viral-delivery vector) comprising any one or more of the polynucleotides disclosed herein. [00562] The term “expression vector” refers to a replicable nucleic acid from which one or more proteins can be expressed when the expression vector is transformed into a suitable expression host cell. [00563] In some embodiments, a vector (e.g., expression vector) further comprises an expression control polynucleotide sequence operably linked to the polynucleotide, a polynucleotide sequence encoding a selectable marker, or both. In some embodiments, an - 119 - 3839034.v1
5708.1076005 expression control polynucleotide sequence comprises a promoter sequence, an enhancer sequence, or both. In some embodiments, an expression control polynucleotide sequence comprises an inducible promoter sequence. The term “promoter” refers to a region of DNA to which RNA polymerase binds and initiates the transcription of a gene. The term “operably linked” means that the nucleic acid is positioned in the recombinant polynucleotide, e.g., vector, in such a way that enables expression of the nucleic acid under control of the element (e.g., promoter) to which it is linked. The term “selectable marker element” is an element that confers a trait suitable for artificial selection. Selectable marker elements can be negative or positive selection markers. [00564] The disclosure also provides, among other things, an expression host cell comprising any one or more of the polynucleotides or expression vectors disclosed herein. [00565] The term “expression host cell” refers to a cell useful for receiving, maintaining, reproducing and/or amplifying a vector. Non-limiting examples of expression host cells include mammalian cells such as hybridoma cells, Chinese hamster ovary (CHO) cells, COS cells, human embryonic kidney (HEK), yeast cells such as Pichia pastoris cells, or bacterial cells such as E. coli, including DH5α, etc. Compositions [00566] The disclosure also provides, among other things, a composition comprising any one of the polypeptides, the polynucleotides, or fusion proteins disclosed herein. In some embodiments, a composition is a pharmaceutical composition. [00567] In some embodiments, a composition (e.g., pharmaceutical composition) further comprises pharmaceutically acceptable carriers, excipients, stabilizers, diluents or tonifiers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)). Suitable pharmaceutically acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed. Non-limiting examples of pharmaceutically acceptable carriers, excipients, stabilizers, diluents or tonifiers include buffers (e.g., phosphate, citrate, histidine), antioxidants (e.g., ascorbic acid or methionine), preservatives, proteins (e.g., serum albumin, gelatin or immunoglobulins); hydrophilic polymers, amino acids, carbohydrates (e.g., monosaccharides, disaccharides, glucose, mannose or dextrins); chelating agents (e.g., EDTA), sugars (e.g., sucrose, mannitol, trehalose or sorbitol), salt-forming counter-ions (e.g., sodium), metal complexes (e.g., Zn-protein complexes); non-ionic surfactants (e.g., Tween), PLURONICS™ and polyethylene glycol (PEG). - 120 - 3839034.v1
5708.1076005 [00568] In some embodiments, a composition (e.g., a pharmaceutical composition) is formulated for a suitable administration schedule and route. Non-limiting examples of administration routes include oral, rectal, mucosal, intravenous, intramuscular, subcutaneous, and topical, etc. In some embodiments, a composition (e.g., a pharmaceutical composition) is stored in the form of an aqueous solution or a dried formulation (e.g., lyophilized). [00569] In some embodiments, a composition is formulated to be administered by infusion (e.g., intravenous infusion). In other embodiments a composition is formulated for subcutaneous administration. [00570] In some embodiments, a composition is provided in a dosage form, e.g., in a prefilled syringe or autoinjector. [00571] In some embodiments, a pharmaceutical composition comprises from about 50 mg to about 300 mg of a polypeptide or fusion protein disclosed herein, for example, about: 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 120 mg, 140 mg, 150 mg, 160 mg, 180 mg, 200 mg, 220 mg, 240 mg, 250 mg, 260 mg, 280 mg, or 300 mg. In some embodiments, a pharmaceutical composition comprises from about 60 mg to about 300 mg of a polypeptide or fusion protein disclosed herein, for example, about: 60-280 mg, 80-280 mg, 80-260 mg, 100-260 mg, 100-250 mg, 120-250 mg, 120-240 mg, 140-240 mg, 140-220 mg, 150-250 mg, 150-200 mg, 160-220 mg, 160-200 mg, or 180-200 mg. [00572] In some embodiments, a pharmaceutical composition comprises from about 50 mg/ml to about 200 mg/ml of a polypeptide or fusion protein disclosed herein, for example, about: 50 mg/ml, 60 mg/ml, 70 mg/ml, 80 mg/ml, 90 mg/ml, 100 mg/ml, 120 mg/ml, 140 mg/ml, 150 mg/ml, 160 mg/ml, 180 mg/ml, or 200 mg/ml of a polypeptide or fusion protein disclosed herein. In some embodiments, a pharmaceutical composition comprises from about 60 mg/ml to about 200 mg/ml of a polypeptide or fusion protein disclosed herein, for example, about: 60-180 mg/ml, 80-180 mg/ml, 80-160 mg/ml, 100-160 mg/ml, 100-150 mg/ml, 120-150 mg/ml or 120- 140 mg/ml. [00573] In some embodiments, a composition is formulated to be administered with at least one additional therapeutic agent as a combination therapy. [00574] In some embodiments, a composition further comprises at least one additional therapeutic agent. [00575] In some embodiments, at least one additional therapeutic agent comprises any one of the polypeptides described herein (e.g., the Reference Antibody, a different RBD 4 binder, a S2 binder, or any combination thereof). In some embodiments, at least one additional therapeutic - 121 - 3839034.v1
5708.1076005 agent comprises bamlanivimab, etesevimab, casirivimab, imdevimab, Cilgavimab, Tixagevimab, AZD7442 (Tixagevimab-Cilgavimab), Regdanvimab, or Sotrovimab. In some embodiments, a second therapeutic agent comprises Sotrovimab. [00576] In some embodiments, at least one additional therapeutic agent comprises: a) an antibody or an antigen-binding fragment thereof that specifically binds SARS- CoV-2-Spike; b) a polynucleotide comprising a nucleotide sequence encoding the antibody or the antigen-binding fragment thereof of a); c) an antiviral agent; d) an ACE2 inhibitor; e) an antibiotic; f) an antimalarial agent; g) a vaccine; or any combination of a) to g). [00577] In some embodiments: a) an antibody or an antigen-binding fragment thereof that specifically binds SARS- CoV-2-Spike comprises bamlanivimab, etesevimab, bebtelovimab, casirivimab, imdevimab, Cilgavimab, Tixagevimab, AZD7442 (Tixagevimab-Cilgavimab), Regdanvimab, Sotrovimab, or a combination thereof; b) an antibody or an antigen-binding fragment thereof that specifically binds SARS- CoV-2-Spike binds an S2 domain of SARS-CoV-2-Spike; c) an antiviral agent comprises oseltamivir (Tamiflu), favipiravir, amantadine, remdesivir, rimantadine, pleconaril, an anti-sense RNA to SARS-CoV-2, a siRNA to SARS-CoV-2, or a combination thereof; d) an ACE2 inhibitor comprises an RNAi to ACE2, a siRNA to ACE2, a CRISPR- based inhibitor of ACE2, a soluble ACE2, a soluble ACE2 variant, an anti-ACE2 antibody, or a combination thereof; e) an antibiotic comprises azithromycin; f) an antimalarial agent comprises a chloroquine; g) a vaccine comprises a nucleic acid vaccine and/or an inactivated virus vaccine; or any combination of a) to g). [00578] Non-limiting examples of additional therapeutic agents include antibiotics (e.g., azithromycin), antibodies or antigen-binding fragments thereof (e.g., other SARS-CoV-2- - 122 - 3839034.v1
5708.1076005 binding antibodies or antigen-binding fragments), antimalarial agents (e.g., chloroquine or hydroxychloroquine), antiviral agents (e.g., Molnupiravir (LAGEVRIO, Merck), PF-07817883 (Pfizer), STI-1558 (Sorrento Therapeutics), PBI-0451 (Pardes Biosciences), EDP-235 (Enanta Pharmaceuticals), favipiravir, lopinavir, and/or ritonavir), cytokines (e.g., type 1 interferons such as interferon beta-1a), nucleotide analogs (e.g., remdesivir), protease inhibitors (e.g., danoprevir), and Renin-Angiotensin-Aldosterone System Inhibitors (e.g., ACE2 inhibitors or angiotensin-receptor blockers (ARBs)). [00579] In some embodiments, an antiviral agent comprises amantadine, Molnupiravir (LAGEVRIO, Merck), PF-07817883 (Pfizer), STI-1558 (Sorrento Therapeutics), PBI-0451 (Pardes Biosciences), EDP-235 (Enanta Pharmaceuticals), favipiravir, lopinavir, oseltamivir (Tamiflu), pleconaril, rimantadine, ritonavir, an anti-sense RNA to SARS-CoV-2, an siRNA to SARS-CoV-2, an additional anti-SARS-CoV-2 monoclonal antibody, or any combination thereof. [00580] In some embodiments, an antiviral agent comprises Molnupiravir (LAGEVRIO, Merck), PF-07817883 (Pfizer), STI-1558 (Sorrento Therapeutics), PBI-0451 (Pardes Biosciences), EDP-235 (Enanta Pharmaceuticals), or any combination thereof. [00581] In some embodiments, an anti-SARS-CoV-2 antibody targets S1 domain of a Spike protein of SARS-CoV-2. In some embodiments, an anti-SARS-CoV-2 antibody targets class 4 region of a S1 domain. In some embodiments, an anti-SARS-CoV-2 monoclonal antibody targets RBD (e.g., RBD class 1, 2, or 3 epitopes) of S1 domain of SARS-CoV-2. In some embodiments, an anti-SARS-CoV-2 antibody targets class 3 region of S1 domain. In some embodiments, an anti-SARS-CoV-2 antibody targets the N-terminal domain (NTD)-nonsupersite region of S1 domain. In some embodiments, an anti-SARS-CoV-2 antibody targets SD1 region of S1 domain. [00582] In some embodiments, an anti-SARS-CoV-2 monoclonal antibody targets (e.g., binds) S2 domain of a Spike protein of SARS-CoV-2. In some embodiments, an anti-SARS- CoV-2 monoclonal antibody comprises a neutralizing monoclonal antibody (e.g., as determined using a neutralization assay described herein or otherwise known in the art). Non-limiting examples of anti-SARS-CoV-2 monoclonal antibodies include Bamlanivimab (LY-CoV555 or LY3819253), Etesevimab (LY-CoV016 or LY3832479), Bebtelovimab (LY-CoV1404, LY3853113), Casirivimab (REGN10933), Imdevimab (REGN10987), Cilgavimab, Tixagevimab, AZD7442/ EVUSHELD® (Tixagevimab-Cilgavimab), Regdanvimab, Sotrovimab (Vir Biotechnology, Inc.), ADG20 (Adagio Therapeutics, Inc.), Ensovibep (MP0420) (DARPin, Novartis), and P2G3 (Aerium Tx). - 123 - 3839034.v1
5708.1076005 [00583] In some embodiments, at least one additional therapeutic agent comprises an antibody or an antigen-binding fragment thereof that specifically binds an S2 domain of SARS-CoV-2- Spike. [00584] In some embodiments, an antibody or an antigen-binding fragment thereof that specifically binds an S2 domain of SARS-CoV-2-Spike comprises a VH domain comprising an HCDR1, an HCDR2, and an HCDR3, and a VL domain comprising an LCDR1, an LCDR2, and an LCDR3 of an antibody comprising a VH amino acid sequence and a VL amino acid sequence, respectively, of: SEQ ID NO:53 and SEQ ID NO:75 (S2_AB-1); SEQ ID NO:57 and SEQ ID NO:76 (S2_AB-2); SEQ ID NO:58 and SEQ ID NO:77 (S2_AB-3); SEQ ID NO:59 and SEQ ID NO:78 (S2_AB-4); SEQ ID NO:60 and SEQ ID NO:75 (S2_AB-5); SEQ ID NO:61 and SEQ ID NO:79 (S2_AB-6); SEQ ID NO:62 and SEQ ID NO:80 (S2_AB-7); SEQ ID NO:63 and SEQ ID NO:81 (S2_AB-8); SEQ ID NO:64 and SEQ ID NO:82 (S2_AB-9); SEQ ID NO:65 and SEQ ID NO:83 (S2_AB-10); SEQ ID NO:66 and SEQ ID NO:84 (S2_AB-11); SEQ ID NO:67 and SEQ ID NO:80 (S2_AB-12); SEQ ID NO:68 and SEQ ID NO:75 (S2_AB-13); SEQ ID NO:62 and SEQ ID NO:74 (S2_AB-14); SEQ ID NO:69 and SEQ ID NO:85 (S2_AB-15); SEQ ID NO:70 and SEQ ID NO:86 (S2_AB-16); SEQ ID NO:58 and SEQ ID NO:87 (S2_AB-17); SEQ ID NO:71 and SEQ ID NO:88 (S2_AB-18); SEQ ID NO:53 and SEQ ID NO:85 (S2_AB-19); SEQ ID NO:72 and SEQ ID NO:85 (S2_AB-20); SEQ ID NO:94 and SEQ ID NO:113 (S2_AB-21); SEQ ID NO:95 and SEQ ID NO:114 (S2_AB-22); SEQ ID NO:53 and SEQ ID NO:115 (S2_AB-23); SEQ ID NO:96 and SEQ ID NO:80 (S2_AB-24); SEQ ID NO:97 and SEQ ID NO:116 (S2_AB-25); - 124 - 3839034.v1
5708.1076005 SEQ ID NO:98 and SEQ ID NO:75 (S2_AB-26); SEQ ID NO:99 and SEQ ID NO:80 (S2_AB-27); SEQ ID NO:100 and SEQ ID NO:85 (S2_AB-28); SEQ ID NO:101 and SEQ ID NO:80 (S2_AB-29); SEQ ID NO:101 and SEQ ID NO:117 (S2_AB-30); SEQ ID NO:102 and SEQ ID NO:118 (S2_AB-31); SEQ ID NO:103 and SEQ ID NO:119 (S2_AB-32); SEQ ID NO:104 and SEQ ID NO:120 (S2_AB-33); SEQ ID NO:105 and SEQ ID NO:115 (S2_AB-34); SEQ ID NO:106 and SEQ ID NO:80 (S2_AB-35); SEQ ID NO:107 and SEQ ID NO:121 (S2_AB-36); SEQ ID NO:108 and SEQ ID NO:75 (S2_AB-37); SEQ ID NO:109 and SEQ ID NO:80 (S2_AB-38); SEQ ID NO:110 and SEQ ID NO:87 (S2_AB-39); SEQ ID NO:111 and SEQ ID NO:117 (S2_AB-40); SEQ ID NO:562 and SEQ ID NO:573 (S2_AB-41); SEQ ID NO:563 and SEQ ID NO:76 (S2_AB-42); SEQ ID NO:564 and SEQ ID NO:75 (S2_AB-43); SEQ ID NO:565 and SEQ ID NO:574 (S2_AB-44); SEQ ID NO:566 and SEQ ID NO:80 (S2_AB-45); SEQ ID NO:567 and SEQ ID NO:75 (S2_AB-46); SEQ ID NO:568 and SEQ ID NO:574 (S2_AB-47); SEQ ID NO:569 and SEQ ID NO:77 (S2_AB-48); SEQ ID NO:570 and SEQ ID NO:76 (S2_AB-49); SEQ ID NO:571 and SEQ ID NO:575 (S2_AB-50); or SEQ ID NO:56 and SEQ ID NO:80 (S2_AB-51). [00585] In some embodiments, an antibody or an antigen-binding fragment thereof that specifically binds an S2 domain of SARS-CoV-2-Spike comprises an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2, and an LCDR3 of an antibody comprising a VH amino acid sequence of SEQ ID NO:53 and a VL amino acid sequence of SEQ ID NO:75 (S2_AB-1). [00586] In some embodiments, an antibody or an antigen-binding fragment thereof that specifically binds an S2 domain of SARS-CoV-2-Spike comprises: a) an HCDR1 comprising GYTFTRYW (SEQ ID NO:557); - 125 - 3839034.v1
5708.1076005 b) an HCDR2 comprising IYPGDSDV (SEQ ID NO:558); c) an HCDR3 comprising ARLPQYCSKGVCYRWFDP (SEQ ID NO:559); d) an LCDR1 comprising QGISSW (SEQ ID NO:560); e) an LCDR2 comprising AAS; and f) an LCDR3 comprising QQGHSFPYT (SEQ ID NO:561). [00587] In some embodiments, an antibody or an antigen-binding fragment thereof that specifically binds an S2 domain of SARS-CoV-2-Spike comprises: a) an HCDR1 consisting of GYTFTRYW (SEQ ID NO:557); b) an HCDR2 consisting of IYPGDSDV (SEQ ID NO:558); c) an HCDR3 consisting of ARLPQYCSKGVCYRWFDP (SEQ ID NO:559); d) an LCDR1 consisting of QGISSW (SEQ ID NO:560); e) an LCDR2 consisting of AAS; and f) an LCDR3 consisting of QQGHSFPYT (SEQ ID NO:561). [00588] In some embodiments, an antibody or an antigen-binding fragment thereof that specifically binds an S2 domain of SARS-CoV-2-Spike comprises: a VH domain comprising the amino acid sequence of SEQ ID NO:53 and a VL domain comprising the amino acid sequence of SEQ ID NO:75 (S2_AB-1); a VH domain comprising the amino acid sequence of SEQ ID NO:57 and a VL domain comprising the amino acid sequence of SEQ ID NO:76 (S2_AB-2); a VH domain comprising the amino acid sequence of SEQ ID NO:58 and a VL domain comprising the amino acid sequence of SEQ ID NO:77 (S2_AB-3); a VH domain comprising the amino acid sequence of SEQ ID NO:59 and a VL domain comprising the amino acid sequence of SEQ ID NO:78 (S2_AB-4); a VH domain comprising the amino acid sequence of SEQ ID NO:60 and a VL domain comprising the amino acid sequence of SEQ ID NO:75 (S2_AB-5); a VH domain comprising the amino acid sequence of SEQ ID NO:61 and a VL domain comprising the amino acid sequence of SEQ ID NO:79 (S2_AB-6); a VH domain comprising the amino acid sequence of SEQ ID NO:62 and a VL domain comprising the amino acid sequence of SEQ ID NO:80 (S2_AB-7); a VH domain comprising the amino acid sequence of SEQ ID NO:63 and a VL domain comprising the amino acid sequence of SEQ ID NO:81 (S2_AB-8); a VH domain comprising the amino acid sequence of SEQ ID NO:64 and a VL domain comprising the amino acid sequence of SEQ ID NO:82 (S2_AB-9); - 126 - 3839034.v1
5708.1076005 a VH domain comprising the amino acid sequence of SEQ ID NO:65 and a VL domain comprising the amino acid sequence of SEQ ID NO:83 (S2_AB-10); a VH domain comprising the amino acid sequence of SEQ ID NO:66 and a VL domain comprising the amino acid sequence of SEQ ID NO:84 (S2_AB-11); a VH domain comprising the amino acid sequence of SEQ ID NO:67 and a VL domain comprising the amino acid sequence of SEQ ID NO:80 (S2_AB-12); a VH domain comprising the amino acid sequence of SEQ ID NO:68 and a VL domain comprising the amino acid sequence of SEQ ID NO:75 (S2_AB-13); a VH domain comprising the amino acid sequence of SEQ ID NO:62 and a VL domain comprising the amino acid sequence of SEQ ID NO:74 (S2_AB-14); a VH domain comprising the amino acid sequence of SEQ ID NO:69 and a VL domain comprising the amino acid sequence of SEQ ID NO:85 (S2_AB-15); a VH domain comprising the amino acid sequence of SEQ ID NO:70 and a VL domain comprising the amino acid sequence of SEQ ID NO:86 (S2_AB-16); a VH domain comprising the amino acid sequence of SEQ ID NO:58 and a VL domain comprising the amino acid sequence of SEQ ID NO:87 (S2_AB-17); a VH domain comprising the amino acid sequence of SEQ ID NO:71 and a VL domain comprising the amino acid sequence of SEQ ID NO:88 (S2_AB-18); a VH domain comprising the amino acid sequence of SEQ ID NO:53 and a VL domain comprising the amino acid sequence of SEQ ID NO:85 (S2_AB-19); a VH domain comprising the amino acid sequence of SEQ ID NO:72 and a VL domain comprising the amino acid sequence of SEQ ID NO:85 (S2_AB-20); a VH domain comprising the amino acid sequence of SEQ ID NO:94 and a VL domain comprising the amino acid sequence of SEQ ID NO:113 (S2_AB-21); a VH domain comprising the amino acid sequence of SEQ ID NO:95 and a VL domain comprising the amino acid sequence of SEQ ID NO:114 (S2_AB-22); a VH domain comprising the amino acid sequence of SEQ ID NO:53 and a VL domain comprising the amino acid sequence of SEQ ID NO:115 (S2_AB-23); a VH domain comprising the amino acid sequence of SEQ ID NO:96 and a VL domain comprising the amino acid sequence of SEQ ID NO:80 (S2_AB-24); a VH domain comprising the amino acid sequence of SEQ ID NO:97 and a VL domain comprising the amino acid sequence of SEQ ID NO:116 (S2_AB-25); - 127 - 3839034.v1
5708.1076005 a VH domain comprising the amino acid sequence of SEQ ID NO:98 and a VL domain comprising the amino acid sequence of SEQ ID NO:75 (S2_AB-26); a VH domain comprising the amino acid sequence of SEQ ID NO:99 and a VL domain comprising the amino acid sequence of SEQ ID NO:80 (S2_AB-27); a VH domain comprising the amino acid sequence of SEQ ID NO:100 and a VL domain comprising the amino acid sequence of SEQ ID NO:85 (S2_AB-28); a VH domain comprising the amino acid sequence of SEQ ID NO:101 and a VL domain comprising the amino acid sequence of SEQ ID NO:80 (S2_AB-29); a VH domain comprising the amino acid sequence of SEQ ID NO:101 and a VL domain comprising the amino acid sequence of SEQ ID NO:117 (S2_AB-30); a VH domain comprising the amino acid sequence of SEQ ID NO:102 and a VL domain comprising the amino acid sequence of SEQ ID NO:118 (S2_AB-31); a VH domain comprising the amino acid sequence of SEQ ID NO:103 and a VL domain comprising the amino acid sequence of SEQ ID NO:119 (S2_AB-32); a VH domain comprising the amino acid sequence of SEQ ID NO:104 and a VL domain comprising the amino acid sequence of SEQ ID NO:120 (S2_AB-33); a VH domain comprising the amino acid sequence of SEQ ID NO:105 and a VL domain comprising the amino acid sequence of SEQ ID NO:115 (S2_AB-34); a VH domain comprising the amino acid sequence of SEQ ID NO:106 and a VL domain comprising the amino acid sequence of SEQ ID NO:80 (S2_AB-35); a VH domain comprising the amino acid sequence of SEQ ID NO:107 and a VL domain comprising the amino acid sequence of SEQ ID NO:121 (S2_AB-36); a VH domain comprising the amino acid sequence of SEQ ID NO:108 and a VL domain comprising the amino acid sequence of SEQ ID NO:75 (S2_AB-37); a VH domain comprising the amino acid sequence of SEQ ID NO:109 and a VL domain comprising the amino acid sequence of SEQ ID NO:80 (S2_AB-38); a VH domain comprising the amino acid sequence of SEQ ID NO:110 and a VL domain comprising the amino acid sequence of SEQ ID NO:87 (S2_AB-39); a VH domain comprising the amino acid sequence of SEQ ID NO:111 and a VL domain comprising the amino acid sequence of SEQ ID NO:117 (S2_AB-40); a VH domain comprising the amino acid sequence of SEQ ID NO:562 and a VL domain comprising the amino acid sequence of SEQ ID NO:573 (S2_AB-41); - 128 - 3839034.v1
5708.1076005 a VH domain comprising the amino acid sequence of SEQ ID NO:563 and a VL domain comprising the amino acid sequence of SEQ ID NO:76 (S2_AB-42); a VH domain comprising the amino acid sequence of SEQ ID NO:564 and a VL domain comprising the amino acid sequence of SEQ ID NO:75 (S2_AB-43); a VH domain comprising the amino acid sequence of SEQ ID NO:565 and a VL domain comprising the amino acid sequence of SEQ ID NO:574 (S2_AB-44); a VH domain comprising the amino acid sequence of SEQ ID NO:566 and a VL domain comprising the amino acid sequence of SEQ ID NO:80 (S2_AB-45); a VH domain comprising the amino acid sequence of SEQ ID NO:567 and a VL domain comprising the amino acid sequence of SEQ ID NO:75 (S2_AB-46); a VH domain comprising the amino acid sequence of SEQ ID NO:568 and a VL domain comprising the amino acid sequence of SEQ ID NO:574 (S2_AB-47); a VH domain comprising the amino acid sequence of SEQ ID NO:569 and a VL domain comprising the amino acid sequence of SEQ ID NO:77 (S2_AB-48); a VH domain comprising the amino acid sequence of SEQ ID NO:570 and a VL domain comprising the amino acid sequence of SEQ ID NO:76 (S2_AB-49); a VH domain comprising the amino acid sequence of SEQ ID NO:571 and a VL domain comprising the amino acid sequence of SEQ ID NO:575 (S2_AB-50); or a VH domain comprising the amino acid sequence of SEQ ID NO:56 and a VL domain comprising the amino acid sequence of SEQ ID NO:80 (S2_AB-51). [00589] In some embodiments, an antibody or an antigen-binding fragment thereof that specifically binds an S2 domain of SARS-CoV-2-Spike comprises: a) a VH domain comprising the amino acid sequence of SEQ ID NO:53; and b) a VL domain comprising the amino acid sequence of SEQ ID NO:75. [00590] In some embodiments, a composition (e.g., a pharmaceutical composition) comprises: a) an antibody or an antigen-binding fragment thereof comprising: i. a VH domain comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO:24, an HCDR2 comprising the amino acid sequence of SEQ ID NO:28, and an HCDR3 comprising the amino acid sequence of SEQ ID NO:33; and ii. a VL domain comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO:37, an LCDR2 comprising the amino acid sequence of - 129 - 3839034.v1
5708.1076005 SEQ ID NO:40; and an LCDR3 comprising the amino acid sequence of SEQ ID NO:44; and b) an antibody or an antigen-binding fragment thereof comprising: i. a VH domain comprising an HCDR1 comprising GYTFTRYW (SEQ ID NO:557), an HCDR2 comprising IYPGDSDV (SEQ ID NO:558), and an HCDR3 comprising ARLPQYCSKGVCYRWFDP (SEQ ID NO:559); and ii. a VL domain comprising an LCDR1 comprising QGISSW (SEQ ID NO:560), an LCDR2 comprising AAS, and an LCDR3 comprising QQGHSFPYT (SEQ ID NO:561). [00591] In some embodiments, a composition (e.g., a pharmaceutical composition) comprises: a) an antibody or an antigen-binding fragment thereof comprising: i. a VH domain comprising an HCDR1 consisting of the amino acid sequence of SEQ ID NO:24, an HCDR2 consisting of the amino acid sequence of SEQ ID NO:28, and an HCDR3 consisting of the amino acid sequence of SEQ ID NO:33; and ii. a VL domain comprising an LCDR 1 consisting of the amino acid sequence of SEQ ID NO:37, an LCDR2 consisting of the amino acid sequence of SEQ ID NO:40, and an LCDR3 consisting of the amino acid sequence of SEQ ID NO:44; and b) an antibody or an antigen-binding fragment thereof comprising: i. a VH domain comprising an HCDR1 consisting of GYTFTRYW (SEQ ID NO:557), an HCDR2 consisting of IYPGDSDV (SEQ ID NO:558), and an HCDR3 consisting of ARLPQYCSKGVCYRWFDP (SEQ ID NO:559); and ii. a VL domain comprising an LCDR1 consisting of QGISSW (SEQ ID NO:560), an LCDR2 consisting of AAS, and an LCDR3 consisting of QQGHSFPYT (SEQ ID NO:561). [00592] In some embodiments, a composition (e.g., a pharmaceutical composition) comprises: a) an antibody or an antigen-binding fragment thereof comprising a VH domain comprising the amino acid sequence of SEQ ID NO:5 and a VL domain comprising the amino acid sequence of SEQ ID NO:14; and - 130 - 3839034.v1
5708.1076005 b) an antibody or an antigen-binding fragment thereof comprising a VH domain comprising the amino acid sequence of SEQ ID NO:53 and a VL domain comprising the amino acid sequence of SEQ ID NO:75. [00593] In some embodiments, a composition (e.g., a pharmaceutical composition) comprises: a) an antibody or an antigen-binding fragment thereof comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:578 and a light chain comprising the amino acid sequence of SEQ ID NO:592; and b) an antibody or an antigen-binding fragment thereof comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:622 and a light chain comprising the amino acid sequence of SEQ ID NO:623. [00594] S2_AB-1 heavy chain sequence: EVQLVESGAEVKKPGESLKISCKGSGYTFTRYWIGWVRQMPGKGLEWMGIIYPGDSD VRYSPSFQGHVTISADKSISTAYLQWNSLKASDTAMYYCARLPQYCSKGVCYRWFDP WGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHT CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ PREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD GSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK (SEQ ID NO:622). [00595] S2_AB-1 light chain sequence: [00596] EIVLTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASS LQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGHSFPYTFGQGTNLEIKRTVAAP SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:623). Methods of Use [00597] The disclosure also provides, among other things, a method of neutralizing a SARS- CoV-2 protein in a subject, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and, wherein as an active ingredient, any one of the polypeptides, polynucleotides, fusion proteins, or compositions disclosed herein. [00598] The disclosure also provides, among other things, a method of treating a subject in need thereof, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and, wherein as an active - 131 - 3839034.v1
5708.1076005 ingredient, any one of the polypeptides, polynucleotides, fusion proteins, or compositions disclosed herein. [00599] The disclosure also provides, among other things, a method of treating a SARS-CoV- 2 infection in a subject, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and, wherein as an active ingredient, any one of the polypeptides, polynucleotides, fusion proteins, or compositions disclosed herein. [00600] The disclosure also provides, among other things, a method of reducing viral load of SARS-CoV-2 in a subject, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and, wherein as an active ingredient, any one of the polypeptides, polynucleotides, fusion proteins, or compositions disclosed herein. [00601] The disclosure also provides, among other things, a method of reducing (e.g., preventing) a SARS-CoV-2 infection in a subject, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and, wherein as an active ingredient, any one of the polypeptides, polynucleotides, fusion proteins, or compositions disclosed herein. [00602] The disclosure also provides, among other things, a method of reducing (e.g., preventing) a SARS-CoV-2 infection in a subject, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and, wherein as an active ingredient, any one of the polypeptides, polynucleotides, fusion proteins, or compositions disclosed herein. [00603] In some embodiments, a method disclosed herein (e.g., neutralizing a SARS-CoV-2 protein in a subject, treating a subject in need thereof, treating a SARS-CoV-2 infection in a subject, reducing viral load of SARS-CoV-2 in a subject, reducing (e.g., preventing) a SARS- CoV-2 infection in a subject, or reducing (e.g., preventing) a SARS-CoV-2 infection in a subject) comprises administering to the subject an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an antibody or an antigen- binding fragment thereof comprising: a) a VH domain comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO:24, an HCDR2 comprising the amino acid sequence of SEQ ID NO:28, and an HCDR3 comprising the amino acid sequence of SEQ ID NO:33; and - 132 - 3839034.v1
5708.1076005 b) a VL domain comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO:37, an LCDR2 comprising the amino acid sequence of SEQ ID NO:40; and an LCDR3 comprising the amino acid sequence of SEQ ID NO:44. [00604] In some embodiments, a method disclosed herein (e.g., neutralizing a SARS-CoV-2 protein in a subject, treating a subject in need thereof, treating a SARS-CoV-2 infection in a subject, reducing viral load of SARS-CoV-2 in a subject, reducing (e.g., preventing) a SARS- CoV-2 infection in a subject, or reducing (e.g., preventing) a SARS-CoV-2 infection in a subject) comprises administering to the subject an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and: a) an antibody or an antigen-binding fragment thereof comprising: i. a VH domain comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO:24, an HCDR2 comprising the amino acid sequence of SEQ ID NO:28, and an HCDR3 comprising the amino acid sequence of SEQ ID NO:33; and ii. a VL domain comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO:37, an LCDR2 comprising the amino acid sequence of SEQ ID NO:40; and an LCDR3 comprising the amino acid sequence of SEQ ID NO:44; and b) an antibody or an antigen-binding fragment thereof comprising: i. a VH domain comprising an HCDR1 comprising GYTFTRYW (SEQ ID NO:557), an HCDR2 comprising IYPGDSDV (SEQ ID NO:558), and an HCDR3 comprising ARLPQYCSKGVCYRWFDP (SEQ ID NO:559); and ii. a VL domain comprising an LCDR1 comprising QGISSW (SEQ ID NO:560), an LCDR2 comprising AAS, and an LCDR3 comprising QQGHSFPYT (SEQ ID NO:561). [00605] In some embodiments, a method disclosed herein (e.g., neutralizing a SARS-CoV-2 protein in a subject, treating a subject in need thereof, treating a SARS-CoV-2 infection in a subject, reducing viral load of SARS-CoV-2 in a subject, reducing (e.g., preventing) a SARS- CoV-2 infection in a subject, or reducing (e.g., preventing) a SARS-CoV-2 infection in a subject) comprises administering to the subject an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an antibody or an antigen- binding fragment thereof comprising: - 133 - 3839034.v1
5708.1076005 a) a VH domain comprising an HCDR1 consisting of the amino acid sequence of SEQ ID NO:24, an HCDR2 consisting of the amino acid sequence of SEQ ID NO:28, and an HCDR3 consisting of the amino acid sequence of SEQ ID NO:33; and b) a VL domain comprising an LCDR 1 consisting of the amino acid sequence of SEQ ID NO:37, an LCDR2 consisting of the amino acid sequence of SEQ ID NO:40, and an LCDR3 consisting of the amino acid sequence of SEQ ID NO:44. [00606] In some embodiments, a method disclosed herein (e.g., neutralizing a SARS-CoV-2 protein in a subject, treating a subject in need thereof, treating a SARS-CoV-2 infection in a subject, reducing viral load of SARS-CoV-2 in a subject, reducing (e.g., preventing) a SARS- CoV-2 infection in a subject, or reducing (e.g., preventing) a SARS-CoV-2 infection in a subject) comprises administering to the subject an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and: a) an antibody or an antigen-binding fragment thereof comprising: i. a VH domain comprising an HCDR1 consisting of the amino acid sequence of SEQ ID NO:24, an HCDR2 consisting of the amino acid sequence of SEQ ID NO:28, and an HCDR3 consisting of the amino acid sequence of SEQ ID NO:33; and ii. a VL domain comprising an LCDR 1 consisting of the amino acid sequence of SEQ ID NO:37, an LCDR2 consisting of the amino acid sequence of SEQ ID NO:40, and an LCDR3 consisting of the amino acid sequence of SEQ ID NO:44; and b) an antibody or an antigen-binding fragment thereof comprising: i. a VH domain comprising an HCDR1 consisting of GYTFTRYW (SEQ ID NO:557), an HCDR2 consisting of IYPGDSDV (SEQ ID NO:558), and an HCDR3 consisting of ARLPQYCSKGVCYRWFDP (SEQ ID NO:559); and ii. a VL domain comprising an LCDR1 consisting of QGISSW (SEQ ID NO:560), an LCDR2 consisting of AAS, and an LCDR3 consisting of QQGHSFPYT (SEQ ID NO:561). [00607] In some embodiments, a method disclosed herein (e.g., neutralizing a SARS-CoV-2 protein in a subject, treating a subject in need thereof, treating a SARS-CoV-2 infection in a subject, reducing viral load of SARS-CoV-2 in a subject, reducing (e.g., preventing) a SARS- - 134 - 3839034.v1
5708.1076005 CoV-2 infection in a subject, or reducing (e.g., preventing) a SARS-CoV-2 infection in a subject) comprises administering to the subject an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an antibody or an antigen- binding fragment thereof comprising a VH domain comprising the amino acid sequence of SEQ ID NO:5 and a VL domain comprising the amino acid sequence of SEQ ID NO:14. [00608] In some embodiments, a method disclosed herein (e.g., neutralizing a SARS-CoV-2 protein in a subject, treating a subject in need thereof, treating a SARS-CoV-2 infection in a subject, reducing viral load of SARS-CoV-2 in a subject, reducing (e.g., preventing) a SARS- CoV-2 infection in a subject, or reducing (e.g., preventing) a SARS-CoV-2 infection in a subject) comprises administering to the subject an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and: a) an antibody or an antigen-binding fragment thereof comprising a VH domain comprising the amino acid sequence of SEQ ID NO:5 and a VL domain comprising the amino acid sequence of SEQ ID NO:14; and b) an antibody or an antigen-binding fragment thereof comprising a VH domain comprising the amino acid sequence of SEQ ID NO:53 and a VL domain comprising the amino acid sequence of SEQ ID NO:75. [00609] In some embodiments, a method disclosed herein (e.g., neutralizing a SARS-CoV-2 protein in a subject, treating a subject in need thereof, treating a SARS-CoV-2 infection in a subject, reducing viral load of SARS-CoV-2 in a subject, reducing (e.g., preventing) a SARS- CoV-2 infection in a subject, or reducing (e.g., preventing) a SARS-CoV-2 infection in a subject) comprises administering to the subject an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an antibody or an antigen- binding fragment thereof comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:578 and a light chain comprising the amino acid sequence of SEQ ID NO:592. [00610] In some embodiments, a method disclosed herein (e.g., neutralizing a SARS-CoV-2 protein in a subject, treating a subject in need thereof, treating a SARS-CoV-2 infection in a subject, reducing viral load of SARS-CoV-2 in a subject, reducing (e.g., preventing) a SARS- CoV-2 infection in a subject, or reducing (e.g., preventing) a SARS-CoV-2 infection in a subject) comprises administering to the subject an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and: - 135 - 3839034.v1
5708.1076005 a) an antibody or an antigen-binding fragment thereof comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:578 and a light chain comprising the amino acid sequence of SEQ ID NO:592; and b) an antibody or an antigen-binding fragment thereof comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:622 and a light chain comprising the amino acid sequence of SEQ ID NO:623. [00611] The disclosure also provides, among other things, a method of reducing infectivity of SARS-CoV-2 of a cell in a subject, comprising contacting the cell with any one of the polypeptides, polynucleotides, fusion proteins, or compositions disclosed herein. [00612] The disclosure also provides, among other things, a method of reducing (e.g., inhibiting) binding of SARS-CoV-2 to a target cell, comprising contacting the target cell with any one of the polypeptides, polynucleotides, fusion proteins, or compositions disclosed herein. [00613] The disclosure also provides, among other things, a method of reducing (e.g., inhibiting) binding of SARS-CoV-2 to a target protein on a target cell, comprising contacting the target cell with any one of the polypeptides, polynucleotides, fusion proteins, or compositions disclosed herein. [00614] The disclosure also provides, among other things, a method of reducing (e.g., inhibiting) virus mediated fusion with a target cell, comprising contacting the target cell with any one of the polypeptides, polynucleotides, fusion proteins, or compositions disclosed herein. [00615] In some embodiments, a method disclosed herein (e.g., reducing infectivity of SARS- CoV-2 of a cell in a subject, reducing (e.g., inhibiting) binding of SARS-CoV-2 to a target cell, reducing (e.g., inhibiting) binding of SARS-CoV-2 to a target protein on a target cell, or reducing (e.g., inhibiting) virus mediated fusion with a target cell), comprises contacting the target cell with an antibody or an antigen-binding fragment thereof comprising: a) a VH domain comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO:24, an HCDR2 comprising the amino acid sequence of SEQ ID NO:28, and an HCDR3 comprising the amino acid sequence of SEQ ID NO:33; and b) a VL domain comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO:37, an LCDR2 comprising the amino acid sequence of SEQ ID NO:40; and an LCDR3 comprising the amino acid sequence of SEQ ID NO:44. [00616] In some embodiments, a method disclosed herein (e.g., reducing infectivity of SARS- CoV-2 of a cell in a subject, reducing (e.g., inhibiting) binding of SARS-CoV-2 to a target cell, reducing (e.g., inhibiting) binding of SARS-CoV-2 to a target protein on a target cell, or - 136 - 3839034.v1
5708.1076005 reducing (e.g., inhibiting) virus mediated fusion with a target cell), comprises contacting the target cell with: a) an antibody or an antigen-binding fragment thereof comprising: i. a VH domain comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO:24, an HCDR2 comprising the amino acid sequence of SEQ ID NO:28, and an HCDR3 comprising the amino acid sequence of SEQ ID NO:33; and ii. a VL domain comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO:37, an LCDR2 comprising the amino acid sequence of SEQ ID NO:40; and an LCDR3 comprising the amino acid sequence of SEQ ID NO:44; and b) an antibody or an antigen-binding fragment thereof comprising: i. a VH domain comprising an HCDR1 comprising GYTFTRYW (SEQ ID NO:557), an HCDR2 comprising IYPGDSDV (SEQ ID NO:558), and an HCDR3 comprising ARLPQYCSKGVCYRWFDP (SEQ ID NO:559); and ii. a VL domain comprising an LCDR1 comprising QGISSW (SEQ ID NO:560), an LCDR2 comprising AAS, and an LCDR3 comprising QQGHSFPYT (SEQ ID NO:561). [00617] In some embodiments, a method disclosed herein (e.g., reducing infectivity of SARS- CoV-2 of a cell in a subject, reducing (e.g., inhibiting) binding of SARS-CoV-2 to a target cell, reducing (e.g., inhibiting) binding of SARS-CoV-2 to a target protein on a target cell, or reducing (e.g., inhibiting) virus mediated fusion with a target cell), comprises contacting the target cell with an antibody or an antigen-binding fragment thereof comprising: a) a VH domain comprising an HCDR1 consisting of the amino acid sequence of SEQ ID NO:24, an HCDR2 consisting of the amino acid sequence of SEQ ID NO:28, and an HCDR3 consisting of the amino acid sequence of SEQ ID NO:33; and b) a VL domain comprising an LCDR 1 consisting of the amino acid sequence of SEQ ID NO:37, an LCDR2 consisting of the amino acid sequence of SEQ ID NO:40, and an LCDR3 consisting of the amino acid sequence of SEQ ID NO:44. [00618] In some embodiments, a method disclosed herein (e.g., reducing infectivity of SARS- CoV-2 of a cell in a subject, reducing (e.g., inhibiting) binding of SARS-CoV-2 to a target cell, - 137 - 3839034.v1
5708.1076005 reducing (e.g., inhibiting) binding of SARS-CoV-2 to a target protein on a target cell, or reducing (e.g., inhibiting) virus mediated fusion with a target cell), comprises contacting the target cell with: a) an antibody or an antigen-binding fragment thereof comprising: i. a VH domain comprising an HCDR1 consisting of the amino acid sequence of SEQ ID NO:24, an HCDR2 consisting of the amino acid sequence of SEQ ID NO:28, and an HCDR3 consisting of the amino acid sequence of SEQ ID NO:33; and ii. a VL domain comprising an LCDR 1 consisting of the amino acid sequence of SEQ ID NO:37, an LCDR2 consisting of the amino acid sequence of SEQ ID NO:40, and an LCDR3 consisting of the amino acid sequence of SEQ ID NO:44; and b) an antibody or an antigen-binding fragment thereof comprising: i. a VH domain comprising an HCDR1 consisting of GYTFTRYW (SEQ ID NO:557), an HCDR2 consisting of IYPGDSDV (SEQ ID NO:558), and an HCDR3 consisting of ARLPQYCSKGVCYRWFDP (SEQ ID NO:559); and ii. a VL domain comprising an LCDR1 consisting of QGISSW (SEQ ID NO:560), an LCDR2 consisting of AAS, and an LCDR3 consisting of QQGHSFPYT (SEQ ID NO:561). [00619] In some embodiments, a method disclosed herein (e.g., reducing infectivity of SARS- CoV-2 of a cell in a subject, reducing (e.g., inhibiting) binding of SARS-CoV-2 to a target cell, reducing (e.g., inhibiting) binding of SARS-CoV-2 to a target protein on a target cell, or reducing (e.g., inhibiting) virus mediated fusion with a target cell), comprises contacting the target cell with an antibody or an antigen-binding fragment thereof comprising a VH domain comprising the amino acid sequence of SEQ ID NO:5 and a VL domain comprising the amino acid sequence of SEQ ID NO:14. [00620] In some embodiments, a method disclosed herein (e.g., reducing infectivity of SARS- CoV-2 of a cell in a subject, reducing (e.g., inhibiting) binding of SARS-CoV-2 to a target cell, reducing (e.g., inhibiting) binding of SARS-CoV-2 to a target protein on a target cell, or reducing (e.g., inhibiting) virus mediated fusion with a target cell), comprises contacting the target cell with: - 138 - 3839034.v1
5708.1076005 a) an antibody or an antigen-binding fragment thereof comprising a VH domain comprising the amino acid sequence of SEQ ID NO:5 and a VL domain comprising the amino acid sequence of SEQ ID NO:14; and b) an antibody or an antigen-binding fragment thereof comprising a VH domain comprising the amino acid sequence of SEQ ID NO:53 and a VL domain comprising the amino acid sequence of SEQ ID NO:75. [00621] In some embodiments, a method disclosed herein (e.g., reducing infectivity of SARS- CoV-2 of a cell in a subject, reducing (e.g., inhibiting) binding of SARS-CoV-2 to a target cell, reducing (e.g., inhibiting) binding of SARS-CoV-2 to a target protein on a target cell, or reducing (e.g., inhibiting) virus mediated fusion with a target cell), comprises contacting the target cell with an antibody or an antigen-binding fragment thereof comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:578 and a light chain comprising the amino acid sequence of SEQ ID NO:592. [00622] In some embodiments, a method disclosed herein (e.g., reducing infectivity of SARS- CoV-2 of a cell in a subject, reducing (e.g., inhibiting) binding of SARS-CoV-2 to a target cell, reducing (e.g., inhibiting) binding of SARS-CoV-2 to a target protein on a target cell, or reducing (e.g., inhibiting) virus mediated fusion with a target cell), comprises contacting the target cell with: a) an antibody or an antigen-binding fragment thereof comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:578 and a light chain comprising the amino acid sequence of SEQ ID NO:592; and b) an antibody or an antigen-binding fragment thereof comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:622 and a light chain comprising the amino acid sequence of SEQ ID NO:623. [00623] In some embodiments, a likelihood of SARS-CoV-2 infection in a subject is reduced by at least about 10%, e.g., by at least about: 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. [00624] In some embodiments, the likelihood of SARS-CoV-2 infection in a subject in the presence of a polypeptide is about 1-90% relative to the likelihood in the absence of the polypeptide, for example, about: 2-90%, 2-85%, 3-85%, 3-80%, 4-80%, 4-75%, 5-75%, 5-70%, 6-70%, 6-65%, 7-65%, 7-60%, 8-60%, 8-55%, 9-55%, 9-50%, 10-50%, 10-45%, 15-45%, 15- 40%, 20-40%, 20-35%, 25-35%, or 25-30%. - 139 - 3839034.v1
5708.1076005 [00625] In some embodiments, a subject has (e.g., confirmed by testing, such as by PCR or rapid test), or is suspected of having, COVID-19. In some embodiments, a subject has COVID- 19. In some embodiments, a subject has been diagnosed with COVID-19. In some embodiments, a subject is at risk of developing COVID-19. [00626] In some embodiments, a subject is a mammal. In some embodiments, a subject is a mammal selected from the group consisting of a dog, a cat, a mouse, a rat, a hamster, a guinea pig, a horse, a pig, a sheep, a cow, a chimpanzee, a macaque, a cynomolgus, and a human. In some embodiments, a subject is a primate. In some embodiments, a subject is a human. [00627] In some embodiments, a subject has a heart disease. In some embodiments, a subject has a heart disease selected from the group consisting of a congenital heart disease, a coronary artery disease, a hypertensive heart disease, an inflammatory heart disease, a pulmonary heart disease, a rheumatic heart disease, a valvular heart disease, a cardiomyopathy, heart failure, and combinations thereof. In some embodiments, a subject has a congestive heart failure. In some embodiments, a subject has an inflammatory heart disease selected from the group consisting of endocarditis, cardiomegaly, myocarditis, and combinations thereof. [00628] In some embodiments, a subject has diabetes. [00629] In some embodiments, a subject has a lung disease. Non-limiting examples of lung diseases include acute respiratory distress syndromes, asthma, bronchitis, COPD, emphysema, lung tumors, pleural cavity diseases (e.g., pleural mesothelioma or tension pneumothorax), pulmonary vascular diseases (e.g., embolisms, edema, arterial hypertension or hemorrhage), or respiratory tract infections (e.g., pneumonia or other upper or lower respiratory tract infections). [00630] In some embodiments, a subject is a tobacco smoker. [00631] In some embodiments, a subject is immune-compromised (e.g., has an underlying disorder or is on immunosuppressive therapy). [00632] In some embodiments, a subject is 40 years or older, e.g., at least: 45, 50, 55, 60, 65, 70, 75, 80, 85, or 90 years old. [00633] In some embodiments, a method is used for prophylactic therapy. In some embodiments, an effective dosage is sufficient to prevent the subject of being infected by SARS- CoV-2. [00634] In some embodiments, a method is used for treating SARS-CoV-2 infection. [00635] In some embodiments, an effective dosage is sufficient to reduce viral load in a subject. In some embodiments, reduction in viral load is by at least about 10%, e.g., by at least about: 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, - 140 - 3839034.v1
5708.1076005 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. In some embodiments, reduction in viral load is about 10-99%, e.g., about: 10-98%, 15-98%, 15-97%, 20-97%, 20-96%, 25-96%, 25-95%, 30-95%, 30-94%, 35-94%, 35-93%, 40-93%, 40-92%, 45-92%, 45-91%, 50-91%, 50- 90%, 55-90%, 55-85%, 60-85%, 60-80%, 65-80%, 65-75%, or 70-75%. [00636] In some embodiments, an effective dosage is sufficient to inhibit binding of a virus to its target proteins, target cells, or both. In some embodiments, reduction in binding is by at least about 10%, e.g., by at least about: 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. In some embodiments, reduction in binding is about 10-99%, e.g., about: 10-98%, 15-98%, 15- 97%, 20-97%, 20-96%, 25-96%, 25-95%, 30-95%, 30-94%, 35-94%, 35-93%, 40-93%, 40-92%, 45-92%, 45-91%, 50-91%, 50-90%, 55-90%, 55-85%, 60-85%, 60-80%, 65-80%, 65-75%, or 70-75%. [00637] In some embodiments, an effective dosage is sufficient to inhibit virus-mediated fusion with a target cell. In some embodiments, reduction in fusion is by at least about 10%, e.g., by at least about: 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. In some embodiments, reduction in fusion is about 10-99%, e.g., about: 10-98%, 15-98%, 15-97%, 20-97%, 20-96%, 25-96%, 25-95%, 30-95%, 30-94%, 35-94%, 35-93%, 40-93%, 40-92%, 45-92%, 45-91%, 50- 91%, 50-90%, 55-90%, 55-85%, 60-85%, 60-80%, 65-80%, 65-75%, or 70-75%. [00638] In some embodiments, an effective dosage is sufficient to interfere with conformational changes in a viral envelope protein necessary for cell infectivity. [00639] A therapeutic agent described herein can be administered via a variety of routes of administration, including, for example, oral, dietary, topical, transdermal, rectal, parenteral (e.g., intra-arterial, intravenous, intramuscular, subcutaneous injection, intradermal injection), intravenous infusion, and inhalation (e.g., intrabronchial, intranasal or oral inhalation, intranasal drops) routes of administration, depending on the compound and the particular disease to be treated. Administration can be local or systemic as indicated. A preferred mode of administration can vary depending on the particular compound chosen. [00640] In some embodiments, a polypeptide, polynucleotide, fusion protein, composition (e.g., pharmaceutical composition) is administered to a subject as a monotherapy. [00641] In some embodiments, a polypeptide, c polynucleotide, fusion protein, composition (e.g., pharmaceutical composition) is administered to a subject in combination with at least one additional therapeutic agent (e.g., concurrently or sequentially with at least one additional - 141 - 3839034.v1
5708.1076005 therapeutic agent) or prophylactic agent (e.g., concurrently or sequentially with at least one additional prophylactic agent). In some embodiments, a subject has been previously treated with at least one additional therapeutic agent prior to being administered a polypeptide, polynucleotide, fusion protein, composition (e.g., pharmaceutical composition) disclosed herein. In some embodiments, a method disclosed herein comprises administering a therapeutically effective amount of at least one additional therapeutic agent to a subject at the same time as, or following administration of a polypeptide, polynucleotide, fusion protein, composition (e.g., pharmaceutical composition) disclosed herein. In some embodiments, a method disclosed herein comprises administering a therapeutically effective amount of at least one prophylactic agent to a subject before, at the same time as, or following administration of a polypeptide, polynucleotide, fusion protein, composition (e.g., pharmaceutical composition) disclosed herein. In some embodiments, a subject previously received a therapeutic or prophylactic agent. In some embodiments, a subject was previously infected with a betacoronavirus, such as SARS-CoV-2. [00642] In some embodiments, a subject is further treated (previously, concurrently, or sequentially) with (e.g., an effective amount of) one or more SARS-CoV-2 spike S2-specific antibodies or antigen-binding fragments thereof, such as CV3-25 or a variant thereof. Additional examples of SARS-CoV-2 spike S2-specific antibodies or antigen-binding fragments thereof include, for example, those described herein as S2_AB-1, S2_AB-2, S2_AB-3, S2_AB-4, S2_AB-5, S2_AB-6, S2_AB-7¸ S2_AB-8¸ S2_AB-9¸ S2_AB-10, S2_AB-11, S2_AB-12, S2_AB-13, S2_AB-14, S2_AB-15, S2_AB-16, S2_AB-17, S2_AB-18, S2_AB-19, S2_AB-20, S2_AB-21, S2_AB-22, S2_AB-23, S2_AB-24, S2_AB-25, S2_AB-26, S2_AB-27, S2_AB-28, S2_AB-29, S2_AB-30, S2_AB-31, S2_AB-32, S2_AB-33, S2_AB-34, S2_AB-35, S2_AB-36, S2_AB-37, S2_AB-38, S2_AB-39, and S2_AB-40 having VH and VL sequences in Tables 4 and 5 herein, respectively, and those described in U.S. Patent Application Nos.63/364,331 (filed on May 6, 2022), 63/364,328 (filed on May 6, 2022), 63/381,131 (filed on October 26, 2022), 63/381,132 (filed on October 26, 2022), 63/424,945 (filed on November 13, 2022), 63/383,695 (filed on November 14, 2022), 63/385,957 (filed on December 2, 2022), 63/478,650 (filed on January 5, 2023), 63/480,903 (filed on January 20, 2023), 63/492,206 (filed on March 24, 2023), 18/313,306 (filed on May 05, 2023), and Patent Cooperation Treaty Application No. PCT/US2023/066714 (filed on May 05, 2023), the entire contents of each of the aforementioned applications are incorporated herein by reference. Additional examples of anti-SARS-CoV-2 antibodies include those described in U.S. Patent No.11,168,128, U.S. Patent No.11,192,940, WO 2022/010912 A1, WO 2022/010921 A1, WO 2022/047033 A1, WO 2021/173753 A1, WO - 142 - 3839034.v1
5708.1076005 2021/158521 A1, WO 2021/203053 A1, WO 2021/211775 A1, WO 2021/226560 A1, the contents of each of which are incorporated herein by reference. Further examples of anti-SARS- CoV-2 antibodies are provided at www.covid19treatmentguidelines.nih.gov/therapies/anti-sars- cov-2-antibody-products/anti-sars-cov-2-monoclonal-antibodies. [00643] In some embodiments, a subject is further treated (previously, concurrently, or sequentially) with one or more SARS-CoV-2 RBD-class 3 antibodies (or antigen-binding fragments thereof), such as, for example, one or more of Sotrovimab, Bebtelovimab, AZD1061, P2G3, and EVUSHELD®. [00644] In some embodiments, the subject is further treated (previously, concurrently, or sequentially) with one or more SARS-CoV-2 N-terminal domain (NTD)-nonsupersite antibodies (or antigen-binding fragments thereof). [00645] In some embodiments, the subject is further treated (previously, concurrently, or sequentially) with one or more SARS-CoV-2 SD1 antibodies (or antigen-binding fragments thereof). [00646] In some embodiments, the ACE2 inhibitor is selected from the group consisting of an RNAi to ACE2, an siRNA to ACE2, a CRISPR-based inhibitor of ACE2, a soluble ACE2, a soluble ACE2 variant, an anti-ACE2 antibody, a vaccine, and combinations thereof. In some embodiments, the antibiotic is azithromycin. In some embodiments, the antimalarial agent comprises chloroquine or hydroxychloroquine. In some embodiments, the vaccine is a nucleic acid vaccine or an inactivated virus vaccine. In some embodiments, the vaccine is mrna-1273, BNT162, INO-4800, AZD1222, Ad5-nCoV, PiCoVacc, NVX-CoV2373, JNJ-78436735, or a combination thereof. [00647] Administration of the two or more therapeutic agents encompasses co-administration of the therapeutic agents in a substantially simultaneous manner, such as in a pharmaceutical combination. In some embodiments, such administration encompasses co-administration in multiple containers, or separate containers (e.g., capsules, powders, and liquids) for each therapeutic agent. Such administration also encompasses use of each type of therapeutic agent in a sequential manner, either at approximately the same time or at different times. The composition described herein and the second therapeutic agent can be administered via the same administration route or via different administration routes. - 143 - 3839034.v1
5708.1076005 Embodiments of the Disclosure 1. A polypeptide that specifically binds a spike receptor-binding domain (RBD) class 4 epitope of a betacoronavirus Spike glycoprotein (SARS-CoV-2-Spike), wherein the polypeptide has one or more properties selected from: a broadly neutralizing activity against a plurality of known and predicted betacoronaviruses (e.g., viruses and strains set forth in FIGs.6, 12, and 13 such as SARS CoV-2 Omicron BQ.1, SARS CoV-2 Omicron XBB (+K444T, L452R, F486V, R493Q, N658S), and/or SARS CoV-2 XBB); a binding affinity for an RBD domain class 4 epitope that is highly conserved across a plurality of betacoronaviruses (e.g., viruses and strains set forth in FIGs.6, 12, and 13 such as SARS CoV-2 Omicron BQ.1, SARS CoV-2 Omicron XBB (+K444T, L452R, F486V, R493Q, N658S), and/or SARS CoV-2 XBB); and an inhibitory activity against potential emerging betacoronavirus escape variants (e.g., viruses and strains set forth in FIGs.6, 12, and 13 such as SARS CoV-2 Omicron BQ.1, SARS CoV-2 Omicron XBB (+K444T, L452R, F486V, R493Q, N658S), and/or SARS CoV-2 XBB). 2. A polypeptide that specifically binds a severe acute respiratory syndrome coronavirus 2 Spike glycoprotein (SARS-CoV-2-Spike), comprising a paratope that is substantially similar to a paratope of an antibody comprising an amino acid sequence selected from: SEQ ID NO:4 and SEQ ID NO:9 (AB-1a); SEQ ID NO:4 and SEQ ID NO:10 (AB-1b); SEQ ID NO:4 and SEQ ID NO:11 (AB-1c); SEQ ID NO:4 and SEQ ID NO:12 (AB-1d); SEQ ID NO:5 and SEQ ID NO:13 (AB-2a); SEQ ID NO:5 and SEQ ID NO:14 (AB-2b); SEQ ID NO:5 and SEQ ID NO:15 (AB-2c); SEQ ID NO:5 and SEQ ID NO:16 (AB-2d); SEQ ID NO:6 and SEQ ID NO:17 (AB-3a); SEQ ID NO:6 and SEQ ID NO:18 (AB-3b); SEQ ID NO:6 and SEQ ID NO:19 (AB-3c); SEQ ID NO:6 and SEQ ID NO:20 (AB-3d); or any combination of the foregoing. - 144 - 3839034.v1
5708.1076005 3. The polypeptide of Embodiment 1 or 2, comprising an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL). 4. A polypeptide that specifically binds a severe acute respiratory syndrome coronavirus 2 Spike glycoprotein (SARS-CoV-2-Spike), comprising: a) an immunoglobulin heavy chain variable domain (VH) amino acid sequence comprising a heavy chain complementarity determining region 1 (HCDR1), a heavy chain complementarity determining region 2 (HCDR2) and a heavy chain complementarity determining region 3 (HCDR3) that are substantially similar to an HCDR1, HCDR2, and HCDR3, respectively, of the amino acid sequence of SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6; and b) an immunoglobulin light chain variable domain (VL) amino acid sequence comprising a light chain complementarity determining region 1 (LCDR1), a light chain complementarity determining region 2 (LCDR2), and a light chain complementarity determining region 3 (LCDR3) that are substantially similar to an LCDR1, LCDR2 and LCDR3, respectively, of the amino acid sequence of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, or SEQ ID NO:20. 5. The polypeptide of any one of Embodiments 1-4, comprising the HCDR1, HCDR2, and HCDR3, and LCDR1, LCDR2, and LCDR3, of an antibody comprising an amino acid sequence selected from: SEQ ID NO:4 and SEQ ID NO:9 (AB-1a); SEQ ID NO:4 and SEQ ID NO:10 (AB-1b); SEQ ID NO:4 and SEQ ID NO:11 (AB-1c); SEQ ID NO:4 and SEQ ID NO:12 (AB-1d); SEQ ID NO:5 and SEQ ID NO:13 (AB-2a); SEQ ID NO:5 and SEQ ID NO:14 (AB-2b); SEQ ID NO:5 and SEQ ID NO:15 (AB-2c); SEQ ID NO:5 and SEQ ID NO:16 (AB-2d); SEQ ID NO:6 and SEQ ID NO:17 (AB-3a); SEQ ID NO:6 and SEQ ID NO:18 (AB-3b); SEQ ID NO:6 and SEQ ID NO:19 (AB-3c); or - 145 - 3839034.v1
5708.1076005 SEQ ID NO:6 and SEQ ID NO:20 (AB-3d). 6. The polypeptide of Embodiment 4 or 5, comprising a paratope that is identical to a paratope of an antibody comprising an amino acid sequence selected from: SEQ ID NO:4 and SEQ ID NO:9 (AB-1a); SEQ ID NO:4 and SEQ ID NO:10 (AB-1b); SEQ ID NO:4 and SEQ ID NO:11 (AB-1c); SEQ ID NO:4 and SEQ ID NO:12 (AB-1d); SEQ ID NO:5 and SEQ ID NO:13 (AB-2a); SEQ ID NO:5 and SEQ ID NO:14 (AB-2b); SEQ ID NO:5 and SEQ ID NO:15 (AB-2c); SEQ ID NO:5 and SEQ ID NO:16 (AB-2d); SEQ ID NO:6 and SEQ ID NO:17 (AB-3a); SEQ ID NO:6 and SEQ ID NO:18 (AB-3b); SEQ ID NO:6 and SEQ ID NO:19 (AB-3c); or SEQ ID NO:6 and SEQ ID NO:20 (AB-3d). 7. A polypeptide that specifically binds a severe acute respiratory syndrome coronavirus 2 Spike glycoprotein (SARS-CoV-2-Spike), comprising an immunoglobulin heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO:2, wherein: X1 is not G; X2 is not I; X3 is not F; X4 is not N; X5 is not M; X6 is not S; X7 is not M; X8 is not N; X9 is not G; X10 is not N; X11 is not I; or any combination of the foregoing. 8. The polypeptide of Embodiment 7, comprising an immunoglobulin light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO:7, wherein: - 146 - 3839034.v1
5708.1076005 X12 is not N; X13 is not D; X14 is not C; X15 is not N; X16 is not S; X17 is not L; X18 is not S; X19 is not G; X20 is not N; or any combination of the foregoing. 9. A polypeptide that specifically binds a severe acute respiratory syndrome coronavirus 2 Spike glycoprotein (SARS-CoV-2-Spike), comprising an immunoglobulin heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO:2, wherein: X1 is G or D; X2 is I, T or Y; X3 is F, S or D; X4 is N or D; X5 is M or L; X6 is S or F; X7 is M, Y or A; X8 is N or H; X9 is G or P; X10 is N or D; X11 is I or F; or any combination of the foregoing. 10. The polypeptide of Embodiment 9, wherein: X1 is D; X2 is T or Y; X3 is S or D; X4 is D; X5 is L; X6 is F; - 147 - 3839034.v1
5708.1076005 X7 is Y or A; X8 is H; X9 is P; X10 is D; X11 is F; or any combination of the foregoing. 11. The polypeptide of Embodiment 9 or 10, comprising an immunoglobulin light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO:7, wherein: X12 is N or S; X13 is D or R; X14 is C, A, S, or Y; X15 is N or R; X16 is S or D; X17 is L or S; X18 is S or F; X19 is G or D; X20 is N or H; or any combination of the foregoing. 12. The polypeptide of Embodiment 11, wherein: X12 is S; X13 is R; X14 is A, S, or Y; X15 is R; X16 is D; X17 is S; X18 is F; X19 is D; X20 is H; or any combination of the foregoing. 13. The polypeptide of any one of Embodiments 1-4 and 6-12, wherein the VH comprises a heavy chain complementarity determining region 1 (HCDR1), a heavy chain complementarity determining region 2 (HCDR2) and a heavy chain complementarity - 148 - 3839034.v1
5708.1076005 determining region 3 (HCDR3) that are identical in amino acid sequence to the HCDR1, HCDR2 and HCDR3, respectively, of SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6. 14. The polypeptide of any one of Embodiments 1-4 and 6-13, wherein the VL comprises a light chain complementarity determining region 1 (LCDR1), light chain complementarity determining region 2 (LCDR2) and light chain complementarity determining region 3 (LCDR3) that are identical in amino acid sequence to the LCDR1, LCDR2 and LCDR3, respectively, of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19 or SEQ ID NO:20. 15. The polypeptide of any one of Embodiments 1-5 and 7-14, wherein the polypeptide comprises a paratope that is identical to a paratope of a VH/VL combination selected from the amino acid sequence of: SEQ ID NO:4 and SEQ ID NO:9 (AB-1a); SEQ ID NO:4 and SEQ ID NO:10 (AB-1b); SEQ ID NO:4 and SEQ ID NO:11 (AB-1c); SEQ ID NO:4 and SEQ ID NO:12 (AB-1d); SEQ ID NO:5 and SEQ ID NO:13 (AB-2a); SEQ ID NO:5 and SEQ ID NO:14 (AB-2b); SEQ ID NO:5 and SEQ ID NO:15 (AB-2c); SEQ ID NO:5 and SEQ ID NO:16 (AB-2d); SEQ ID NO:6 and SEQ ID NO:17 (AB-3a); SEQ ID NO:6 and SEQ ID NO:18 (AB-3b); SEQ ID NO:6 and SEQ ID NO:19 (AB-3c); or SEQ ID NO:6 and SEQ ID NO:20 (AB-3d). 16. The polypeptide of any one of Embodiments 1-15, wherein the VH has at least 85% sequence identity to the amino acid sequence of SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6, or any combination of the foregoing. 17. The polypeptide of any one of Embodiments 1-16, wherein the VH comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6, or any combination of the foregoing. - 149 - 3839034.v1
5708.1076005 18. The polypeptide of any one of Embodiments 1-17, wherein the VL has at least 85% sequence identity to the amino acid sequence of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19 or SEQ ID NO:20, or any combination of the foregoing. 19. The polypeptide of any one of Embodiments 1-18, wherein the VL comprises about 1-10 amino acid substitutions, relative to the amino acid sequence of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19 or SEQ ID NO:20, or any combination of the foregoing. 20. The polypeptide of Embodiment 17 or 19, wherein the amino acid substitutions are conservative substitutions. 21. The polypeptide of Embodiment 20, wherein the amino acid substitutions are highly conservative substitutions. 22. The polypeptide of any one of Embodiments 1-20, wherein: a) the VH comprises the amino acid sequence of SEQ ID NO:4; and b) the VL comprises the amino acid sequence of SEQ ID NO:9 (AB-1a). 23. The polypeptide of any one of Embodiments 1-20, wherein: a) the VH comprises the amino acid sequence of SEQ ID NO:4; and b) the VL comprises the amino acid sequence of SEQ ID NO:10 (AB-1b). 24. The polypeptide of any one of Embodiments 1-20, wherein: a) the VH comprises the amino acid sequence of SEQ ID NO:4; and b) the VL comprises the amino acid sequence of SEQ ID NO:11 (AB-1c). 25. The polypeptide of any one of Embodiments 1-20, wherein: a) the VH comprises the amino acid sequence of SEQ ID NO:4; and b) the VL comprises the amino acid sequence of SEQ ID NO:12 (AB-1d). 26. The polypeptide of any one of Embodiments 1-20, wherein: a) the VH comprises the amino acid sequence of SEQ ID NO:5; and b) the VL comprises the amino acid sequence of SEQ ID NO:13 (AB-2a). - 150 - 3839034.v1
5708.1076005 27. The polypeptide of any one of Embodiments 1-20, wherein: a) the VH comprises the amino acid sequence of SEQ ID NO:5; and b) the VL comprises the amino acid sequence of SEQ ID NO:14 (AB-2b). 28. The polypeptide of any one of Embodiments 1-20, wherein: a) the VH comprises the amino acid sequence of SEQ ID NO:5; and b) the VL comprises the amino acid sequence of SEQ ID NO:15 (AB-2c). 29. The polypeptide of any one of Embodiments 1-20, wherein: a) the VH comprises the amino acid sequence of SEQ ID NO:5; and b) the VL comprises the amino acid sequence of SEQ ID NO:16 (AB-2d). 30. The polypeptide of any one of Embodiments 1-20, wherein: a) the VH comprises the amino acid sequence of SEQ ID NO:6; and b) the VL comprises the amino acid sequence of SEQ ID NO:17 (AB-3a). 31. The polypeptide of any one of Embodiments 1-20, wherein: a) the VH comprises the amino acid sequence of SEQ ID NO:6; and b) the VL comprises the amino acid sequence of SEQ ID NO:18 (AB-3b). 32. The polypeptide of any one of Embodiments 1-20, wherein: a) the VH comprises the amino acid sequence of SEQ ID NO:6; and b) the VL comprises the amino acid sequence of SEQ ID NO:19 (AB-3c). 33. The polypeptide of any one of Embodiments 1-20, wherein: a) the VH comprises the amino acid sequence of SEQ ID NO:6; and b) the VL comprises the amino acid sequence of SEQ ID NO:20 (AB-3d). 34. The polypeptide of any one of Embodiments 3-21, wherein the VH and VL are humanized, contain human framework regions, or a combination thereof. 35. The polypeptide of any one of Embodiments 1-34, wherein the polypeptide is an antibody or an antigen-binding fragment thereof. 36. The polypeptide of Embodiment 35, wherein the antigen binding fragment is selected from Fab, F(ab’)2, Fab’, scFv, or Fv. - 151 - 3839034.v1
5708.1076005 37. The polypeptide of Embodiment 35, comprising an antibody heavy chain constant domain sequence, an antibody light chain constant domain sequence, or both an antibody heavy chain constant domain sequence and an antibody light chain constant domain sequence. 38. The polypeptide of Embodiment 37, wherein the antibody heavy chain constant domain is selected from the group consisting of an IgA constant domain, an IgD constant domain, an IgE constant domain, an IgG constant domain and an IgM constant domain. 39. The polypeptide of Embodiment 38, wherein the antibody heavy chain constant domain is an IgG1 heavy chain constant domain. 40. The polypeptide of any one of Embodiments 37-39, comprising an antibody light chain constant domain selected from the group consisting of a κ constant domain or a λ constant domain. 41. The polypeptide of Embodiment 40, wherein the antibody light chain constant domain is a κ light chain constant domain. 42. The polypeptide of any one of Embodiments 1-41, wherein the polypeptide is conjugated to a heterologous moiety. 43. The polypeptide of Embodiment 42, wherein the heterologous moiety is a therapeutic agent, a diagnostic agent or a combination thereof 44. The polypeptide of Embodiment 42, wherein the heterologous moiety is selected from the group consisting of polyethylene glycol (PEG), hexadecanoic acid, a hydrogel, a lipid nanoparticle, a polymer nanoparticle, and a heterologous polypeptide sequence, or a combination thereof. 45. The polypeptide of Embodiment 44, wherein the polymer nanoparticle comprises poly(lactic-co-glycolic) acid (PLGA). 46. The polypeptide of Embodiment 42, wherein the heterologous polypeptide sequence comprises a carrier polypeptide. 47. The polypeptide of Embodiment 46, wherein the carrier polypeptide is albumin or an Fc polypeptide. - 152 - 3839034.v1
5708.1076005 48. The polypeptide of any one of Embodiments 1-47, wherein the polypeptide: a) binds SARS-CoV-2 with a KD of 1 µM or less; b) neutralizes SARS-CoV-2 infection of human host cells with an IC50 of about 25,000 ng/mL or less; c) reduces infectivity of SARS-CoV-2 in human cells, or any combination of the foregoing, optionally, wherein SARS-CoV-2 is of a strain set forth in FIGs.6, 12 and/or 13, such as SARS CoV-2 Omicron BQ.1, SARS CoV-2 Omicron XBB (+K444T, L452R, F486V, R493Q, N658S), or SARS CoV-2 XBB. 49. The polypeptide of Embodiment 48, wherein the SARS-CoV-2 is a variant comprising T19R, 156del, 157del, R158G, L452R, T478K, D614G, P681R and D950N, and optionally comprising G142D. 50. The polypeptide of Embodiment 48 or 49, wherein the polypeptide binds SARS-CoV-2 with a KD of 100 nM or less. 51. The polypeptide of Embodiment 48, wherein the polypeptide neutralizes SARS-CoV-2 infection of human host cells with an IC50 of about 25,000 ng/mL or less. 52. The polypeptide of Embodiment 48, wherein the polypeptide reduces infectivity of SARS-CoV-2 in human cells by at least about 30%. 53. A fusion protein comprising the polypeptide of any one of Embodiments 1-52. 54. A polynucleotide (e.g., DNA or RNA; linear or circular; optionally containing one or more modified nucleotides) comprising a sequence encoding the polypeptide of any one of Embodiments 1-52 or the fusion protein of Embodiment 53. 55. A vector (e.g., an expression vector, including a viral-delivery vector) comprising the polynucleotide of Embodiment 54. 56. A host cell comprising the polynucleotide of Embodiment 54 or the vector of Embodiment 55. 57. A composition comprising the polypeptide of any one of Embodiments 1-52 or the fusion protein of Embodiment 53 or the polynucleotide of Embodiment 54. - 153 - 3839034.v1
5708.1076005 58. The composition of Embodiment 57, comprising one or more pharmaceutical excipients, diluents, or carriers. 59. A method of treating a subject in need thereof, comprising administering an effective amount of the composition of Embodiment 57 or 58 to the subject. 60. A method of reducing infectivity of a betacoronavirius, such as SARS-CoV-2, of a cell in a subject, comprising contacting the cell with an effective amount of the composition of Embodiment 57 or 58, optionally, wherein the betacoronavirius is one set forth in FIGs. 6, 12 and/or 13, such as SARS CoV-2 Omicron BQ.1, SARS CoV-2 Omicron XBB (+K444T, L452R, F486V, R493Q, N658S), or SARS CoV-2 XBB. 61. The method of Embodiment 59 or 60, wherein the subject has (e.g., confirmed by testing, such as by PCR or rapid test), or is suspected of having, COVID-19. 62. The method of Embodiment 59 or 60, wherein the subject is at risk of developing COVID-19. 63. The method of any one of Embodiments 59-62, wherein the subject is a human. 64. The method of any one of Embodiments 59-63, wherein the subject has a heart disease. 65. The method of Embodiment 64, wherein the heart disease is selected from the group consisting of a congestive heart disease, a coronary artery disease, a hypertensive heart disease, an inflammatory heart disease, a pulmonary heart disease, a rheumatic heart disease, a valvular heart disease, a cardiomyopathy, heart failure, and combinations thereof. 66. The method of Embodiment 65, wherein the heart failure is a congestive heart failure. 67. The method of Embodiment 65, wherein the inflammatory heart disease is selected from the group consisting of endocarditis, cardiomegaly, myocarditis, and combinations thereof. 68. The method of any one of Embodiments 59-67, wherein the subject has diabetes. 69. The method of any one of Embodiments 59-68, wherein the subject has a lung disease. - 154 - 3839034.v1
5708.1076005 70. The method of Embodiment 69, wherein the lung disease is selected from the group consisting of acute respiratory distress syndrome, asthma, bronchitis, COPD, emphysema, a lung tumor, a pleural cavity disease, a pulmonary vascular disease, a respiratory tract infection, and combinations thereof. 71. The method of Embodiment 70, wherein: a) the respiratory tract infection is an upper respiratory tract infection, a lower respiratory tract infection, or pneumonia; b) the pleural cavity disease is pleural mesothelioma or tension pneumothorax; c) the pulmonary vascular disease is embolisms, edema, arterial hypertension or hemorrhages; or d) a combination thereof. 72. The method of any one of Embodiments 59-71, wherein the subject is a tobacco smoker. 73. The method of any one of Embodiments 59-72, wherein the subject is immune- compromised. 74. The method of Embodiment 72, wherein the subject is on immunosuppressive therapy. 75. The method of any one of Embodiments 59-74, wherein the subject is 40 years or older. 76. The method of any one of Embodiments 59-75, comprising administering a therapeutically effective amount of an additional therapeutic or prophylactic agent to the subject. 77. The method of Embodiment 76, wherein the additional therapeutic agent is selected from the group consisting of an antiviral agent, an ACE2 inhibitors, an additional SARS-CoV- 2-Spike-binding antibody, an antibiotic, an antimalarial agent, a vaccine, and combinations thereof. 78. The method of Embodiment 77, wherein: a) the additional SARS-CoV-2-Spike-binding antibody is selected from the group consisting of bamlanivimab, etesevimab, bebtelovimab, casirivimab, imdevimab, Cilgavimab, Tixagevimab, AZD7442 (Tixagevimab-Cilgavimab), Regdanvimab, Sotrovimab and combinations thereof; - 155 - 3839034.v1
5708.1076005 b) the antiviral agent is selected from the group consisting of oseltamivir (Tamiflu), favipiravir, amantadine, remdesivir, rimantadine, pleconaril, an anti-sense RNA to SARS-CoV-2, a siRNA to SARS-CoV-2, and combinations thereof; c) the ACE2 inhibitor is selected from the group consisting of an RNAi to ACE2, a siRNA to ACE2, CRISPR-based inhibitor of ACE2, a soluble ACE2, a soluble ACE2 variant, an anti-ACE2 antibody, and combinations thereof; d) the antibiotic comprises azithromycin; e) the antimalarial agent comprises a chloroquine; f) the vaccine is a nucleic acid vaccine or an inactivated virus vaccine; or g) a combination thereof. 79. The method of Embodiment 78, wherein the vaccine is mrna-1273, BNT162, INO-4800, AZD1222, Ad5-nCoV, PiCoVacc, NVX-CoV2373, JNJ-78436735, or a combination thereof. 80. The method of any one of Embodiments 59-79, wherein the subject is further treated (previously, concurrently, or sequentially) with one or more S2 antibodies (or antigen- binding fragments thereof), such as CV3-25 or a variant thereof (e.g., one or more polypeptides disclosed in U.S. Provisional Application No.63/364,331, No.63/381,131, No.63/364,328, and/or No.63/381,132, such as the anti-S2 monoclonal antibody comprising a VH amino acid sequence of SEQ ID NO:53 and a VL amino acid sequence of SEQ ID NO:75). 81. The method of any one of Embodiments 59-80, wherein the subject previously received a therapeutic or prophylactic agent. 82. The method of any one of Embodiments 59-81, wherein the subject was previously infected with a betacoronavirus, such as SARS-CoV-2. *** [00648] Headings used in this application are for convenience only and do not affect the interpretation of this application. [00649] Preferred features of each of the aspects provided by the invention are applicable to all of the other aspects of the invention mutatis mutandis and, without limitation, are exemplified by the dependent claims and also encompass combinations and permutations of individual - 156 - 3839034.v1
5708.1076005 features (e.g., elements, including numerical ranges and exemplary embodiments) of particular embodiments and aspects of the invention, including the working examples. For example, particular experimental parameters exemplified in the working examples can be adapted for use in the claimed invention piecemeal without departing from the invention. For example, for materials that are disclosed, while specific reference of each of the various individual and collective combinations and permutations of these compounds may not be explicitly disclosed, each is specifically contemplated and described herein. Thus, if a class of elements A, B, and C are disclosed as well as a class of elements D, E, and F and an example of a combination of elements A-D is disclosed, then, even if each is not individually recited, each is individually and collectively contemplated. Thus, in this example, each of the combinations A-E, A-F, B-D, B-E, B-F, C-D, C-E, and C-F are specifically contemplated and should be considered disclosed from disclosure of A, B, and C; D, E, and F; and the example combination A-D. Likewise, any subset or combination of these is also specifically contemplated and disclosed. Thus, for example, the sub-groups of A-E, B-F, and C-E are specifically contemplated and should be considered disclosed from disclosure of A, B, and C; D, E, and F; and the example combination A-D. This concept applies to all aspects of this application, including elements of a composition of matter and steps of method of making or using the compositions. [00650] The forgoing aspects of the invention, as recognized by the person having ordinary skill in the art following the teachings of the specification, can be claimed in any combination or permutation to the extent that they are novel and non-obvious over the prior art—thus, to the extent an element is described in one or more references known to the person having ordinary skill in the art, they may be excluded from the claimed invention by, inter alia, a negative proviso or disclaimer of the feature or combination of features. EXEMPLIFICATION Example 1. Materials and Methods [00651] Binding Assay (DELFIA) [00652] Polystyrene MaxiSorp plates (ThermoFisher, Waltham, MA, Cat # 460372) were coated with phosphate buffered saline (PBS)-diluted Spike proteins at 5 µg/ml and incubated overnight at 4°C. Plates were washed with Tris-buffered saline Tween® 20 buffer (TBS-T) (ThermoFisher, Waltham, MA, Cat # 28360) and blocked with an assay diluent (BioLegend, San Diego, CA, Cat # 421205) for 1 hour at room temperature. Serial dilutions (1:4) of the antibodies were made in PBS/bovine serum albumin (BSA) starting from 4.5 µg/ml. After one wash with - 157 - 3839034.v1
5708.1076005 TBS-T, the serially diluted antibodies were transferred to the pre-coated plates and incubated for 1 hour at room temperature. Next, the plates were washed 3 times with TBS-T, and a Europium- labeled secondary antibody (PerkinElmer, Waltham, MA, Cat # 1244-330) was added for 30 minutes at room temperature. Following the incubation, the plates were washed 3 times in TBS- T, and an enhancement solution (PerkinElmer, Waltham, MA, Cat # 4001-0010) was applied. Time-resolved fluorescence was read at 615nm with an EnVision plate reader (PerkinElmer, Waltham, MA). [00653] Pseudovirus Neutralization Assay [00654] For pseudovirus neutralization, Vero-TMPRSS2 cells were plated in tissue culture treated 384-well plate (ThermoFisher, Waltham, MA, Cat # 164610) at density of 3.5 x 103 cells/per well in volume of 20 µl. Plates were briefly spun down at < 50g and incubated at 37oC, 5% CO2 for 2-4 hours. To generate 5-, 10-, or 12-point titration curves, the antibodies were 3-, 4- , or 6-fold serially diluted in PBS/0.2% BSA/1x Penicillin-Streptomycin (Pen-Strep) buffer, starting from 72 µg/ml, 18 µg/ml or 4 µg/ml (4x final concentration), in round bottom 96-well plates (ThermoFisher, Waltham, MA, Cat # 268200). The antibodies were mixed with equal volumes of diluted SARS-CoV-2 pseudoviruses (lentiviruses pseudotyped with SARS-CoV-2 Delta, BA.1, SARS-CoV-1 or WIV1 Spike, and VSV-dG pseudotyped with SARS-CoV-2 D614G, Delta, BA.2, BA.2.12.1, BA.4/5, BA.4/5 + K444T, BQ.1, BQ.1.1, XBB.1, XBB.1.5, XBB.1.5.10, EG.5.1, SARS-CoV-1 or WIV1 Spike). Antibody-virus mixtures were incubated at 37oC, 5% CO2 for 30 - 60 minutes. A volume of 20 µl of antibody-virus mixture was then transferred to 384 well plates pre-seeded with Vero-TMPRSS2 cells. The 384-well plates were briefly centrifuged at < 50 × g and incubated at 37oC, 5% CO2 for 24 (VSV-dG) or 72 (lentiviruses) hours. At the end of incubation, 40 µl of luciferase detection buffer (BPS Bioscience ONE-STEPS™ Luciferase Assay System, BPS Bioscience, San Diego, CA Cat # 60690-3) was added to each well of the cell culture plates. The plates were centrifuged for < 5 seconds at 50 × g, then incubated for 15 minutes with gentle rocking. The luminescence signals were recorded with an EnVision plate reader. [00655] The results were expressed as percentage neutralization and analyzed with Prism 9.5.0 software (GraphPad Software, Boston, MA). Percentage neutralization was calculated with the following formula, where “signalpositiveControl” is defined by the average luminescence signal of wells containing cells without pseudovirus, “signalnegativeControl” is defined as the average - 158 - 3839034.v1
5708.1076005 luminescence signal of wells containing cells with pseudovirus, “signalwell” is defined as the average luminescence signal of wells containing cells with both antibody and pseudovirus: Percentage neutralization = 1 ― ^^ ^^ ^^ ^^ ^ ^ ^^ ^ ^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^ ^ ^ ^ ^ ^ ^ ^ ^^ ^ ^^ ^ ^^ ― ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ― ^^ ^^ ^ ^^ ^ ^^ ^ ^^ ^ ^ ^^ ^ ^^ ^ ^^ ^ ^ ^ ^ ^ ^ ^^ ^ ^ ^^ ^ ^ ^^ ^ ^ ^ ^^ ^^ ^ ^^ ^ ^ ^^ ^ ^ ^^ ^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ⋅ 100 [00656] Half maximal effective concentration (EC50) values and 95% confidence intervals were derived for each Log-transformed antibody titration curve using log(inhibitor) vs. response -- Variable slope (four parameters) equation.80% or 90% maximal effective concentration (respectively EC80 and EC90) values and 95% confidence intervals were derived for each Log- transformed antibody titration curve using log(agonist) vs. response -- Find ECanything equation by setting F parameter respectively to 80 or 90. The following equations were used: logEC50=logECF - (1/HillSlope)*log(F/(100-F)); Y=Bottom + (Top-Bottom)/(1+10^((LogEC50- X)*HillSlope)). Maximal neutralization (Emax) values and 95% confidence intervals were defined as percentage neutralization at top concentration. Area under the curve (AUC) was calculated for each Log-transformed antibody titration curve as total peak area. [00657] Live Virus Neutralization Assay [00658] Live virus neutralization assays were performed at Virology Research Services (Sittingbourne, United Kingdom). SARS-CoV-2 Delta, BA.1, or BA.5 live viruses were incubated with a 3-fold or a 4-fold serial dilution of each antibody for 1 hour, after which the mix were added to Vero cells. Antiviral activity was determined 6 hours later using an immunofluorescence-based assay. [00659] The results were expressed as percentage neutralization and analyzed with Prism 9.5.0 software (GraphPad Software, Boston, MA). Percentage neutralization was calculated with the following formula, where % Infection Sample is the percentage infection of any given dilution of test article; % Infection Uninfected Control is the percentage infection measured in untreated wells that have not been infected (background signal), and % Infection Infected Control if the percentage infection in untreated wells that have been infected with the same amount of virus as the test articles (maximum infection): Normalized % inhibition = 1 ― % ^^ ^^ ^ % ^ ^^ ^ ^ ^^ ^ ^ ^^ ^^ ^ ^^ ^ ^ ^^ ^ ^^ ^ ^ ^^ ^ ^ ^^ ^ ^ ^^ ^^ ^ ^^ ^ ^ ^^ ^ ^ ^ ^^ ^^ ^^ ^ ^ ^^ ^ ^^ ^ ^^ ― ^^ ^^ ^ % ^ ^^ ^ ―^ ^^ ^ %^ ^^ ^ ^^ ^ ^ ^^ ^ ^^ ^ ^^ ^ ^ ^^ ^ ^^ ^ ^^ ^ ^ ^ ^ ^ ^ ^ ^^ ^ ^ ^^ ^ ^^ ^ ^ ^^ ^ ^^ ^^ ^ ^^ ^ ^^ ^ ^ ^^ ^^ ^ ^^ ^ ^ ^ ^^ ^ ^ ^^ ^^ ^^ ^ ^^ ^ ^ ^^ ^ ^^ ^^ ^^ ^^ ^^ ^^ ⋅ 100 [00660] Half maximal effective concentration (EC50) values and 95% confidence intervals were derived for each Log-transformed antibody titration curve using log(inhibitor) vs. response -- Variable slope (four parameters) equation.90% maximal effective concentration (EC90) values and 95% confidence intervals were derived for each Log-transformed antibody titration curve - 159 - 3839034.v1
5708.1076005 using log(agonist) vs. response -- Find ECanything equation by setting F parameter to 90. The following equations were used: logEC50=logECF - (1/HillSlope)*log(F/(100-F)); Y=Bottom + (Top-Bottom)/(1+10^((LogEC50-X)*HillSlope)). Maximal neutralization (Emax) values and 95% confidence intervals were defined as percentage neutralization at top concentration. Example 2. Generating and Characterizing RBD-Binding Polypeptides [00661] The aim of the project learning campaign (i.e., the first generation campaign) was to improve antibody binding profile and function and reduce the number of sequence liabilities. The generation campaign chose a human IgG1 antibody isolated from a convalescent donor and targeting the RBD class 4 epitope as a Reference Antibody. The RBD class 4 epitope is poorly immunogenic. Variant sets of antibodies were generated, and the following datasets were acquired: (1) developability: HPLC-SEC (see, e.g., FIG.6 “% SEC Mono”), AC-SINS (see, e.g., FIG.6 “AC-SINS”), polyspecificity (see, e.g., FIG.6 “PSR-DNA and PSR-Insulin”); (2) binding of RBD proteins expressed on yeast and representative of SARS-CoV-2-related clade 1b, SARS- CoV-related clade 1, Asia non-ACE2 bat Sarbecovirus clade 2, Africa+Europe bat Sarbecovirus clade 3 (see, e.g., FIGs.8A-8B); (3) neutralization of pseudotyped lentiviruses or VSV-dG: SARS-CoV-2 Delta, SARS-CoV-2 Omicron BA.1, SARS-CoV-2 Omicron BA.2, SARS-CoV-2 Omicron BA.2.12.1, SARS-CoV-2 Omicron BA.4/5, WIV1 (see, e.g., FIGs.3A-3B, 4A-4B, 5A- 5B and 7A-7B). [00662] Many generated antibodies (see, e.g., Table 1, Table 2, and Table 3 for antibody VH, VL, and CDR sequences, respectively) bound Spike proteins of SARS-CoV-2-related viruses with high affinity (FIG.5A), and some of them also neutralized SARS-CoV-2 Delta and BA.2 (FIGs.3A-3B, 4A-4B, 5A-5B and 7A-7B). [00663] Many generated class 4 anti-RBD antibodies showed robust binding to RBDs of several SARS-CoV-2 variants and SARS-CoV-2-related Sarbecoviruses (FIGs.8A-8B and FIGs. 13A-13B). AB-2b, AB-4a and AB-3a bound RBDs of all SARS-CoV-2 variants tested so far, including pre-Omicron lineages and Omicron sublineages. AB-4a and AB-3a robustly bound to emerging Omicron variants (XBB, BQ.1) while other clinical-stage antibodies (Sotrovimab, AZD1061, Bebtelovimab) showed low-to-no binding (FIGs.8A-8B). Similarly, AB-2b robustly binds to prevalent Omicron variants (e.g., XBB1.5), while other clinical-stage antibodies (e.g., Bebtelovimab) show low-to-no binding (FIG.13A). AB-2b, AB-4a and AB-3a also bound RBDs of several SARS-CoV-2-related sarbecoviruses (FIGs.8A-8B and FIG.13A). Binding to RBDs was assessed through yeast surface display. Many generated class 4 anti-RBD antibodies also - 160 - 3839034.v1
5708.1076005 showed robust binding to RBDs of several non-SARS-CoV-2 Sarbecoviruses (FIG.8B and FIG. 13B). Overall, the unique binding profiles of Generate class 4 anti-RBD antibodies support their potential use for pandemic response and preparedness. [00664] As part of the screening campaigns, antibodies able to neutralize pseudoviruses not included in the training set were identified. For example, BA.2 (see, e.g., FIGs.3A-3B) and BA.4/5 (see, e.g., FIGs.4A-4B) neutralizers were identified in the variant set VS-317 , and further enriched in the variant set VS-341 (FIGs.4A-4B). BA.4/5 neutralization only partially correlated with binding to BA.4/5 Spike and was observed with antibodies having 9 or more amino acid mutations compared to the reference antibody (FIGs.5A-5B). Overall, class 4 anti- RBD screening hits with robust neutralization of SARS-CoV-2 BA.4/5 were identified (FIGs. 7A-7B). [00665] RBD sequences representative of SARS-CoV-2 variants, SARS-CoV-2-related Sarbecoviruses clade 1b, SARS-CoV-related Sarbecoviruses clade 1a, and Sarbecoviruses clades 2 and 3 were expressed on yeast to assess binding to selected class 4 anti-RBD screening hits (AB-3a and AB-4a) as well as clinical-stage antibodies Sotrovimab, AZD1061 and Bebtelovimab. AB-3a and AB-4a showed robust binding to all RBDs of SARS-CoV-2 variants including the emerging variants XBB and BQ.1, as well as several non-SARS-CoV-2 Sarbecoviruses, while clinical-stage antibodies showed more limited binding profiles (FIGs.8A- 8B). [00666] AB-4a was further tested for neutralization of a BA.4/5 pseudovirus harboring the escape mutation K444T observed in emerging SARS-CoV-2 variants. AB-4a neutralizes the BA.4/5+K444T pseudovirus and further enhances the neutralization profile of an anti-S2 antibody (FIG.9; see also Table 6 and Table 7 for VH and VL sequences of anti-S2 antibodies, respectively). [00667] AB-3a was tested for neutralization of the BA.4/5+K444T pseudovirus. AB-3a neutralizes the BA.4/5+K444T pseudovirus and further enhanced the neutralization profile of an anti-S2 antibody. Of note, enhancement of the anti-S2 antibody neutralization profile is observed in combination with clinical-stage antibodies as well (Sotrovimab, Bebtelovimab) (FIGs.10A- 10B). AB-3a was also tested for neutralization of the BQ.1.1 pseudovirus. AB-3a neutralizes the BQ.1.1 pseudovirus and further enhanced the neutralization profile of an anti-S2 antibody (FIGs. 11A-11D). [00668] AB-2b was tested for neutralization of the D614G, Delta, BQ1.1 or XBB.1.5 pseudovirus. AB-2b neutralized the D614G, Delta, BQ1.1 and XBB.1.5 pseudovirus (FIG.14A- - 161 - 3839034.v1
5708.1076005 14B). AB-2b also improved neutralization of Omicron BQ1.1 and XBB.1.5 by S2_AB-1, an anti-S2 antibody (FIGs.14A-14B). [00669] AB-2b was tested for neutralization of the D614G, SARS-CoV-1, and WIV1 pseudoviruses. As shown in FIGs.15A-15B, AB-2b, alone or combined with S2_AB-1, potently neutralizes VSV-dG pseudoviruses representative of D614G, SARS-CoV-1 and WIV1. Neutralization of additional variants by AB-2b, alone or in combination with different amounts of S2_AB-1, is shown in FIGs.15C-15D. [00670] AB-4a was also tested for neutralization of the Delta and BA.5 live viruses. AB-4a neutralizes the Delta and BA.5 live viruses and further enhanced the neutralization profile of an anti-S2 antibody (FIGs.12A-12C). Example 3. Prophylactic Efficacy of a Combination of Antibodies Targeting the RBD (Class 4 Epitope) and S2 Domains in a Hamster Challenge Model [00671] Male hamsters were injected intraperitoneally on Day -1 with the following antibodies as indicated in FIG.16: isotype (anti-RSV protein F antibody palivizumab/SYNAGIS® variable regions (VH/VL) expressed as human IgG1 with the LS mutation); sotrovimab VH/VL - hIgG1-LS (sotrovimab variable regions (VH/VL) expressed as human IgG1 with the LS mutation); AB-2b (class 4 anti-RBD antibody expressed as human IgG1 with the LS mutation); S2_AB-1 (anti-S2 stem helix antibody expressed as human IgG1 with the LS mutation). Isotype was injected along with other antibodies to ensure comparable dosing (24 mg/kg) across all groups. On Day 0, all hamsters were intranasally inoculated with SARS-CoV-2 Omicron BA.2. On day 4, the hamsters were sacrificed, their lungs were collected, and viral titers were measured as median tissue culture infectious dose (TCID50). As shown in FIG.16, AB-2b has comparable activity to sotrovimab VH/VL - hIgG1-LS in terms of lung viral titer reduction (as measured by TCID50). However, a combination of AB-2b and S2_AB-1 achieved a much greater reduction in lung viral titer. Example 4. Cryo-EM experiments on AB-2b Fab [00672] Expression and Purification of SARS-CoV-2 BA.1 spike trimer [00673] SARS-CoV-2 BA.1 spike trimer and AB-2b Fab were expressed in EXPI293® cells following the Gibco® EXPI293® Expression System protocol. In brief, three million cells were transfected with approximately 1 µg of plasmid DNA. The cells were incubated at 37℃ with 80% relative humidity and 8% CO2 on an orbital shaker at 150 RPM. Four days post- - 162 - 3839034.v1
5708.1076005 transfection, the cells were harvested and pelleted at 3,900 × g for 30 mins at 4℃. The supernatant was decanted into 0.22 µm filter units and stored at 4℃ until purification. The SARS-CoV-2 BA.1 spike trimer was purified using Nickel Sepharose Excel resin (Cytiva, Marlborough, MA). The AB-2b Fab was purified using the LambdaFabSelect resin (Cytiva). [00674] Complexation of BA.1 with AB-2b Fab [00675] SARS-CoV-2 BA.1 spike trimer was incubated with AB-2b Fab at a 1:2 molar ratio at 4℃ overnight with gentle mixing. The complex was purified by size exclusion chromatography on a SUPEROSE® 6 Increase 10/300 GL column equilibrated in 50 mM HEPES (pH8.0), 150 mM NaCl. Each fraction was analyzed by aSEC (absolute size exclusion chromatography) and SDS-PAGE (electrophoresis) to confirm complex formation between the BA.1 spike protein and AB-2b Fab. Fractions containing the complex were pooled and vitrified on the Vitrobot Mark IV (Thermo Fisher Scientific). [00676] Cryo-EM Data Collection [00677] Cryo-EM images were acquired on a Krios G4 cryo-TEM using EPU software (v3.2). The Krios was operated at 300 kV with a Falcon4i direct electron detector and a Selectris energy filter with a zero-loss slit width of 10 eV. A total of 6587 movies were collected at 165,000x magnification at a pixel size of 0.730 Å. The total dose per movie was 51.05 electrons per square angstrom. The targeted defocus range was between 0.5-2.4 µm. [00678] Cryo-EM Processing [00679] Following collection, all processing was performed using cryoSPARC. First, movies were corrected for beam-induced motion using a patch motion correction. Next, the contrast transfer function parameters of micrographs were estimated using the patch CTF estimation. Individual particles were auto-picked and then clustered into distinct class averages. The class averages with highest resolution features were selected for a homogeneous refinement with C3 symmetry, owing to the three-fold rotational symmetry of the SARS-CoV-2 spike. To better resolve the FAB-RBD density (which is seen to be highly dynamic), a mask around this region was generated in ChimeraX (v1.6.1) and used for a local-refinement in cryoSPARC. The densities of the local refinement of the FAB-RBD and the homogeneous refinement of the rest of the spike were then combined into a single composite map using a smooth density mask around the FAB-RBD, computed as:
- 163 - 3839034.v1
5708.1076005 where ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ is the final composite map, ^^ ^^ ^^ ^^/ ^^ ^^ ^^ is the map generated from the local refinement, ^^ ^^ ^^ ^^ ^^ ^^ is the map generated as a homogeneous refinement, and ^^ ^^ ^^ ^^/ ^^ ^^ ^^ is the mask around the FAB-RBD density. [00680] Model building [00681] Initial models were built as a homology model of the initial design. Each component of the structure (RBD, FAB, Spike main chain) was individually docked into the composite density map. The structure was then computationally reassembled followed by energy minimization using the GROMACS (v2023.1) molecular dynamics software. The minimized structure then underwent real-space refinement using PHENIX (v1.20.1), with secondary- structure and torsion restrains present. [00682] FIGs.17A-17B depict structural analysis of AB-2b Fab binding to SARS-CoV-2 BA.1 RBD and related contact residues. AB-2b binds to leucine at position 371 and phenylalanine at position 375, which are mutations highly prevalent in the Omicron lineage but not present in non-Omicron lineages, potentially explaining its binding and neutralization breadth within the Omicron lineage. [00683] FIG.17C shows a low-pass filtered Cryo-EM map of the SARS-CoV-2 BA.1 spike trimer with AB-3a Fab binding the RBD and an anti-S2 antibody, S2_AB-1, binding the S2 stem helix. The map is shown from a side profile (top panel) and from below (bottom panel). Each of the presumptive Fabs is labeled. FIG.17D shows a density-docked atomic model of the SARS- CoV-2 spike assembly with bound RBD-binding (AB-3a) and S2-binding (S2_AB-1) Fabs. A high-resolution structure of the SARS-CoV-2 spike trimer with the S2 stem helix is resolved. The bottom panel of FIG.17D depicts three anti-S2 Fabs (S2_AB-1) docked into the propeller shaped density around the S2 stem helix. [00684] Table 8 represents epitope mapping (amino acid contacts) of: Reference Ab with spike of SARS-CoV-2 ancestral strain; lead molecule AB-2b with spike of SARS-CoV-2 Omicron BA.1, both predicted from the design and experimentally determined through cryo-EM. The table also report amino acid differences between SARS-CoV-2 ancestral strain and Omicron BA.1 spike proteins that fall within Reference Ab or AB-2b epitopes. [00685] Tables 9-10 represent paratope mapping (amino acid contacts) of lead molecule AB- 2b light chain (Table 9) and heavy chain (Table 10) with spike of SARS-CoV-2 Omicron BA.1, both predicted from the design and experimentally determined through cryo-EM. - 164 - 3839034.v1
5708.1076005 Table 1. VH Amino Acid Sequences
Table 2. VL Amino Acid Sequences
- 165 - 3839034.v1
5708.1076005
- 166 - 3839034.v1
5708.1076005 Table 3. CDR Amino Acid Sequences
- 167 - 3839034.v1
5708.1076005 Table 4. VH & VL Amino Acid Sequences (Bold letters correspond to CDRs as determined by IMGT.)
- 168 - 3839034.v1
5708.1076005
- 169 - 3839034.v1
5708.1076005
- 170 - 3839034.v1
5708.1076005
- 171 - 3839034.v1
5708.1076005
- 172 - 3839034.v1
5708.1076005
- 173 - 3839034.v1
5708.1076005
- 174 - 3839034.v1
5708.1076005
- 175 - 3839034.v1
5708.1076005
- 176 - 3839034.v1
5708.1076005
- 177 - 3839034.v1
5708.1076005
- 178 - 3839034.v1
5708.1076005
- 179 - 3839034.v1
5708.1076005
- 180 - 3839034.v1
5708.1076005
- 181 - 3839034.v1
5708.1076005
- 182 - 3839034.v1
5708.1076005
- 183 - 3839034.v1
5708.1076005
- 184 - 3839034.v1
5708.1076005 Table 5. VH & VL SEQ ID Numbers (Part 1)
- 185 - 3839034.v1
5708.1076005 Table 5. VH & VL SEQ ID Numbers (Part 2)
- 186 - 3839034.v1
5708.1076005 Table 5. VH & VL SEQ ID Numbers (Part 3)
- 187 - 3839034.v1
5708.1076005 Table 5. VH & VL SEQ ID Numbers (Part 4)
- 188 - 3839034.v1
5708.1076005 Table 6. VH Amino Acid Sequences of anti-S2 polypeptides (e.g., monoclonal antibodies)
- 189 - 3839034.v1
5708.1076005
- 190 - 3839034.v1
5708.1076005
- 191 - 3839034.v1
5708.1076005
Table 7. VL Amino Acid Sequences of anti-S2 polypeptides (e.g., monoclonal antibodies)
- 192 - 3839034.v1
5708.1076005
- 193 - 3839034.v1
5708.1076005
- 194 - 3839034.v1
5708.1076005 Table 8. Epitope map of homologous antibody (the Reference Antibody) and AB-2b predicted from design or based on experimental data (cryo-electron microscopy [cryo-EM]).
*: Amino acids that differ between ancestral strain (first column) and BA.1 (second column). - 195 - 3839034.v1
5708.1076005 Table 9. Paratope map (light-chain) of the AB-2b designed structure and the experimental model determined from cryo-electron microscopy.
Table 10. Paratope map (heavy-chain) of the AB-2b designed structure and the experimental model determined from cryo-electron microscopy.
- 196 - 3839034.v1
5708.1076005 Table 11. Neutralization potencies of novel anti-RBD class 4 hits optimized from AB-2b
Neutralization data of screening hits identified from optimization of AB-2b. Results with the reference antibody Reference Ab are also reported for comparison. Pseudoviruses representative of the following SARS-CoV-2 variants have been tested: ancestral strain (D614G), BQ.1.1, XBB.1, XBB.1.5.10, EG.5.1. Neutralization data are expressed as EC50 values for individual pseudoviruses and also as composite score (a metric that summarize neutralization data across all pseudoviruses [the higher the better]). REFERENCES 1. Li et al., Structural Basis and Mode of Action for Two Broadly Neutralizing Antibodies Against SARS-CoV-2 Emerging Variants of Concern, Cell Reports 38(2):110210 (2021). - 197 - 3839034.v1
5708.1076005 2. Ingraham et al., Generative models for graph-based protein design, 33rd Conference on Neural Information Processing Systems (NeurIPS 2019), Vancouver, Canada. 3. Zhou et al., A general-purpose protein design framework based on mining sequence– structure relationships in known protein structures, Proc Natl Acad Sci U S A.117(2):1059- 68 (2020). 4. Baud et al. Real estimates of mortality following COVID-19 infection, Lancet Infect Dis. 20(7):773 (2020). 5. Baden & Rubin,Covid-19 - The Search for Effective Therapy, N Engl J Med.382(19):1851- 52 (2020). 6. Jennewein et al., Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects, Cell Rep.36(2):109353 (2021). [00686] The teachings of all patents, published applications and references cited herein are incorporated by reference in their entirety. [00687] While example embodiments have been particularly shown and described, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the embodiments encompassed by the appended claims. - 198 - 3839034.v1
Claims
5708.1076005 CLAIMS What is claimed is: 1. A polypeptide comprising: a) an immunoglobulin heavy chain variable (VH) domain comprising a heavy chain complementarity-determining region (HCDR) 1, an HCDR2, and an HCDR3 having 100% sequence identity to an HCDR1, an HCDR2, and an HCDR3, respectively, of a VH domain set forth in Table 1 or Table 4 herein; and b) an immunoglobulin light chain variable (VL) domain comprising a light chain complementarity-determining region (LCDR) 1, an LCDR2, and an LCDR3 having 100% sequence identity to an LCDR1, an LCDR2, and an LCDR3, respectively, of a VL domain set forth in Table 2 or Table 4 herein, wherein the polypeptide is an antibody or an antigen-binding fragment thereof. 2. The polypeptide of claim 1, wherein: a) the VH domain of the polypeptide comprises an HCDR1, an HCDR2, and an HCDR3, of a VH comprising the amino acid sequence of SEQ ID NO:5; and b) the VL domain comprises an LCDR1, an LCDR2, and an LCDR3, of a VL comprising the amino acid sequence of SEQ ID NO:14. 3. The polypeptide of claim 1 or 2, comprising: a) an HCDR1 comprising the amino acid sequence of SEQ ID NO:24, b) an HCDR2 comprising the amino acid sequence of SEQ ID NO:28, c) an HCDR3 comprising the amino acid sequence of SEQ ID NO:33; d) an LCDR 1 comprising the amino acid sequence of SEQ ID NO:37; e) an LCDR2 comprising the amino acid sequence of SEQ ID NO:40; and f) an LCDR3 comprising the amino acid sequence of SEQ ID NO:44. 4. The polypeptide of any one of claims 1-3, comprising: a) an HCDR1 consisting of the amino acid sequence of SEQ ID NO:24, b) an HCDR2 consisting of the amino acid sequence of SEQ ID NO:28, c) an HCDR3 consisting of the amino acid sequence of SEQ ID NO:33; d) an LCDR 1 consisting of the amino acid sequence of SEQ ID NO:37; e) an LCDR2 consisting of the amino acid sequence of SEQ ID NO:40; and f) an LCDR3 consisting of the amino acid sequence of SEQ ID NO:44. - 199 - 3839034.v1
5708.1076005 5. The polypeptide of any one of claims 1-4, comprising: a) a VH that is humanized and/or contains human framework regions; b) a VL that is humanized and/or contains human framework regions; or both a) and b). 6. The polypeptide of any one of claims 1-5, wherein: a) the VH domain of the polypeptide comprises an amino acid sequence having 100% sequence identity to the amino acid sequence of a VH domain set forth in Table 1 or Table 4 herein; and b) the VL domain of the polypeptide comprises an amino acid sequence having 100% sequence identity to the amino acid sequence of a VL domain set forth in Table 2 or Table 4 herein, wherein the VH domain and the VL domain are selected from a VH/VL combination set forth in Table 5 herein. 7. The polypeptide of any one of claims 1-6, comprising: a) a VH comprising the amino acid sequence of SEQ ID NO:5; and b) a VL comprising the amino acid sequence of SEQ ID NO:14. 8. The polypeptide of any one of claims 1-7, wherein the polypeptide is an antigen-binding fragment comprising a single-chain fragment variable (scFv), a variable heavy domain of heavy chain (VHH), a fragment antigen-binding (Fab), a Fab’, or a F(ab’)2. 9. The polypeptide of any one of claims 1-8, comprising: a) an antibody heavy chain constant domain; b) an antibody light chain constant domain; or both. 10. The polypeptide of any one of claims 1-9, comprising an IgG1, IgG2, IgG3, or IgG4 antibody heavy chain constant domain. 11. The polypeptide of any one of claims 1-10, comprising an IgG1 antibody heavy chain constant domain. - 200 - 3839034.v1
5708.1076005 12. The polypeptide of any one of claims 9-11, wherein the antibody heavy chain constant domain comprises at least one mutation which increases serum half-life of the antibody or antigen-binding fragment thereof in humans. 13. The polypeptide of claim 12, wherein the antibody heavy chain constant domain comprises, relative to a wild-type human IgG constant domain, amino acid substitutions with methionine and serine at amino acid residues 428 and 434, respectively, and wherein the amino acid residues are numbered according to the EU index as in Kabat. 14. The polypeptide of any one of claims 1-13, comprising: a) an antibody heavy chain (HC) having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:576; b) an antibody light chain (LC) having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:577; or both a) and b). 15. The polypeptide of any one of claims 1-14, comprising: a) an antibody HC comprising the amino acid sequence of SEQ ID NO:576; b) an antibody LC comprising the amino acid sequence of SEQ ID NO:577; or both a) and b). 16. The polypeptide of any one of claims 1-13, comprising: a) an antibody heavy chain (HC) having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:576; b) an antibody light chain (LC) having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:52; or both a) and b). 17. The polypeptide of any one of claims 1-13 and 16, comprising: a) an antibody HC comprising the amino acid sequence of SEQ ID NO:576; b) an antibody LC comprising the amino acid sequence of SEQ ID NO:52; or both a) and b). 18. The polypeptide of any one of claims 1-17, wherein the polypeptide specifically binds a spike receptor-binding domain (RBD) class 4 epitope of a betacoronavirus Spike glycoprotein (SARS-CoV-2-Spike). - 201 - 3839034.v1
5708.1076005 19. The polypeptide of any one of claims 1-18, wherein the polypeptide is conjugated to a heterologous moiety. 20. The polypeptide of claim 19, wherein the heterologous moiety is a therapeutic agent, a diagnostic agent or a combination thereof 21. The polypeptide of claim 19 or 20, wherein the heterologous moiety comprises polyethylene glycol (PEG), hexadecanoic acid, a hydrogel, a lipid nanoparticle, a polymer nanoparticle, a heterologous polypeptide sequence, or a combination thereof. 22. The polypeptide of claim 21, wherein the polymer nanoparticle comprises poly(lactic-co- glycolic acid) (PLGA). 23. The polypeptide of claim 21, wherein the heterologous polypeptide sequence comprises a carrier polypeptide. 24. The polypeptide of claim 23, wherein the carrier polypeptide is albumin or an Fc polypeptide. 25. A polynucleotide comprising a nucleotide sequence encoding the polypeptide of any one of claims 1-24. 26. A host cell comprising the polynucleotide of claim 25. 27. A method of making the polypeptide of any one of claims 1-24, comprising culturing a host cell comprising a nucleotide sequence encoding the polypeptide under conditions where the polypeptide is expressed in the host cell. 28. A composition comprising the polypeptide of any one of claims 1-24 or the polynucleotide of claim 25. 29. The composition of claim 28, further comprising at least one additional therapeutic agent. 30. The composition of claim 29, wherein the at least one additional therapeutic agent comprises: a) an antibody or an antigen-binding fragment thereof that specifically binds SARS- CoV-2-Spike; - 202 - 3839034.v1
5708.1076005 b) a polynucleotide comprising a nucleotide sequence encoding the antibody or the antigen-binding fragment thereof of a); c) an antiviral agent; d) an ACE2 inhibitor; e) an antibiotic; f) an antimalarial agent; g) a vaccine; or any combination of a) to g). 31. The composition of claim 30, wherein: a) the antibody or the antigen-binding fragment thereof that specifically binds SARS-CoV-2-Spike comprises bamlanivimab, etesevimab, bebtelovimab, casirivimab, imdevimab, Cilgavimab, Tixagevimab, AZD7442 (Tixagevimab- Cilgavimab), Regdanvimab, Sotrovimab, or a combination thereof; b) the antibody or the antigen-binding fragment thereof that specifically binds SARS-CoV-2-Spike binds an S2 domain of SARS-CoV-2-Spike; c) the antiviral agent comprises oseltamivir (Tamiflu), favipiravir, amantadine, remdesivir, rimantadine, pleconaril, an anti-sense RNA to SARS-CoV-2, a siRNA to SARS-CoV-2, or a combination thereof; d) the ACE2 inhibitor comprises an RNAi to ACE2, a siRNA to ACE2, a CRISPR- based inhibitor of ACE2, a soluble ACE2, a soluble ACE2 variant, an anti-ACE2 antibody, or a combination thereof; e) the antibiotic comprises azithromycin; f) the antimalarial agent comprises a chloroquine; g) the vaccine comprises a nucleic acid vaccine and/or an inactivated virus vaccine; or any combination of a) to g). 32. The composition of any one of claims 29-31, wherein the at least one additional therapeutic agent comprises an antibody or an antigen-binding fragment thereof that specifically binds an S2 domain of SARS-CoV-2-Spike. 33. The composition of claim 32, wherein the antibody or the antigen-binding fragment thereof that specifically binds an S2 domain of SARS-CoV-2-Spike comprises a VH domain comprising an HCDR1, an HCDR2, and an HCDR3, and a VL domain - 203 - 3839034.v1
5708.1076005 comprising an LCDR1, an LCDR2, and an LCDR3 of an antibody comprising a VH amino acid sequence and a VL amino acid sequence, respectively, of: SEQ ID NO:53 and SEQ ID NO:75 (S2_AB-1); SEQ ID NO:57 and SEQ ID NO:76 (S2_AB-2); SEQ ID NO:58 and SEQ ID NO:77 (S2_AB-3); SEQ ID NO:59 and SEQ ID NO:78 (S2_AB-4); SEQ ID NO:60 and SEQ ID NO:75 (S2_AB-5); SEQ ID NO:61 and SEQ ID NO:79 (S2_AB-6); SEQ ID NO:62 and SEQ ID NO:80 (S2_AB-7); SEQ ID NO:63 and SEQ ID NO:81 (S2_AB-8); SEQ ID NO:64 and SEQ ID NO:82 (S2_AB-9); SEQ ID NO:65 and SEQ ID NO:83 (S2_AB-10); SEQ ID NO:66 and SEQ ID NO:84 (S2_AB-11); SEQ ID NO:67 and SEQ ID NO:80 (S2_AB-12); SEQ ID NO:68 and SEQ ID NO:75 (S2_AB-13); SEQ ID NO:62 and SEQ ID NO:74 (S2_AB-14); SEQ ID NO:69 and SEQ ID NO:85 (S2_AB-15); SEQ ID NO:70 and SEQ ID NO:86 (S2_AB-16); SEQ ID NO:58 and SEQ ID NO:87 (S2_AB-17); SEQ ID NO:71 and SEQ ID NO:88 (S2_AB-18); SEQ ID NO:53 and SEQ ID NO:85 (S2_AB-19); SEQ ID NO:72 and SEQ ID NO:85 (S2_AB-20); SEQ ID NO:94 and SEQ ID NO:113 (S2_AB-21); SEQ ID NO:95 and SEQ ID NO:114 (S2_AB-22); SEQ ID NO:53 and SEQ ID NO:115 (S2_AB-23); SEQ ID NO:96 and SEQ ID NO:80 (S2_AB-24); SEQ ID NO:97 and SEQ ID NO:116 (S2_AB-25); SEQ ID NO:98 and SEQ ID NO:75 (S2_AB-26); SEQ ID NO:99 and SEQ ID NO:80 (S2_AB-27); SEQ ID NO:100 and SEQ ID NO:85 (S2_AB-28); SEQ ID NO:101 and SEQ ID NO:80 (S2_AB-29); SEQ ID NO:101 and SEQ ID NO:117 (S2_AB-30); SEQ ID NO:102 and SEQ ID NO:118 (S2_AB-31); - 204 - 3839034.v1
5708.1076005 SEQ ID NO:103 and SEQ ID NO:119 (S2_AB-32); SEQ ID NO:104 and SEQ ID NO:120 (S2_AB-33); SEQ ID NO:105 and SEQ ID NO:115 (S2_AB-34); SEQ ID NO:106 and SEQ ID NO:80 (S2_AB-35); SEQ ID NO:107 and SEQ ID NO:121 (S2_AB-36); SEQ ID NO:108 and SEQ ID NO:75 (S2_AB-37); SEQ ID NO:109 and SEQ ID NO:80 (S2_AB-38); SEQ ID NO:110 and SEQ ID NO:87 (S2_AB-39); SEQ ID NO:111 and SEQ ID NO:117 (S2_AB-40); SEQ ID NO:562 and SEQ ID NO:573 (S2_AB-41); SEQ ID NO:563 and SEQ ID NO:76 (S2_AB-42); SEQ ID NO:564 and SEQ ID NO:75 (S2_AB-43); SEQ ID NO:565 and SEQ ID NO:574 (S2_AB-44); SEQ ID NO:566 and SEQ ID NO:80 (S2_AB-45); SEQ ID NO:567 and SEQ ID NO:75 (S2_AB-46); SEQ ID NO:568 and SEQ ID NO:574 (S2_AB-47); SEQ ID NO:569 and SEQ ID NO:77 (S2_AB-48); SEQ ID NO:570 and SEQ ID NO:76 (S2_AB-49); SEQ ID NO:571 and SEQ ID NO:575 (S2_AB-50); or SEQ ID NO:56 and SEQ ID NO:80 (S2_AB-51). 34. The composition of any one of claims 31-33, wherein the antibody or the antigen-binding fragment thereof that specifically binds an S2 domain of SARS-CoV-2-Spike comprises an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2, and an LCDR3 of an antibody comprising a VH amino acid sequence of SEQ ID NO:53 and a VL amino acid sequence of SEQ ID NO:75 (S2_AB-1). 35. The composition of any one of claims 31-34, wherein the antibody or the antigen-binding fragment thereof that specifically binds an S2 domain of SARS-CoV-2-Spike comprises: a) an HCDR1 comprising GYTFTRYW (SEQ ID NO:557); b) an HCDR2 comprising IYPGDSDV (SEQ ID NO:558); c) an HCDR3 comprising ARLPQYCSKGVCYRWFDP (SEQ ID NO:559); d) an LCDR1 comprising QGISSW (SEQ ID NO:560); e) an LCDR2 comprising AAS; and - 205 - 3839034.v1
5708.1076005 f) an LCDR3 comprising QQGHSFPYT (SEQ ID NO:561). 36. The composition of any one of claims 31-35, wherein the antibody or the antigen-binding fragment thereof that specifically binds an S2 domain of SARS-CoV-2-Spike comprises: a) an HCDR1 consisting of GYTFTRYW (SEQ ID NO:557); b) an HCDR2 consisting of IYPGDSDV (SEQ ID NO:558); c) an HCDR3 consisting of ARLPQYCSKGVCYRWFDP (SEQ ID NO:559); d) an LCDR1 consisting of QGISSW (SEQ ID NO:560); e) an LCDR2 consisting of AAS; and f) an LCDR3 consisting of QQGHSFPYT (SEQ ID NO:561). 37. The composition of any one of claims 31-36, wherein the antibody or the antigen-binding fragment thereof that specifically binds an S2 domain of SARS-CoV-2-Spike comprises: a VH comprising the amino acid sequence of SEQ ID NO:53 and a VL comprising the amino acid sequence of SEQ ID NO:75 (S2_AB-1); a VH comprising the amino acid sequence of SEQ ID NO:57 and a VL comprising the amino acid sequence of SEQ ID NO:76 (S2_AB-2); a VH comprising the amino acid sequence of SEQ ID NO:58 and a VL comprising the amino acid sequence of SEQ ID NO:77 (S2_AB-3); a VH comprising the amino acid sequence of SEQ ID NO:59 and a VL comprising the amino acid sequence of SEQ ID NO:78 (S2_AB-4); a VH comprising the amino acid sequence of SEQ ID NO:60 and a VL comprising the amino acid sequence of SEQ ID NO:75 (S2_AB-5); a VH comprising the amino acid sequence of SEQ ID NO:61 and a VL comprising the amino acid sequence of SEQ ID NO:79 (S2_AB-6); a VH comprising the amino acid sequence of SEQ ID NO:62 and a VL comprising the amino acid sequence of SEQ ID NO:80 (S2_AB-7); a VH comprising the amino acid sequence of SEQ ID NO:63 and a VL comprising the amino acid sequence of SEQ ID NO:81 (S2_AB-8); a VH comprising the amino acid sequence of SEQ ID NO:64 and a VL comprising the amino acid sequence of SEQ ID NO:82 (S2_AB-9); a VH comprising the amino acid sequence of SEQ ID NO:65 and a VL comprising the amino acid sequence of SEQ ID NO:83 (S2_AB-10); - 206 - 3839034.v1
5708.1076005 a VH comprising the amino acid sequence of SEQ ID NO:66 and a VL comprising the amino acid sequence of SEQ ID NO:84 (S2_AB-11); a VH comprising the amino acid sequence of SEQ ID NO:67 and a VL comprising the amino acid sequence of SEQ ID NO:80 (S2_AB-12); a VH comprising the amino acid sequence of SEQ ID NO:68 and a VL comprising the amino acid sequence of SEQ ID NO:75 (S2_AB-13); a VH comprising the amino acid sequence of SEQ ID NO:62 and a VL comprising the amino acid sequence of SEQ ID NO:74 (S2_AB-14); a VH comprising the amino acid sequence of SEQ ID NO:69 and a VL comprising the amino acid sequence of SEQ ID NO:85 (S2_AB-15); a VH comprising the amino acid sequence of SEQ ID NO:70 and a VL comprising the amino acid sequence of SEQ ID NO:86 (S2_AB-16); a VH comprising the amino acid sequence of SEQ ID NO:58 and a VL comprising the amino acid sequence of SEQ ID NO:87 (S2_AB-17); a VH comprising the amino acid sequence of SEQ ID NO:71 and a VL comprising the amino acid sequence of SEQ ID NO:88 (S2_AB-18); a VH comprising the amino acid sequence of SEQ ID NO:53 and a VL comprising the amino acid sequence of SEQ ID NO:85 (S2_AB-19); a VH comprising the amino acid sequence of SEQ ID NO:72 and a VL comprising the amino acid sequence of SEQ ID NO:85 (S2_AB-20); a VH comprising the amino acid sequence of SEQ ID NO:94 and a VL comprising the amino acid sequence of SEQ ID NO:113 (S2_AB-21); a VH comprising the amino acid sequence of SEQ ID NO:95 and a VL comprising the amino acid sequence of SEQ ID NO:114 (S2_AB-22); a VH comprising the amino acid sequence of SEQ ID NO:53 and a VL comprising the amino acid sequence of SEQ ID NO:115 (S2_AB-23); a VH comprising the amino acid sequence of SEQ ID NO:96 and a VL comprising the amino acid sequence of SEQ ID NO:80 (S2_AB-24); a VH comprising the amino acid sequence of SEQ ID NO:97 and a VL comprising the amino acid sequence of SEQ ID NO:116 (S2_AB-25); a VH comprising the amino acid sequence of SEQ ID NO:98 and a VL comprising the amino acid sequence of SEQ ID NO:75 (S2_AB-26); - 207 - 3839034.v1
5708.1076005 a VH comprising the amino acid sequence of SEQ ID NO:99 and a VL comprising the amino acid sequence of SEQ ID NO:80 (S2_AB-27); a VH comprising the amino acid sequence of SEQ ID NO:100 and a VL comprising the amino acid sequence of SEQ ID NO:85 (S2_AB-28); a VH comprising the amino acid sequence of SEQ ID NO:101 and a VL comprising the amino acid sequence of SEQ ID NO:80 (S2_AB-29); a VH comprising the amino acid sequence of SEQ ID NO:101 and a VL comprising the amino acid sequence of SEQ ID NO:117 (S2_AB-30); a VH comprising the amino acid sequence of SEQ ID NO:102 and a VL comprising the amino acid sequence of SEQ ID NO:118 (S2_AB-31); a VH comprising the amino acid sequence of SEQ ID NO:103 and a VL comprising the amino acid sequence of SEQ ID NO:119 (S2_AB-32); a VH comprising the amino acid sequence of SEQ ID NO:104 and a VL comprising the amino acid sequence of SEQ ID NO:120 (S2_AB-33); a VH comprising the amino acid sequence of SEQ ID NO:105 and a VL comprising the amino acid sequence of SEQ ID NO:115 (S2_AB-34); a VH comprising the amino acid sequence of SEQ ID NO:106 and a VL comprising the amino acid sequence of SEQ ID NO:80 (S2_AB-35); a VH comprising the amino acid sequence of SEQ ID NO:107 and a VL comprising the amino acid sequence of SEQ ID NO:121 (S2_AB-36); a VH comprising the amino acid sequence of SEQ ID NO:108 and a VL comprising the amino acid sequence of SEQ ID NO:75 (S2_AB-37); a VH comprising the amino acid sequence of SEQ ID NO:109 and a VL comprising the amino acid sequence of SEQ ID NO:80 (S2_AB-38); a VH comprising the amino acid sequence of SEQ ID NO:110 and a VL comprising the amino acid sequence of SEQ ID NO:87 (S2_AB-39); a VH comprising the amino acid sequence of SEQ ID NO:111 and a VL comprising the amino acid sequence of SEQ ID NO:117 (S2_AB-40); a VH comprising the amino acid sequence of SEQ ID NO:562 and a VL comprising the amino acid sequence of SEQ ID NO:573 (S2_AB-41); a VH comprising the amino acid sequence of SEQ ID NO:563 and a VL comprising the amino acid sequence of SEQ ID NO:76 (S2_AB-42); - 208 - 3839034.v1
5708.1076005 a VH comprising the amino acid sequence of SEQ ID NO:564 and a VL comprising the amino acid sequence of SEQ ID NO:75 (S2_AB-43); a VH comprising the amino acid sequence of SEQ ID NO:565 and a VL comprising the amino acid sequence of SEQ ID NO:574 (S2_AB-44); a VH comprising the amino acid sequence of SEQ ID NO:566 and a VL comprising the amino acid sequence of SEQ ID NO:80 (S2_AB-45); a VH comprising the amino acid sequence of SEQ ID NO:567 and a VL comprising the amino acid sequence of SEQ ID NO:75 (S2_AB-46); a VH comprising the amino acid sequence of SEQ ID NO:568 and a VL comprising the amino acid sequence of SEQ ID NO:574 (S2_AB-47); a VH comprising the amino acid sequence of SEQ ID NO:569 and a VL comprising the amino acid sequence of SEQ ID NO:77 (S2_AB-48); a VH comprising the amino acid sequence of SEQ ID NO:570 and a VL comprising the amino acid sequence of SEQ ID NO:76 (S2_AB-49); a VH comprising the amino acid sequence of SEQ ID NO:571 and a VL comprising the amino acid sequence of SEQ ID NO:575 (S2_AB-50); or a VH comprising the amino acid sequence of SEQ ID NO:56 and a VL comprising the amino acid sequence of SEQ ID NO:80 (S2_AB-51). 38. The composition of any one of claims 31-37, wherein the antibody or the antigen-binding fragment thereof that specifically binds an S2 domain of SARS-CoV-2-Spike comprises: a) a VH comprising the amino acid sequence of SEQ ID NO:53; and b) a VL comprising the amino acid sequence of SEQ ID NO:75. 39. The composition of any one of claims 28-38, wherein the composition further comprises one or more pharmaceutical excipients, diluents, and/or carriers. 40. A method of treating a subject in need thereof, comprising administering an effective amount of the polypeptide of any one of claims 1-24, the polynucleotide of claim 25, or the composition of any one of claims 28-39 to the subject. 41. A method of reducing infectivity of SARS-CoV-2 of a cell in a subject, comprising contacting the cell with an effective amount of the polypeptide of any one of claims 1-24 or the composition of any one of claims 28-39. 42. The method of claim 40 or 41, wherein the subject is a human. - 209 - 3839034.v1
5708.1076005 43. The method of any one of claims 40-42, wherein the subject has COVID-19, is suspected of having COVID-19, or is at risk of developing COVID-19. 44. The method of any one of claims 40-43, wherein the subject has a heart disease, has diabetes, has a lung disease, is a tobacco smoker, is on immunosuppressive therapy, is 40 years or older, or any combination thereof. 45. The method of claim 44, wherein: a) the heart disease comprises a congestive heart disease, a coronary artery disease, a hypertensive heart disease, an inflammatory heart disease, a pulmonary heart disease, a rheumatic heart disease, a valvular heart disease, a cardiomyopathy, heart failure, or a combination thereof, optionally wherein: i) the heart failure comprises a congestive heart failure; and/or ii) the inflammatory heart disease comprises endocarditis, cardiomegaly, myocarditis, or a combination thereof; b) the lung disease comprises acute respiratory distress syndrome, asthma, bronchitis, COPD, emphysema, a lung tumor, a pleural cavity disease, a pulmonary vascular disease, a respiratory tract infection, or a combination thereof, optionally wherein: i) the respiratory tract infection comprises an upper respiratory tract infection, a lower respiratory tract infection, and/or pneumonia; ii) the pleural cavity disease comprises pleural mesothelioma and/or tension pneumothorax; iii) the pulmonary vascular disease comprises embolisms, edema, arterial hypertension, and/or hemorrhages; or a combination thereof; or both a) and b). - 210 - 3839034.v1
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263424947P | 2022-11-13 | 2022-11-13 | |
US63/424,947 | 2022-11-13 | ||
US202263383699P | 2022-11-14 | 2022-11-14 | |
US63/383,699 | 2022-11-14 | ||
US202363480919P | 2023-01-20 | 2023-01-20 | |
US63480919 | 2023-01-20 | ||
US202363492211P | 2023-03-24 | 2023-03-24 | |
US63/492,211 | 2023-03-24 | ||
US202363520549P | 2023-08-18 | 2023-08-18 | |
US63/520,549 | 2023-08-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024102674A1 true WO2024102674A1 (en) | 2024-05-16 |
Family
ID=89190797
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/078868 WO2024102674A1 (en) | 2022-11-13 | 2023-11-06 | Antigen binding molecules targeting sars-cov-2 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024102674A1 (en) |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002060919A2 (en) | 2000-12-12 | 2002-08-08 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
WO2021158521A1 (en) | 2020-02-03 | 2021-08-12 | Vir Biotechnology, Inc. | Antibodies against sars-cov-2 and methods of using the same |
WO2021173753A1 (en) | 2020-02-26 | 2021-09-02 | Vir Biotechnology, Inc. | Antibodies against sars-cov-2 and methods of using the same |
WO2021203053A1 (en) | 2020-04-03 | 2021-10-07 | Vir Biotechnology, Inc. | Immunotherapy targeting a conserved region in sars coronaviruses |
WO2021211775A1 (en) | 2020-04-14 | 2021-10-21 | Vir Biotechnology, Inc. | Antibodies against sars-cov-2 and methods of using the same |
WO2021226560A1 (en) | 2020-05-08 | 2021-11-11 | Vir Biotechnology, Inc. | Antibodies against sars-cov-2 |
US11192940B2 (en) | 2020-04-10 | 2021-12-07 | Adagio Therapeutics, Inc. | Compounds specific to coronavirus S protein and uses thereof |
WO2022010921A1 (en) | 2020-07-06 | 2022-01-13 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting sars-cov-2 |
WO2022010912A1 (en) | 2020-07-06 | 2022-01-13 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting sars-cov-2 |
WO2022047033A1 (en) | 2020-08-26 | 2022-03-03 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting sars-cov-2 |
CN114292327A (en) * | 2022-03-10 | 2022-04-08 | 中国科学院微生物研究所 | Human antibody of broad-spectrum novel coronavirus and application thereof |
WO2022140845A1 (en) * | 2020-12-29 | 2022-07-07 | Val-Chum, Limited Partnership | Neutralizing monoclonal antibodies against covid-19 |
WO2022153212A1 (en) * | 2021-01-13 | 2022-07-21 | Axon Neuroscience Se | Antibodies neutralizing sars-cov-2 |
WO2023215910A1 (en) * | 2022-05-06 | 2023-11-09 | Generate Biomedicines, Inc. | Antigen binding molecules targeting sars-cov-2 |
-
2023
- 2023-11-06 WO PCT/US2023/078868 patent/WO2024102674A1/en unknown
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002060919A2 (en) | 2000-12-12 | 2002-08-08 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
WO2021158521A1 (en) | 2020-02-03 | 2021-08-12 | Vir Biotechnology, Inc. | Antibodies against sars-cov-2 and methods of using the same |
WO2021173753A1 (en) | 2020-02-26 | 2021-09-02 | Vir Biotechnology, Inc. | Antibodies against sars-cov-2 and methods of using the same |
US11168128B2 (en) | 2020-02-26 | 2021-11-09 | Vir Biotechnology, Inc. | Antibodies against SARS-CoV-2 and methods of using the same |
WO2021203053A1 (en) | 2020-04-03 | 2021-10-07 | Vir Biotechnology, Inc. | Immunotherapy targeting a conserved region in sars coronaviruses |
US11192940B2 (en) | 2020-04-10 | 2021-12-07 | Adagio Therapeutics, Inc. | Compounds specific to coronavirus S protein and uses thereof |
WO2021211775A1 (en) | 2020-04-14 | 2021-10-21 | Vir Biotechnology, Inc. | Antibodies against sars-cov-2 and methods of using the same |
WO2021226560A1 (en) | 2020-05-08 | 2021-11-11 | Vir Biotechnology, Inc. | Antibodies against sars-cov-2 |
WO2022010921A1 (en) | 2020-07-06 | 2022-01-13 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting sars-cov-2 |
WO2022010912A1 (en) | 2020-07-06 | 2022-01-13 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting sars-cov-2 |
WO2022047033A1 (en) | 2020-08-26 | 2022-03-03 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting sars-cov-2 |
WO2022140845A1 (en) * | 2020-12-29 | 2022-07-07 | Val-Chum, Limited Partnership | Neutralizing monoclonal antibodies against covid-19 |
WO2022153212A1 (en) * | 2021-01-13 | 2022-07-21 | Axon Neuroscience Se | Antibodies neutralizing sars-cov-2 |
CN114292327A (en) * | 2022-03-10 | 2022-04-08 | 中国科学院微生物研究所 | Human antibody of broad-spectrum novel coronavirus and application thereof |
WO2023215910A1 (en) * | 2022-05-06 | 2023-11-09 | Generate Biomedicines, Inc. | Antigen binding molecules targeting sars-cov-2 |
Non-Patent Citations (34)
Title |
---|
"Remington: The Science and Practice of Pharmacy", 2006, LIPINCOTT WILLIAMS AND WILKINS, article "Pharmaceutical Manufacturing", pages: 691 - 1092 |
"Remington's Pharmaceutical Sciences", 1980 |
AL-LAZIKANI, J. MOLEC. BIOL, vol. 273, 1997, pages 927 - 948 |
ALMAGRO, J. MOL. RECOGNIT, vol. 17, 2004, pages 132 - 143 |
AUSUBE ET AL., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, 1992 |
AUSUBEL ET AL., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY) |
BADENRUBIN: "Covid-19 - The Search for Effective Therapy", N ENGL J MED, vol. 382, no. 19, 2020, pages 1851 - 52 |
BAUD ET AL.: "Real estimates of mortality following COVID-19 infection,", LANCET INFECT DIS, vol. 20, no. 7, 2020, pages 773, XP086202406, DOI: 10.1016/S1473-3099(20)30195-X |
CHOTHIA, C ET AL., J. MOL. BIOL., vol. 196, 1987, pages 901 - 917 |
CHOTHIA, NATURE, vol. 342, 1989, pages 877 |
DACON CHERRELLE ET AL: "Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses", CELL HOST & MICROBE, ELSEVIER, NL, vol. 31, no. 1, 7 November 2022 (2022-11-07), pages 97, XP087246812, ISSN: 1931-3128, [retrieved on 20221107], DOI: 10.1016/J.CHOM.2022.10.010 * |
DUMET ET AL.: "Insights into the IgG heavy chain engineering patent landscape as applied to IgG4 antibody development", MABS, vol. 11, no. 8, 2019, pages 1341 - 50, XP055732501, DOI: 10.1080/19420862.2019.1664365 |
HASTIE KATHRYN M. ET AL: "Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study", SCIENCE, vol. 374, no. 6566, 22 October 2021 (2021-10-22), US, pages 472 - 478, XP055888933, ISSN: 0036-8075, Retrieved from the Internet <URL:http://dx.doi.org/10.1126/science.abh2315> DOI: 10.1126/science.abh2315 * |
HASTIE KATHRYN M. ET AL: "Supplementary Materials and Figures for "Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study"", SCIENCE, vol. 374, no. 6566, 22 October 2021 (2021-10-22), US, XP055888947, ISSN: 0036-8075, Retrieved from the Internet <URL:https://www.science.org/doi/suppl/10.1126/science.abh2315/suppl_file/science.abh2315_sm.pdf> DOI: 10.1126/science.abh2315 * |
INGRAHAM ET AL.: "Generative models for graph-based protein design", 33RD CONFERENCE ON NEURAL INFORMATION PROCESSING SYSTEMS, 2019 |
JENNEWEIN ET AL.: "Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects,", CELL REP, vol. 36, no. 2, 2021, pages 109353, XP093064815, DOI: 10.1016/j.celrep.2021.109353 |
KABAT, E.A. ET AL.: "U.S. Department of Health and Human Services", 1991, JOHN WILEY AND SONS, article "Sequences of Proteins of Immunological Interest" |
LI ET AL.: "Structural Basis and Mode of Action for Two Broadly Neutralizing Antibodies Against SARS-Col 2 Emerging Variants of Concern", CELL REPORTS, vol. 38, no. 2, 2021, pages 110210, XP093039741, DOI: 10.1016/j.celrep.2021.110210 |
LI WENWEI ET AL: "Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern", CELL REPORTS, vol. 38, no. 2, 1 January 2022 (2022-01-01), US, pages 110210, XP093039741, ISSN: 2211-1247, Retrieved from the Internet <URL:https://www.sciencedirect.com/science/article/pii/S2211124721017149/pdfft?md5=6f566a0b46d18b5286e233371aeedeb2&pid=1-s2.0-S2211124721017149-main.pdf> DOI: 10.1016/j.celrep.2021.110210 * |
NEEDLEMANWUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443 |
PATROPRZYBYCIEN, BIOTECHNOL BIOENG, vol. 52, no. 2, 1996, pages 193 - 203 |
PEARSONLIPMAN, PROC. NAT'L. ACAD. SCI. USA, vol. 85, 1988, pages 2444 |
PINTO DORA ET AL: "CORONAVIRUS Broad betacoronavirus neutralization by a stem helix-specific human antibody", 3 September 2021 (2021-09-03), XP055896554, Retrieved from the Internet <URL:https://doi.org/10.1126/science.abj3321> [retrieved on 20220301] * |
PINTO ET AL.: "Cross-neutralization of SARS-Col 2 by a human monoclonal SARS-Col antibody", NATURE, vol. 583, 2020, pages 290 - 95 |
S. M. BERGE ET AL.: "describe pharmaceutically acceptable salts in detail", J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19 |
SAMBROOK ET AL.: "Molecular Cloning: a Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS |
SMITHWATERMAN, ADV. APPL. MATH, vol. 2, 1981, pages 482 |
SONG ET AL.: "Cytokine storm induced by SARS-CoV-2", CLIN CHIM ACTA, vol. 509, 2020, pages 280 - 7, XP086250702, DOI: 10.1016/j.cca.2020.06.017 |
TANG HAONENG ET AL: "Mutational escape prevention by combination of four neutralizing antibodies that target RBD conserved regions and stem helix", VIROLOGICA SINICA, vol. 37, no. 6, 19 November 2022 (2022-11-19), Heidelberg, pages 860 - 873, XP093131005, ISSN: 1995-820X, DOI: 10.1016/j.virs.2022.11.005 * |
VERED KUNIK ET AL., NUCLEIC ACIDS RESEARCH, vol. 40, July 2012 (2012-07-01), pages W521 - W524 |
WANG ZHENG ET AL: "Characterization of RBD-specific cross-neutralizing antibodies responses against SARS-CoV-2 variants from COVID-19 convalescents", FRONTIERS IN IMMUNOLOGY, vol. 14, 10 May 2023 (2023-05-10), Lausanne, CH, XP093130984, ISSN: 1664-3224, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/doi/10.3389/fimmu.2023.1160283> DOI: 10.3389/fimmu.2023.1160283 * |
YANG, D.SINGH, A.WU, H.KROE-BARRETT, R.: "Comparison of biosensor platforms in the evaluation of high affinity antibody-antigen binding kinetics", ANALYTICAL BIOCHEMISTRY, vol. 508, 2016, pages 78 - 96, XP029642360, DOI: 10.1016/j.ab.2016.06.024 |
YUAN MENGQI ET AL: "A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern", JOURNAL OF VIROLOGY, vol. 96, no. 16, 2 August 2022 (2022-08-02), US, XP093131306, ISSN: 0022-538X, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400488/pdf/jvi.00775-22.pdf> DOI: 10.1128/jvi.00775-22 * |
ZHOU ET AL.: "A general-purpose protein design framework based on mining sequence-structure relationships in known protein structures", PROC NATL ACAD SCI U S A, vol. 117, no. 2, 2020, pages 1059 - 68, XP055774148, DOI: 10.1073/pnas.1908723117 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220162332A1 (en) | Activatable anti-pdl1 antibodies, and methods of use thereof | |
US10723786B2 (en) | RSV-specific binding molecule | |
KR102646468B1 (en) | Anti-CD47 antibodies and uses thereof | |
US11345757B2 (en) | Anti-CD39 antibodies | |
JP5734988B2 (en) | RSV specific binding molecule | |
US11993644B2 (en) | Antigen binding molecules targeting SARS-CoV-2 | |
US11981725B2 (en) | Antigen binding molecules targeting SARS-CoV-2 | |
US11987616B2 (en) | Antigen binding molecules targeting SARS-CoV-2 | |
US20230279081A1 (en) | Antigen Binding Molecules Targeting SARS-CoV-2 | |
WO2022162587A1 (en) | Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection | |
CN115666649A (en) | Novel pharmaceutical composition of coronavirus antibody and application thereof | |
KR20220007128A (en) | Anti-SMA Antibodies and Their Uses for the Treatment of Eye or Ocular Diseases | |
KR20200010294A (en) | Therapeutic Anti-CD40 Ligand Antibodies | |
WO2014115893A1 (en) | Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof | |
WO2024102674A1 (en) | Antigen binding molecules targeting sars-cov-2 | |
TW202323276A (en) | Compositions and methods for treating long qt syndrome | |
EP4164673A2 (en) | Methods and compositions related to neutralizing antibodies against human coronavirus | |
US20230212271A1 (en) | Compositions and methods for linear and conformational site-specific antibodies and methods of making the same | |
CN112574297B (en) | Monoclonal antibody against neuraminidase and application thereof | |
WO2024155381A1 (en) | Antibodies for zika virus | |
CN116635410A (en) | Antigen binding molecules targeting SARS-CoV-2 | |
EA046745B1 (en) | METHOD FOR TREATING CANCER WITH AN ACTIVATE ANTIBODY AGAINST PDL1 | |
EA046015B1 (en) | AQUEOUS PHARMACEUTICAL COMPOSITION ANTI-IL17A ANTIBODIES AND ITS APPLICATION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23822167 Country of ref document: EP Kind code of ref document: A1 |